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Mobile resistance elements in Gram-negatives
S1 Plasmids in clinically-signiﬁcant Gram-negative bacteria
A. Carattoli (Rome, IT)
Bacteria carry extrachromosomal, self-replicating genetic elements,
called plasmids. Natural plasmids have systems guaranteeing their au-
tonomous replication but also mechanisms controlling the copy-number
and ensuring stable inheritance during cell division. Plasmids have
evolved as an integral part of the bacterial genome, providing additional
functions to their host. The best example of functions associated to a
plasmid is given by the antimicrobial resistance. Resistance genes located
on plasmids offer immediate advantage to their host under antimicrobial
pressure and they can be easily exchanged among bacteria of different
species and genera, through the natural process of conjugation, rapidly
spreading in bacteria of diverse origin and source.
Plasmids are playing the major role in the diffusions of antimicrobial
resistance in Gram-negative bacteria, promoting the spread of resistance
genes coding b-lactamases such as CTX-M, SHV, TEM, DHA, CMY,
VEB, or aminoglycoside modifying enzymes or proteins mediating
quinolone resistance.
Plasmid-mediated antimicrobial resistance arises from a complex
multifactorial process supported by a panoply of mobile genetic elements
that contain and transfer resistance determinants. Bacterial plasmid
sequence comparisons provided the historical events through which
these genetic determinants are assembled by transposition, homologous
recombination, and illegitimate recombinational events.
Plasmids also play a very important role in bacterial pathogenesis as
carrier of virulence genetic traits. Several resistance plasmids have
been described in Enterobacteriaceae to carry virulence factors, such as
bacteriocins, siderophores, cytotoxins, or adhesion factors and virulence
plasmids have been described to carry resistance genes. Plasmids are
consequently a fashionable ﬁeld of scientiﬁc research.
S2 Insertion sequences, transposons and repeated elements
T. Naas (Paris, FR)
Among the most important issues of clinical microbiology, increasing
prevalence of bacterial pathogens expressing resistance to multiple
antimicrobial agents is of special concern. The observed high frequency
of multiresistance suggests mechanisms by which bacterial species can
concentrate and efﬁciently exchange a variety of resistance determinants.
Lateral gene transfer, which has been proposed as a fundamental process
underlying bacterial diversity, is mainly mediated through plasmids and
phages. While integrons are capable of concentrating resistance genes,
they are uncapable of self-transposition. The mobility of the resistance
genes is mediated by insertions sequences and transposons. Along
with the discovery of novel resistance genes, the number of different
transposable elements isolated and characterised at the nucleotide
sequence level is exploding, and over 1500 different ISs have been
identiﬁed to date.
Bacterial insertion sequences (IS) are small DNA segments (<2.5 kb)
with a simple genetic organisation. Most IS elements exhibit short
terminal inverted-repeat sequences (IR) and encode a transposase, an
enzyme that is required for transposition. These mobile elements play
an important role in assembling sets of “accessory” functions in bacteria
(such as genes forming parts of degradative or catabolic pathways)
and in dissemination of resistance genes. By inserting within a coding
sequence they may inactivate the gene, or by inserting upstream of a
gene they may modify its expression. ISs may also help integration
of plasmids into the chromosome of bacteria. Some ISs, such as
ISEcp1, are capable of mobilising nearby DNA, by a mechanism
similar to one-ended-transposition, while others may form a composite
transposon, being capable of carrying the sequence located between
the two ISs. True transposons such as Tn7, and the large group of
type II transposons of the Tn3 family are complicated structures and
include multiple antibiotic resistance genes carried by integrons. The
association of integrons with transferable elements may promote rapid
dissemination among clinical strains, and create further opportunities for
inclusion of additional resistance determinants. Recently novel genetic
structures, Repeated Elements (Re), have been described being capable
of mobilising resistance genes through a transposition/recombination
process that still needs to be fully understood.
The study of novel resistance mechanisms and their underlying genetic
background revealed novel mobile DNA elements responsible for their
mobilisation. These elements are of interest for clinical microbiology,
since they are associated to the emergence of novel antibiotic resistance
genes, and for fundamental research, since novel genetic mechanisms
for gene mobilisation and dissemination were identiﬁed.
S3 The two mechanisms of gene capture behind most trimethoprim
resistance in enteric bacteria
L. Sundstro¨m (Uppsala, SE)
Synthetic antibacterial drugs such as antifolates, sulfonamides and
quinolones have been widely used in human and veterinary practice
over the last 60 years. The clinical efﬁcacy of these drugs is undermined
by the integration and spreading of resistance borne on transmissible
plasmids and genetic islands. In 1977, Pattishall et al. divided
the plasmid-borne trimethoprim resistance genes into two distinctive
structural classes later referred to as dfrA and dfrB. The number of
identiﬁed gene types has grown to more than 30 at present. We matched
the contexts of all sequenced dfr genes with signatures of two gene
capture mechanisms. These are uptake of gene cassettes in integrons
by site-speciﬁc recombination and one-ended transposition mediated by
IS91-like elements referred to as common regions or ISCR. The data we
assembled showed that trimethoprim resistance in Gram-negative bacte-
ria is spread, at nearly full coverage, via either of these recombinational
paths. Nineteen types of dfr genes in three families, exampliﬁed by the
gene types A1, A12 and B1, are borne on integron-based cassettes while
seven dfr gene types, A3b. A9, A10, A19, A20, A23 and A26 (Grape
et al., unpublished) have been inserted via the second recombination
path. IS91 family insertion elements use a one-ended transpositional
mechanism to produce single-stranded DNA through rolling circle
replication. Integron cassettes use recombination sites that are in fact
recognized by the cognate tyrosine recombinase in the form of harpins.
This suggests that IS91 might enhance excision and integration of
cassettes that are situated within replication range of IS91-like elements.
If the two gene capture systems are indeed engaged in a functional
crosstalk this could explain their frequent co-localisation. The spreading
of resistance to other synthetic drugs differs. For instance, sulfonamide
resistance in Gram-negative bacteria is ubiquitous but much less diverse
with only three gene types in the metagenomic pool. The recombinational
spread of sul genes is cryptic and may be diverse. However, one of the
genes, sul1, is strongly linked with both integrons and common regions
of the IS91 type. Sulfonamides were introduced prior to other modern
antibacterial drugs suggesting that it was the key selecting factor for
making the dual recombinational platform of integrons and IS91-like
elements ﬁxed in most bacterial populations. Quinolone resistance gets
contribution from transmissible qnr alleles of three families reported in
connection with IS91-like regions (Robicscek et al. 2006).
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S4 Common region as a source of spread and expression of
antibiotic resistance genes
T. Walsh (Cardiff, UK)
Bacteria are noteworthy for their remarkable genetic plasticity respond-
ing and adapting to environmental changes that often as not involves
the exchanging of DNA molecules in the same cell and between
bacterial cells. Insertions sequence common regions (ISCRs) were ﬁrst
discovered and reported in the early 1990’s as a DNA sequence of
2,154 bp that was found in two complex class 1 integrons, In6 and
In7. The sequence was initially described as a common region (CR) to
distinguish it from the 5′ and 3′ conserved sequence of class 1 integrons.
ISCRs were also interesting in that they are intimately associated with
different resistance genes carried on each integron. ISCR elements have
been found in many Gram-negative bacteria and have been associated
with an array of different antibiotic resistant functions including qnr,
ESBLs, AmpC b-lactamases, metallo-b-lactamases, aminoglycoside and
chloramphenicol resistance, dhfr and sul genes. Some bacteria contain
several copies of these elements that have probably occurred via
replication followed by homologous recombination. They can be located
on either the chromosome or/and plasmid.
There are now at least 15 known types of ISCR elements that when
aligned share key amino acid motifs with each other and that of IS91.
These motifs have been shown to be involved in DNA recognition and
mobility. ISCR elements are very unusual in that, like IS91, they can
mobilise large sections of adjacent DNA via a rolling circle replication.
Normally, termination of replication occurs at a deﬁned site; misreading
of this site leads to replication of large sections of DNA to the left-hand
end of the element including antibiotic resistance genes. Many elements
are found next to class 1 integrons which we believe to be expressed and
active – possibly driven by a hybrid promoter. The only ISCR element
shown not to be expressed is ISCR2. They are now commonly found
in Enterobacteriaceae, Gram-negative non-fermentors and occasionally
Gram-positive bacteria and have been found in clinical isolates from
every continent. Their impact on the spread of antibiotic resistance genes
is only now beginning to be understood.
Diagnosis and treatment of septic shock
(Symposium arranged with the International
Sepsis Forum)
S5 The innate immune response to P. aeruginosa in human
monocytes is mediated mainly by TLR-2 and mannose receptor
P. Xaplanteri, V. Le Cabec, G. Dimitracopoulos, F. Paliogianni (Patras,
GR; Toulouse, FR)
P. aeruginosa is a human pathogen that causes life threatening
infections in immunocompromised host. We have previously shown that
Extracellular Slime Glycoliprotein (GLP) produced by all mucoid and
non mucoid strains is a potent activator of NFkb transcriptional activity
and TNF-a induction in fresh human monocytes.
Objectives: To examine which innate immune receptors are involved
in signaling proinﬂammatory cytokine production induced by P. aerugi-
nosa.
Methods: We stimulated for 6−24 h fresh human monocytes either with
P. aeruginosa Slime GLP (100mg/mL) or viable bacteria (MOI 10:1)
in the presence or absence of speciﬁc blocking antibodies against
TLR4, TLR2 and Mannose receptor (10mg/mL). Proinﬂammatory
cytokine production (IL-1b, IL-6, TNF-a) was measured in the culture
supernatants by ELISA. Phagocytosis was inhibited by the addition of
Cytochalasin D (1mg/mL) 30min before stimulation. Receptor mediated
activation of NFkb was examined by cotransfection experiments, using
human embryonic kidney (HEK)-293 cells and plasmids encoding
mannose receptor, TLR4 and TLR2−CD14 complex along with NFkb
reporter driving the expression of luciferase gene. NFkb activation was
detected by measuring luciferase activity.
Results: Blocking of phagocytosis or mannose receptor function resulted
in 90% inhibition of proinﬂammatory cytokine production. TLR2
blocking resulted in 70−80% inhibition whereas TLR4 blocking had less
prominent effect (30−40%). Challenging of HEK-293 cells expressing
only mannose receptor with Slime GLP or viable bacteria resulted in
NFkb activation by 6−10 fold and 20−30 fold correspondingly. Co
expression of TLR2 in the same cells increased the NFkb activation
by 3 fold in both ways of stimulation, whereas coexpession of TLR4
resulted in just detectable increase, 1.2−1.5 fold.
Conclusion: Our results suggest that mannose receptor acts not only
as phagocytosis receptor for P. aeruginosa, but also as signaling
receptor and cooperates with TLR2 for maximum NFkb activation and
proinﬂammatoty cytokine production. These ﬁndings provide a new
insight for future development of new immunotherapies.
Challenges in pharmacokinetics and
pharmacodynamics
S11 PK/PD in critically ill patients
F. Scaglione (Milan, IT)
Antimicrobial treatment of infections in critically ill patients remains
a signiﬁcant challenge with persisting high mortality and morbidity.
Early and appropriate antibacterial therapy remains an important
intervention for such patients. To optimise antibacterial therapy, the
clinician should possess not only knowledge of the pharmacokinetic and
pharmacodynamic properties of commonly used antimicrobials, but also
how these parameters may be affected by the pathophysiological changes
occurring during sepsis or septic shock.
Pathophysiological changes can be contrasting. Sepsis, and the non-
antibiotic treatment, increasing renal preload may result in higher
antibacterial clearances. Alternatively, sepsis can induce multiple organ
dysfunction, including renal and/or hepatic dysfunction, causing a
decrease in antibacterial clearance.
Aminoglycosides, b-lactams and carbapenems are distributed in plasma
and interstitial space, therefore their concentrations could be dramatically
affected during sepsis. These drugs can have a higher Vd during sepsis
leading to a reduced Cmax. Some patients with serum creatinine within
the normal range can have higher than normal drug clearances, thereby
producing low serum concentrations. If a drug needs to have a minimum
serum concentration maintained (e.g. b-lactams), a high drug clearance
will lead to underdosage for renally excreted drugs. All b-lactams should,
in such patients, be administered more frequently than suggested in
non-sepsis patients; administration by continuous infusion should be
considered. In relation to the aminoglycosides, this means that not only
are large doses required to be administered, but because of a high CLCR
these antibacterials may also need dosing even more frequently than
every 24 hours.
Regarding the renal clearance of the ﬂuoroquinolones, in the presence
of a high CLCR can be assumed that ﬂuoroquinolone clearance is also
high. If this were true these antibacterials would also need to have higher
daily doses than proposed in the standard literature.
In conclusion the treatment of infections in critical ill patients remains
a signiﬁcant challenge given the persisting high mortality rates. Data
suggest that effective antibacterial therapy remains the most important
intervention available to the clinician. In treating sepsis, a clinician must
be aware of the impact of the various pathophysiological and subsequent
pharmacokinetic changes that can occur during sepsis.
Infection control S3
Infection control
O14 Surgical site infection surveillance in France: the ﬁrst
1999–2004 trend analysis
P. Astagneau, M. Olivier, B. Grandbastien, F. L’Heriteau, J. Jost,
J. Seguier, H. Tronel, H. Senechal, M. Metzger, P. Parneix, B. Coignard
(Paris, Poissy, Nancy, Rennes, Lyon, Bordeaux, St Maurice, FR)
Background: Surgical site infection (SSI) is one of the most frequent
nosocomial infections. Since 1999, a national coordination of regional
networks has been implemented to gather SSI incidence data according
to standardised method. The aim of the current study was to describe
the largest database ever collected in France on SSI and to analyse a
6-year temporal trend.
Methods: Surgery patients were enrolled by voluntary participating
wards in a yearly 3-month incidence survey. In each ward, 200
consecutive surgery procedures should be included and patients followed
up to 30 days after surgery. SSI was deﬁned based on standard CDC
criteria. For each patient, risk factors were collected on the day of
surgery including age, ASA score, Altemeier wound class, type and
duration of procedure, emergency/elective, and when videoscopy surgery
was performed.
Results: During 6 years, the study included 620,176 operations
(17,430,253 operated patient–days follow-up; median post-operative
follow-up: 28 days). The overall SSI incidence rate was 1.68%. Organ
space and deep incisional SSI accounted for 41.7% although their
proportion varied according to the type of surgery. SSI incidence rate
increased from 0.91% [0.88–0.94%] for NNIS-0 patients to 13.8%
[12.5−15.2%] for NNIS-2, 3 patients. The SSI incidence varied from
1.15% for herniorraphy to 9.2% for colon surgery. In NNIS-0 patients,
emergency surgery increased the SSI risk for C-section whereas
videoscopy surgery was at lower risk for cholecystectomy. From 1999 to
2004, NNIS-0 SSI incidence decreased from 1.1 to 0.9 for 100 operated
patients (relative difference: −18%). According to procedure, the trend
remained signiﬁcant only for herniorraphy.
Conclusion: This database provided thorough standardised estimate
of SSI incidence according to various surgery procedures. Impact of
the national policy on SSI incidence remains to be further evaluated,
although encouraging results were evidenced for speciﬁc surgery.
O15 Changes in healthcare-associated infection rates in French
maternity units from 1997 to 2003
A. Vincent, L. Ayzac, R. Girard, E. Caillat-Vallet, C. Chapuis,
A.M. Dumas, C. Gignoux, C. Haond, C. Launay, F. Tissot-Guerraz,
J. Fabry and surveillance networks’ units
Objectives: Healthcare associated infection (HAI) incidence rates after
delivery range from 0.26% to 20.3% according to the mode of delivery,
the maternity activity, women risk factors. Data on HAI surveillance
in maternity units are lacking. The Mater Sud-Est Study Group is a
HAI continuous surveillance network on maternity units located in south
eastern France. We report changes in risk-adjusted HAI rates over a
6-year long surveillance period in this maternity units network.
Methods: 161,077 vaginal deliveries and 37,074 cesarean deliveries
were included in the surveillance between January 1st 1997 and
December 31st 2003. We studied the changes in four HAI: endometritis
and Urinary tract infection (UTI) after vaginal deliveries, surgical site
infection (SSI) and UTI after cesarean deliveries. We used a logistic
regression modeling to estimate risk-adjusted HAI rates. The year of
delivery was considered as a risk factor. The trend of risk-adjusted HAI
rates over the study period was studied by a linear regression of the
year-of-delivery odds ratios for each targeted HAI.
Results: The rate of endometritis and UTI after vaginal deliveries was
0.3% (534/161,077) and 0.5% (728/161,077) respectively. Over the study
period the decrease in endometritis odd ratios was statistically signiﬁcant.
We found no statistically signiﬁcant trend in vaginal delivery’s UTI.
The rate of SSI and UTI after cesarean deliveries was 1.5% (571/37,074)
and 1.8% (685/37,074) respectively. Over the study period the decrease
in SSI and UTI odd ratios was statistically signiﬁcant.
Conclusion: These ﬁndings highlight the positive effect of participating
in a surveillance network for infection control and for improvement of
care.
O16 Bacterial population kinetics on hands during two consecutive
surgical hand disinfection procedures
G. Kampf, C. Ostermeyer, T. Kohlmann (Hamburg, Greifswald, DE)
In Europe, the efﬁcacy of surgical hand antiseptics is investigated
only for a single application. In clinical practice, however, consecutive
applications are common but the effect on the bacterial density on
hands is largely unknown. We therefore studied the effect of different
consecutive applications on the resident bacterial ﬂora on hands.
A propanol-based hand rub (Sterillium®, based on 45% propan-2-ol,
30% propan-1-ol and 0.2% mecetronium etilsulfate) and the reference
alcohol of EN 12791 (60% n-propanol) were tested in two consecutive
applications with 3 h between them. Four variations were tested. The ﬁrst
application of Sterillium was always for 1.5min, the second application
was for 1.5, 1 or 0.5min. The reference alcohol was applied for 3min
(both applications). The efﬁcacy of the three product variations was
compared to the reference treatment of EN 12791. All experiments
were performed in a Latin-square design with 20 volunteers. Pre- and
post-values (immediately and 3 hr after each applications) were obtained
according to EN 12791.
The ﬁrst reference disinfection (3min) reduced the bacterial density by
2.87±1.00 log10-steps (immediate efﬁcacy) and 2.27±1.25 log10-steps
(after 3 h). Sterillium applied for 1.5min yielded a similar reduction
at both sampling times. Immediately after the second 3min reference
disinfection bacterial density was reduced by 0.45±1.05 log10-steps.
Application of Sterillium yielded larger reductions with 0.71±1.32
(0.5min application time), 0.79±1.63 (1min application time), and
1.12±1.04 log10-steps (1.5min application time). The difference between
the four treatments, however, was not signiﬁcant (p = 0.089). After
3 h under the surgical glove bacterial density further decreased with
1.11±1.04 log10-steps for the reference disinfection. A 1min application
of Sterillium yielded the largest reduction (1.89±1.02) followed by a
1.5min treatment (1.67±0.98) and a 0.5min treatment (1.08±0.86).
There was a signiﬁcant difference between all four treatments (p = 0.005;
Friedman test) but none of the short treatments with Sterillium was
signiﬁcantly less effective than the 3min reference treatment (p> 0.05;
Wilcoxon-Wilcox test).
Overall, a simple 1.5min application of a well-formulated propanol-
based hand rub for surgical hand disinfection keeps the bacterial density
as low as possible even in two consecutive surgical procedures of 3 h.
O17 Surveillance of occupational blood and body ﬂuids exposures
P. Parneix, A. Vincent, F. L’He´riteau, N. Floret, H. Se´ne´chal,
D. Abiteboul, E. Reyreaud, B. Coignard and the National Nosocomial
Infection Alert, Investigation & Surveillance Network (RAISIN)
Bordeux, FR
Background: National surveillance of occupational blood and body
ﬂuids exposures (BBFE) in France is conducted since 2002 through
the Nosocomial Infection Early Warning, Investigation and Surveillance
Network (Raisin) in collaboration with Geres (Groupe d’Etude sur le
Risque d’Exposition des Soignants aux Agents Infectieux).
Methods: Participation of healthcare facilities (HCF) is voluntary
and anonymous. BBFE occurring from 01/01/04 to 31/12/04 were
documented using a standardised questionnaire documenting the nature,
circumstances (mechanism, type of device, infectious status of the
source) and follow-up of each BBFE. Incidence of BBFE is reported
per 100 hospitalisation beds, by type of personnel per 100 full time
equivalents (FTE), or by type of material per 100,000 devices.
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Results: In 2004, 13,041 BBFE were documented in 371 participating
HCF, which accounted for 15% of HCF and 29% of hospitalisation beds
in France. BBFE overall incidence was 8.9 per 100 beds. Considering
that all French hospitals account for 465,494 beds, 41,276 [95%CI:
40,896–41,656] BBFE could have occurred in France in 2004. HCV
or HIV status of the source was not known for more than 20% of
documented BBFE. Post-exposure prophylaxis (PEP) was prescribed to
4.5% of exposed personnel (vs. 5.8% in 2003 and 6.3% in 2002); this
decrease may reﬂect the impact of April 2003 French recommendations,
which reduced PEP indications. For the ﬁrst time in 2004, sutures were
the most frequent cause of BBFE associated with needles (more than
subcutaneous injections) and accounted for 1,103 (11%) of all BBFE;
one third occurred among residents, and 20% in ICU or emergency
rooms (beyond surgery or obstetrics). Prevention through education and
use of safety devices (such as blunt suture needles) may thus be a priority.
Data from a cohort of 173 HCF which participated in 2003 and 2004
also were compared and demonstrate signiﬁcant progresses. Compliance
to glove use increased from 58.6% in 2003 to 62.3% in 2004, and BBFE
incidence among nurse assistants fell from 2.3 in 2003 to 2.1 per 100
FTE in 2004. Last, BBFE incidence fell from 17.2 to 13.7 per 100,000
catheters, and from 71.6 to 43.2 per 100,000 implantable venous access
systems.
Conclusion: AES-Raisin is one of the biggest BBFE surveillance
network and results demonstrate an increase in observance to standard
precautions and a signiﬁcant decrease in the incidence of some types of
BBFE. They also point out future priorities for improvement.
O18 A randomised trial of 2% chlorhexidine in 70% alcohol
compared with 10% povidone-iodine for venipuncture site
disinfection: effects on blood culture contamination rates
G. Suwanpimolkul, M. Pongkumpai, W. Kulwichit, C. Suankratay
(Bangkok, TH)
Background: Contaminated blood cultures have been recognized as a
bothersome issue for decades, and continue to cause a frustration for
clinicians. The contamination rates vary widely between institutions from
less than 1% to over 6%. Skin antiseptics can prevent the contamination
of blood cultures. To our knowledge, no randomised trial of 2%
chlorhexidine in 70% alcohol for venipuncture site disinfection has been
conducted.
Objective: Our study was aimed to evaluate the efﬁcacy of venipuncture
site disinfection with 2% chlorhexidine in 70% alcohol compared with
10% povidone-iodine in preventing blood culture contamination.
Patients and Methods: A prospectively randomised investigator-blinded
trial was conducted in all patients hospitalised in Internal Medicine wards
and attended at emergency department at King Chulalongkorn Memorial
Hospital, Bangkok, Thailand from August 15 to October 31, 2006.
Antecubital venipuncture sites were randomly disinfected with either
2% chlorhexidine in 70% alcohol or 10% povidone-iodine, and blood
cultures were drawn by medical students or residents. The blood culture
contamination rate associated with each antiseptic was then determined.
Results: Of 2,146 blood culture collected during the study, 108 (5.03%)
were contaminated with skin ﬂora. The contamination rate for blood
cultures after 2% chlorhexidine in 70% alcohol was 3.2% (34 of
1,068), compared with a rate of 6.9% (74 of 1,078) (P< 0.001) after
10% povidone-iodine. Of the inpatient wards, the contamination rate
was 2.6% (18 of 695) and 3.9% (28 of 709) after 2% chlorhexidine
in 70% alcohol and 10% povidone-iodine, respectively (P = 0.013).
Of emergency department, the contamination rate was 4.3% (16 of
373) and 12.5% (46 of 369) after 2% chlorhexidine in 70% alcohol
and 10% povidone-iodine, respectively (P< 0.001). The most common
contaminant organism was coagulase-negative staphylococci (81%).
Conclusion: 2% chlorhexidine in 70% alcohol is superior to
10% povidone-iodine for venipuncture site disinfection before blood
culture sampling.
O19 Assessing the biological efﬁcacy and rate of recontamination
following hydrogen peroxide vapour decontamination
J. Otter, M. Cummins, F. Ahmad, C. van Tonder, Y. Drabu (Andover,
London, Essex, UK)
Objectives: The inanimate hospital environment can become contam-
inated with nosocomial pathogens. Hydrogen peroxide vapour (HPV)
decontamination has proven effective for the eradication of persistent
environmental contamination but the rate of recontamination following
HPV decontamination is largely unknown. We investigated the extent
of methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-
resistant enterococci (VRE) and gentamicin-resistant Gram-negative rod
(GNR) contamination in a ward side-room occupied by a patient with a
history of MRSA, VRE and GNR infection and colonisation.
Methods: Fifteen standardised sites in the room were sampled using
a selective broth enrichment protocol to culture for MRSA, VRE and
GNR. Sampling was carried out before cleaning, after cleaning, after
HPV decontamination and at intervals over the subsequent 19 days on
two separate occasions.
Results: Environmental contamination was identiﬁed before cleaning
on 60%, 30% and 6.7% of sites for MRSA, GNR and VRE,
respectively and 40%, 10% and 6.7% of sites after cleaning (ﬁgure).
Only one site (3.3%) was contaminated with MRSA after HPV
decontamination (ﬁgure). No recontamination with VRE was identiﬁed
and no recontamination with MRSA and GNR was identiﬁed in
the two days following HPV decontamination (ﬁgure). Substantial
recontamination towards pre-cleaning levels was identiﬁed by day ﬁve
and six after HPV decontamination for MRSA. Recontamination with
GNR at approximately post-cleaning levels was noted on days 7, 8 and
19 (Figure 1).
Fig. 1. Proportion of sites contaminated with MRSA, gentamicin-
resistant Gram-negative bacteria and VRE before cleaning, after
cleaning, after hydrogen peroxide vapour (HPV) decontamination and
at intervals over the subsequent 19 days during two experiments in a
ward side room. (Number of site sampled in parentheses.)
Conclusions: HPV is more effective than standard terminal cleaning
for the eradication of nosocomial pathogens. Recontamination was not
immediate for MRSA and GNR but returned towards pre-cleaning
levels for MRSA and post-cleaning levels for GNR within a week in
a room occupied by a patient colonised with MRSA and GNR. This
ﬁnding has important implications for the optimal deployment of HPV
decontamination in hospitals.
O20 Evaluation of the knowledge of hospital cleaning staff about
prevention of nosocomial infections
M. Tasbakan, S. Calik, H. Pullukcu, O. Sipahi, T. Yamazhan, S. Ulusoy
(Izmir, TR)
Objectives: Increasing morbidity and mortality due to nosocomial
infections (NI) necessitates the more stringent implementation of
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infection control measures. Detection of risk groups and infection
sources and knowing the transmission ways of infections are important
for the prevention from NI. In this study it was aimed to evaluate the
knowledge level and behaviour models of hospital cleaning staff about NI
in our setting which is a 1788 bedded tertiary care educational hospital.
Methods: A questionnaire of with 21 questions was implemented
to the hospital cleaning staff, who volunteered to enter the study.
The questionnaire was composed of two parts: ﬁrst part contained
parameters for determination of sociodemographic properties and the
second contained questions about evaluation of the knowledge about
prevention from NI. Questions were prepared by using the references
about the subject and by the help of the executives of the cleaning staff
ﬁrm and statistics unit. Data were evaluated by SPSS 13.0 programme
using Chi square and Student’s t tests. The questionnaire was completed
by one by one interview method.
Results: A total of 240 of 290 (82.7% of total, 122 male, 118
female, aged 36.2±8.7) hospital cleaning staff volunteered to enter the
study. When evaluated according to the educational status; 55.4% were
graduated from primary school and only 54% had been working in the
hospital more than three years. Mean knowledge level was 18.15±3.97
(maximum 24). Knowledge level was not associated with gender,
educational status and duration of working as cleaning staff (p> 0.05)
but mean knowledge level of the staff working in the clinics was found
higher than staff working in administrative sections (p< 0.05). 71.3% had
received a formal education about prevention from NI before starting
working but their mean knowledge level was not different from the others
(p = 0.294). Only 48% and 50% knew the true order (x,y), while cleaning
the patient rooms. 58.8% thought that they could prevent themselves
from NI by hand washing before and after cleaning process, 80.8% stated
they obeyed handwashing rules and 90.4% stated that they used gloves.
Only 48.3% stated that they dried their hands by paper towels.
Conclusion: Measurement of the level of the knowledge of the hospital
cleaning staff may be beneﬁcial for determination of the existing
problems. Periodical well-established educational programmes should be
started to improve the current situation.
O21 Evaluation of a rapid molecular dipstick assay for the direct
detection of methicillin-resistant Staphylococcus aureus in
clinical specimens
U. Eigner, M. Holfelder, U. Wild, C. Bender, M. Kirstahler, A. Turnwald,
W. Witte, M. Weizenegger, A. Fahr (Heidelberg, Wenigerode, DE)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) causes
increasing healthcare problems worldwide. Rapid and sensitive screening
methods for direct detection of MRSA are essential to limit further
spread in the hospital. The purpose of this study was to evaluate the
new molecular dipstick assay GenoQuick® MRSA (Hain Lifescience,
Nehren, Germany) for the direct and speciﬁc detection of MRSA in
clinical specimens.
Methods: The analytical speciﬁcity of the assay was evaluated by
using a subset of 25 MRSA isolates (including SCCmec types I−V);
17 methicillin-susceptible S. aureus (MSSA) and 38 coagulase-negative
staphylocococi (CoNS) of different culture collections. The lower
detection limit of the assay was determined by serial dilutions of MRSA
strains representing SCCmec types I to IV.
The test was evaluated for direct detection of MRSA in clinical swab
specimens. MRSA carriage was analysed by both the standard culture
methods [Chromagar MRSA (Becton Dickinson, Heidelberg, Germany),
Columbia blood agar, trypticase soy broth] and two PCR assays
[GenoQuick MRSA and GenoType® MRSA Direct (Hain Lifescience)].
Both PCR assays were performed directly from the swab and after
overnight incubation in trypticase soy broth. MRSA isolates were
conﬁrmed using a mecA gene and S. aureus speciﬁc PCR. Susceptibility
testing was performed with an automated system (VITEK2, bioMe´rieux,
Nu¨rtingen, Germany).
Results: The lower detection limit of 25 CFU was determined with
serially diluted MRSA strains. For analytical speciﬁcity all MRSA strains
representing SCCmec types I to V were tested positive by the assay. The
MSSA and CoNS were tested negative, respectively.
Of 187 patient specimens tested for clinical evaluation, 24 were identiﬁed
MRSA-positive by culture and by both PCR assays. One specimen was
positive only by PCR. Among the 163 culture-negative specimens, 162
were negative with both PCR assays.
The GenoQuick assay showed a diagnostic sensitivity of 100%, and a
diagnostic speciﬁcity of 99.4%, a positive predictive value of 96% and a
negative predictive value of 100%. Time-to-result for the direct detection
of MRSA from clinial specimens is reduced to 2h 20min with the
molecular GenoQuick MRSA dipstick assay (2h 5min for ampliﬁcation
and 15min for detection).
Conclusions: The GenoQuick MRSA dip stick assay proved to be a
rapid, sensitive and speciﬁc assay for direct detection of MRSA in
clinical swab specimens in 2h 20min.
O22 Throat swabs are necessary to reliably detect carriers of
Staphylococcus aureus
D. Mertz, R. Frei, B. Jaussi, U. Flu¨ckiger, A. Widmer (Basle, CH)
Background: The anterior nares are considered to be the primary
colonisation site of Staphylococcus aureus (S. aureus) and approximately
30% of healthy people carry the bacteria in their anterior nares. However,
recent studies indicate that the throat may be an additional important
site of colonisation (Nilsson P. J Clin Microbiol 2006). Most screening
programmes for S. aureus including methicillin-resistant S. aureus
(MRSA) require a swab from the nose only, and a swab of the throat is
not considered as standard.
Objectives: To determine the frequency of positive S. aureus cultures
with positive samples from the throat and negative from the nares.
Methods: Specimens were obtained with a sterile polyester ﬁber-tipped
swab moistened with sterile saline from the anterior nares (5 rotations
in each anterior nostril), the posterior wall of the pharynx, and the soft
palate. Swabs were transported to the laboratory in a transport tube (M40
Transystem, Copan, Brescia, Italy) and put in selective enrichment broth
(Chapman broth containing brain heart infusion broth with 6% NaCl,
Biomedics, Madrid, Spain).
Results: A total of 905 individuals were screened for S. aureus between
2000 and 2005. Complete data were unavailable from 54 individuals
who were excluded. Overall, S. aureus was isolated in 386/851 (45.4%)
individuals from any site.
Screening results No. of % of overall
Nares Throat individuals positive
pos pos 196 50.8%
pos neg 119 30.8%
neg pos 71 18.4%
386 100%
neg neg 465
Conclusion: Limiting S. aureus screening to the nares fails to identify
18.4% of carriers. Additional cost can be avoided by pooling the
specimens while maintaining the higher sensitivity. Therefore, optimal
screening for S. aureus should include swabs from both the nares and
the throat. This may be even more important if screening is focused on
MRSA carriage.
O23 Impact of hypochlorite disinfection on MRSA rates
A. Mahamat, F. MacKenzie, K. Brooker, D. Monnet, J. Daure`s,
I. Gould (Nimes, FR; Aberdeen, Elgin, UK; Copenhagen, DK)
Objectives:MRSA rates in a hospital in the North-East of Scotland were
signiﬁcantly declining due to a series of infection control interventions.
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These included terminal disinfection of the environment in isolation
rooms and cohort areas by application of 1:1000 sodium hypochlorite
in place of detergent (ECCMID ’06, abstract P1333). We evaluated the
effect of replacing sodium hypochlorite with a standard detergent.
Methods: From January 1997 to May 2006, monthly percentage, non-
duplicate S. aureus clinical cases caused by MRSA were collated.
In February 2005 hypochlorite cleaning solution as replaced by
a standard detergent. Other infection control measures remained
unchanged. Dynamic regression analysis with linear transfer functions
and interrupted time-series analyses were used to estimate the effect to
the intervention.
Results: Previously, MRSA rates wee successfully reduced due to en-
vironmental screening (p = 0.03), use of hypochlorite for environmental
disinfection (p = 0.002), use of alcohol based hand disinfection (p = 0.03)
and patient admission screening (p< 0.01). Stopping the hypochlorite
disinfection was associated with a sudden increase in clinical cases
of MRSA from 10 to 25% over a 6 month period (p = 0.03), with
levels approaching those seen prior to the start of the infection control
programme in 2001 (see ﬁgure).
Conclusions: Stopping hypochlorite environmental disinfection was
strongly associated with an increase in clinical MRSA cases. This work
adds signiﬁcantly to the meagre published evidence that environmental
contamination is important in the spread of MRSA.
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O24 Multi-drug resistant enterococci among Portuguese swine
after growth promoter ban
C. Novais, A. Freitas, T.M. Coque, J.C. Sousa, L. Peixe (Porto, PT;
Madrid, ES)
Objectives: To determine antibiotic-resistant enterococci in Portuguese
piggery samples and to analyse antibiotic resistance genes among these
strains after European growth promoter ban.
Methods: Samples from waste treatment and dry faeces from 2
pig farms in the South of Portugal were studied during 2006.
Samples were plated onto selective Slanetz-Bartley agar with or
without antibiotics. Bacterial identiﬁcation was performed by both
standard biochemical proﬁles and ampliﬁcation of species speciﬁc
genes. Antibiotic susceptibility (12 antibiotics) was determined by
disk diffusion method (CLSI). Detection of genes coding for resis-
tance [vanA, B, C1, C2, ermA,B, C, tetM, L, O,K, S, aac(6′)-Ie-aph(2′′)-
Ia, aph(2′′)-Ib,Ic,Id, aph(3′)-IIIa, vat E] were searched by PCR.
Results: We identiﬁed 84 enterococci (9 E. faecalis, 17 E. faecium,
1 E. gallinarum, 2 E. casseliﬂavus and 55 Enterococcus spp.). Most
isolates showed decreased susceptibility to tetracycline, minocycline,
erythromycin, and quinupristin-dalfopristin (95%, 94%, 80%, 54%,
respectively), and to a lesser extent to high-level of resistance (HLR)
of streptomycin, nitrofurantoin, ciproﬂoxacin, HLR to gentamicin,
chloramphenicol and ampicillin (52%, 33%, 32%, 21%, 11%, 10%).
All were susceptible to glycopeptides. Non-susceptible isolates to
tetracyclines, aminoglycosides and macrolides contained tetM (55%),
tetL (54%), tetM+tetL (32%), tetS (5%), aac(6′)-Ie-aph(2′′)-Ia (89%),
aac(6′)-Ie-aph(2′′)-Ia+aph(3′)-IIIa (47%), ermB (49%). vanC1 was
linked to E. gallinarum, and vanC2 to E. casseliﬂavus as expected.
Conclusions: Although all growth promoters were progressively
removed from EU in the course of the last 10 years, antibiotic multi-
resistant enterococci were isolated in Portuguese piggeries. Whether
persistence of these antibiotic resistant strains is due to selection by
antibiotics or other agents deserves further studies.
O25 Experiences and results from the surveillance programme of
resistance in feed, food and animals in Norway (NORM-VET)
2000–2005
M. Norstro¨m, H. Tharaldsen, M. Sunde (Oslo, NO)
Objectives: The monitoring programme for antimicrobial resistance
in the veterinary and food production sectors (NORM-VET) was
established in 2000. The goals of the programme are to monitor
the antimicrobial resistance situation in feed, food and animals over
time, in relation to the human situation and to the resistance situation
in other countries. Data from NORM-VET could form a basis for
risk assessments and be a tool for targeting interventions and further
to evaluate the effectiveness of such interventions. This study was
performed to summarise the experiences and results obtained during
the ﬁrst six years of the programme.
Methods: The zoonotic agents Salmonella (from feed, animals and
food) and Campylobacter jejuni (from broiler and broiler meat) were
monitored annually. E. coli and Enterococcus spp. (indicator bacteria)
were sampled from various animal species and meat products biannually.
Speciﬁc clinical isolates from the routine diagnostic have been included
biannually. The isolates have mainly been tested using a microdilution
technique (VetMICTM). The minimum inhibitory concentrations were
recorded and analysed in WHONET 5.3. For the categorising of the
isolates as resistant or susceptible epidemiological cut-off values were
applied.
Results: The occurrence of resistance in the monitored species and
products is in an international perspective low and the results from the
ﬁrst six years of the programme show that the situation is stable.
Conclusion: Evaluation of the ﬁrst six years of the programme has
recognized that the relatively low number of isolates of each species
and source included complicates the conclusions possible to draw from
the data, especially evaluating trends over time. Even though the run
costs of the programme has been limited to a minimum, it is still
useful for the purpose of monitoring antimicrobial resistance within a
country as Norway, where the resistance problem in the animal and
food sectors still is at a very low level. It also consists as valuable
source for further research of antimicrobial resistance mechanisms and
development. However, the use of this source to perform risk assessments
is limited as there still is a lack of even more speciﬁc data as for instance
data on usage at animal or farm level.
O26 Comparison of antibiotic susceptibilities of Staphylococcus au-
reus and S. intermedius isolates from dog owners and their dogs
M. Boost, S. Lai, D. Ko, M. O’Donoghue (Kowloon, HK)
Objectives: Antibiotic resistance in veterinary isolates has been reported
to be higher than in human isolates due to frequent empirical use, and
there are concerns about transfer of resistance between staphylococcal
species. S. intermedius is the more common colonising species in dogs,
but S. aureus, including MRSA, may also be present. Case reports
suggest there can be cross-infection between companion animals and
man. Increasing concern about MRSA in the community has led to
recommendations for surveillance of antibiotic resistance in isolates from
companion animals. This study compared antibiotic resistance in isolates
of S. aureus and S. intermedius from dogs and their owners.
Methods: A cross-sectional study of owners and their dogs was
performed using a convenience sample of 800 pairs recruited at six
veterinary practices. Nasal swabs were collected from both owner and
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dog, and held at 4ºC in transport medium until culture within 8 h of
collection. Subjects completed a questionnaire providing demographic
information of owner and dog, and stating if the dog had received
antibiotics within the last 3 months.
Swabs were inoculated onto blood agar and mannitol salt agar and
placed in 5% salt meat broth for enrichment. S. aureus or S. intermedius
were identiﬁed by means of coagulase, VP, polymyxin susceptibility, and
trehalose fermentation. Several colonies of each isolate were tested for
susceptibility to methicillin. Antibiotic susceptibilities were determined
by disc diffusion and interpreted using CLSI guidelines.
Results: S. aureus: 168 owners (25%) and 64 dogs (8.5%) were
colonised. 16 owners and their dogs were concurrently colonised. 6 dogs
(1.3%) and 4 humans (0.5%) were colonised with MRSA. Resistance
to oxacillin, clindamycin, gentamicin, tetracycline and fusidic acid was
signiﬁcantly higher in dog isolates.
S. intermedius: 64 dogs (7.9%) and 8 owners (1.1%) carried
S. intermedius. Four colonised owners had colonised dogs. Methicillin
resistance was not detected. Resistance to chloramphenicol, clindamycin,
tetracycline, and cotrimoxazole was higher in dog isolates. Resistance to
ﬂuoroquinolones and gentamicin was only displayed by dog isolates.
Conclusions: Methicillin resistance was found only in S. aureus, but
resistance to other antibiotics was higher in S. intermedius. Dog isolates
were more resistant than human for both species. Veterinary use of
antibiotics may increase resistance and the risk of transmission of
resistant strains.
O27 European Antimicrobial Susceptibility Surveillance in
Animals (EASSA): Results (2002/2003) for enteric bacteria
from healthy cattle, pigs and chickens from 8 countries
S. Simjee, A. de Jong, M. McConville, R. Bywater, M. Chaton-Schaffner,
E. Deroover, U. Klein, T. Shryock, R. Simmons, K. Smets, F. Stewart,
V. Thomas, M. Valle, H. Marion (Brussels, BE; Edinburgh, UK)
Objectives: Antimicrobial susceptibility to human-use antibiotics
was investigated among the commensal bacteria E. coli (Ec) and
Enterococcus spp. (Ent) from healthy food animals at slaughter across
the EU.
Methods: Colon or caecal content was randomly collected at 4 abattoirs
per country (n = 5 per host). Each herd/ﬂock was sampled once. Ec
and Ent were isolated using standard methods. Antibiotic susceptibility
testing was done by agar dilution (CLSI, M31-A2) against 9 (Ec) and
5 (Ent) antibiotics in a central laboratory. Resistance (CLSI, M100-S16)
was assessed per drug/organism/country.
Results: A total 1465 Ec were recovered (cattle n = 490, pigs n = 494,
chickens n = 481). Mean resistance (%) for Ec was: ampicillin (A) 3,
29, 53; cefepime 0, 0, 0; cefotaxime 0, 0, 0.4; ciproﬂoxacin 1, 0.4,
6; chloramphenicol 2, 16, 15; colistin 0, 0.4, 0; gentamicin (G) 1, 2,
2; tetracycline 8, 66, 65; and trimethoprim-sulfamethoxazole 4, 42, 52
respectively. For Ec, Italy and Spain consistently showed the highest
resistance; Denmark showed the lowest. A total of 718 Ent isolates were
recovered, comprising 356 E. faecium, 83 E. faecalis and 279 other
species including E. durans, E. hirae and E. casseliﬂavus. All Ent but one
bovine isolate, were susceptible to linezolid. For E. faecium resistance to
A and G was 0−2%; vancomycin (V) resistance amounted to 1.9 to 3.5%,
whereas resistance to quinupristin/dalfopristin (Q/D) combination varied:
8% (cattle), 19% (pigs) and 20% (chickens). Though low prevalence of
E. faecalis limited conclusions, particularly in chickens (n = 6), G and V
resistance was low in cattle and pigs (0–11%), resistance to Q/D was
very high (46 and 83%, respectively). In the other Ent species, resistance
among the 3 hosts to G and V was low (0−1.6%). Resistance to A was
absent except in chickens: 9.8%. Q/D resistance was among the highest:
5−9% for livestock hosts; 26% in poultry. Striking differences among
countries were absent for Ent.
Conclusion: This pan-EU survey, with uniform methodology, shows that
antimicrobial resistance among enteric commensal bacteria at slaughter
was variable. For Ec, prevalence of antimicrobial resistance varied for
older antimicrobials and between countries but resistance to newer
medically important antimicrobials was absent or very low. With respect
to Ent, antimicrobial resistance rates varied for quinupristin/dalfopristin,
but resistance was absent or very low for other antimicrobials including
linezolid and vancomycin.
O28 Demography and antibacterial susceptibility of community-
acquired respiratory tract infection pathogens in Year 6 vs
Year 5 of the PROTEKT surveillance programme
D.J. Farrell, C. Couturier, D. Felmingham (London, UK; Paris, FR)
Objectives: Patterns of antibacterial resistance among community-
acquired respiratory tract infection (CARTI) pathogens vary among
countries. PROTEKT is a global surveillance study monitoring
antibacterial resistance among CARTI pathogens. We report here the
results of the sixth year of the PROTEKT study (Y6: 2004–2005) and
changes compared to Y5 (2003–2004).
Methods: Clinical isolates of Streptococcus pneumoniae (SPN) and
Haemophilus inﬂuenzae (HI) from respiratory samples were submitted
from 93 centres from 28 countries. MICs and susceptibilities were
determined according to CLSI guidelines. Genotyping was performed
to deﬁne macrolide resistance mechanisms. Frequencies were compared
for Y5-Y6 common sites using c2 or Fisher’s exact tests as appropriate
with a = 0.05.
Results: In Y6, a total of 5182 SPN and 1609 HI were collected. SPN/HI
distribution by site were: sputum & BAL (55%/72%), blood (19%/2%),
nasopharynx (10%/13%), ear (10%/7%), sinus (6%/6%). The distribution
of specimens by age groups were: 2 y 12%, 3−14 y 14%, 15−64 y 44%,
and >64 y 30%. SPN penicillin and erythromycin resistance (PR and ER)
prevalences were 19% and 35% respectively [20% erm(B), 9% mef(A),
5% erm(B)+mef(A), and 1% ribosomal mutation]. SPN with both PR
and ER was >25% in Far East, South Africa and France and >15%
in Hungary, Poland, US and Australia. Signiﬁcant increases in PR were
seen in Poland and China. Falls in PR were seen in Italy, Spain and Japan.
Erythromycin resistance was stable in all countries except Germany and
Venezuela (decrease). SPN with multiple drug resistance (>2 antibiotic
classes) increased in Poland and decreased in Russia. Prevalence of
isolates resistant to at least 5 antibiotic classes increased in China. Beta-
lactamase (BL) production in HI was 14% overall, while 2.9% of HI
were BL negative and ampicillin resistant (BLNAR). BL production
frequencies were stable in all countries except South Africa (increase).
Telithromycin showed a sustained activity against both SPN (99.6%
susceptible, MIC50/90 0.015/0.25mg/L) and HI (99.3% susceptible,
MIC50/90 1/2mg/L).
Conclusions: Resistance to several ﬁrst-line antibacterials is a continuing
problem worldwide. The last 2 years of PROTEKT indicate changing
patterns of resistance in several countries. Telithromycin exhibited
signiﬁcant in vitro activity against the principal CARTI pathogens,
including strains resistant to other agents.
O29 Community-acquired respiratory tract infections in Europe
caused by S. pneumoniae, H. inﬂuenzae and Moraxella
catarrhalis: report from 10 years of monitoring by the
SENTRY Program
R. Jones, M. Stilwell, T. Fritsche, H. Sader (North Liberty, US)
Objectives: To determine the antimicrobial susceptibility (S) patterns for
S. pneumoniae (SPN), H. inﬂuenzae (HI) and M. catarrhalis (MCAT)
when tested by reference CLSI methods using samples collected from
1997–2006 in 13 European (EUR) nations. Trends in S and the
occurrences of well deﬁned resistance (R) mechanisms were assessed.
Methods: A collection of community-acquired respiratory tract infec-
tions (CA-RTI) pathogens (6,753 SPN; 6,280 HI; and 1,908 MCAT for
all years) were annually forwarded to a central reference laboratory for S
test processing and conﬁrmation of organism identity. All antimicrobials
were tested by CLSI methods, results interpreted by M100-S16 (2006)
and quality control rigidly applied to assure accuracy. Analysis of trends
used mean S rates by nation for the initial and last 3 years sampled.
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Thirty sites and drugs were monitored each year for one-decade. Beta-
lactamase (BL) was measured with the nitroceﬁn test.
Results: SPN strains in EUR were very S to amoxicillin ± clavulanate
(A/C; 96.9%), cefepime (FEP; 97.1%), ceftriaxone (CRO; 97.8%),
respiratory ﬂuoroquinolones (FQ; 99.0%), rifampicin (RF; 99.2%),
tigecycline (98.9%) and vancomycin (100%). Penicillin (PEN)-R (29.9%
non-S) and erythromycin (ERY)-R (28.5% non-S) continues to evolve,
differing among nations (range, 3.3% [Germany] to 60.6% [Israel] for
PEN; range, 4.1% [Sweden] to 52.9% [France] for ERY). Trends toward
greater PEN- and ERY-R were noted in 7 and 12 countries, respectively.
FQ-R (0.9% overall) indicated by levoﬂoxacin MIC at 4mg/L was
>1% in Belgium, Italy (7.8%; clonal), Spain, UK, Israel and Ireland.
MCAT had a uniform BL-production rate (95%, range 92–100%) across
EUR and macrolides (MIC90, 0.25mg/L), tetracyclines (2mg/L),
FQs (0.06mg/L) and enzyme stable b-lactams remained very potent.
BL(+) rates in HI ranged from 3.6% (Germany) to 23.9−30.8% (France,
Israel). BLNAR HI strains (Table) were found in 5 nations (range,
0.5−1.7%) with an overall average of only 0.3%. A/C-R was rare (0.4%)
and noted in 3 nations; highest (5.5%) in Spain. HI-S rates of >90% were
documented for A/C, azithromycin, CRO, FQs, RF, chloramphenicol, oral
cephems and tetracyclines.
Key R patterns among CA-RTI pathogens (SENTRY Program, 1997–
2006)
Country R rates (%)a
PNSPa ENSPa BLP-HI BLNAR BLP-MCAT
Belgium 14 29 16 1.7 97
France 48 53 31 0.8 95
Germany 3 19 4 0 92
Greece 60 52 12 0 97
Ireland 33 21 13 0 93
Israel 61 27 24 0 100
Italy 12 48 4 1.2 96
Poland 29 27 8 0 97
Spain 41 38 17 1.2 96
Sweden 6 4 12 0 96
Switzerland 23 22 12 0 95
Turkey 46 25 5 0.5 100
UK 3 7 16 0 93
All EUR 30 28 16 0.3 95
aAverage of last 3 years of participation. PNSP = PEN-non-S SPN,
ENSP = ERY-non-S SPN; BLP = b-lactamase production, BLNAR =
b-lactamase-negative AMP-R.
Conclusions: The SENTRY Program has consistently monitored EUR
CA-RTI pathogens and observed relatively stable R patterns among HI
and MCAT but variable rates among nations. SPN R-rates for PEN,
macrolides and to a lesser extent FQs continues to evolve at varying
velocities among the 13 countries sampled from 1997–2006. These
results corroborate data reported by EARRS for 2004.
O30 Carriage of quinolone-resistant Escherichia coli among
healthy Israeli Arab children attending daycare centres in
northern Israel
A. Athamna, K. Muhsen, M. Athamna, D. Roth, A. Spungin-Bialik,
T. Halperin, D. Cohen (Kfar Qaraa, Tel Aviv, Tel Hashomer, IL)
Objectives: To determine the rate, characteristics and risk factors of
intestinal carriage of nalidixic acid (NA) resistant E. coli (E. coli NAR)
in healthy children who have never received quinolones as antibiotic
treatment.
Methods: Two consecutive surveys, 10 months apart, were carried
out to determine the prevalence of E. coli NAR in a cohort of
healthy children aged 3−5 years from 9 Day Care Centers (DCC)
in 3 Arab villages of northern Israel. Parents were interviewed on
demographic and socioeconomic characteristics and medical history
of the children and their families. Stool samples obtained from the
cohort of children and from a sub-sample of siblings and mothers were
inoculated onto MacConkey agar plates, containing NA (32mg/mL). The
NA Minimal Inhibitory Concentration (MIC) was determined by the
broth microdilution technique. The E. coli NAR strains were examined
for ciproﬂoxacin resistance. Selected strains were evaluated for efﬂux
pumps activity and for point mutations in the gyrA and parC genes.
Uni- and multivariable analyses were used to identify risk factors of
E. coli NAR carriage.
Results: We found that 17.2% (34/198) of the children carried E. coli
NAR in the ﬁrst survey and 42.3 (85/208) in the second. Among the
children examined in both surveys (n = 147), 9.4% harboured E. coli
NAR in the ﬁrst survey but became negative in the second while 38.5%
children found negative in the ﬁrst survey carried E. coli NAR in the
second. E. coli NAR were isolated in both screenings among 11 (9.4%)
children. 21% and 34% of the E. coli NAR strains were also resistant
to ciproﬂoxacin in the ﬁrst and second surveys, respectively. Persistent
resistance to NA was associated with an increase in MIC, number of
mutations in the gyrA and parC genes and presence of efﬂux pumps.
Acquisition of resistance to NA was signiﬁcantly higher in two of the
DCCs located in one of the 3 villages. The carriage of E. coli NAR
was not associated with the child’s age or gender, use of antibiotics, or
carriage of E. coli NAR among mothers and siblings.
Conclusions: The lack of evidence for intra-familiar spread of E. coli
NAR and the signiﬁcant acquisition of E. coli NAR in 2 speciﬁc DCCs
suggest that other means of transmission such as the food or waterborne
routs may explain the high carriage rate of E. coli NAR. Persistent
carriage of E. coli NAR is of concern in view of the association with
an increase in both phenotypic and genetic markers of resistance to
quinolones.
O31 Antimicrobial resistance of Neisseria gonorrhoeae in the
Russian Federation in 2006
A.A. Kubanova, N.V. Frigo, T.V. Priputnevich, S.V. Sidorenko (Moscow,
RU)
Objectives: Antimicrobial resistance in Neisseria gonorrhoeae (Ng)
remains an important issue affecting treatment recommendations. The
present study was designed to ascertain the current status of antimicrobial
susceptibility patterns of Ng in different regions of Russia.
Methods: Isolates of Ng were obtained from patients with acute
gonorrhoea who visited sexual transmitted disease clinics in 36 regions
of Russia from March through October 2006 in a frame of the Russian
National Program on Control and Prevention of sexually transmitted
infections. The susceptibility to ciproﬂoxacin, penicillin, ceftriaxone,
spectinomycin and tetracycline, was determined by the agar dilution
method according to CLSI. Ng ATCC 49226 was used for quality
control. Beta-lactamase production was detected by nitroceﬁn disks
(Ceﬁnase; BBL Microbiology Systems).
Results: Among 463 isolates included in the study 73.4% demonstrated
resistance to tetracycline, and 73.8% to penicillin; b-lactamase produc-
tion was detected in 2.8% of isolates; all isolates were susceptible to
ceftriaxone. Prevalence of resistance to ciproﬂoxacin varied in different
geographical regions from 45.2% (Volga region) to 100% (Ural region);
in total 45.3% of isolates demonstrated high level of resistance, and
5.1% an intermediate level. Amino acid substitutions in GyrA (S91F,
D95G), and ParC (S87R) were the main mechanisms of resistance to
ciproﬂoxacin. A high level of resistance to spectinomycin was detected
in South region: 19.2%; in the Central, East, North-West, Siberia and
Volga regions the rates of resistance varied from 2.9% to 8.6%.
Conclusions: Guidelines for antimicrobial treatment of gonorrhoea were
proposed as a result of the present study. In the majority of regions of
Russia treatment options are limited to ceftriaxone, and in some regions
to ceftriaxone and spectinomycin.
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O32 Increasing prevalence of glycopeptide hetero-resistant
Staphylococcus aureus from the Detroit Metropolitan Area
over a 20-year period (1986–2006)
M. Rybak, J. Chin, K. Lau, H. Sader, R. Jones (Detroit, North Liberty,
US)
Background: Glycopeptide hetero-resistance has been associated with
clinical failures to vancomycin (VAN) treatment. Recent previous
prevalence studies have reported rates as low as 0.7% and as high as
27%. We evaluated the prevalence of hGISA in methicillin-resistant
S. aureus (MRSA) isolates collected from the Detroit metropolitan area
from 1986–2006.
Methods: 1,351 MRSA clinical isolates were screened for hetero-
resistance against VAN and teicoplanin (TEIC) using a modiﬁed Etest
method with a 48 h incubation period and a 2 McFarland inoculum
density as described by Walsh et al. (J. Clin. Microbiol. 2001; 39: 2439–
2444). Isolates that demonstrated heteroresistance to either vancomycin,
teicoplanin or both were considered hGISA. To conﬁrm accuracy of the
modiﬁed Etest method in detecting hGISA, a subpopulation analysis
(PAP) with Mu3 as a control strain were performed on all hGISA strains
determined by the Etest method. PAP was performed with an inoculum
of 109 CFU/mL on brain heart infusion agar plates containing 0, 0.5,
1, 1.5, 2, 3, 4, and 8mg/L VAN and TEIC. Colonies were counted and
plotted against VAN and TEIC concentrations which was then used to
calculate an area under the curve (AUC). The criteria used for detection
of hGISAs were AUC ratios of 0.9.
Results: We report an increasing prevalence rate of hGISAs from
4% between the years 1986–1993 to 25.1% between 2003–2006. The
accuracy of the modiﬁed Etest method with PAP was found to be
83.3%. Adjusting for the accuracy of the modiﬁed Etest method yielded
prevalence rates of ranged from 3.3% to 21% for hGISA between the
years 1986–1993, 1994–2002, and 2003–2006, which still demonstrates
a signiﬁcant increase.
Conclusions: The observed prevalence rates of hGISAs represented a
substantial increase in the isolates collected over a 20-year period. Based
on the inability of current clinical screening methods to detect hGISA,
these ﬁndings may have serious implications on treatment outcomes with
glycopeptides.
O33 Activity of linezolid against a worldwide collection of
uncommonly isolated Gram-positive organisms (3,251 strains)
R. Jones, J. Ross, M. Stilwell (North Liberty, US)
Objectives: To assess the worldwide spectrum of linezolid when tested
by CLSI reference methods (M7-A7, 2006) against species of Gram-
positive cocci that are rare in occurrence (<1%) and are not within
the indicated organisms approved by regulatory agencies (US-FDA or
EMEA). Using a large surveillance platform (SENTRY Antimicrobial
Surveillance Program, 1997–2006), these organisms were tested to
provide knowledge of oxazolidinone potency and emerging resistance (R)
rates to ensure potential efﬁcacy when needed for chemotherapy of
serious infections.
Methods: Linezolid was tested against 3,251 strains distributed among
9 major bacterial groups: Aerococcus spp. (22), Bacillus spp. (202),
Corynebacteria (342), various enterococci (6 species; 378), Listeria
monocytogenes (137), Micrococcus luteus (29), Rothia mucilaginosus
(18), beta-haemolytic (BST; 3 serotypes, 865) and viridans group
streptococci (VGS; 12 spp.; 1,258). All strains were tested by CLSI
broth microdilution methods with appropriate supplements; all quality
control results were within published CLSI limits (M100-S16, 2006).
Linezolid-R strains (MIC, 8mg/L) were processed by PCR for target
site mutations.
Results: Generally, linezolid was very active against all 32 species
examined with 4 strains (0.12%) having a MIC at 4mg/L (E. avium
[1], E. casseliﬂavus [2], E. gallinarum [1]) tested and only 1 R (S. oralis;
MIC at >8mg/L) isolate having a proven G2576T mutation. Streptococci
(2,123) overall had a MIC90 of 1mg/L (range, 1−2mg/L), and the 378
rarely cultured enterococci had a MIC90 of 2mg/L (range, 2mg/L).
Corynebacterium spp. (342) were most susceptible (S) to linezolid
(MIC50, 0.25mg/L) while enterococci and Listeria were 4- to 8-fold
less S (MIC50, 2mg/L). Evaluations of R trends in those species failed
to identify any MIC creep over the seven years monitored (data not
shown).
Table. Linezolid potency against uncommonly isolated Gram-positive organisms
(3,251).




0.25 0.5 1 2 4 50% 90%
Aerococcus spp. (92) 4.5 31.8 63.6 100.0 – 1 2
Bacillus spp. (142) 4.9 31.7 97.2 100.0 - 1 1
B. cereus (60) 3.3 30.0 98.3 100.0 - 1 1
Corynebacterium spp. (238) 68.2 92.4 99.6 100.0 0.25 0.5
C. amycolatum (11) 100.0 - - - - 0.25 0.25
C. jeikium (59) 67,8 98.3 100.0 - - 0.25 0.5
C. pseudodiphtheriﬁcum (11) 36.4 90.9 100.0 - - 0.5 0.5
C. striatum (25) 88.0 100.0 - - - 0.25 0.5
Enterococcus avium (116) 0.0 4.3 52.6 99.1 100.0 1 2
E. casseliﬂavus (65) 0.0 0.0 23.1 96.9 100.0 2 2
E. durans (49) 2.0 8.2 32.7 100.0 - 2 2
E. gallinarum (119) 0.0 1.7 30.3 99.2 100.0 2 2
E. hirae (16) 0.0 0.0 37.5 100.0 - 2 2
E. rafﬁnosus (13) 0.0 0.0 46.2 100.0 - 2 2
Listeria monocytogenes (137) 0.0 0.7 29.2 100.0 - 2 2
Micrococcus luteus (29) 3.4 75.9 100.0 - - 0.5 1
Rothia mucilaginosus (18) 16.7 83.3 94.4 100.0 - 0.5 1
Streptococci (2,123) 4.5 39.5 96.9 99.9 99.9 1 1
Conclusions: Linezolid, the ﬁrst oxazolidinone to be used in clinical
practice, has maintained excellent activity against these rare Gram-
positive species as well as frequently cultured and indicated species
S. aureus, coagulase-negative staphylococci and enterococci (E. faecium,
E. faecalis). All but 5/1 isolates were inhibited by 2/4mg/L (>99.8%
S) of linezolid if CLSI breakpoints were applied to the testing of these
species. Continued R surveillance should be considered for linezolid
especially for these rarely isolated Gram-positive species as this agent
is more widely used.
Community-acquired methicillin-resistant
Staphylococcus aureus
S41 Global epidemiology of CA-MRSA
J. Etienne, A. Tristan, M. Bes, H. Meugnier, G. Lina, M-E. Reverdy,
F. Vandenesch (Lyon, FR)
Objective: Community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) were described at the beginning of this decade
and since 2003 an impressive worldwide spread of Panton Valentine
leukocidin (PVL)-positive CA-MRSA clones have been observed. The
objective is to characterise the PVL-positive clones spreading presently
all over the world.
Methods: A collection of 469 isolates of PVL-positive CA-MRSA
isolates collected from around the world between 1999 and 2006 was
characterised by the French National Reference Center for Staphylococci.
Results: This study shows that:
i. The continent-speciﬁc clones of PVL-positive CA-MRSA described
in 2003 have now spread to other continents. Schematically in 2003,
ST80 was detected in Europe, ST8 and ST1 in the USA, and ST30 in
Oceania. In 2006, intercontinental exchanges of several clones were
observed: the ST8 clone (USA300) from the USA towards Europe;
the ST1 clone (USA400) from the USA towards Europe and Asia;
the ST59 clone (USA1000) from the USA towards Asia; the ST80
clone from Europe towards Asia.
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ii. On a given continent, PVL-positive CA-MRSA have spread from
country to country. For instance, in Europe, PVL-positive CA-MRSA
of ST80 were recently detected in Slovenia, Romania and Croatia.
iii. New PVL-positive CA-MRSA clones are emerging on different
genetic backgrounds. While most of the clones described in 2003
had an agr3 background, the newly described clones are agr1 or agr2.
Clone ST22 (agr1) has been found in Europe only and clone ST377
(agr1 with a type V SCCmec) was reported simultaneously in Europe
and Australia.
iv. PVL-positive CA-MRSA, which were initially susceptible to most
antistaphylococcal antibiotics, have acquired new antibiotic resistance
determinants, to gentamicin and oﬂoxacin for instance.
v. The prevalence of PVL-positive CA-MRSA varies considerably from
one continent to another (high for instance in the USA (~50%),
Greece and Algeria, low in most European countries).
vi. PVL-positive CA-MRSA are gradually causing an increasing number
of hospital-acquired infections in countries where their prevalence is
high.
Conclusion: To counter this emerging global threat to public health,
systematic surveillance of both hospital and community isolates is
required, together with measures designed to limit their spread.
S42 The impact of community-acquired MRSA in low-prevalence
countries
R. Skov (Copenhagen, DK)
In the Nordic countries and the Netherlands, nosocomial MRSA has
successfully been contained for more than 25 years keeping the
prevalence of MRSA at <1% in these countries. This has been
accomplished by enforcing preventive contact isolation of all hospitalised
patients suspected or conﬁrmed as MRSA positive. This has been
facilitated by the fact that in these countries the predominant risk factor
for patients for MRSA acquisition was hospitalisation abroad, making
these at-risk patients relatively easy to identify. Additionally, secondary
cases seldom arose after hospital discharge.
The recent change in epidemiology where transmission of MRSA
increasingly occurs outside hospitals has changed the situation, and
an increasing number of MRSA has been reported in all the above
mentioned countries.
Since the mid-1990s the number of new cases of MRSA in Denmark has
increased by 10-fold. The majority of these MRSA has been identiﬁed
in primary healthcare (community onset) and, in approximately 33% of
the cases, the patient had had no connection with healthcare institutions
for at least one year prior to the diagnosis. These cases have therefore
been considered as community acquired (CA-MRSA).
CA-MRSA infections have especially been reported from children and
younger adults. Skin and soft tissue infections dominate and represent
approximately 90% of the cases. Approximately 30% of CA-MRSA
cases have been reported in persons with another ethnicity than Danish.
This could indicate that there is a continued inﬂux of MRSA from
high prevalence areas into Denmark. Strains belonging to the ST80-
IV complex have been the most frequent cause of CA-MRSA in
Denmark, however, an increasing diversiﬁcation has recently been
observed including almost all strains known as associated with CA-
MRSA.
During the same time period the number of MRSA diagnosed in hospitals
also increased. This has happened despite continued use of contact
isolation of MRSA positive patients during. Hospitalisation of MRSA
carriers not identiﬁed on admission due to lack of risk factors is probably
one important factor responsible for the increased number of nosocomial
MRSA in Denmark.
An increase in the prevalence of MRSA outside hospitals including in
otherwise healthy persons, is thus of great concern as this not only gives
rise to CA-MRSA infections but also inevitably will increase the risk of
nosocomial MRSA infec-tions and outbreaks.
In order to keep Denmark as a low prevalence country we believe that
MRSA should be contained and eradicated not only in hospitalised
patients but also when diagnosed in the community. This has lead to new
national guidelines for preven-tion and eradication of MRSA including
making both carriage and infection with MRSA mandatory reportable.
S43 How, when and whom to screen
K. Christiansen (Perth, AU)
The ﬁrst question to ask when considering any screening programme
for the identiﬁcation of CA-MRSA carriage is why? The importance
of epidemiological data cannot be underestimated. Data on prevalence
can inform empirical therapy requirements or help in the design of
intervention strategies. Prevalence can be established for the population
in general, or, speciﬁc subgroups such as children, military personnel,
indigenous or disadvantaged populations can be targeted. Community
intervention measures similar to the ‘search and destroy’ techniques
used in hospitals would require large-scale screening. A narrower
approach concentrating on high-risk groups to enable programmes such
as education on hygiene to reduce transmission would allow a more
targeted screening programme. A second more pragmatic area for
screening is on admission or during hospitalisation. In some areas in
the world there is a blurring of the boundaries of CA-MRSA and
HA-MRSA. These organisms have now been reported as a cause of
hospital acquired bacteraemia, surgical and prosthetic joint infection and
to colonise neonates and adult patients in hospitals. Targeted screening
of high-risk patients or all patients on entry into high-risk units are
strategies to prevent CA-MRSA from becoming endemic in hospitals.
Screening to control recognized outbreaks entails identiﬁcation of the
reservoir to enable appropriate isolation, cohorting and decolonisation
measures. The value of screening healthcare workers for carriage of
CA-MRSA has yet to be established.
How to screen is the next question. Which site(s) give the best
yield? Which laboratory method should be used? The ideal test
would have high negative and positive predictive values, be rapid,
inexpensive, applicable to the routine laboratory, and have high through
put capabilities. Currently used tests are traditional microbiological
culture and identiﬁcation methods, use of selective media including
various types of CHROMagar and molecular techniques using real time
PCR. The requirement for broth ampliﬁcation increases the sensitivity for
some of these methods but also increases the time to identiﬁcation. There
are many different CA-MRSA clones in the world, in Western Australia
alone there are over 40 different multi locus sequence (MLST)/SCCmec
CA-MRSA clones. Any molecular test must therefore have the ability
to identify all clones in diverse regions of the world.
The last questions are when and whom to screen. The answer is very
much dependent on the purpose of the screening. The range can be from
large-scale periodic population screening for epidemiological purposes
to continual hospital unit, high-risk patient screening.
There are no established guidelines or recommendations for screening
for CA-MRSA. Many questions have yet to be answered particularly,
whether control of transmission in the community is possible. By looking
at what evidence is available we can move a step closer to control of
this very signiﬁcant community pathogen.
S44 Optimisation of control strategies and treatment
S. Cosgrove (Baltimore, US)
Rates of infections caused by CA-MRSA continue to increase, causing
over 50% of skin and soft tissue infections seen in the emergency
department in a recent report. Strategies for control of CA-MRSA in
patients and their families include use of infection control techniques in
the household as well as decolonisation with mupirocin, chlorhexidine,
and antibiotics in some cases. Given that CA-MRSA has been now
been implicated in healthcare-associated infections, efforts to reduce
the spread of this organism within the healthcare environment are
also important and include appropriate hand-hygiene, isolation, and
environmental decontamination. Incision and debridement remains
critical in the management of most CA-MRSA infections. The use of
antibiotics is indicated in many CA-MRSA infections and therapeutic
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options include older agents, such as clindamycin, trimethoprim-
sulfamethoxazole, tetracyclines, and rifampin, and newer agents such
as linezolid. In addition, new agents are in development.
Pathogenesis and epidemiology of invasive
pneumococcal infections
S45 Recent discoveries in the pathogenesis of pneumococcal
pneumonia
D.H. Dockrell (Shefﬁeld, UK)
Pneumococcal pneumonia is a pathogen of global signiﬁcance and
represents a leading cause of infection-related mortality at all ages.
Recent developments in the ﬁeld of pneumococcal pathogenesis
reﬂect signiﬁcant developments in both genomics and proteomics.
The breadth of microbial genetic diversity is increasingly being
recognized. Our understanding of the importance of traditional virulence
factors such as polysaccharide capsule, pneumolysin and generation of
hydrogen peroxide is evolving while important roles for factors such
as pneumococcal pili are emerging. Genetic screens are identifying
increasing roles for previously poorly characterised proteins involved
in metabolism and transport of key molecules. The importance of the
physical state of the bacteria in different tissue compartments is also
becoming evident. An improved range of models of various aspects
of infection ranging from colonisation and sub-clinical infection to
fulminant pneumonia and invasive disease are allowing assessment of
both microbial and host factors central to disease pathogenesis. The
range of receptors involved in the innate response to pneumococci in
the respiratory tract is starting to be appreciated and includes Toll-
like receptors and receptors primarily involved in the phagocytosis
of bacteria. The interaction between soluble factors and the resident
phagocytes of the lung is being clariﬁed and the complexity of cytokine
networks involved in the innate host response is being elucidated.
Important roles for T-lymphocytes, Natural Killer cells and dendritic
cells in the response to pneumococci are being identiﬁed. Furthermore
our understanding of the regulation of the inﬂammatory response and of
the signiﬁcant role of apoptosis in the regulation of the inﬂammatory
response has lead to important insights into how cell survival and
outcome of infection are closely linked. These observations are enabling
a more scientiﬁc interpretation of many of the central clinical features
of pneumococcal pneumonia and may encourage novel approaches to
therapy to improve disease responses.
S46 Invasive disease potential of pneumococcal clones carried by
children
H. de Lencastre, R. Sa´-Lea˜o, M. Ramirez, J. Melo-Cristino (Oeiras,
Lisbon, PT)
Streptococcus pneumoniae (the pneumococcus) continues to be a leading
cause of morbidity and mortality worldwide particularly among young
children, the elderly and the immunocompromised of all ages. Infection
is preceded by colonisation of the nasopharynx, which is the ecological
niche of pneumococci. In most individuals colonisation is asymptomatic
and does not evolve to disease. The carrier state is more frequent in
young children and may reach over 70% in some populations such
as those attending day-care centres. Indeed, this latter group has been
found to be a major reservoir of pneumococci playing a key role on the
ampliﬁcation and transmission of the bacteria to other individuals. Of
interest, several drug-resistant clones internationally disseminated have
been found to be frequently carried by this population. In recent years,
there has been some debate on the relative contribution of serotype and
genetic background to the invasive disease potential of pneumococcal
strains. We will present a study that addresses this question. The study
was conducted in Portugal and results from the detailed comparison of
two large collections of pneumococcal isolates: a group of over 450
invasive disease isolates and a group of over 750 colonisation isolates
collected during the same time period which were characterised in
detail by antibiogram, serotype, PFGE macro-restriction proﬁles, and
multilocus sequence typing. The invasive disease potential of serotypes
and clones will be discussed.
S47 Epidemiology of invasive pneumococcal infections
A. Brueggemann (Oxford, UK)
Pneumococci cause a spectrum of diseases in humans, from reasonably
mild diseases like sinusitis and conjunctivitis to potentially life-
threatening diseases like meningitis and bacteraemia. The current
conjugate vaccines are ideally aimed at protecting against all pneumo-
coccal disease, but have been very successful at preventing invasive
pneumococcal disease. Understanding invasive disease epidemiology,
both preceding vaccine implementation and after vaccine introduction, is
crucial to the design and development of future vaccines. Several recent
studies have shown that pneumococcal serotypes differ in their invasive
disease potential, and this has particular relevance for the selection of
serotypes to include in future conjugate vaccines. It is also essential to
understand the serotype-speciﬁc changes that have occurred subsequent
to conjugate vaccine implementation in the USA, as a model for what
might occur post-vaccine implementation in other countries.
S48 Recent discoveries in prevention of pneumococcal disease
K. Klugman (Atlanta, US)
The recent history of pneumococcal disease prevention is dominated
by the development in the 1990’s of conjugate pneumococcal vaccine
for administration to infants, and its implementation starting in 2000
in the USA. The vaccine as currently formulated affords protection
against invasive pneumococcal disease (IPD) due to the 7 most common
serotypes causing IPD among children less than 2 years of age prior
to vaccine introduction in the USA. This formulation is not optimal
for many developing countries where serotypes such as 1 and 5 are
important. Global, second generation vaccines therefore include at least
10 serotypes. The importance of prevention of pneumococcal disease
extends beyond IPD to pneumonia, meningitis, otitis media, prevention
of antibiotic-resistant infections, and even prevention of mortality in
young infants. Each of these presents speciﬁc challenges. The vaccine
has been shown to prevent between 25% and 37% of all cause X-ray
conﬁrmed pneumonias and this implies a level of protection against
pneumococcal pneumonia due to vaccine serotypes in excess of 70%.
This reduction in pneumonia has translated into a reduction in all-
cause mortality due to the vaccine of 16% in rural Africa. The major
preventable burden of disease in Africa may be among HIV infected
children where the vaccine has also been shown to reduce pneumonia
burden. An innovative aspect of the vaccine is the fact that it may
reduce the pneumococcal super infections that follow viral respiratory
infections, such as inﬂuenza, and conjugate vaccination of children may
thus be a useful adjunct to pandemic inﬂuenza planning preparedness.
The interruption of carriage of vaccine serotypes has been shown to
reduce IPD in adults in the USA due to herd immunity so the population
beneﬁt in an inﬂuenza pandemic may extend beyond protection just of
immunised children. Herd immunity has also recently been shown to
protect young un-immunised infants from IPD. Conjugate vaccine has
had little impact on all cause otitis media in randomised trials, but
post-marketing studies in the USA suggest that healthcare utilisation
for otitis episodes has reduced signiﬁcantly post vaccine introduction
suggesting a major role for herd immunity and allowing physicians
to feel more comfortable in a “wait and see” attitude to otitis once
the prospects of signiﬁcant complications due to the pneumococcus are
likely to be rare. The conjugation of pneumococcal polysaccharides to
Haemophilus inﬂuenzae protein D has allowed the development of a
more efﬁcacious vaccine against otitis media. There has been a dramatic
reduction in antibiotic resistance among vaccine serotypes causing IPD in
the USA, in both children and adults, but resistance, driven by continuing
high levels of antibiotic use, is now selecting resistance in non-vaccine
S12 17th ECCMID / 25th ICC, Oral presentations
serotypes. In particular, multiresistant global clones of serotype 19A
are now dominant in the USA and a 13-valent vaccine formulation
including serotype 19A is under development. The implementation of
immunisation programmes including conjugate pneumococcal vaccine
to infants in European countries affords the opportunity to monitor the
impact on all of these health outcomes in both children and adults.
Infective endocarditis – time for change?
S50 Treatment options for infective endocarditis: new drugs for
bad bugs?
R. Corey (Durham, US)
In the USA infections due to both hospital and community-acquired
methicillin resistant Staphylococcus aureus (MRSA) are increasing
rapidly in both frequency and severity. As a result new treatment options
are badly needed.
This presentation will ﬁrst address the role of traditional therapy focusing
on the gradual development of increasing resistance to vancomycin
among MRSA. Next it will focus on alternative oral therapies such
as clindamycin, cotrimoxazole and minocycline and their role in the
treatment of community-acquired MRSA, an organism that has displaced
“traditional” MRSA in many venues. The efﬁcacy of the newly approved
antibiotics linezolid, daptomycin, and tigecycline will be addressed
through the presentation of the results of large phase 3 clinical trials
in complicated skin and skin structure infections, hospital-acquired
pneumonia, and bacteraemia. Discussion will focus on the efﬁcacy
of these agents in the MRSA subgroups. Finally, the efﬁcacy of
antibiotics in development will be presented again focusing on the
MRSA subgroups from phase 2 and 3 studies. These antibiotics will
include dalbavancin, telavancin, oritavancin, iclaprim, ceftobiprole and
ceftaroline.
As the epidemiology of staphylococcal infections changes new
therapeutic agents are becoming available to clinicians. Therapeutic
utility will depend on understanding the unique characteristics and
efﬁcacy of the new agents in clinical trials in order to clearly understand
their role in the new therapeutic paradigms.
New tricks for old drugs
S53 Recent and emerging uses of long-acting tetracyclines
H.M. Lode (Berlin, DE)
Antimicrobial resistance is a serious problem with increasing strains
of bacteria becoming resistant to many or all available antibiotics.
Tetracyclines were already introduced 50 years ago but have undergone
a considerable resistance development in nosocomial and community-
acquired pathogens. In June 2005, a minocycline derivative, the new
glycylcycline antimicrobial tygecycline, was approved by the FDA for
treatment of complicated intra-abdominal and complicated skin and skin-
structure infections. Tigecycline, a bacteriostatic agent, binds to the
30S ribosome unit, blocks entry of amino-acyl tRNA molecules, and
prevents protein synthesis; it has a broad antibacterial spectrum with
activity against Gram-positive and Gram-negative pathogens, including
multidrug-resistant organisms and anaerobes. The modiﬁcation of the
basic tetracycline molecule has overcome the two resistance mechanisms
seen with tetracyclines (efﬂux, ribosome protection). Tigecycline exhibits
linear pharmacokinetics, has a long half-life (24−48 hours), is highly
protein bound (71−89%), and has a large volume of distribution
(7−9L/kg).
Tigecycline is not extensively metabolised; the primary route of
elimination is biliary excretion (59%) and 33% is excreted unchanged
in urine. The recommended dosing regimen is an initial dose of 100mg,
followed by 50mg every 12 hours. Time above MIC and AUC/MIC ratio
are the most important pharmacodynamic parameters.
In two double-blind studies the safety and efﬁcacy of tigecycline versus
aztreonam plus vancomycin were compared in hospitalised adults with
complicated skin and skin-structure infections. Over 1000 patients were
randomised and the results of the pooled analysis determined that
tigecycline monotherapy was as effective and statistically non-inferior
to aztreonam plus vancomycin.
Two double-blind studies including more than 1000 patients analysed
safety and efﬁcacy of tigecycline versus imipenem/cilastatin in adults
with complicated intra-abdominal infections. Results of the pooled
analysis determined that tigecycline was efﬁcacious and statistically non-
inferior to imipenem.
Nausea (20−30%) and vomiting (15−20%) are the most common adverse
effects observed in clinical trials. They usually occur within the ﬁrst two
days of therapy, are more common in women (48%) than in men (24%),
and may also be age related.
Tigecycline is an important addition to the antimicrobial armentarium.
It has a broad spectrum of activity and its ability to evade numerous
mechanisms of resistance makes it a promising solution to the treatment
of multi-drug resistant organisms. This is very helpful in selected patients
in the ICU.
S54 Parenteral colistin: ﬁnally a useful drug?
F. Jacobs (Brussels, BE)
The increasing resistance of Gram-negative bacteria and particularly
amongst Pseudomonas aeruginosa and Acinetobacter baumannii, raises
a major therapeutic problem. The lack of new effective agents in
the near future has revived interest in the re-use of some molecules,
abandoned because of their toxicities. Colistin (colistimethate sodium) is
a polymyxin antibiotic available in parenteral formulation and used for
intravenous, aerosolised and intrathecal/intraventricular administration.
The bactericidal activity of colistin is due to a detergent effect on the
cell membrane and therefore not dependent upon bacterial metabolic
activity. Because this drug was developed during the 1950s, only little
pharmacokinetic and pharmacodynamic information are available and
the optimal daily dose for severely ill patients is still unknown.
Colistin, used both intravenously and by inhalation, was used until last
decade mainly in cystic ﬁbrosis patients. Recently, colistin has been used
in non cystic ﬁbrosis patients as a salvage therapy for the treatment of
infections with Gram-negative bacteria resistant to all other antibiotics.
Clinical reports on the efﬁcacy of intravenous colistin in these patients
are not randomised studies and in most of them, colistin was frequently
associated with other antimicrobial agents with a lack of a control group.
A good outcome occurred in most infections (52−75%) but with the
poorest results observed in pneumonia (25%).
In vitro studies have shown synergistic effect between colistin and
rifampin but no clinical study has been designed to conﬁrm this synergy.
Nephrotoxicity and neurotoxicity are the most common toxicities of
colistin. However recent studies demonstrated a reduced toxicity as
compared with previous studies, even if a higher dosage is used. This
low renal toxicity rate was observed in both critically ill patients and
patients treated with prolonged courses of colistin. There are also
recent clinical reports on the use of colistin in continuous intravenous
infusion to minimise potential toxicity. This reduction of toxicity without
impairment of efﬁcacy (concentration-dependent killing in in-vitro time-
kill studies) should be conﬁrmed by further studies. Neurotoxicity has
also been more frequently reported in case of renal dysfunction.
Development of resistance to colistin is a major problem, especially in
A. baumannii. This highlights the urgent need to preserve this molecule
by the best appropriate dose regimen and by an optimal synergistic
combination with other antibiotics.
S55 Facts and myths about fosfomycin
F. Gudiol (Barcelona, ES)
Fosfomycin is a phosphonic broad spectrum antibiotic discovered in
Spain in 1969, licensed in many countries since then, but used only
sporadically in the clinical setting. In fact, It is not mentioned speciﬁcally
in the current editions of the most prestigious textbooks of internal
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medicine or infectious diseases. The emergence of infections caused by
bacteria resistant to almost all antimicrobial agents may have renewed the
interest for addressing the contributions, limitations and future clinical
indications of this drug.
Fosfomycin exhibits a rapid bactericidal activity against a large number
of aerobic Gram positive and Gram negative bacterial species by
inhibiting the initial step of cell wall syntesis. Some important
multiresistant pathogens such as penicillin-resistant pneumococci,
methicillin-resistant staphylococci, vancomycin-resistant enterococci and
ESBL-producing enterobacteriaceae are usually susceptible to the drug.
To date, no cross-resistance with other antibiotics has been reported.
Favourable pharmacokinetic properties include a low molecular weight,
a negligible protein binding, a large volume of distribution in human
tissues and a good penetration into the inﬂamed CSF. The disodium salt
of fosfomycin can be administered intravenously in high doses due to its
very low toxicity, achieving plasmatic peak levels that are several times
above the MIC of susceptible microorganisms (breakpoint 64 g/mL). An
oral salt of fosfomycin and tromethamine with enhanced bioavailability
is also available since 1990.
The major drawback of fosfomycin is the frequent development
of resistance during therapy. This phenomenon, which has been
demonstrated in “in vitro” and “in vivo” studies, precludes its parenteral
use as a single agent in the clinical practice. As a counterbalance,
fosfomycin can act synergistically with other antibiotics, especially with
those that inhibit later points in cell-wall synthesis. Such synergism
has been shown repeatedly against different strains of Staphylcoccus
aureus, CNS, Streptococcus pneumoniae and Pseudomonas aeruginosa.
Moreover, in experimental animal models of MRSA endocarditis
and cefalosporin-resistant pneumococcal meningitis, fosfomycin and
b-lactam (or vancomycin) combinations have proved to be superior
than monotherapies, preventing the emergence of drug-resistant popu-
lations as well. However, the reported clinical experience with these
combinations is very scarce and, therefore, there are not evidence-based
recommendations supporting its use.
On the other hand, various clinical trials have indicated that fosfomycin
trometamol, as a sole antibiotic, is effective and safe for the treatment of
uncomplicated UTI, providing high and long lasting urinary fosfomycin
levels, which help to prevent the emergence of resistant strains. Because
of the increasing prevalence of CTX-M type ESBL-producing E. coli
in the community, the oral administration of a single dose of 3 gr.
of fosfomycin trometamol may be considered nowadays as a ﬁrst line
therapy for uncomplicated UTI in young women. However, the possible
emergence of fosfomycin-resistant mutants among ESBL-producing
enterobacteriaceae should be taken into account.
In conclusion, after 40 years of its discovery, only the oral form
of fosfomycin – tromethamine – has attained a solid position in the
antimicrobial guidelines. Combinations of iv fosfomycin with other
antibiotics may be considered in selected cases, but whether these
combinations yield improved outcomes in speciﬁc infections due to
multirresistant pathogens remains to be determined. Logistic reasons
and ﬁnancial limitations will make difﬁcult the realisation of appropriate
prospective studies to answer this issue in the near future.
S56 Chloramphenicol: Goodbye Hello
W. Graninger (Vienna, AT)
Chloramphenicol is still used extensively in non-industrialised countries
for the treatment of severe infections like pneumonia and typhoid fever
because it is cheap and effective.
Chloramphenicol proved to be an effective alternative for the treatment
of pneumococcal and meningococcal disease and also in patients
with meningitis caused by Haemophilus inﬂuenzae. Chloramphenicol’s
loss of favour began in the 1960s, when it was shown to have
two distinct toxic effects on hematopoiesis: a frequently observed,
dose-dependent anaemia, reversible on cessation of therapy, and an
irreversible, ‘idiosyncratic’ aplastic anaemia, which had an incidence
of approximately 1 case per 30,000 courses of therapy, a high case
fatality rate, and no correlation with the or duration of treatment. The
use of chloramphenicol has then become restricted to life-threatening
infections for which there are no acceptable alternative treatments like
brain abscesses.
Analogues of chloramphenicol have been developed that lack the
aromatic NO2 group that is thought to cause irreversible marrow
aplasia. Although the clinical efﬁcacy of such compounds has not been
evaluated, they are effective in vitro against most bacteria, even those
that are resistant to chloramphenicol. The data provided in support of a
hypothesis that these molecules needed a nitro group in order to cause the
blood dyscrasias were insufﬁcient in themselves. Florfenicol has followed
chloramphenicol in veterinary medicine. The potential for ﬂorfenicol
to cause blood dyscrasias, such as aplastic anaemia, in humans was
discussed in relation to the chemically related chemicals chloramphenicol
and thiamphenicol. Human epidemiological data could not be used to
demonstrate the safety of ﬂorfenicol as ﬂorfenicol has never been used in
human medicine. Nevertheless, because there is as yet no way to monitor
the potential for irreversible bone marrow toxicity, it is unlikely that such
compounds will become available for the treatment of chloramphenicol-
resistant infections in general – and meningococcal disease in particular.
The future of chloramphenicol is not entirely certain. On one hand,
it is a well-studied, long-standing treatment for ﬁghting a number of
different infections; it is also very inexpensive and consequently has
very widespread use. It would, however, be a very good thing if we
could ﬁnd a new drug or group of drugs that produced similar results in
ﬁghting infection but did not have as many serious side effects. It would
take a long time before any drug could ever replace chloramphenicol,
because of both its broad use and its very low cost.
Tropical medicine: from basic science to ﬁeld
work
O57 Evaluation of malaria status and immune response to
Plasmodium falciparum MSP-2
A. Khosravi, M. Hommel (Ilam, IR; Paris, FR)
Objectives of study: MSP-2 is a highly polymorphic 45−53 kDa
merozoite surface antigen and very immunogenic malaria antigen, which
is considered as a promising vaccine candidate. The 3 S and 5 S end
regions of the gene are highly conserved, whereas a large central region
is variable. Many studies have suggested a protective role for speciﬁc IgG
antibodies against variable regions of MSP-2. This study was designed
to analyse the reactivity of human sera from people living in a malaria-
endemic area of The Gambia (village of Keneba) against different
domains of MSP-2. The association of haemoglobin and parasitaemia as
two indicators of clinical malaria with acquired immunity were analysed
to elucidate the pattern of protective immunity.
Materials and Methods: The current study was designed and carried
out in Liverpool School of Tropical Medicine. 179 human sera were
randomly selected from McGregor’s Keneba Sera Collection (1966–
1980). Different domains of MSP-2 were synthesized using GST gene
fusion system and crude schizont extract was prepared from in vitro
culture of Plasmodium falciparum. Total IgG and IgG subclass responses
were measured by ELISA after a checkerboard study was performed
for each antigen to standardise the concentration of both antigens and
antibody.
Results: Most sera predominantly recognized the immunodominant
regions of the molecule. Increasing the age was negatively correlated
with parasitaemia and positively with IgG antibody responses and
haemoglobin levels indicating that total IgG responses to domains 2,
3 and crude schizont extract coincidental to a decrease in parasitaemia
density and frequency. IgG3 response was the main IgG in those who had
no parasitaemia at the ﬁnal time point. IgG2 and IgG3 were increased
amongst individuals with no parasitaemia and with higher levels of
haemoglobin at higher ages that had exposure to parasite over a long
period of time.
Conclusion: IgG3 was the main antibody, mainly against domain 3 of
MSP-2, that was associated with increase in haemoglobin levels and
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decrease in parasitaemia suggesting that domain 3 is preferred over
other domains and crude schizont extract in presenting a clearer picture
of immunity against malaria. These results could be an evidence of
protective role of these antibodies against malaria disease and, therefore,
domains 3 can be considered as reliable vaccine candidate antigens.
O58 Presence of dengue virus genome in the bone marrow of
asymptomatic adults in a dengue-hyperendemic country:
implication for complicated dengue pathogenesis
O. Putcharoen, S. Krajiw, V. Nilratanakul, P. Rojnuckarin,
P. Bhattarakosol, A. Nisalak, C. Pancharoen, U. Thisyakorn,
W. Kulwichit (Bangkok, TH)
Objectives: Our country is hyperendemic for dengue virus infection.
Serosurveillance indicates that almost all native adults have been
infected, mostly asymptomatically. A long-held mechanism explaining
clinical severity involves sequential infections by different serotypes.
Even though some of its peer ﬂaviviruses are known to reside persistently
within the host and contribute to host illnesses, dengue virus has not been
shown to behave in a similar fashion. As dengue is a haematotropic
virus, we sought to ﬁnd evidence of its persistence in the bone marrow
of previously-infected persons.
Methods: We studied patients clinically suspected or known of
haematologic malignancies and indicated to have diagnostic bone
marrow initial or follow-up studies. A fraction of cellular marrow was
employed for RNA extraction and reverse transcription-polymerase chain
reaction (RT-PCR) by dengue-speciﬁc primers. Serologic assessment
by haemagglutunation inhibition test (HI) for dengue and chikungunya
viruses and by enzyme-linked immunosorbent assay (ELISA) for dengue
was performed on the study of bone marrow study and, in some cases,
14−60 days later, to minimise a chance of including patients with
recent dengue infection. Serologic interpretation was made according
to standard criteria. Demographic data of all patients were analysed,
especially for the history of recent febrile illnesses which could be due
to dengue infection.
Results: Of 83 enrolled patients, dengue genome was detected in cellular
marrow of 6 cases (table). All these 6 cases were in the stage of remission
of their haematologic diseases. They had had no prior history of recent
febrile illnesses and HI and ELISA results of single or paired sera from
these patients were compatible with either remote (#1−5) or remote/no
(#6) infection by ﬂaviviviruses. As for the rest, one may have had fairly
recent dengue infection and one had rising titers for chikungunya virus.









1st, 2nd IgM &
1st, 2nd IgG
1. B cell lymphoma 44y F 1:160, NA 2, NA & 16, NA
2. Multiple myeloma 48y M 1:40, NA 24, NA & 1, NA
3. Multiple myeloma 52y M 1:40, NA 4, NA & 3, NA
4. CML 56y M 1:40, 1:80 0, 1 & 4, 6
5. B cell lyrnphoma 38y F 1:40, 1:40 0, 0 & 2, 2
6. CML> 54y F <1:20, <1:20 0, 0 & 10, 5
Abbreviations: CML, chronic myelogenous leukaemia; F, female;
M, male; NA, data not available.
Conclusions: Sequential infections by different serotypes seem to be a
key in severe dengue pathogenesis. Its peer ﬂaviviruses, however, have
been shown both in vitro and in vivo to do so. The persistent ﬁrst-
serotype dengue genome, defective or complete, could possibly confer a
biological inﬂuence when co-infected with a second serotype later on in
their life. Our understanding of dengue pathogenesis is far from perfect,
and this ﬁnding may open up a door to a new arena of dengue research.
O59 Dynamics of Plasmodium falciparum alleles in children with
normal haemoglobin and with sickle cell trait in western
Uganda
G. Kiwanuka, H. Joshi, W. Isharaza, K. Eschrich (Mbarara, UG;
New Delhi, IN; Leipzig, DE)
This is the ﬁrst study to characterise Plasmodium falciparum population
in relation to haemoglobin type in western Uganda.
General objective: To investigate the composition of P. falciparum in
children aged 3 months to 15 years in Western Uganda and characterise
the genotype of P. falciparum with the longest duration of carriage
in sickle cell trait. Speciﬁc objectives: To study the allelic variants
of P. falciparum in children aged 3 months to 15 years reporting at
Mbarara University Teaching Hospital and Kagando Hospital, in western
Uganda; to analyse the duration of carriage of speciﬁc parasite genotypes
in relation to the type of haemoglobin of the children; to characterise
P. falciparum harboured by asymptomatic malaria carriers with sickle
cell trait; to investigate the effect of turnover of P. falciparum genotypes
on parasite density.
Methods: Microscopic identiﬁcation of malaria parasites and estimation
of parasitaemia was done using Giemsa-stained thick and thin blood
ﬁlms. Haemoglobin phenotype was determined by electrophoresis of
blood samples on cellulose acetate membrane in alkaline buffer. Nested
PCR using speciﬁc primers for merozoite surface protein (MSP) 1 and
2 allelic families was used to genotype P. falciparum in 291 isolates
collected from children in two districts Mbarara and Kasese.
Results: Extensive genetic diversity was detected among symptomatic
children in Mbarara (20 MSP1; 31 MSP2 alleles) and Kasese (19 MSP1;
30 MSP2 alleles). Multiplicity of infection (MOI) with MSP2, a high
polymorphic genetic marker, was higher in Kagando than in Mbarara
being 2.1 and 2.7 genotypes/PCR positive-sample, respectively. The
difference in MOI in children in the two districts was statistically
signiﬁcant (MSP1 P< 0.0001; MSP2 P = 0.036). Clear differences in
the distribution of individual alleles of FC27, IC and RO33 were
apparent in the study areas. A deletion of a 12-amino acid sequence
in RO33 160 bp allele yielded RO33 130 bp, which predominated in
symptomatic children in Mbarara. About 13% of asymptomatic children
in Kisinga, Kasese carried HbAS. MOI was age-dependent and higher
in children with HbAS than with HbAA. Haemoglobin type inﬂuenced
the distribution of FC27-type alleles among asymptomatic children
Kagando.
Conclusion: P. falciparum polymorphism is extensive in western
Uganda, and most of the infections are composed of multi-clonal
infections. HbAS increases MOI and is important in development of
naturally acquired immunity.
O60 TLR-cascade in malaria: role in antiparasitic clearance
J.P. Cramer, B. Lepenies, C. Ho¨lscher, M. Freudenberg, G.D. Burchard,
T. Jacobs (Hamburg, Borstel, Freiburg, DE)
Objectives: Host innate immunity is important for early parasite control
but also contributes to disease pathology. Antigenic variability of the
parasite as well as host immune response mechanisms have been
analysed in numerous studies. Yet, little is known about the initial
recognition of parasite antigens by host immune receptors in blood stage
malaria.
Methods: In a murine malaria model, the role of the TLR cascade
for parasite clearance and for initiating innate and cell mediated
immunity was analysed. Mice deﬁcient for TLR2/4, TLR4, TLR9, and
MyD88 as well as controls were infected with non-lethal Plasmodium
yoelii. Parasitaemia and survival were assessed. In addition, on day
6 post infectionem cytokine levels were measured in serum and in
cultured spleen cells after 48 h stimulation with anti CD3. To assess
T cell stimulation, respective activation markers were assessed by ﬂow
cytometry.
Results: In vivo, MyD88 −/− mice showed signiﬁcant higher parasite
loads and a mortality of 38% compared to 0% in controls. However, time
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needed to completely eliminate parasite from blood in surviving mice did
not differ between groups. Parasitaemia in TLR2/4 −/− and TLR9−/−
mice and in controls was similar. MyD88 −/− mice had signiﬁcantly
lower levels of IL-12 and IFN-g. T cell proliferation as well as T-cell
activation was not altered.
Conclusion: MyD88 plays an important role in eliminating blood stage
parasites. This is reﬂected by reduced levels of co-stimulatory as well
as pro-inﬂammatory cytokines.
O61 TLR2, but not TLR4 mediates Onchocerca volvulus induced
corneal inﬂammation
K. Daehnel, E. Pearlman (Cleveland, US)
Objectives: This study was designed to identify the role of TLR2 and
TLR4 in the development of Onchocerca volvulus induced keratitis.
Methods: Bone-marrow derived dendritic cell cultures were obtained
from C57Bl/6, TLR2−/−, TLR4−/− and TLR2/4 −/− mice and
stimulated in vitro with O. volvulus extract. Dendritic cell activation was
measured by IL-6 and RANTES production and by CD40 expression by
ﬂow cytometry.
C57Bl/6 and TLR2−/− mice were then immunised with O. volvulus
extract and soluble antigen was injected into the corneal stroma.
Neutrophil and eosinophil migration into the corneal stroma was
determined by immunohistochemistry, and ﬁlaria-speciﬁc IL-5 and
IFN-g production by splenocytes was measured by ELISA.
Results: Incubation of dendritic cells with ﬁlarial extracts induced
production of IL-6 and RANTES and up-regulation of CD40. In contrast,
there was no elevation of any of these factors in dendritic cells obtained
from TLR2−/− or TLR2/4 −/− mice, but dendritic cells from TLR4−/−
mice responded similar to C57Bl/6 dendritic cells.
Immunisation of C57Bl/6 and TLR2−/− mice caused increased ﬁlaria-
speciﬁc IL-5 production by splenocytes. In contrast, IFN-g production
was only increased in splenocyte cultures from C57Bl/6 mice, but not in
cultures from TLR2−/− mice. In the C57Bl/6 corneas, injection of ﬁlarial
antigens induced neutrophil and eosinophil inﬁltration. In TLR2−/−
mice, neutrophil migration into the corneal stroma was completely
abrogated, whereas eosinophil migration remained unaffected.
Conclusion: We conclude that TLR2 plays an important role in early
recognition of ﬁlarial antigens, the induction of ﬁlaria-speciﬁc T cells
and neutrophil migration to the corneal stroma.
Ongoing studies are examining the role of IL-6 and IFN-g in the
development of adaptive immune responses and corneal inﬂammation.
O62 Prevalence of Hymenolepis nana and other intestinal parasites
as mixed infection among children in Ilam, and impact of
single-dose praziquantel against H. nana
A. Khosravi, A. Dalimi Asl, A. Kaikhavandi (Ilam, IR)
Objective of study: This study was designed to evaluate the prevalence
of intestinal parasitic infections in primary and secondary School
children in relation to some individual and social risk factors such as the
parent’s job, the water supply source, raw vegetable consumption, area
of living, gender, etc., in Ilam and assess the impact of two different
doses of Praziquantel against H. nana infection.
Methods: The mixed infection of Hymenolepis nana and other intestinal
parasites were studied in a 3 years prospective study using 1140 stool
samples that were randomly collected from 5 regions of the city, the
North, the East, the West, the South and the City Centre. Samples were
tested using microscopy, direct examination, and then Formalin Ether
diagnose tests were carried out to compare the results. Three groups
each of 30 infected individuals were selected randomly and they were
given Praziquantel 15mg/kg, 20mg/kg and Placebo respectively.
Results: The overall prevalence of H. nana was 13.4% with no
signiﬁcant difference for males and females. The parent’s jobs, age
of children and source of water supply had no signiﬁcant correlation
with the prevalence of infection while a strong correlation was found
with raw vegetable consumption. 46.96 percent of all children were
shown to have parasitic infection with the highest prevalence reported
for Trichuriasis and Giardiasis, 26% and 25.30% respectively. Amongst
34 percent of individuals who had H. nana infection Giardia Lamblia
were also diagnosed as a mixed infection; 3% of individuals who had
H. nana infection were diagnosed with Taenia Saginata infection too.
Abdominal disorders, lack of appetite, dizziness, vomiting and diarrhoea
were the main reported symptoms. The cure rate of Praziquantel against
Hymenolepis nana infection was about 100% using both doses of drug.
Discussion: There is a high rate of parasitic infection, some with mixed
infection, in children of primary and secondary schools in Iran with
higher prevalence for those living in poor parts of country like Ilam.
H. nana is a worldwide parasitic infection distributed amongst children
affecting their growth and also their quality of study. The high prevalence
and also the mixed infection reported in this study suggested that the
Health Services should work more effectively and promote their impact
on the knowledge, attitude and practice of children. Praziquantel cured
the infection using single dose appropriately which is in agreement with
other studies.
O63 Chagas’ disease: a growing problem in Spain
A. Salinas, M. De Go´rgolas, M. Ferna´ndez-Guerrero (Madrid, ES)
Background: Chagas’ disease is a parasitic infection caused by
Trypanosoma cruzi. It is endemic in Central and South America and,
during the last few years, a large number of migrants from these areas
have settle in Spain. Therefore the diagnosis of Chagas’disease has
become a common event in our clinical practice.
Methods: We have reviewed all cases of Chagas’ disease during the
last 2 years. Speciﬁc serology (ELISA) was the diagnostic procedure.
Epidemiological, clinical, cardiac ultrasound, serological and therapeutic
aspects were analysed.
Results: During 2004 and 2005 we studied 7 patients with Chagas’
disease. 3 men and 4 women with a mean age of 38.8 y (24−51 y).
85% were from rural areas of Bolivia (Cochabamba and Valle del
Potosı´) and one patient came from the North of Argentina. All patients
had positive antibodies against T. cruzi performed in their countries.
The main clinical complaints were: dizziness (1p), dyspnea (2p),
palpitations (1p) or asymptomatic screening (3p). 2 cases had positive
xenodiagnosis. All cases but 2 were asymptomatic, having normal ECG
and cardiac ultrasound. 2 women had arrhythmia: one atrial ﬁbrillation
and ventricular tachycardia requiring a DAI and the other had ventricular
dysfunction and constipation. All cases but one previously treated
received therapy with benznidazole for 30−60 days with good tolerance.
A pregnant woman did not receive treatment.
Conclusions: The new entry of immigrants to Spain, coming from rural
endemic areas of Chagas’ disease of Bolivia and other Southamerican
countries should make us suspect this entity in young people with cardiac
or gastro-intestinal disturbances.
O64 Survival of dengue virus in the urine of acutely-infected
patients – implications for pathogenesis and for a possible un-
recognized mode of transmission for an arthropod-borne virus
V. Yingsiwaphat, P. Siriyasatien, K. Arunyingmongkol, S. Krajiw,
J. Pupaibool, A. Nisalak, C. Pancharoen, U. Thisyakorn, W. Kulwichit
(Bangkok, TH)
Objectives: Dengue virus infection is considered the world’s most
important arthropod-borne disease. We have earlier reported a pilot study
that dengue, like some other viruses, can be detected by RT-PCR in urine
from a number of patients, even in an early postfebrile period. Here we
wish to report a follow-up study with more cases and with our success
in isolating the virus from early and late urine specimens of acutely-
infected patients.
Methods: Hospitalised patients suspected of dengue infection were
enrolled. Diagnosis was conﬁrmed by standard criteria of enzyme-linked
immunosorbent assay (ELISA) and/or haemagglutination inhibition test
(HI). Patients with negative dengue serologies served as negative
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controls. Dengue-speciﬁc PCR, with primers targeting conserved
sequences in the 3′-untranslated region, was performed in urine
specimens with a strict and properly-evaluated protocol. Pairs of febrile
and postfebrile urine specimens from 1 adult and 3 paediatric dengue
cases with positive dengue-speciﬁc PCR in urine, together with those
of 1 adult and 2 paediatric negative controls, were processed and
then employed for Aedes aegypti intrathoracic inoculation. To minimise
urinary toxicity to mosquitoes, 3 forms of processed urine were used:
diluted urine pellets, diluted urine supernatants ﬁltered though 0.2-mm
membrane, and diluted urine supernatants mixed with antimicrobials.
Each form of each specimen was inoculated into 20 mosquitoes.
Surviving mosquitoes were dissected 14 days after inoculation. Dengue-
speciﬁc PCR was performed on extracts from the body parts of all
injected mosquitoes.
Results: Of 237 dengue patients enrolled, the virus was detected in
122/189 paediatric and 20/48 adult urine specimens by PCR (64.55%
and 41.67% respectively). Live dengue viruses were detected in all
febrile and postfebrile urine specimens of dengue cases but in none of
negative controls (Table). The virus was isolated as late as 14 days after
defervescence. Filtered urine supernatants served as the best specimen
type, with the least urinary toxic effects to mosquitoes.
Specimens # cases with virus isolated/total # cases






febrile urine 1/4 (25%) 3/4 (75%) 4/4 (100%)
postfebrile urine 0/4 (0%) 3/4 (75%) 4/4 (100%)
Nondengue
febrile urine 0/3 (0%) 0/3 (0%) 0/3 (0%)
postfebrile urine 0/3 (0%) 0/3 (0%) 0/3 (0%)
Conclusion: Dengue virus is not only excreted in urine in at least
half of the patients, but it is also live and culturable. These ﬁndings
have implications for dengue pathogenesis and for public health. Urine
is implicated as a potential mode of transmission for certain viruses.
Whether the arthropod-borne dengue will be added to the list is subject
to further investigation.
O65 Spatiotemporal variations of malaria incidence and protective
efﬁcacy of intermittent preventive antimalarial treatment of
infants
J. May, R. Kobbe, B. Kreuels, S. Adjei, O. Adjei on behalf of the
Agona IPTi Trial Team
Background: Intermittent preventive antimalarial treatment of infants
(IPTi) is considered a promising malaria control strategy. Among the
factors that inﬂuence the extent of protection provided by IPTi are
malaria endemicity, seasonality, drug resistance patterns and the IPTi
application schedule. Studies modeling the effect of malaria incidences
on IPTi are scarce. The aim of this study was to describe how far
protective efﬁcacy of IPTi depends on the incidence rate of clinical
malaria.
Methods: One-thousand seventy infants were enrolled in a registered
controlled trial on the efﬁcacy of sulfadoxine-pyrimethamine based
IPTi in the Ashanti Region, Ghana. In an ecological analysis, malaria
incidence rates in the ﬁrst year following IPTi were stratiﬁed by
the village of residence and month of birth of participants and the
spatiotemporal variation of the malaria incidence on the protective
efﬁcacy of IPTi was analysed.
Findings: The rate of malaria attacks during the ﬁrst year of follow-
up was highly dependent on the month of birth and on the village
of residence of the children. Protective efﬁcacy of the ﬁrst IPTi
administration (IPTi-1) correlated with malaria incidences in children
living in a particular village or born in a particular month (r2 0.48,
p< 0.04 and r2 0.63, p< 0.003, respectively). A corresponding trend was
seen after the second (IPTi-2) and third (IPTi-3) drug administration.
Interpretation: Correlations between IPTi efﬁcacy and malaria inci-
dences may have implications on IPTi implementation strategies and,
most likely, on that of other malaria control measures.
Inﬂuenza A: update on epidemiology,
virology and pandemic preparedness
planning
S83 The role of mathematical modelling in pandemic preparedness
S. Cauchemez, N.M. Ferguson (London, UK)
I will discuss the role mathematical modelling in pandemic planning and
response. Recent research examining whether antiviral prophylaxis and
social distance measures could be used to contain a nascent pandemic
at its point of origin will then be reviewed. Containment is potentially
feasible, but requires rapid detection of the initial transmissible case
cluster and a rapid and organised response to each new case. These may
be demanding criteria for much of SE Asia. If containment fails, slowing
spread becomes a policy priority and in that context I will discuss the
potential impact of restrictions on international travel. To conclude, I will
discuss pandemic mitigation strategies which make best use of limited
vaccine and antiviral supplies.
Infection in cancer patients (jointly
arranged with the International
Immunocompromised Host Society)
S84 Update on the epidemiology of infections in cancer patients
G. Maschmeyer (Potsdam, DE)
Infections are among the most frequent complications occurring in
cancer patients undergoing antineoplastic chemo- or immunotherapy.
Invasive fungal infections today represent the main causes of fatal
outcome. Early diagnosis of probable or proven invasive aspergillosis
is therefore one of the most important objectives of supportive care in
patients with profound and prolonged neutropenia. With the advent of
more effective and well-tolerated antifungals active against aspergillosis,
the incidence of other mould infections such as zygomycosis is on the
rise.
The use of highly aggressive chemotherapy induces severe mucosal
damage in many cancer patients. Apart from neutropaenic enterocolitis,
a broad spectrum of infections associated with impairment of mucosal
barriers may be clinically important, e.g., streptococcal bacteraemia,
septic enterococcal infection, or candidaemia. The widely spread use
of multi-lumen central venous catheters causes a considerable number
of bloodstream infections caused by coagulase-negative staphylococci,
S. aureus, Gram-negative bacilli, or Candida spp. Primary removal of
foreign material may be important for the successful management of
these catheter-related infections.
Allogeneic hematopoietic stem cell transplantation with reduced-
intensity conditioning has become more common also for treatment of
aggressive haematologic malignancies in elderly patients as well as in
patients with severe co-morbidity, who formerly have not been taken into
consideration for myeloablative transplant procedures. Despite a marked
reduction of complications related to pancytopenia combined with acute
graft-versus-host reaction, the rate of severe and life-threatening fungal
infections and cytomegalovirus diseases has turned out to be comparable
to conventional allogeneic transplantation. Most importantly, more than
half of these infectious complications emerge after more than 90 days
post transplant, i.e., in patients already managed on an outpatient basis.
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The broad introduction of monoclonal antibodies to CD20 and CD52
and of nucleoside analogs into the treatment of patients with B- or
T-cell lymphomas has lead to long-term depletion of B cells, eventually
associated with decreasing levels of serum immunoglobulins, and T-cell
deﬁciency lasting for many years. Particularly in patients being treated
with these compounds for relapsed or refractory malignancy, a high
number of infections caused by pathogenic viruses such as CMV, invasive
fungi or Pneumocystis jiroveci are observed. Targeted prophylaxis is
warranted for selected patient groups, whereas high alertness and early
pre-emptive antimicrobial intervention is mandatory in the majority of
these patients.
Tuberculosis: fast forward to new approaches
S88 VNTR typing as the next gold standard in the molecular
epidemiology of tuberculosis
D. van Soolingen, J. van Ingen, K. Kremer, S. Ferreira, P. de Haas,
M. Sebek, M. Borgdorff, P. Supply (Bilthoven, NL; Lille, FR; The
Hague, NL)
In the last decade, IS6110 restriction fragment length polymorphism
(RFLP) typing has gained recognition as the gold standard in the
molecular epidemiology of tuberculosis. The application of RFLP
typing has provided new insights in, e.g., the natural history of
tuberculosis infection and (inter-)national transmission of multi-drug
resistant tuberculosis in Europe (to be presented). However, this method
is technically demanding and labour intensive, and requires weeks of
culturing to obtain sufﬁcient DNA. The complex RFLP patterns are
difﬁcult to interpret and exchange.
The new generation genotyping of Mycobacterium tuberculosis –
based on the detection of the variable number of tandem repeats
(VNTRs) of mycobacterial interspersed repetitive units (MIRUs) – is
increasingly used to solve these problems. VNTR typing is based on
PCR ampliﬁcation of multiple genomic loci to determine the number of
tandem repeats at these sites. This typing is much easier to perform than
IS6110-RFLP typing, and is applicable to crude low-concentration DNA
extracts. Current studies are even oriented to apply VNTR typing directly
to clinical material. Moreover, the results are expressed as numerical
codes and are, therefore, easy to compare and exchange.
Recently, in an international collaboration, the resolution, stability and
technical applicability of 29 MIRU-VNTR loci was compared. This study
comprised the initially explored 12 loci (as applied in the USA) and
most of the exploitable loci disclosed in the international context so
far. The typing results of 824 M. tuberculosis isolates revealed the 24
most optimal loci. The use of 15 selected loci is recommended as the
new international gold standard for typing of M. tuberculosis complex
isolates. A recent study pointed out that VNTR typing on basis of 24
loci is useful to study the phylogeny of the complex.
As experienced after the standardisation of IS6110 RFLP typing in
1993, it is expected that the recent (December 2006; J. Clin. Microbiol.)
international consensus on VNTR typing will facilitate the comparison
of molecular epidemiological data from various geographic regions,
the spread of multi-drug resistance in Europe, the establishment of
an international VNTR database and the meta-analysis of worldwide
typing results in order to study the population structure and spread of
M. tuberculosis.
Many institutes in the world have large databases of IS6110 RFLP
patterns of M. tuberculosis isolates from extended time periods. Because
in the epidemiology of tuberculosis transmission and manifestation of
the disease can be separated in time by multiple years, the switch to
VNTR typing can not be done without any overlap of the application of
the two typing methods. During the ECCMID meeting the ﬁrst re-typing
results in The Netherlands and considerations underlying the choice of
isolates to be re-typed will be discussed.
S89 Genetic aspects of tuberculosis: persistence and pathogenesis
L.W. Riley (Berkeley, US)
A large proportion of new cases of tuberculosis (TB) in the world
arise from a reservoir of people latently infected with Mycobacterium
tuberculosis (Mtb). In TB endemic areas of the world, the average time
to diagnosis a case of TB after the onset of active disease is 6 months.
During these 6 months, such a case of TB is likely to infect, on the
average, 10 close contacts. If one of these 10 newly infected contacts
then develops TB sometime in his life time, he will infect 10 other
persons before diagnosis. The cycle then repeats itself. Thus, if a TB
control programme is only focused on the treatment of active cases,
TB will never come under control. The fundamental question in TB
control, therefore, is “can we predict who among the latently infected
people will progress to active disease so that such a person can be given
preventive treatment?” To answer this question, the mechanism of Mtb
persistence and reactivation needs to be better understood. A variety
of models for bacterial persistence has been proposed recently. Most
genetic studies that provide evidence for the putative role of a gene in
persistence are based on demonstrating that an Mtb strain disrupted in
such a gene is attenuated in an animal model of TB. However, several
recent gene disruption studies have shown that Mtb mutants can also
become hypervirulent in an animal model. This suggests that some Mtb
genes may actually help to temper the virulence potential of Mtb so that
the organism can establish a stable niche in a host without harming the
host. We provide evidence that a cluster of genes in an operon called
mce1 in Mtb is involved in lipid transport and metabolism that helps to
remodel the bacterial cell envelope. The operon appears to respond to
a signal induced by the host’s granuloma cell turnover, while the host’s
proinﬂammatory cells that comprise the granulomas appear to respond
to the changing bacterial cell envelope lipid turnover. An Mtb mutant
disrupted in the mce1 operon becomes hypervirulent in a mouse model
of TB; it is unable to induce well-organised granulomas in mouse lungs,
and the mouse dies from an uncontrolled bacterial proliferation. This
mutant accumulates free mycolic acids on its surface. On the other hand,
an Mtb strain disrupted in the negative regulator of the operon (mce1R)
constitutively expresses the mce1 genes in vivo. This mutant is also
hypervirulent but for an opposite reason-it causes rapidly progressive,
hyper-proinﬂammatory response. Thus, the mce1 operon appears to serve
as a homeostatic regulator of pro-inﬂammatory response by the host,
helping to establish a balanced relationship favourable to both the host
and Mtb. Understanding and exploiting this relationship may lead to
new ways to predict a subset of latently infected people who progresses
to active disease; it may also lead to the development of a therapeutic
vaccine to prevent latently infected people from ever developing TB.
S90 Global overview of new anti-TB compounds
N. Doi (Tokyo, JP)
General trend: In response of the serious clinical demands, and
the initiative of the Global Alliance for TB drug Development (TB-
Alliance), 7 new Anti-TB drug candidates: nitroimidazopyran (PA-824;
Chiron), moxiﬂoxacin (MFLX: Bayer), gatiﬂoxacin (GFLX; Kyorin),
diarylquinoline (TMC-207; Johnson & Johnson), nitroimidazo-oxazole
(OPC-67683; Otsuka), Pyrolle LL-3858 (Lupin) and diamine SQ-109
(Sequella) are in progress in clinical trials phase-I to -III. Majority of the
novel candidates listed above lack interactions with iso-enzyme CYP3A4
of P-450, indicating available into the combination therapy with anti-
retroviral drugs for the treatment of HIV/TB co-infection cases. Among
them, PA-824, TMC-207, SQ-109 and OPC-67683 proved to be effective
against (X)MDR-TB; they have been studied to introduce into the ﬁrst-
line drugs in near future.
New candidates developing in Japan: (1) OPC-67683 (Otsuka Pharm)
shows a speciﬁc potent activity only against M. tuberculosis, whereas
it is ineffective against clinically important NTM (non-tuberculous
mycobacteria) species including M. avium and M. intracellulare. OPC-
67683 is now in progress at clinical trial phase-II. (2) Recently, DC-159a,
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a novel respiratory quinolone was synthezised (Daiichi Pharm), showing
a potent anti-mycobacterial activity against Quinolone-Resistant-MDR-
or XDR-M. tuberculosis. DC-159a exhibits the best gEBA (early
bactericidal activity: after 3-, 6- and 9-day treatment) h in murine TB
model, which was superior to those of MFLX, LVFX, INH and RFP.
DC-159a is in progress in preclinical stage.
Toward the next generation chemotherapy: To ﬁght with (X)MDR-TB,
Latent-TB as well as HIV/TB, next generation of standard combination
chemotherapy is urgently required. Varieties of different classes of novel
candidates allow an encouraging scope for the establishment of 3 to
4 months of short-course treatment of TB in near future. Now, new
projects are launching to shorten the total treatment duration, based
on the systematic PK/PD study and drug-drug interaction study among
current-/novel-anti-TB drugs and anti-retroviral-drugs.
S91 The global tuberculosis epidemic: burden, challenges and the
international control strategy
M.C. Raviglione (Geneva, CH)
Tuberculosis (TB) is a disease of poverty that impedes development.
Its global burden is huge. WHO estimates that, in 2005, 8.8 million
new cases occurred world-wide and that 1.6 million patients died
of TB. The vast majority of cases and deaths (>90%) were in the
developing countries. The highest incidence rates (>300 cases per
100,000 population) were in sub-Saharan Africa, and the highest
numbers of cases (about 60% of all) were in Asia. However, TB is
everywhere and there is no country in the world that has eliminated it
or is near elimination. The HIV epidemic has fuelled TB incidence in
many settings, especially in Africa. Multidrug-resistant TB (MDR-TB) is
particularly frequent in the former USSR and in China (up to 14% of all
new cases), and extensively drug-resistant TB (XDR-TB) has emerged
in all continents and caused major concern in South Africa, where it has
appeared among persons living with HIV/AIDS. Globally, the curve of
TB incidence seems to have ﬂattened, largely the result of the possible
peaking of the epidemic in Africa. In other regions, incidence is stable
or in decline, thanks to recent control efforts.
Clear targets for TB control exist, as deﬁned within the Millennium
Development Goals (MDG) and by the Stop TB Partnership. To reach
a stable decline in incidence (MDG 6) and to halve prevalence and
mortality by 2015, several challenges must be faced. First of all, DOTS
(the 5-element essential strategy promoted by WHO since 1995) needs to
be fully implemented everywhere and of high quality, so that diagnosis,
treatment and monitoring can be guaranteed in all settings and for all
patients, and the operational targets of at least 70% case detection and
85% cure can be achieved. Second, the association of TB and HIV
and the emergence of severe drug resistance require speciﬁc policies
and interventions in most countries. Third, general health systems and
services, especially at primary care level, must be robust enough to
allow TB control and care practices to be effective; hence, national TB
programmes need to engage in the broad discussion on health system
strengthening and contribute to it. Fourth, it is clear that in most settings
in 2007, many non-state sector practitioners or some public practitioners
not linked with national programmes, are delivering sub-standard TB
care. Thus, it is necessary to ensure that they are fully engaged in
sound care delivery. Fifth, communities are playing an increasingly
important role in contributing to their health; however, too few are
adequately informed on TB and active in its care and control, thus
losing an opportunity to mobilise more resources and increase political
commitment at all levels. Finally, research is still badly under-funded and
too slow in delivering new tools that could radically improve current
practices in diagnosis, treatment and prevention. A renewed effort is
necessary if new tools are to be made available quickly.
To face these challenges, WHO has recently launched the new Stop TB
Strategy, built around the cost-effective DOTS approach. The Strategy
consists of six components: (i) pursue high quality DOTS expansion
and enhancement; (ii) address TB/HIV, MDR-TB and other challenges;
(iii) contribute to health system strengthening; (iv) engage all care
providers; (v) empower people with TB and communities; (vi) enable
and promote research. If fully implemented, this new Strategy will allow
a proper response to the modern challenges to TB control. The Stop TB
Strategy underpins the Global Plan to Stop TB 2006–2015, which deﬁnes
the ﬁnancial requirements and the gaps to be ﬁlled in order to reach the
2015 goals.
Pathogenesis of bacterial infections
O92 Presence of a pneumococcus-like capsulation locus in viridans
group streptococci
J. Van Eldere, P. Janssen, C. Massonet, V. Pintens, R. Merckx (Leuven,
BE)
Objective: To study the presence of pneumococcal virulence genes in
viridans group streptococci
Methods: 109 viridans group streptococci from respiratory samples of
hospitalised patients and Streptococcus mitis, S. pneumoniae, S. oralis,
S. infantis, S. peroris, S. sanguinis and S. parasanguinis type strains were
tested for presence of the genes for capsular polysaccharide synthesis
protein A (cpsA), competence stimulating peptide (comC), autolysin
(lytA), choline kinase (licA), hyaluronidase (hya), pneumococcal
surface adhesin A (psaA), pneumococcal surface protein (pspC) and
pneumolysin (ply).
Results: Four strains (termed Sv29, Sv5, Sv26 and Sv30) contained
the cpsA fragment. Sv29 contained licA and SV29 plus Sv5 contained
comC. API20, PCR identiﬁcation based on the species-speciﬁc D-Ala:D-
Ala ligase gene (Garnier, JCM 1997, 35, 2337), whole cell protein
proﬁling, high-resolution genotyping (AFLP) and sequence analysis of
the 16S rRNA gene conﬁrmed that Sv5, Sv26, Sv29, and Sv30 clustered
in a single group and belonged to the S. mitis group. It is not clear
whether they belong to a known species or constitute a new species
within the S. mitis group.
Strain Sv29 was sequenced up- and downstream of cpsA. Ap-
proximately 25 kb of DNA (9 kb upstream of the cpsA start and
15 kb downstream) were comprised between an upstream dexB and a
downstream aliA gene. 14 genes were found between the cpsA start
and the aliA stop, comprising genes identical to the pneumococcal
capsulation genes wzg (capsular polysaccharide expression regulator),
wzh (Wze phosphotyrosine phosphatase), wzd (Wze phosphorylation),
wze (autophosphorylating protein-tyrosine kinase), wchA (undecaprenyl
phosphate glucose-phosphotransferase), wzy (oligosaccharide repeat
unit polymerase), wzx (ﬂippase) and several genes with putative
glycosyl, glycerol and acetyl transferase activity and a putative UDP-
galactopyranose mutase. Four genes were upstream between the cpsA
start and the dexB start, comprising dexB, aliA-like orf1 and 2 genes
and an unidentiﬁed gene. Expression of the capsulation locus genes was
demonstrated. A Quellung reaction with multivalent antiserum to detect
capsular polysaccharides remained negative in Sv29 and in Sv5, 26 and
30.
Conclusion:We report for the ﬁrst time the presence of a pneumococcal-
like capsulation locus in S. mitis group streptococci that are not
S. pneumoniae. These genes may represent a new an unknown source of
capsule variation in S. pneumoniae
O93 Membrane cofactor protein (CD46) binding to clinical isolates
of Streptococcus pyogenes: binding to M type 18 strains is
independent of Emm or Enn proteins
M. Oliver, M. Feito, A. Sa´nchez, D. Pe´rez, S. Rodrı´guez de Cordoba,
S. Albertı´, J. Rojo (Palma de Mallorca, Madrid, ES)
Previous studies have shown that Membrane cofactor protein (MCP)
CD46 is the cellular receptor of keratinocytes for S. pyogenes of the M
types M6, M5 and M22. However, data using other M types and cells
have cast some doubts on the role of CD46 as the main receptor for
S. pyogenes in all human cells.
Objective: The aim of the present study was to analyse the binding of
CD46 to clinical isolates of S. pyogenes of different M types.
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Methods: Twenty six S. pyogenes clinical isolates from different origins
and expressing different M types were included in this study. To
investigate the role of the hyaluronic acid capsule, the Emm18 protein
and the Enn18 protein, we used a set of mutants derived from the
wild type strain 87–282 including the Emm18 protein deﬁcient mutant
282KZ and the capsule deﬁcient mutant TX72. Isogenic mutants TX74
and TX76, derived from TX72, deﬁcient in the Emm18 protein and the
Enn18 protein, respectively, were also included in the study.
Binding of CD46 was determined by incubation of the bacteria with
puriﬁed recombinant soluble human CD46. CD46 binding to each strain
was determined by Western blot analysis using policlonal anti-CD46
antibodies. Binding of CD46 to puriﬁed recombinant Emm18 protein
was determined by ELISA.
Results: Binding assays showed that CD46 binding to S. pyogenes was
highly variable among the 17 different M types tested, being M type
18 strains among those showing the strongest binding. The binding of
puriﬁed human CD46 to M type 18 strains was independent of the
expression of the hyaluronic acid capsule, since the highly mucoid strain
87–282 bound CD46 as efﬁciently as the derived capsule deﬁcient mutant
TX72.
Surprisingly, the Emm18 protein deﬁcient mutants 282-KZ and TX74
bound CD46. Moreover, CD46 did not bind to puriﬁed recombinant
Emm18 constructs, suggesting that the Emm18 protein is not involved
in the binding of CD46 to the M type 18 strains. To test another protein
candidate for CD46 binding to S. pyogenes M type 18, we generated the
strain TX76. TX76 bound CD46 as efﬁciently as the strains TX72 and
TX74.
Conclusion: Binding of human CD46 to S. pyogenes is highly
heterogeneous and do not depend on the presence of hyaluronic acid
capsule. Despite Emm proteins have been assumed to mediate binding
of S. pyogenes to CD46, M type18 strains bind CD46 very efﬁciently
through a cell surface protein different from the Emm and Enn proteins.
O94 Recognition of Staphylococcus aureus by plasmacytoid
dendritic cells is species-speciﬁc but not related to alpha-toxin
or protein A expression
M. Parcina, C. Wendt, K. Heeg, I.B. Bekeredjian-Ding (Heidelberg, DE)
Objectives: Plasmacytoid dendritic cells (pDC) represent the major
source of type I interferons (IFN-I) in the human body. IFN-I are secreted
in response to viral infection and represent early mediators of innate
immune defence. Less is known about the role of IFN-I in bacterial
infections. Since S. aureus has been shown to induce IFN-I we asked
whether other staphylococci stimulate human pDC and addressed the
molecular mechanism of staphylococcal IFN-I induction.
Methods: pDC were isolated from PBMC of healthy donors by positive
selection with anti-BDCA4-coated microbeads. Cells were stimulated
with bacteria (1:5) in 96 well plates (0.5×106/mL) for 24 hours. IFN-a
concentrations were measured in the supernatants by ELISA. Alpha-
toxin and protein A gene expression in clinical isolates was measured
by PCR. Recombinant alpha-toxin and protein A were used to stimulate
pDC. S. aureus strains Cowan I and Wood 46 were purchased from
DSMZ.
Results:
– All Staphylococcus aureus isolates stimulated IFN-a secretion from
human pDC.
– All clinical isolates of coagulase-negative staphylococci failed to
display signiﬁcant stimulatory activity.
– Only viable S. aureus cells stimulated signiﬁcant amounts of IFN-a.
Based on these results we assumed that S. aureus may stimulate pDC
by secreting a S. aureus-speciﬁc substance:
– Since alpha-toxin has been shown to activate immune cells we
stimulated pDC with recombinant alpha-toxin or with clinical
S. aureus isolates typiﬁed as alpha-toxin positive or negative by gene
analysis. Alpha-toxin failed to induce IFN-a secretion and S. aureus
isolates stimulated pDC independent of alpha-toxin gene expression.
– Recombinant protein A (SpA) failed to promote IFN-a synthesis
from pDC. Moreover, no differences between Wood 46 strain (SpA-
deﬁcient) and Cowan I strain (high producer of SpA) were observed.
Induction of IFN-a by clinical S. aureus isolates was not dependent
on SpA gene expression.
Conclusions: Stimulation of human pDC by S. aureus is species-speciﬁc
since coagulase-negative staphylococci fail to induce signiﬁcant IFN-I
responses. Since viability of S. aureus is required for pDC stimulation we
assumed that S. aureus activates pDC via secretion of S. aureus-speciﬁc
molecules. Two major pathogenic factors, SpA and alpha-toxin, failed to
stimulate IFN-a synthesis. We conclude that other molecules speciﬁc for
S. aureus are recognized by pDC, thus triggering IFN-I defence against
pathogenic staphylococci.
O95 A teicoplanin-resistant mutant of methicillin-resistant
Staphylococcus aureus exhibits increased uptake and
improved survival in non-professional phagocytes
A. Renzoni, E. Huggler, D. Lew, W. Kelley, P. Vaudaux (Geneva, CH)
Background: Signiﬁcant pleiotropic changes in genes coding for
virulence and autolysis have been observed in glycopeptide-intermediate
strains of S. aureus. We previously reported higher expression of
ﬁbronectin-binding proteins (FnBPs), known to promote endocytic
uptake of S. aureus by epithelial and endothelial cell lines, by a
teicoplanin-resistant (TeiR) isogenic derivative (strain 14−4) compared
to its teicoplanin-susceptible (TeiS) MRSA parent (strain MRGR3) or its
TeiS revertant (strain 14−4rev). In contrast, TeiR strain 14−4 was shown
to display lower levels of mRNAs coding for alpha-toxin and its global
regulator agr, which are potentially involved in lysis of eukaryotic cells.
This study analysed the potential impact of these molecular changes on
bacterial invasion and survival.
Methods: Quantitative uptake of TeiR and TeiS strains was evaluated
after 2 h of incubation at 37ºC with human embryonic kidney 293
cells at a 10:1 ratio, by a lysostaphin protection assay, and expressed
as percentage of control strain S. aureus Cowan I uptake. Differential
intracellular survival of all S. aureus strains from 2 to 24 h was evaluated
by CFU counts of Triton X-100-lysed 293 cells, following lysostaphin
inactivation.
Results: Endocytic uptake of TeiR strain 14−4 was equivalent to that of
Cowan I but 4-fold higher than that of TeiS strains MRGR3 and 14−4rev.
Even more spectacular differences were recorded for the endocytic
survival of strain 14−4, which showed an 11-fold increase in CFU counts
at 24 h, as opposed to Cowan I and the TeiS strains MRGR3 and 14−4rev,
whose intracellular CFU counts showed marginal (<2-fold) changes from
2 to 24 h. Infected 293 cells showed no evidence of lysis at 24 h, as
assessed by the Trypan blue dye exclusion test.
Conclusions: The increased endocytic uptake of TeiR strain 14−4
compared to its TeiS counterparts may be a consequence of the higher
expression of FnBPs by the TeiR strain. The improved intracellular
survival and proliferation of TeiR strain 14−4 is an interesting in vitro
observation, whose cellular and molecular basis has yet to be explained
and would deserve further investigations. Intracellular location might
confer a signiﬁcant ﬁtness beneﬁt to glycopeptide-intermediate isolates
of MRSA, not only in experimental in vitro models but also in relevant
in vivo situations.
O96 Staphylococcus aureus in cystic ﬁbrosis patients: Agr-alleles,
resistance and virulence determinants
V. Caﬁso, T. Bertuccio, D. Spina, V. Demelio, S. Chiarenza, C. Sciuto,
A. Sciacca, S. Stefani (Catania, IT)
Objectives: Staphylococcus aureus can be a respiratory pathogen in
cystic ﬁbrosis (CF) and its pathogenicity is related to a combination
of virulence and antibiotic-resistance genes. Little is known about the
agr-group in CF-isolates.
This study investigated the antibiotic-resistance, the distribution of 16
virulence determinants in 98 S. aureus strains (single or serial isolates-
same strains removed), subdivided in agr-classes, isolated during a period
of 18 months from the sputum of 60 CF patients, receiving various
courses of antibiotic-therapy.
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Methods: The following were performed: agr-typing by ScaI-RFLP
method; investigation of virulence genes by multiplex-PCR; antibiotic-
resistance by the disk diffusion method according to the CLSI guidelines.
Results: MRSA was isolated in 8% of cases. All staphylococci showed
the following resistance proﬁle: 37% for ERY, 21% for GM, 5% for DA,
14% for CIP, 11% for LVX, 12% for RD, 6% for TE and 3% for C.
Among the strains, agrII was the most prevalent (35%) while agrI-III-IV
were isolated approximately in 21% of cases. Within the agr-groups the
distribution of virulence determinants revealed a common conserved-
core background (sarA-rnaIII-spa-icaA-hla-hlg), whereas accessory-
genes were always represented, in different combinations, and co-
possessed signiﬁcantly. Capsule type-5 was prevalent in agrI while type-8
was prevalent in agrII/III. agrI was associated with the presence of
many virulence-genes such as cytotoxins and proteases (sea-lukE- splB)
and in one agrI isolate lukS/F-PVL was found; agrII also possessed
an adhesin sdrE; agrIII was associated with adhesins and enterotoxin
(fnbA-sea-cna), the exfoliatinA was never detected; agrIV possessed
the cytotoxin lukE, adhesin cna and exfoliatinA, eta. Protease gene
(splB) was always found associated with cytotoxin lukE in agrI-II-III
and, mostly, sdrE adhesin was associated with these. A frequent inverse-
correlation was found between cna and lukE-splB in all agr-groups and
a close correlation was observed between cap8 and cna in agrIII-IV.
Conclusion: Our data demonstrated for the ﬁrst time an increase of
MRSA in our centre; furthermore, CF-persistent infections were not
associated with a distinct agr-speciﬁcity group or a diffused antibiotic-
resistance of the strains, but rather S. aureus isolates have a complex
distribution and combination of virulence determinants which contribute
to S. aureus pathogenicity in CF patients.
O97 Increased proliferation of dentate granule cells in human
bacterial meningitis
J. Gerber, S.C. Tauber, I. Armbrecht, W. Bru¨ck, R. Nau (Gottingen, DE)
Objectives: Proliferation and differentiation of neural progenitor cells
in the dentate gyrus is increased after infection in animal models of
pneumococcal meningitis.
Methods: To evaluate neurogenesis in patients with acute infection of
the central nervous system, brain sections of 18 patients dying from
bacterial meningitis and 8 patients dying from non-neurological diseases
were investigated by immunohistochemistry.
Results: In the dentate gyrus of the hippocampal formation, the density
of Proliferating Cell Nuclear Antigen (PCNA)-expressing cells was
higher in patients with bacterial meningitis compared to the control group
(p = 0.02). Furthermore, the number of cells expressing the immature
neuronal marker protein TUC-4 was increased in brain sections of
persons dying from bacterial meningitis compared to control cases
(p = 0.004). In the subventricular zone, no difference of cells expressing
TUC-4 was observed between both groups (p = 0.39). Immature neurons
expressing TUC-4 had no morphological features of apoptotic cell death
and no evidence of DNA fragmentation.
Conclusion: The increased proliferation of neural progenitors suggests
that endogenous mechanisms may limit consequences of neuronal
destruction after meningitis. Stimulation of neurogenesis might help to
improve therapy of acute inﬂammatory diseases of the brain.
O98 Continuous stimulation of cerebral Toll-like receptor 9 by
intraventricular CpG-DNA causes chronic inﬂammation,
ependymal damage and deﬁcits of memory function
J. Gerber, S.C. Tauber, G. Rohde, J. Weishaupt, R. Nau (Gottingen, DE)
Objectives: Toll-like receptors (TLR) are important factors of innate
immunity. TLR9 is a ligand for bacterial DNA or synthetic CpG-DNA
oligonucleotides and stimulates the immune response by activation of
the MyD88 complex. In our experiments, the effect of chronic TLR9
activation by CpG-DNA in the central nervous system (CNS) was
investigated.
Methods: C57Bl6-mice (n = 21) were trained to ﬁnd a hidden under-
water platform within less than 90 s (18 trials over 3 days). Swim
tracks and the latency to escape from the water were recorded by a
video camera. Thereafter, mice received CpG-DNA (0.001mg/d) or the
same volume of sterile saline over 28 days into the right ventricle
after stereotactic implantation of a catheter connected to a subcutaneous
osmotic pump. Water maze testing was peformed weekly.
Results: After initiation of treatment, the latency to reach the hidden
platform in the water maze was sigiﬁcantly longer in mice receiving
CpG-DNA than in control animals (p = 0.006 at day 28 after initiation
of treatment). Histology showed profound inﬂammation with invasion
and activation of T- and B-cells and axonal damage. Furthermore,
ependymal damage and loss was seen in CpG-treated animals. Additional
experiments with TLR9-deﬁcient mice showed no major inﬂammation
after CpG-treatment over 28 days.
Conclusion: Chronic activation of TLR9 in the CNS causes inﬂamma-
tion, ependymal loss and memory deﬁcits.
O99 Increased ﬁbronectin levels in the cerebrospinal ﬂuid of pa-
tients suffering from bacterial meningitis aggravate toll-like re-
ceptor induced inﬂammation in primary mouse microglial cells
M. Goos, P. Lange, R. Bergmann, S. Ebert, R. Nau (Gottingen,
Eschborn, DE)
Objectives: Fibronectin, an extracellular matrix (ECM) protein, is
discussed to be a potent stimulator of the innate immune system
through Toll-like-receptor 4. Toll-like receptors (TLR) play a key role
in the recognition of products from virtually all classes of pathogenic
organisms. In central nervous system (CNS) infections several ECM
proteins and bacterial compounds are elevated in the cerebrospinal ﬂuid
(CSF). For this reason, we hypothetised that endogenous and pathogen-
derived molecules may jointly stimulate the innate immune system and
increase the neuronal damage in bacterial meningitis.
Methods: Levels of ﬁbronectin were measured in the CSF of patients
suffering from bacterial meningitis, multiple sclerosis and with an
elevated CSF protein due to other causes and compared to healthy
controls. In primary cultures of mouse microglial cells the interaction
of endogenous and exogenous stimulators of the innate immunity
was examined after application of deﬁned Toll-like receptor (TLR)
agonists [lipopolysaccharide (LPS) (TLR4), tripalmytoyl-cysteinyl-seryl-
(lysyl)3-lysine (Pam3Cys) (TLR2) and single-stranded unmethylated
cytosine-guanosine (CpG) oligodesoxynucleotide (TLR9)] alone and in
combination with ﬁbronectin. Supernatants of stimulated glial cultures
and unstimulated controls were analysed for nitric oxide (NO) and
tumour necrosis factor-alpha (TNF-a).
Fibronectin in CSF
Results: Fibronectin was elevated in the CSF of patients suffering
from bacterial meningitis and with an elevated CSF protein due to
other causes, but not in patients with multiple sclerosis and in healthy
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control patients. Co-administration of ﬁbronectin in a concentration
which occurs in bacterial meningitis [10 mg/mL] with CpG, LPS or
Pam3Cys to primary cultured microglial cells led to an additive release
of NO and TNF-a.
Conclusion: The inﬂammatory reaction to the TLR agonists CpG,
LPS and Pam3Cys in primary cultured microglial cells is enhanced by
ﬁbronectin in concentrations occurring in CSF during CNS infections.
Exogenous–endogenous Co-activation leads to stronger microglial
stimulation and may be in part responsible for neuronal damage
occurring in these diseases.
O100 Streptococcus agalactiae invasion of human brain
microvascular endothelial cells is promoted by the
laminin-binding protein
T. Tenenbaum, B. Spellerberg, R. Adam, M. Vogel, K.S. Kim,
H. Schroten (Dusseldorf, Ulm, DE; Baltimore, US)
Objectives: Streptococcus agalactiae (S. agalactiae) can cause severe
pneumonia, sepsis and meningitis in neonates and remains one of the
most prevalent causes of invasive neonatal infections. During the course
of infection, S. agalactiae colonises and invades a number of host
compartments, thereby interacting with different host tissues. In this
study, we investigated the role of S. agalactiae laminin-binding protein
(Lmb) on adherence to and invasion of human brain microvascular
endothelial cells (HBMEC).
Methods: In standard adherence and invasion assays we evaluated the
capacity of scpB-lmb and lmb mutants of S. agalactiae to adhere to
and invade into HBMEC and performed inhibition studies using wild-
type S. agalactiae in combination with recombinant Lmb or polyclonal
Lmb-antibodies. Furthermore interleukin (IL)-8 release was detected by
ELISA.
Results: Deletion of the scpB-lmb region, coding for the C5a
peptidase and Lmb, respectively, resulted in a decreased invasion of
S. agalactiae into HBMEC. Decreased invasion was also seen in lmb
mutant strains. Finally, host cell invasion was signiﬁcantly blocked
in competition experiments with either puriﬁed recombinant Lmb or
a polyclonal antibody directed against the Lmb of S. agalactiae.
The S. agalactiae scpB-lmb mutant induced an equal amount of the
neutrophil chemoattractant IL-8 release in comparison to the wild-type.
Conclusion: Taken together, our studies support the conclusion that Lmb
promotes invasion of S. agalactiae into HBMEC but does not play a role
in IL-8 release from HBMEC.
O101 A proposed mechanism of action of glucocorticosteroids in
severe sepsis
E. Giamarellos-Bourboulis, S. Orfanos, A. Pelekanou, A. Kotanidou,
I. Tzepi, A. Armaganidis, E. Spyridaki, I. Dimopoulou (Athens, GR)
Objective: To investigate the mechanism of action of glucocorticos-
teroids (GL) in severe sepsis (SS).
Methods: 0.1ml of blood sampled from 33 patients within 24 hours
of presentation of SS, was incubated with 0.1ml of RPMI 1640 for
18 h at 37ºC in 5% CO2 with 10 ng/mL of endotoxin (LPS) in the
absence/presence of 10M of dexamethasone (DEX). Soluble triggering
receptor expressed on myeloid cells-1 (sTREM-1) and tumour necrosis
factor (TNF)-a were estimated in supernatants by ELISA. Sepsis was
induced in 60 mice, both wild-type (WT) and TNF-deﬁcient (KO),
by the intraperitoneal challenge of 7log10 CFU of multidrug-resistant
Pseudomonas aeruginosa. They were equally divided in the following
groups: A, WT-controls; B, WT pre-treatment with DEX; C, KO-
controls; D: KO pre-treatment with DEX. Survival was recorded for
six animals of each group; another nine were sacriﬁced six hours post
challenge for estimation of sTREM-1 in serum and of TREM-1 on cell
membranes of neutrophils. Blood was also drawn form two KO mice
and treated as blood of patients with SS.
Results: According to the effect of DEX on LPS-triggered blood,
patients were divided in two groups: those where sTREM-1 was
increased (n = 11) and those where sTREM-1 was decreased (n = 22).
Death occurred in nil (0%) and 11 (50%) of them respectively
(p = 0.005). The former patients survived longer than the latter (log-
rank: 7.42, p = 0.0065). Median changes of sTREM-1 for them were
+20.52 and −62.03 pg/mL (p< 0.0001) and of TNF-a −84.40 and
−405.40 pg/mL respectively (p = 0.048). Results from the animal study
are summarised in the Table. sTREM-1 after stimulation of blood from
KO mice with LPS was 117.74 pg/mL; it was increased to 179.05 pg/mL
after the addition of DEX.
A B C D
Median survival (hours) 18 18 18 >168
Median TREM-1 (%) 36.61 19.01 24.81 13.61
Median sTREM-1 (pg/mL) 751.14 261.51 565.83 423.28
Conclusions: Survival beneﬁt for SS is observed when DEX promotes
increase of sTREM-1 in LPS-triggered blood. The action of DEX is
antagonised by TNF-a because (a) survival is extended for KO mice pre-
treated with DEX; these mice have low TREM-1 and high sTREM-1,
and (b) DEX stimulates production of sTREM-1 by KO blood. Findings
are compatible with the existence of a protease mediating cleavage of
TREM-1 from cell membranes; DEX behaves as agonist and TNF-a as
antagonist. It might be hypothesised that the beneﬁcial effect of GL in
SS is seen for patients with low expression of the TNF gene.
Improving diagnosis in the microbiology
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O102 Usefulness of analysis of the Vbeta repertoire of T cells for
the early diagnosis of staphylococcal and streptococcal toxic
shock syndrome
D. Thomas, T. Ferry, T. Perpoint, J.C. Richard, C. Guillaume,
B. Allaouchiche, F. Vandenesch, D. Peyramond, J. Etienne (Lyon, FR)
Objectives: Staphylococcal and streptococcal toxic-shock syndrome
(TSS) are severe illnesses associated with the production of superanti-
genic toxins, which activate speciﬁc fractions of the T-cell population
by linking the Vbeta domain of the T-cell receptor. Each superantigenic
toxin is associated with a characteristic Vbeta “signature” in vitro.
We postulate that an early analysis of the Vbeta repertoire of T cells
in vivo during TSS may facilitate the diagnosis and the introduction of
antitoxinic agents.
Methods: We have prospectively included in 2005 and 2006 patients
with streptococcal or staphylococcal TSS according to case deﬁnition.
The Vbeta repertoire of T cells (24 Vbeta segments) was analysed by
ﬂow cytometry with fresh PBMC obtained in the ﬁrst 48 hours of
admission. The presence of each superantigenic toxin gene in S. aureus
and S. pyogenes isolates were detected by PCR.
Results: Four patients with staphylococcal (three menstrual and one
non-menstrual) and two patients with streptococcal TSS (one postpartal
and another associated with S. pyogenes bloodstream infection) were
included in the study.
In cases of menstrual S. aureus TSS, a Vbeta 2 expansion corresponding
to the signature of TSST-1, was detected at admission. Corresponding
isolates were positive for the gene encoding TSST-1. A Vbeta
ampliﬁcation corresponding to the signature of SEB was detected in
the patient with staphylococcal non-menstrual TSS. The corresponding
isolate was positive for the gene encoding SEB but also genes encoding
SEA and SED. All patients received clindamycin, when cultures detected
S. aureus (none received linezolid as all isolates were susceptible to
methicillin), and the latter received intravenous immunoglobulins (IVIg).
In cases of S. pyogenes TSS, a Vbeta signature of SPEB was detected
in the patient with the postpartal TSS. No Vbeta signature was detected
in the other patient who developped severe disseminated intravascular
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coagulation requiring limb amputations. The two corresponding isolates
were positive for the gene encoding SPEB. All patients with
streptococcal TSS received clindamycin and IVIg when cultures detected
S. pyogenes.
Conclusion: The analysis of the Vbeta repertoire in patients with
staphylococcal and streptococcal TSS may be a useful tool for the early
diagnosis, apart in the case of associated severe bloodstream infection.
Such analysis may facilitate the early introduction of anti-toxinic agents
such as clindamycin, linezolid or IVIg.
O103 Microcalorimetry – a novel method for rapid diagnosis of
bloodstream infections
J. Antheaume, S. Salzmann, A. Steinhuber, R. Frei, A. Daniels,
A. Trampuz (Basle, CH)
Background: Early detection of microorganisms in blood is essential for
early diagnosis and treatment of bloodstream infections. Calorimetric
detection of microbial growth may be more sensitive and rapid than
blood culture systems. We compared microbial detection in spiked blood
specimens using a commercial system (CO2 detection by colour change)
and an isothermal microcalorimeter.
Methods: Escherichia coli (ATCC 25922) or Staphylococcus aureus
(ATCC 29213) were added at 3 different concentrations to anticoagulated
blood obtained from healthy volunteers. Aliquots of 7.5ml spiked blood
were added into aerobic blood culture bottles containing 40ml growth
medium and incubated in the blood culture instrument (BacT/ALERT,
bioMe´rieux, Durham, NC, USA). Before incubation, 1ml of the bottle
content was inoculated in glass ampoules containing 2ml sterile
trypticase soy broth for calorimetry (TAM III, Thermometric AB,
Ja¨rfa¨lla, Sweden). Blood cultures and calorimetry ampoules were
simultaneously loaded in corresponding instruments and incubated at
37ºC for 72 hours. Time to positivity was deﬁned as the interval from
incubation start until positive signal (BacT/ALERT) or until the heat
ﬂow rate increased 10mW above baseline (calorimeter detection limit =
~0.3mW).
Results: Time to positivity was considerably shorter using calorimetry
(Table). Blood without added pathogens produced no heat signal above
baseline. Spiked specimen heat signals rose to >100mW as the pathogens
multiplied during the incubation period.
Pathogen
(cfu/mL blood)






E. coli (105) 8 3.2 761
E. coli (103) 11.8 5.4 733
E. coli (101) 12.2 7.3 741
S. aureus (105) 10.5 4.4 278
S. aureus (103) 17 7.8 244
S. aureus (101) 20.8 12.9 114
Conclusion: Microcalorimetry has the potential to detect bloodstream
infections earlier with a smaller volume of blood than commercial blood
culture systems and for routine use in microbial screening of blood
cultures.
O104 A novel chromogenic medium for vancomycin-resistant
Enterococcus faecium and Enterococcus faecalis detection
G. Cuzon, T. Naas, N. Fortineau, P. Nordmann (Kremlin-Bicetre, FR)
Objectives: Vancomycin-resistant enterococci (VRE) are widespread
worldwide. Since August 2004, several wards at the Bicetre hospital
faced a clonal outbreak of a vancomycin-resistant Enterococcus faecium
strain BCT-1 expressing an heterogeneous VanD-phenotype vanA
genotype (Naas et al., 2005, JCM, 43, 3642). Rapid identiﬁcation of
VRE carriers from surveillance cultures is crucial in order to control
the VRE spread. We assessed a new selective chromogenic medium
VRE ID (bioMe´rieux, France) that enables isolation and presumptive
identiﬁcation of VRE directly from rectal swab samples.
Methods: Within a month 191 patients totalising 199 rectal swabs were
evaluated for VRE colonisation. Rectal swabs were ﬁrst grown for 18
h in a bile broth (AES, France) containing 3mg/mL vancomycin, at
37ºC, prior to plating on either the conventional Enterococcosel-Agar-
Vancomycin medium (BD, France) or the chromogenic VRE ID medium.
Suspect colonies growing on each media were identiﬁed and tested
for glycopeptide susceptibility. Molecular characterisation of resistance
genes and comparison of the strains (pulse ﬁeld gel electrophoresis
[PFGE]) were performed.
Results: A total of 11 VRE isolates (all E. faecium) were recovered from
199 specimens (17.7%). After 48h of incubation these VRE isolates
were all recovered on each agar medium (sensitivity 100% for both);
the positive predictive values were 20.8% and 91.7% for Enterococcosel
Agar Vancomycin and VRE ID, respectively. PFGE revealed that these
E. faecium isolates were undistinguishable or clonally related to the
epidemic clone. All of them were of vanA genotype.
Conclusions: Chromogenic VRE ID medium showed higher speciﬁcity
to the conventional method for detection of VRE. The chromogenic
and selective characters of VRE ID medium enhanced recovery and
identiﬁcation of VRE and reduced unnecessary conﬁrmations and time-
consuming tests.
O105 Evaluation of a rapid test panel, the API Strep 20, the
BD Phoenix and VITEK2 automated instruments, and
Raman spectroscopy for species identiﬁcation of Enterococci
J. Top, M. Scholtes, K. Maquelin, R. Willems, M. Bonten, M. Wolfhagen,
R. Hegge, M. Asbroek, M. Bruins, M. Leverstein-van Hall (Utrecht,
Rotterdam, Zwolle, NL)
Objectives: The identiﬁcation of vancomycin-resistant enterococci
(VRE) has become an important component of infection-control
programmes. The differentiation between vanA/B-VRE [high-level
and transferable vancomycin resistance in Enterococcus faecium and
Enterococcus faecalis (Efe/Efa)] and vanC-VRE [intrinsic low-level
vancomycin-resistance in Enterococcus casseliﬂavus and Enterococcus
gallinarum (Ecas/Egal] is relevant since in contrast to vanA/B-
VRE, vanC-VRE have not been implicated in outbreaks. Furthermore,
vancomycin treatment failure has been associated with infections caused
by vanC-VRE. Differentiation of vanC-VRE from other enterococcal
species by adequate identiﬁcation is therefore relevant since low-level
resistance may not be detected using the CSLI breakpoints.
In the current study we evaluated a simple rapid test panel (RTP), the BD
Phoenix and VITEK2, the API Strep 20 and Raman spectroscopy for
their accuracy to identify clinical relevant enterococcal species and their
sensitivities and speciﬁcities to distinguish Efe/Efa from vanC positive
enterococci.
Method: In total 96 clinical enterococcal strains comprising 8 different
species were analysed. A genotypic test based on the sequence of
the rpoA gene was used as reference method. The phenotypic test
panel provided a species identiﬁcation within 4 hours, testing the
reduction of litmus milk, acidiﬁcation of arabinose and methyl-alpha-
D-glucopyranoside, hydrolysis of L-arginine, pigment production and
motility. Raman spectroscopy is a relatively new identiﬁcation method
under development yielding results within 1 minute.
Results: The table shows the accuracy of the different tests relative
to the sequence-based identiﬁcation varied between 86% (BD Phoenix)
and 96% (Raman). The best method to distinguish Efe/Efa from vanC
positive species was the RTP with a sensitivity and speciﬁcity of 100%
The API method performed poorly with a relative high sensitivity of
98.6% but very low speciﬁcity (41.7%). With this method 7/12 Ecas/Egal
were identiﬁed as E. faecium.
Conclusions: All methods were comparable regarding the identiﬁcation
of enterococci. However, from the routine laboratory tests the RTP
was the most rapid and reliable method to distinguish Efe/Efa from
Ecas/Egal. Raman spectroscopy is a very promising fast alternative.
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The API revealed a high percentage of false positive E. faecium
identiﬁcations, which may result in unnecessary infection control
interventions.




Sens. (%) Spec. (%)
Rapid phenotypic tests 88 (92) 100 100
API Strep 20 35 (39) 93.6 41.7
BD Phoenix 83 (86) 98.4 100
VITEK2 84 (88) 98.5 91.7
Raman spectroscopya 244 (96) 99.5 36.1
aA selection of 85 strains were tested in triplo.
O106 Rapid identiﬁcation of viridans streptococci by
mass-spectrometric discrimination
C. Friedichs, K. Eschrich, C. Rodloff (Leipzig, DE)
Objectives: Viridans streptococci (VS) are responsible for several
systemic diseases such as endocarditis, abscesses and bacteraemia.
Conventional identiﬁcation of these organisms is laborious and not
always reliable. The aim of the present study was to evaluate the
use of intact cell matrix-assisted laser desorption time-of-ﬂight mass
spectrometry (MALDI-TOF-MS) for rapid identiﬁcation of 10 different
species of VS.
Methods: A total of 99 VS strains were analysed with MALDI-TOF-MS.
As MALDI-TOF reference database for each of the 10 different species
(S. intermedius, S. mutans, S. oralis, S. parasanguinis, S. salivarius,
S. sanguinis, S. mitis, S. constellatus ssp. constellatus, S. anginosus
and S. gordonii) one reference strain (DSMZ, Braunschweig, Germany)
and 3 reliable isolates from our reference stock were used. To evaluate
the mass-spectrometric discrimination results all strains were identiﬁed
parallel with phenotypic (rapid ID 32 STREP system) and genotypic
(species speciﬁc PCRs and sequence analysis of the 16 S rRNA gene)
methods.
Results: The MALDI-TOF-MS identiﬁed 71 strains as mitis group
(37 S. oralis, 23 S. mitis, 10 S. parasanguinis, 1 S. sanguinis,
0 S. gordonii); 23 as anginosus group (19 S. anginosus, 2 S. intermedius,
2 S. constellatus) and 5 S. salivarius strains. The comparison of the
species identiﬁcation results of the MALDI-TOF analyses and the
phenotypic/genotypic identiﬁcation systems showed a consistency of
100% on species level.
Conclusions: The results of the present study showed that mass-
spectrometry might be used as a rapid method for identiﬁcation of VS
from clinical samples. The method was able to discriminate reliably
species of the rather homogeneous mitis group, which is still difﬁcult
with genotypic or phenotypic identiﬁcation methods.
O107 Circulating Candida antibodies precede invasive candidiasis
in patients with haematological malignancy
F.M. Verduyn Lunel, J.P. Donnelly, H.L. van der Lee, N.M.A. Blijlevens,
P.E. Verweij (Nijmegen, NL)
Objectives: Antibodies (Ab) are generally not considered useful for the
early diagnosis of invasive fungal infection. We studied the kinetics
of Candida antigen (Ag) and Ab in patients with haematological
malignancy using two systems commercially available in Europe
(Platelia Candida EIA and Platelia Candida Ab/Ac/Ak, Marnes-La-
Coquette, France, and Serion ELISA Antigen Candida and Serion ELISA
Classic Candida albicans IgG/IgM/IgA, Institut Virion\Serion GmbH,
Wu¨rzburg, Germany).
Methods: Serum or plasma samples were available from 21 haematology
patients (242 samples) with proven invasive candidiasis (IC) collected
between ﬁrst admission and 253 days after the candidaemia. The control
group consisted of 35 patients who had undergone HSCT but without
evidence for IC (135 samples). Ab and Ag were determined using 2
detection systems (Biorad and Serion), and the reactivity was related to
Candida colonisation, mucositis and number of days of neutropenia.
Results: Ab and Ag were detected in more samples from patients
with IC as compared to the control group for both systems (P< 0.05).
Ab was detected at a median of −23 (Biorad) and −20 (Serion) days
before positive blood culture as opposed to −1 and −11 days, resp.,
for Ag. Ab was detected more frequently in patients with >10 days
of neutropenia (corresponding with multiple episodes of neutropenia)
as compared to those with <10 days of neutropenia (P< 0.05). When
analysing individual patients Ab were ﬁrst detected following a previous
episode of neutropenia, suggesting subclinical IC. In the control group
the Biorad test was negative in 91.1% (Ag) and 93.3% (Ab) of samples
and the Serion test in 93.3% (Ag) and 97.6% (Ab). Reactivity in this
group did not correspond with colonisation or mucositis.
Conclusion: Candida Ab are very early markers of IC in haematology
patients who have undergone multiple courses of chemotherapy. These
data suggest that subclinical invasive Candida infection causes an
Ab response and precedes clinically manifest invasive Candida disease.
O108 Evaluation of the increase rate of MRSA detection using
enrichment
A. Curry, M. Walsh, N. Cahill, E. Collins, S. Knowles (Dublin, IE)
The objective of the work carried out was to determine the increase rate
of MRSA detection using an enrichment step compared to direct culture
on chromogenic agar.
MRSA screening swabs from neonates in the NICU were compared: each
swab was ﬁrst cultured directly onto chromogenic MRSA ID agar and
then incubated in Brain Heart Infusion broth for 24 hours. The broths
were subsequently subcultuerd onto MRSA ID agar. All plates were
incubated for 48 hours aerobically at 37ºC and checked for the presence
of green colonies, which is indicative for MRSA, at 24 and 48 hours. All
green colonies had conﬁrmatory tests for MRSA. The limit of detection
was determined for both direct and enriched cultures on MRSA ID agar
using doubling dilutions up to 1/4096 from an initial 0.5 McFarland
suspension. Plates were incubated for 24 hours aerobically at 37ºC after
which colony counts were performed.
A total of 1181 swabs were tested using direct and enriched culture
methods. With direct culture, 16 isolates of MRSA were detected after
24 hours incubation and a further 6 after 48 hours incubation (22 in
total). Following enrichment, 34 isolates were detected after 24 hours
incubation and one more following 48 hours incubation (35 in total).
Enrichment yielded a 59% increase in the number of isolates of MRSA
detected compared to direct culture. The limit of detection for direct
culture was 69,000 cfu/mL at 1/128 dilution with 84,000 cfu/mL at
1/2048 dilution following enrichment.
Results showed that the limit of detection was higher following
enrichment indicating a 16-fold increase in sensitivity compared to
direct culture. The comparison of patient samples correlated with
this by showing an increase of 59% in the rate of detection of
MRSA following enrichment. In conclusion enrichment has proven to
dramatically increase the sensitivity and rate of detection of MRSA
compared to direct culture alone and in order to ensure maximum
sensitivity in the detection of MRSA enrichment should be employed
as the method of choice in routine laboratories.
O109 Phenotypical expression of extended spectrum b-lactamases
in Enterobacteriaceae: prevalence in 3 university hospitals
in Germany, 2003–2006 and implications for screening
A.-S. Endres, I. Noll, T. Eckmanns, W. Pﬁster, N. Wellinghausen,
S. Ziesing, G. Krause (Berlin, Jena, Ulm, Hannover, DE)
Objectives: Resistance of Enterobacteriaceae (EB) to third-generation
cephalosporines has increased during the recent years. Especially strains
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expressing extended spectrum b-lactamases (ESBL) limit therapeutic
options. The CLSI has established recommendations for phenotypical
screening of ESBL in Klebsiella and E. coli. However, similar standards
for ESBL in other EB are missing. Using the data set of the German
Network for Antimicrobial Resistance Surveillance (GENARS) we
assessed the prevalence of ESBL in selected species of EB in order
to estimate applicability for screening in EB other than Klebsiella and
E. coli.
Methods: Analysis is based on ﬁrst isolates of EB collected from Jan
2003 to Sept 2006 in 3 university hospitals. Antimicrobial susceptibility
is determined as Minimal Inhibitory Concentration by the automated
test system Micronaut® with microdilution panels for several ESBL test
substrates including ceftazidime (CAZ), cefotaxime (CTX), cefpodoxime
proxetil (CPP) and cefpodoxime/clavulanic acid (CPC). According to
CLSI guidelines, these antibiotics are used as indicators for (a) ESBL
screening: CAZ 2mg/L or CTX 2mg/L or CPP 8mg/L and (b)
ESBL phenotypical conﬁrmation: ratio of CPP and CPC 8 in E. coli
and Klebsiella spp. With this procedure the presence of a K1 b-lactamase
of K. oxytoca is phenotypically excluded.
Test results for ESBL screening and conﬁrmation and indices for ESBL screening
by species in Enterobacteriaceae (n = 28,990) in Germany 2003–2006a









prev sens spec ppv
K. oxytoca 83 39 36 1,515 1.673 7.3 68.0 97.7 69.7
K. pneumoniae 172 12 119 2,696 2,999 6.1 93.5 95.8 59.1
E. coli 298 28 334 13,059 13,719 2.4 91.4 97.5 47.2
P. mirabilis 31 4 75 2,397 2,507 1.4 88.6 97.0 29.2
Citrobacter spp. 11 5 116 700 832 1.9 68.8 85.8 8.7
Serratia spp. 5 2 89 527 623 1.1 71.4 85.6 5.3
Enterobacter spp. 22 4 478 1,133 1,637 1.6 84.6 70.3 4.4
C. freundii 10 0 237 582 829 1.2 100.0 71.1 4.0
E. cloacae 20 0 774 1,377 2,171 0.9 100.0 64.0 2.5
S. marcescens 2 0 118 636 756 0.3 100.0 84.4 1.7
M. morganii 5 1 421 217 644 0.9 83.3 34.0 1.2
Total 659 95 2,797 24,839 28,390
ascr: screening; cnf: conﬁrmation; prev, prevalence; sens, sensitivity; spec, speci-
ﬁcity; ppv: positive predictive value.
Results: Data of 28,390 isolates were analysed (see the table).
Proportions of conﬁrmed ESBL are highest in K. pneumoniae (5.7%)
followed by K. oxytoca (5.0%) and E. coli (2.2%) compared to 0.3%
to 1.3% in the remaining EB. Isolates with positive conﬁrmatory ESBL
test and negative screening occur in all species, most prominently in
K. oxytoca (2.3%). The proportion of non-conﬁrmed positive screenings
ranges from 2.2% to 4% in E. coli, Klebsiella spp. and P. mirabilis
compared to 13.9% to 65.4% in other EB. In the study population the
positive predictive value is highest for K. oxytoca (69%), K. pneumoniae
(59%) and E. coli (48%) and below 30% for all other EB.
Conclusion: Phenotypical ESBL screening according to CLSI guidelines
indicate a lack of sensitivity for K. oxytoca. Therefore, new screening
algorithms for detection of resistance due to b-lactamases have to be
created and should probably include genotypical properties in EB.
O110 Predictive value of C-reactive protein and procalcitonin for
bacteraemia in adult community-acquired infection
S.-Y. Chen, W.-C. Chiang, H.-Y. Sun, J.-L. Wang, S.-C. Chang, C.-C. Lee,
A.M.-F. Yen, G.H.-M. Wu, T.H.-H. Chen, P.-R. Hsueh (Taipei, TW)
Objectives: The value of C-reactive protein (CRP) and procalcitonin
(PCT) in predicting bacteraemia has not been compared in a clinical
model based on variables from clinical assessment and routine laboratory
tests.
Methods: Eighty-four bacteraemic and 474 non-bacteraemic adult
patients with community-acquired infections were prospectively studied.
A basic model of septic evaluation integrating routine clinical and
laboratory variables, and infection site was developed and analysed for
its predictive value alone and with further incorporation of either CRP or
PCT. The area under the receiver-operating characteristic curves (AUC)
of the CRP-incorporated and PCT-incorporated model were compared to
the AUC of the clinical model.
Results: The independent predictors of bacteraemia identiﬁed in
the clinical model were age  60 years-old (OR 1.80; 95%CI:
1.03−3.14), presence of fever (OR 2.56; 95%CI: 1.09−5.97), body
temperature higher than 38.3ºC at blood culture (OR 2.23; 95%CI:
1.20−4.13), hypotension (OR 3.83; 95%CI: 1.23−11.99), heart rate
120 beats/min (OR 2.34; 95%CI: 1.29−4.22), leukocyte count 
15,000 cells/mL (OR 2.15; 95%CI: 1.12−4.12), lymphopenia (OR 5.89;
95%CI: 3.17−10.96), thrombocytopenia (OR 2.36; 95%CI: 1.33−4.21),
hepatobiliary tract infection (OR 8.43; 95%CI: 3.13−22.7), urinary tract
infection (OR 2.41; 95%CI: 1.24−4.69), and orthopaedic site infection
(OR 56.64; 95%CI: 6.14–522.52). The value of the AUC in the clinical
model was 0.829 (95%CI: 0.781−0.878). Adding CRP level to the basic
clinical model did not change any of the identiﬁed predictors. In the
PCT-incorporated model, PCT 0.5 ng/mL became a new independent
predictor (OR 4.69; 95%CI: 2.62−8.41) and increased the value of the
AUC to 0.848 (95%CI: 0.803−0.894). However, the difference between
the AUC of the clinical model and the PCT-incorporated model was not
signiﬁcant (P = 0.388).
Figure 1. Area under the receiver operating characteristics curves of the
clinical model, PCT-incorporated model, and univariate analyses with
procalcitonin (PCT) and C-reactive protein (CRP) for the prediction of
bacteraemia.
Conclusion: The limited additional help of the inﬂammatory markers
CRP or PCT in bacteraemia prediction compared to a model of
clinical assessment and routine laboratory information required for septic
evaluation suggest the need for further justiﬁcation of the use of these
measurements in cost-constrained settings.
O111 A new chromogenic agar medium, chromID VRE®, to
screen for vancomycin-resistant Enterococcus faecium and
Enterococcus faecalis
N. Ledeboer, R. Tibbetts, M. Dunne (Saint Louis, US)
Objectives: Enterococcus species are members of the normal intestinal
ﬂora, and are the most common aerobic Gram-positive cocci found in
the large bowel of humans. The organisms have gained more notoriety,
however, as nosocomial pathogens, now grouped as the third most
common blood borne pathogen in the United States. At least one factor
accounting for this pathogenicity is their propensity to carry plasmid-
mediated resistance markers to vancomycin. The development of reliable
and rapid methods for the identiﬁcation of patients colonised with
vancomycin-resistant enterococci (VRE) is central to the prevention
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of person-to-person transmission of this agent within the hospital
environment. To this end, we conducted clinical trials for a chromogenic
agar medium designed by bioMe´rieux (France) (chromID VRE) to
recover VRE from stool and identify the isolated colonies as either
Enterococcus faecium (VREfm) or E. faecalis (VREfs) based on different
colony colour.
Methods: We compared the performance of this medium with bile
esculin azide agar supplemented with vancomycin (BEAV). For this
study, 120 stool samples were plated on each test medium and examined
after 24 and 48 hours of incubation. Culture positive results were
further identiﬁed using biochemical reactions (VITEK2®), vancomycin
susceptibilities, and PCR.
Results: At 24 hours, the sensitivity and speciﬁcity were: BEAV: 96%,
73%; chromID VRE: 90%, 89%. The positive predictive values for
identiﬁcation of positive samples by the chromogenic medium and
BEAV at 24 hours were: chromID VRE 83%, BEAV 68%. Increased
length of incubation (48 hr) did not signiﬁcantly improve sensitivity,
speciﬁcity, or positive predictive value for either medium. In addition,
chromID VRE identiﬁed 2 isolates of VREfs that were not recovered
using BEAV. Furthermore, the chromID VRE was capable of identifying
patients colonised with both VREfm and VREfs – a feature useful for
epidemiology follow-up that is not available with BEAV.
Conclusions: We conclude that this new and innovative chromogenic
agar, chromID VRE, provides improved recovery of VRE from stool
specimens and the added advantage of differentiation between VREfs and
VREfm with an increase of speciﬁcity towards enterococci intrinsically
resistant to vancomycin. Extended incubation beyond 24 hours did not
signiﬁcantly improve recovery of VRE and resulted in a decreased
speciﬁcity.
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O112 Recent trends in epidemiology of MRSA in Finland
A. Vainio, M. Karde´n-Lilja, S. Ibrahem, O. Lyytika¨inen,
J. Vuopio-Varkila (Helsinki, FI)
Objectives: In Finland, a worrisome increase in the annual numbers of
MRSA cases was observed from 2001 to 2004. Active control measures
were implemented from 2005 to decrease MRSA cases. We report here
the recent changes in MRSA epidemiology.
Methods: All MRSA isolates are notiﬁed by local laboratories to
National Infectious Disease Register (NIDR) at National Public Health
Institute (KTL) and tested at National Reference Laboratory at KTL
by genotyping and antimicrobial susceptibility testing. Pulsed ﬁeld gel
electrophoresis (PFGE) was used as the primary genotyping method to
distinguish different MRSA strains. In addition, multi locus sequence
typing (MLST), staphylococcal cassette chromosome mec (SCCmec)
analysis, and spa-typing were used to analyse representatives of each
new epidemic MRSA strain. The clonal complex analysis was performed
by BURP and eBURST programmes. The presence of PVL genes (lukS-
PV – lukF-PV) was detected by PCR.
Results: The annual number of MRSA isolates reported to the NIDR
rose over ten-fold, from 120 in 1997 to 1458 in 2004. In 2005 and
2006 (−30.9.2006) 1375 and 1004 new MRSA cases were detected,
respectively. In general, the predominant MRSA strain types remained
the same during 2004–2006: FIN-16, FIN-7, FIN-10, FIN-21 and FIN-4.
However, in 2006 the number of FIN-7 strains showed an increasing trend
whereas FIN-21 decreased from year 2005. Community-MRSA strains
(FIN-4, FIN-7 and FIN-10) composed 30% of all MRSA cases in 2005.
Eleven new epidemic MRSA strains have been identiﬁed since 2005. The
number of cases within these outbreaks has been small. Four strains were
resistant to B-lactam antibiotics only; the remainders showed resistance
also to one or two other antibiotic groups. All except three strains were
members of known MLST clonal complexes: CC5 (ST335, ST874, ST5,
ST788), CC8 (ST8), CC45 (ST45) and CC59 (ST375). For one strain
(ST849) no predicted founder could be identiﬁed and two strains (ST93
and ST853) were singletons. Four of the strains possessed SCCmec
type IV, three SCCmec type V and one SCCmec type I. Three strains
harboured a nontypeable SCCmec type.
Conclusions: The increasing trend in MRSA case numbers turned to a
decline in 2005. Since then, several new epidemic MRSA strains have
been detected. They differ from earlier strains as being non-multiresistant
with SCCmec types IV, V or nontypeable. The outbreaks have been small
and local, which speaks for the success of active control measures.
O113 Differences in the molecular epidemiology of methicillin-
resistant Staphylococcus aureus within the Dutch–German
EUREGIO MRSA-net Twente/Mu¨nsterland
A. Mellmann, I. Daniels-Haardt, R. Ko¨ck, A.-K. Sonntag, F. Verhoeven,
J. van Gemert-Pijnen, R. Hendrix, A. Friedrich (Mu¨nster, DE;
Enschede, NL)
Objectives: The increasing cross-border transfer of patients and
healthcare workers (HCW) within the EU causes enormous problems
with regard to control the spread of multi-resistant pathogens. Especially
within the Dutch–German border region, there are great differences in
the prevalence of methicillin-resistant Staphylococcus aureus (MRSA):
the Netherlands <1%, Germany ~5−25%. In addition, within the last two
years an increasing number of community-acquired (CA)-MRSA could
also be noted in the Netherlands, which represent an additional danger.
The objective of this study was to elucidate the molecular cross-border
epidemiology of MRSA within the EUREGIO Twente/Mu¨nsterland.
Methods: The ﬁrst MRSA isolates of all patients and HCWs obtained
within the EUREGIO MRSA-net Twente/Mu¨nsterland were typed. The
epidemiological backbone of the project is a typing network providing a
common language based on S. aureus protein A (spa) gene sequencing.
Results: Since the beginning of the project in July 2005, more than
1400 isolates from in- and out-patients and nursing home inhabitants
were typed. Three spa types (t025, t091, t162) were detected only within
the Euregio. The spa types t004, t009, t012, t024, t036, t051 and t084
were determined in the German part of the Euregio, only. However, the
majority of spa types on the German side were in concordance to the
national epidemiological trend with spa t001, t002, t003, t004 and t032
as the most common spa types. The spa type t044 – often associated
with CA-MRSA in central Europe – was detected on both sides; 1% on
the German and ~15% on the Dutch side of the border, underlining
the emerging problem of CA-MRSA. Focusing on hospitalised patients,
MRSA in blood cultures – only detected on the German side – were
mainly spa type t001, t003, t004, t008 and t032.
Conclusion: In summary, the use of spa typing elucidated differences
in the regional epidemiology of MRSA. However, cross-border spread
of MRSA was also detected. Therefore, new co-ordinated regional and
cross-border strategies have to be developed in the MRSA-net to ﬁght
against MRSA.
O114 Prevalence of methicillin-resistant Staphylococcus aureus in
the southern and eastern Mediterranean – ﬁnal results from
the ARMed project
M.A. Borg, E.A. Scicluna, N. van de Sande-Bruinsma, M. de Kraker,
E.W. Tiemersma, J. Monen, H. Grundmann and ARMed Project
Collaborators
Objective: The high prevalence of methicillin resistant Staphylococcus
aureus (MRSA) within the northern Mediterranean countries of Europe
has already been documented. However, the concomitant situation in
centres within the southern and eastern countries of the region was
previously unknown. The Antibiotic Resistance Surveillance and Control
in the Mediterranean Region (ARMed) project [www.slh.gov.mt/armed]
provided a ﬁrst time opportunity for a longitudinal multi-year study
of trends of antimicrobial resistance amongst this species within these
countries.
Methods: The ARMed project used comparable protocols to those
adopted and validated by the European Antimicrobial Resistance
Surveillance System (EARSS) and collected susceptibility test results
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from invasive isolates of S. aureus routinely isolated from blood in
59 participating laboratories within Algeria, Cyprus, Egypt, Jordan,
Lebanon, Malta, Morocco, Tunisia and Turkey, who also took part in
a external quality assurance programme throughout the project. The
laboratories followed their routine procedures and breakpoints, which
in 86.8% of the participants were based on CLSI (formerly NCCLS)
guidelines. MRSA incidences at country level for 2005 were calculated
by combining resistance data from the ARMed database with information
on total number of patient days on the basis of hospital codes.
Results: A total of 5,353 S. aureus isolates were reported to ARMed for
the whole study period (2003–2005), with an average MRSA proportion
of 38%. MRSA incidence ranged from 4.61 per 100,000 patient days
in Morocco to 18.37 in Egypt. Laboratories in Egypt, Jordan, Cyprus
and Malta reported prevalence in excess of 50% in at least two out
of the three study years. Furthermore, over the study period, signiﬁcant
increases were observed in Egypt (33% to 63%) and Malta (43% to 55%)
whilst decreases were reported in Jordan (66% to 32%) and Turkey
(43% to 35%).
Conclusion: ARMed resistance data has improved the MRSA epidemi-
ological picture within the whole Mediterranean area and conﬁrmed that
the region as a whole exhibits a high prevalence. Other data from the
whole region collected by ARMed as well as by other projects appears
to suggest that antimicrobial consumption together with sub-optimal
infection control infrastructure and activities may be important drivers
behind this high prevalence situation and merit further research in the
future.
O115 Molecular epidemiology of non-multiresistant and
community-associated MRSA in Geneva, Switzerland, over
a 13-year period
P. Francois, S. Harbarth, D. Pittet, J. Schrenzel (Geneva, CH)
To evaluate the molecular epidemiology of methicillin-resistant Staphy-
lococcus aureus strains differing from the multiresistant, healthcare-
associated clone endemic in Geneva, we identiﬁed two collections
of 151 non-multiresistant strains over a 13-year period. Extensive
characterisation included staphylococcal chromosome cassette mec and
accessory gene regulator type determinations, toxin content, as well
as genotyping. Our collection contained an extraordinary diversity of
strains in terms of genome content, including internationally well-
known isolates. Fifty-eight percent (n = 92) of strains contained one
important toxin. A large proportion harboured a SCCmec IV (n = 75)
or V cassette (n = 7). The most important clusters were composed of
PVL positive ST80 (n = 39), ST5 containing PVL or TSST (n = 15)
and ST88 harbouring the exfoliatin A (n = 10). A homogeneous cluster
of PVL positive, gentamicin-resistant strains (ST152 MRSA V) was
found in 5 patients from Kosovo. Other strains showed previously
uncharacterised genome contents (e.g. PVL negative ST1-MRSA-V) or
proﬁles rarely observed in Europe (ST59 MRSA-IV or ST8-MRSA-
IV). Several unusual clusters were detected, including one cluster in
neonatology (PVL positive strain ST5 MRSA-IV) and transmission
between 2 prison inmates (ST8 MRSA-IV). Our observation suggests
that the molecular epidemiology of non multiresistant MRSA in the
Geneva is very diverse and rapidly evolving through constant importation
and community transmission of new strains.
O116 Community-onset MRSA bacteraemia: characteristics of
patients presenting to hospital
A. Pearson, M. Murray, A. Jones, M. Painter, A. Charlett, C. Jackson
(London, UK)
Objectives: To examine the distribution of patients with MRSA
bacteraemia detected within 2 days of presentation in acute NHS
hospitals in England from an analysis of approximately 7000 MRSA
bacteraemias reported between October 2005 and September 2006.
Methods: In October 2005, an enhanced mandatory MRSA bacteraemia
surveillance system (MESS) was introduced, including collection of
additional data such as patient socio-demographic characteristics (e.g.
age, gender, patient location), Trust characteristics (e.g. region, Trust
type/size, location) and patient clinical characteristics (e.g. timing of
MRSA bacteraemia detection, source of admission, specialty under
which MRSA was detected). A subset of data on patients’ risk factors is
also collected and includes variables such as source of bacteraemia and
previous contact with the health delivery system. Data were extracted for
the period October 2005 to September 2006 from the MESS database,
representing approximately 7000 reported MRSA bacteraemias in 172
acute NHS Trusts. Standardised screen formats were used to record the
dates of admission and onset of bacteraemia, location of patient prior to
admission, location and specialty at the time of diagnosis.
Results: A signiﬁcant proportion of MRSA bacteraemias (34%) were
detected within 2 days of presentation to the Trust. More speciﬁcally,
9% were detected at presentation to the Trust and a further 25% within 2
days of admission. Of those detected on presentation (and not admitted),
over one third (44%) were seen at Accident and Emergency and a further
14% were regular attendees, e.g. at renal units. Most patients with MRSA
bacteraemia detected within 2 days of presentation to the Trust were
admitted from home (66%), 16% came from nursing homes and 7%
from other Acute Trust hospitals. Data on patients’ risk factors indicate
that skin and soft tissue infections and UTIs are the most common risk
factors for developing MRSA bacteraemia within 2 days of presentation.
Conclusion: Preliminary results appear to support the hypothesis that
a large proportion of patients presenting with MRSA bacteraemia at
admission have had prior healthcare interactions in the preceding three
months. Identiﬁcation of readmission patterns may provide a useful
means of targeting interventions to prevent some of these MRSA
bacteraemias, whether originating from previous hospital admissions or
from nursing homes in the community healthcare setting.
O117 Heteregeneous but higher adhesive properties of
hospital-acquired MRSA Lyon clone isolates in comparison
to MSSA isolates
T. Ferry, S. de Bentzmann, L. Mayor, M. Bes, F. Vandenesch, J. Etienne
(Lyon, Marseille, FR)
Objectives: The success of pandemic hospital-acquired MRSA clones
may be due to high adhesive properties. Adhesion is mediated by various
different cell wall proteins called adhesins that are tightly regulated. The
accessory gene regulator (agr) is one acting regulator. agr dysfunction
is associated with overexpression of certain adhesins and seems to be
responsible of the success of the CMRSA-3 clone in Canada. In this
way, we compared adhesive properties, the adhesin gene content and the
functionality of agr of MRSA Lyon clone isolates to those of MSSA
isolates.
Methods: We studied S. aureus isolates responsible for bloodstream
infections in intensive care units in 2003. Nineteen isolates were
susceptible to methicillin and 13 MRSA isolates had characteristics
of the MRSA Lyon clone (sequence type 8, agr allele type 1 and
positive for the sea gene). The binding behaviour onto airway epithelial
cells (HAECs) were determined by quantifying the number of adherent
bacteria per cell (30 cells per strain were used). The adhesin gene proﬁle
(bbp, can, eno, ebpS, ﬁb, clfA, clfB, fnbA and fnbB) was determined
with multiplex PCR for each isolates. The dysfunction of agr was
detected by the absence of delta-haemolysin production.
Results: The number of S. aureus isolates per cell was more
homogeneous for MSSA isolates than MRSA isolates, but the adhesion
of MRSA isolates was signiﬁcantly higher than MSSA isolates (68.94
± 8.483 and 34.31 ± 3.446, respectively, p< 0.001) (Figure). MRSA
isolates were all positive for eno, ﬁb, clfA, clfB, fnbA and fnbB,
only. MSSA isolates were all positive for eno, clfA, clfB and fnbB
and inconstantly positive for others. The absence of delta-haemolysin
production tended to be more frequent among MRSA isolates (7/13
versus 16/19 isolates), but the difference was not signiﬁcant (p = 0.11).
No correlation between the adhesive property and the absence of delta-
haemolysin production was observed, both in MRSA and in MSSA
isolates.
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Conclusion: We demonstrated that adhesive properties onto HAECs
of MRSA Lyon clone isolates was higher than that MSSA isolates,
but was heterogeneous despite similar genetic background and adhesin
gene proﬁle. This could be the result of overexpression of adhesins
independently of an agr dysfunction.
O118 Community-associated MRSA ST8-SCCmecIVa (USA-300):
experience in England and Wales
A.M. Kearns, M. Ganner, R.L.R. Hill, C. East, I. McCormick Smith,
M.A. Ganner, M.J. Ellington (London, UK)
Objectives: Although many distinct genetic lineages of community-
associated MRSA (CA-MRSA) have been reported worldwide, one clone
has proved highly successful in the USA. The ST8-SCCmec IVa (or so-
called USA-300) clone has been associated with community outbreaks,
nosocomial transmission, and identiﬁed as the primary cause of skin
and soft tissue infections (SSTI) presenting to Emergency Departments
across the USA. Following enhanced surveillance for CA-MRSA, and
in the light of these observations, we have mapped the epidemiology of
this clone in England and Wales.
Methods: Over a 2 year period (2004/5), all MRSAs referred to
the national Staphylococcus Reference Unit for England and Wales
were characterised microbiologically. Isolates identiﬁed as CA-MRSA
were subjected to detailed characterisation (including MLST, spa
typing, toxin gene proﬁling, PFGE and antibiotic susceptibility testing).
Epidemiologic, demographic and clinical data were also collated.
Results: Of ca. 300 CA-MRSA identiﬁed, 40 belonged to the
ST8-SCCmecIVa clonal lineage; the third most common CA-MRSA
occurring nationally. All 40 isolates were PVL-positive, spa t008 and
belonged to agr group 1. Nine different sub-types were distinguishable
by PFGE; almost half belonged to a single pulsotype. All were resistant
to b-lactams; resistance to erythromycin, ciproﬂoxacin, gentamicin,
tetracycline and fusidic acid was variable. All were susceptible to
clindamycin, trimethoprim, vancomycin, linezolid and mupirocin. The
majority of patients (32, 80%) were community-based, including
23 males and 17 females; ages ranged from <1 to 89 y (median 25 y).
60% presented with skin infections (e.g. boils, abscesses or insect
bites) and 25% with soft tissue infections. One patient died. Most
cases were sporadic, but 4 community-based clusters were identiﬁed
involving MSMs, household contacts and individuals attending the same
GP surgery. Eight patients gave a history of foreign travel (e.g. the USA),
the remainder were acquired domestically.
Conclusion: The ST8-IVa lineage of CA-MRSA has been occurring in
England and Wales since at least 2002. Whilst numbers remain small,
the occurrence of community-based clusters and the death of one patient
give cause for concern. The emergence of resistance to multiple classes
of antimicrobials allied to evidence of clonal expansion highlight the
need for continued surveillance to underpin effective therapeutic and
infection control strategies.
O119 Community MRSA ST8 (“USA300”) has arrived in Central
Europe
W. Witte, C. Cuny, B. Strommenger, U. Nu¨bel (Wernigerode, DE)
Objective: Community MRSA (cMRSA) “USA300”, MLST ST8 was
reported as particularly epidemic in Northern America. This cMRSA
exhibits a few characteristics by which it can be detected easily. Here we
report about characterisation of MRSA exhibiting spa sequence type t008
(congruent with MLST ST8) from community and nosocomial infections
in Germany in order to assess the emergence and spread of the epidemic
community MRSA “USA 300” in Central Europe.
Methods: Multilocus sequence typing (MLST), grouping of SCCmec
elements by means of PCR, PCR demonstration of lukS-lukF arcA
(arginindeiminase, indicator for ACME-island; msrA (macrolide efﬂux),
mphB (macrolide phosphotransferase), and fosB.
Results: MRSA exhibiting t008, MLST ST8 which are exhibiting
resistance to oxacillin and to ciproﬂoxacin but lacking lukS-lukF, arcA,
msrA, mphB are known from community acquired wound infections and
nasal colonisation in the Stuttgart area since 2000. Community acquired
MRSA exhibiting t008, MLST8 and containing lukS-lukF, arcA, msrA,
mphB have been recorded from deep seated infections of skin and soft
tissue in Saarland, Rhineland-Pfalz, North-Rhine-Westphalia, and lower
Saxony as well as in Tyrol (Austria) since 2004. In two cases spread to
other patients occurred after admission of affected patients to surgical
wards. ArcA, msrA, mphB are characteristic for community MRSA
“USA 300” and were not detected in representatives of epidemic hospital
MRSA and also not in other clonal lineages of lukS-lukF containing
community MRSA.
Conclusion: lukS-lukF containing MRSA carrying other acquired genes
which are characteristic for MRSA “USA 300” have been recorded
from several locations in Germany. For reliable early warning MRSA
exhibiting spa t008 should be further characterised for containing lukS-
lukF, arcA, and mphB.
O120 Characteristics of complicated skin and skin structure
infections due to staphylococci and the presence of
Panton-Valentine leukocidin
R. Strauss, K. Amsler, M. Jacobs, K. Bush, G. Noel (Raritan, US)
Objectives: An association has been proposed between Panton-Valentine
leukocidin (PVL) and virulence in methicillin-resistant Staphylococcus
aureus (MRSA) causing skin or respiratory tract infections. In a
multicentre trial comparing ceftobiprole (BPR), an investigational
cephalosporin, to vancomycin (VAN) in patients with complicated
skin and skin structure infections (cSSSI), PVL-positive S. aureus
characteristics were analysed and assessed for both MRSA and
methicillin-susceptible (MSSA) isolates.
Methods: S. aureus isolates were analysed for PVL by multiplex PCR
(n = 415). In vitro susceptibility (CLSI methodology) and a mecA probe
were used to identify MRSA. Infection type was categorised as abscess,
wound, or cellulitis. Infections with a depth either to the fascial plane
or muscle were considered deep infections.
Results: Of 784 patients enrolled, S. aureus was identiﬁed in 494
baseline isolates from pus, leading edge of cellulitis, or debrided
tissue. PVL was signiﬁcantly more common in abscesses compared
to wound infections or cellulitis among both MRSA (P< 0.001) and
MSSA infections (P< 0.005). There was a trend for higher WBC counts
among PVL-positive MRSA and MSSA isolates compared to PVL-
negative MRSA and MSSA isolates. PVL-positive MRSA infections
were associated with signiﬁcantly lower rates of fever (P< 0.001) and
lower levels of C-reactive protein (CRP) (P< 0.005) compared to PVL-
negative MRSA infections. Lower overall cure rates were observed in
PVL-positive MRSA infections (overall 89.3%; BPR 93%; VAN 85%).
Overall cure rates for PVL-negative MRSA and PVL-positive or negative
MSSA were >94% in both treatment arms.
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% MRSA % MSSA
PVL(+) PVL(−) PVL(+) PVL(−)
Infection type, %
abscess
70.5 (67/95)* 26.3 (15/57) 68.0 (68/100)* 48.2 (79/164)
Deep infections, % 33.6 (32/95) 38.6 (22/57) 26.0 (26/100) 34.1 (56/164)
WBC> 104, % 32.2 (28/87) 21.3 (10/47) 41.4 (36/87) 31.0 (45/145)
Temperature >38ºC 14.7 (14/95)* 42.1 (24/57) 44.0 (44/100) 40.2 (66/164)
CRP> 50mg/dL 28.0 (26/93)* 51.9 (28/54) 36.2 (34/94) 41.4 (67/162)
Conclusion: PVL-positive MRSA and MSSA were widely prevalent in
cSSSI. The presence of PVL in both MRSA and MSSA was signiﬁcantly
associated with abscess compared to wound infections or cellulitis in this
cSSSI trial. Lower fever and CRP levels in patients with PVL-positive
MRSA infections may indicate impaired host responses to PVL-positive
S. aureus. The presence of PVL was associated with lowest cure rates in
patients with MRSA infections; however, cure rates in patients treated
with BPR exceeded 90%.
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O140 Micafungin versus caspofungin in patients with invasive
candidiasis or candidaemia: a Phase III, randomised,
double-blind, parallel group, non-inferiority study
B. Dupont, J. De Waele, R. Betts, C. Rotstein, M. Nucci, L. Arnold,
L. Kovanda, C. Wu, D. Buell (Paris, FR; Ghent, BE; Rochester, US;
Hamilton, CA; Rio de Janeiro, BR; Deerﬁeld, US)
Objectives: To determine the efﬁcacy and safety of two doses of
intravenous micafungin (MICA) versus caspofungin (CAS) as an
antifungal treatment for patients with conﬁrmed invasive candidiasis or
candidaemia.
Methods: Patients aged  18 years with conﬁrmed invasive candidiasis
or candidaemia were randomised 1:1:1 to receive MICA 100mg/day
(MICA100), 150mg/day (MICA150) or CAS (70mg on day 1 and
50mg/day thereafter). The primary efﬁcacy endpoint was treatment
success by investigators’ assessment at the end of blinded intravenous
therapy, deﬁned as a positive clinical response and a positive mycological
response. Patients who died during therapy or had missing values
were considered treatment failures. Non-inferiority was deﬁned as the
lower bound of 95%CIs for treatment difference for MICA versus
CAS exceeding −15%. Secondary efﬁcacy endpoints included treatment
success as assessed by the data review panel, clinical response,
mycological response, incidence of emergent invasive fungal infections
throughout the study and incidence of relapse post-treatment.
Treatment success MICA CAS
100mg 150mg




2.5 (−5.9, 11.0) −1. 1 (−9. 3, 7.8)
aAdjusted for baselin APACHE Il score and geographic region.
Results: The full analysis set (FAS) was the primary analysis set for
efﬁcacy and comprised 593 patients: 199 receiving MICA100, 202
receiving MICA150 and 192 receiving CAS. Overall treatment success
was seen in 73.9% of MICA100, 70.3% of MICA150 and 71.4% of
CAS patients. The two-sided 95%CIs exceeded the predeﬁned non-
inferiority margin of −15%; both MICA doses were therefore non-
inferior to CAS. The data review panel assessments conﬁrmed this
result. On secondary efﬁcacy endpoints, the three treatment arms were
similar in terms of clinical and mycological response, and there were
no signiﬁcant differences in the incidence of emergent fungal infections
during the study and in the incidence of relapse post-treatment. There
were no clinically signiﬁcant differences between the three treatment
arms in terms of adverse events, including those of special interest, such
as hepatic and renal function adverse events. The incidence of death
during treatment was similar across treatment groups.
Conclusion: MICA100 and MICA150 were equally effective and were
non-inferior to CAS on the primary efﬁcacy endpoint of treatment
success as deﬁned by the investigator. There were no signiﬁcant
differences between the MICA treatment arms and CAS on all secondary
endpoints. All three treatment regimens had similar safety proﬁles.
O141 Micafungin versus liposomal amphotericin B (AmBisome®)
in paediatric patients with invasive candidiasis or
candidaemia
A. Arrieta, F. Queiroz-Telles, E. Berezin, A. Freire, S. Diekmann,
S. Koblinger (Orange, US; Curitiba, Sa˜o Paulo, Belo Horizonte, BR;
Munich, DE)
Objective: To compare the efﬁcacy and safety of micafungin (MICA)
with AmBisome® (L-AmB) in a paediatric subpopulation in a large,
randomised, phase III trial in patients with invasive candidiasis or
candidaemia.
Methods: In this double-blind, multicentre study, non-neutropaenic
and neutropaenic paediatric patients aged 15 years with clinical and
microbiological evidence of invasive candidiasis or candidaemia were
randomised 1:1 to receive intravenous MICA (2mg/kg/day) or L-AmB
(3mg/kg/day) for a minimum of 14 days. All randomised patients were
included in the full analysis set (FAS). Efﬁcacy analyses were also
performed for the per protocol set (PPS), which included all patients
who had conﬁrmed invasive candidiasis or candidaemia but did not have
a further invasive infection caused by a non-Candida fungal pathogen,
for whom the investigator’s assessment of overall treatment success at the
end of therapy (EOT) was available, and who received at least ﬁve doses
of study drug and did not receive a prohibited antifungal medication.
The safety set included all FAS patients. Overall treatment success was
based on clinical and mycological response at the end of therapy, as
assessed by the investigator. The post-treatment follow-up period was
12 weeks.
Results: A total of 106 patients (52 MICA and 54 L-AmB patients) were
included in the FAS; 83 patients were included in the PPS. Age groups,
including prematurity at birth, were well represented; candidaemia was
the primary infection in the majority of patients in both treatment
groups. The key efﬁcacy results are shown in the table. The incidence
of treatment-related adverse events (AEs) was lower with MICA than
with L-AmB (36.5% versus 42.6%, respectively), as was the incidence
of serious AEs (3.8% versus 9.3%, respectively). In addition, fewer
patients receiving MICA than L-AmB discontinued therapy because of
AEs (3.8% versus 16.7%, respectively).
Treatment success, n (%)
MICA L-AmB
FAS
Overall 36/52 (69.2) 40/54 (74.1)
By neutropaenic status at baseline:
<500 cells/mL 5/7 (71.4) 10/13 (76.9)
500 cells/mL 31/45 (68.9) 30/41 (73.2)
PPS
Overall 35/41 (85.4) 37/42 (88.1)
<500 cells/mL 5/5 (100) 9/10 (90.0)
500 cells/mL 30/36 (83.3) 28/32 (87.5)
Conclusion: MICA was as effective as L-AmB in paediatric patients
with candidaemia or invasive candidiasis, irrespective of neutropaenic
status. Fewer MICA patients experienced treatment-related AEs, and
there were fewer discontinuations due to AEs compared with L-AmB.
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O142 Once daily, levoﬂoxacin 750mg for 5 days in the treatment
of acute pyelonephritis and associated bacteraemia
P. Brown, J. Peterson, M. Khashab, S. Kaul, A. Fisher, J. Kahn
(Detroit, Raritan, US)
Objective: Urinary tract infections, in particular, pyelonephritis, have
been identiﬁed as a common cause of Gram-negative bacteraemia.
Studies that evaluated the prevalence of positive blood cultures in acute
pyelonephritis (AP) yielded a blood pathogen in up to 23% of patients.
The current clinical study represents one of the largest cohorts of patients
with AP studied to date and provides an opportunity to assess the
incidence, clinical presentation and outcome of bacteraemia in patients
with AP.
Methods: This was a randomised, double-blind study. Subjects >18 yrs
were stratiﬁed depending on diagnosis (cUTI or AP), residence, and
catheter status. Subjects were randomised to treatment with iv/oral
levoﬂoxacin (levo) 750mg qd, 5d or iv/oral ciproﬂoxacin (cipro)
400/500mg bid, 10d. Blood cultures were obtained at study entry and,
if positive, again at Posttherapy.
Results: 1109 subjects were enrolled; 1093 were randomised and
received >1 dose of study drug; 619 had a conﬁrmed clinical
diagnosis and a study entry uropathogen (modiﬁed intent-to-treat
[mITT] population). 192 mITT subjects were diagnosed with AP. Urine
eradication rates for subjects with AP were 86.2% (81/94) for levo
and 80.6% (79/98) for cipro (95%CI: −16.0, 4.9). 23 AP subjects (11
levo, 12 cipro) had a positive blood culture at study entry. 5 of the
23 subjects were hospitalised. All blood cultures identiﬁed E. coli.
One cipro-resistant isolate (MIC> 32) was isolated from a cipro-treated
subject. 9 levo subjects were clinical successes, 2 were failures. With
cipro, 7 subjects were clinical successes, 2 were failures and for 3, the
outcome was unknown. The urine pathogen was eradicated in 10 and
was unknown for 1 levo subject compared to eradicated in 7, persisted
in 3, and unknown in 2 cipro-treated subjects. A repeat blood culture
was obtained for 7 levo and 8 cipro subjects, with the blood pathogen
eradicated in all subjects. For one other cipro-treated subject, the blood
pathogen was presumed persisted based on clinical failure. The outcome
for the cipro-resitant E. coli was unknown.
Conclusions: For the overall population (cUTI and AP) and for the cUTI
and AP cohorts. 5 doses of levo were non-inferior to 20 doses of cipro.
Levo and cipro eradicated blood pathogens in all subjects who had a 2nd
blood culture.
O143 Baseline characteristics of patients, with or without MRSA,
in two double-blind, randomised, multinational, Phase 3
studies comparing telavancin with vancomycin for the
treatment of complicated skin and skin structure infections
G.R. Corey, M.E. Stryjewski, V.G. Fowler Jr., A. Lentnek, A. Hopkins,
M.M. Kitt, S.L. Barriere for the ATLAS Study Group
Objectives: Telavancin is a novel, rapidly bactericidal lipoglycopeptide
with concentration-dependent killing activity against clinically important
Gram-positive pathogens. It has a unique multifunctional mechanism
of action that includes inhibiting bacterial cell wall synthesis and
disrupting the functional integrity of the bacterial plasma membrane. Two
identically designed, double-blind, randomised, multinational Phase 3
studies, ATLAS 1 and ATLAS 2, have compared the efﬁcacy and safety
of telavancin with vancomycin in adults with a complicated skin and
skin structure infection (cSSSI).
Methods: The ATLAS studies recruited men and women, who were 18
years of age or over. All patients had a cSSSI (major abscess, infected
burn, deep/extensive cellulitis, infected ulcer or wound infection)
requiring 7 days of IV antibiotic therapy. Here we report the baseline
demographic and clinical characteristics of study participants by MRSA
status.
Results: Of the 1867 patients treated in the two studies, 38.5% (n = 719)
had an infection caused by MRSA (37.7% [350/928] of telavancin-
treated patients and 39.3% [369/939] of vancomycin-treated patients).
Approximately two-thirds of patients were from the USA; the remainder
were recruited from Canada, Australia, South Africa, Russia and various
other countries across Europe, Asia and South America. Patients with
infections due to MRSA tended to be younger (<65 years of age) and
a greater proportion were of Black race compared with patients with
infections not due to MRSA (non-MRSA; Table). MRSA was most
commonly associated with major abscesses, whereas non-MRSA was
most commonly associated with deep/extensive cellulitis. Regardless of
MRSA status, cSSSI occurred more frequently on the lower extremities.
Table. Patient demographic and clinical characteristics
MRSAa Non-MRSA
(n = 719) (n = l 148)
Age, years (mean) 44.6 51.4
Age <65 years, n (%) 632 (88) 882 (77)
Men, n (%) 421 (59) 655 (57)
Raceb, n (%)
Caucasian 536 (75) 911 (79)
Black 149 (21) 111 (10)
Hispanic/Latino 140 (19) 247 (22)
Diabetes, n (%) 149 (21) 315 (27)
Type of cSSSIc, n (%)
Major abscess 423 (59) 367 (32)
Wound infection 115 (16) 153 (13)
Deep/extensive cellulitis 153 (21) 538 (47)
Infected ulcer 20 (3) 73 (6)
Infected burn 8 (1) 17 (1)
Site of infection, n (%)
Head/neck 58 (8) 71 (6)
Front torso 111 (15) 149 (13)
Back torso 108 (15) 99 (9)
Upper extremities 145 (20) 179 (16)
Lower extremities 297 (41) 650 (57)
aMRSA, methicillin-resistant Staphylococcus aureus.
bPatients could indicate more than one racial category.
bcSSSI, complicated skin and skin structure infection.
Conclusion: Together, ATLAS 1 and 2 represent the largest prospective,
double-blind studies ever conducted in patients with cSSSIs. The MRSA
cohort was also the largest ever enrolled in a registrational programme.
MRSA infections appeared to be more common in patients who were
younger, of Black racial origin, and in those with a major abscess
compared with patients with infections not due to MRSA.
O144 Efﬁcacy and safety of aminoglycoside monotherapy: system-
atic review and meta-analysis of randomised controlled trials
L. Vidal, A. Gafter-Gvili, S. Borok, A. Fraser, L. Leibovici, M. Paul
(Petah-Tikva, IL; Bristol, UK)
Objectives: The use of aminoglycosides has decreased due to doubts
regarding lack of efﬁcacy and adverse effects. Yet, the prevalence of
microbial resistance to aminoglycosides has remained low. This study
sought to compare the efﬁcacy and adverse effects of aminoglycosides
as a single antibiotic to other antibiotics for the treatment of patients
with infection.
Methods: We searched for randomised trials comparing the efﬁcacy of
aminoglycoside antibiotic treatment to non-aminoglycoside antibiotic in
patients with infection in the Cochrane Library, MEDLINE, EMBASE,
LILACS, databases of ongoing trials and conference proceedings. Two
reviewers assessed trial eligibility, quality and extract data. Pooled
relative risks (RR) with 95% conﬁdence intervals (CI) were calculated
for dichotomous data.
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Results: The search yielded 37 trials. 27 trials assessed patients
with urinary tract infection, 5 trials assessed patients with other
source of infection and 5 did not deﬁne the source of infection.
Aminoglycosides were equally effective as comparator in analysis of
mortality (RR 1.26, 95%CI: 0.68, 2.31, n = 458) and treatment failure
(RR 1.10, 95%CI: 0.96, 1.27, n = 1908), but were associated with
signiﬁcant more bacteriological failure (RR 1.39, 95%CI: 1.14, 1.68,
n = 1242). Subgroup analyses according to quality of trial, type of
antibiotics, source of infection and, rate of clinical sepsis did not alter
the outcomes. Less adverse effects in total but more nephrotoxic effects
were observed in patients treated with aminoglycosides.
Conclusions: The present data supports the use of aminoglycosides
as treatment for urinary tract infection but not as single treatment for
patients with infections other than the urinary tract.
Molecular typing
O145 Microarray technology reveals genomic diversity and
phylogeny in Mycobacterium ulcerans
M. Kaeser (Basle, CH)
Background: Mycobacterium ulcerans is the etiologic agent of Buruli
ulcer, the third most common mycobacterial disease occurring in more
than 30 countries and characterised by devastating chronic necrotising
skin ulcers. Elucidation of the transmission and epidemiology of
M. ulcerans is hampered by a remarkable lack of genetic diversity, and
no molecular genotyping method is available that has sufﬁcient high
resolution for micro-epidemiological studies.
Methods: We conducted comparative genomic hybridisation of 30
M. ulcerans strains of world-wide origin with a newly developed
plasmid-based microarray technology, suitable for organisms lacking
genome sequence information. Resulting genomic differences were
analysed by PCR and sequencing and subjected to in silico sequence
comparison with Mycobacterium marinum.
Results: The microarray based comparative genomic analysis revealed
ﬁrst extensive large insertional/deletional sequence polymorphisms
among the clinical M. ulcerans isolates, depicting progressing genome
shrinkage. Categorisation of the deleted genes revealed biological
functions possibly no longer required for the pathogen developing
from the environmental mycobacterium, M. marinum. In depth analysis
showed evidence that the Asian and Southern American strains are
closer to the progenitor than isolates from African and Australian
countries, giving ﬁrst hints towards the existence of two major lineages
of the pathogen M. ulcerans with different evolutionary histories in their
genome arrangement.
Conclusions: The comparative analysis of the genomes of M. ulcerans
isolates suggests that this emerging pathogen is adapting to a more
stable environment, probably to a mammalian host including man. The
signiﬁcant genomic diversity revealed by analysis with a prototype
microarray suggests that a whole genome microarray, currently under
development, may lead to a genomic ﬁngerprinting method urgently
needed for micro-epidemiological studies and aiming to characterise
transmission pathways and environmental reservoirs of M. ulcerans.
O146 Genotypic and phenotypic diversity of clinical Bordetella
pertussis isolates in the UK from 1920 to 2005
D. Litt, N. Fry, S. Neal, J. Duncan, T. Harrison (London, UK)
Objectives: To measure the genetic diversity of the population of
B. pertussis clinical isolates at different times in UK anti-pertussis
vaccination history using multi-locus VNTR analysis (MLVA) and
to further characterise isolates using ptxA and prnA genotyping and
ﬁmbrial serotyping.
Methods: More than 600 isolates collected between 1920 and 1995
were divided into groups around important dates in UK vaccination
history and typed using a 6-allele MLVA scheme. Genetic diversity was
calculated from the resulting MLVA types using the method of Hunter
and Gaston. ptxA and prnA genotyping and ﬁmbrial serotyping were
also performed.
Results: MLVA revealed that the genetic diversity of UK B. pertussis
isolates was greatest during the period before mass vaccination with
whole-cell vaccines was introduced in 1957 [diversity index (DI) = 0.88
(n = 69)]. Between 1963–1967, when vaccine coverage was ~80%,
diversity fell [DI = 0.74 (n = 14)] and MLVA-29, previously a minor type,
became dominant (50% of isolates).
Between 1977–1986, when vaccine coverage fell to a low of 31% and
epidemics occurred in the UK, diversity increased to a level almost as
high as before vaccination [DI = 0.84 (n = 157)]. Interestingly, during this
period MLVA-29 was still the most common type, but many new MLVA
types, the prnA(2) and prnA(3) genotypes and the serotype 1,3 emerged.
MLVA-27 ﬁrst appeared in 1983.
In 1998–2001, several years after vaccine coverage had risen to >95%,
DI had fallen again to 0.66 (n = 108) and MLVA-27 was co-dominant
(43%) with MLVA-70 (41%). During the period 2002–2005, when
vaccine coverage remained high and a fourth dose was added to the
schedule, DI declined further and MLVA-27 increased its dominance. In
2005, DI = 0.46 (n = 109) and 73% of isolates was MLVA-27.
Conclusion: MLVA reveals much greater genetic diversity in the UK
B. pertussis population than previously shown using prnA and ptxA
genotyping and ﬁmbrial serotyping. Genetic diversity fell during periods
of high vaccine coverage, but increased when vaccination dropped as
the result of a health scare in the late 1970s. During this window of
high diversity, many new MLVA types emerged and new prnA, ptxA
and ﬁmbrial serotypes appeared. In recent years, under high vaccine
coverage, diversity has fallen and a single clone “MLVA-27 prnA(2)
ptxA(1) serotype 1,3” has come to dominate the UK population.
O147 Precise identiﬁcation and phylogenetic relationships of
major multi-resistant clones of Acinetobacter baumannii by
multilocus sequence typing
L. Diancourt, V. Passet, A. Nemec, L. Dijkshoorn, S. Brisse (Paris,
FR; Prague, CZ; Leiden, NL)
Multidrug resistant (MDR) Acinetobacter baumannii strains that infect
hospitalised patients are among the most dreadful nosocomial bacteria
in European and US hospitals. Evidence from banding pattern typing
methods (AFLP and ribotyping) suggested that three clones are
responsible for a majority of hospital outbreaks caused by MDR strains
in European hospitals (Dijkshoorn et al., 1996; Van Dessel et al., 2004).
These three pan-European clones were recently shown to be responsible
for more than 60% of MDR A. baumannii infections in a US hospital
(Hujer et al., 2006). Precise identiﬁcation of strains belonging to clones
I to III is therefore crucial for infection control and patient management.
However, banding-pattern methods are difﬁcult to standardise and
provide limited information on phylogenetic relationships among strains.
Using MLST, i.e. sequencing of internal portions of seven housekeeping
genes (total 2,976 nt), we analysed a set of 155 strains of A. baumannii,
including 80 strains belonging to clones I, II and III and 75 other
strains representing the breadth of known AFLP diversity. A total of
59 distinct sequence types (STs) were found. Phylogenetic analysis
based on allelic proﬁles revealed that strains from clones I, II and III
fell into three unrelated clonal complexes, each made of a central,
predominant genotype and a few (one to four) single locus variants.
The only exception was one double-locus variant strain of clone III.
Interestingly, the 75 strains from the AFLP diversity set had at least
three distinct loci when compared to members of the MDR clones.
We conclude that each of the three major clones can readily be
demarcated from other A. baumannii members, and that molecular
diagnostics could be developed to identify them rapidly. Analysis of
the recombination/mutation rate shows that nucleotides do not change
by recombination more frequently than by mutation, showing that
recombination is unlikely to disrupt the clonal frame of the clones, which
can therefore be expected to be stable over very long periods of time.
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O148 Correspondence between typing methods results: a
web-based quantitative analysis tool
J.A. Carrico, F.R. Pinto, J. Melo-Cristino, H. de Lencastre,
J.S. Almeida, M. Ramirez (Lisbon, PT; Houston, US)
Objectives: Molecular epidemiology studies of clinically relevant
microorganisms frequently focus on a comparison between the assigned
types of different typing methods. Therefore, there is a critical need
to understand the correspondence between types produced by different
methods. This may be useful not only for the comparison of the genetic
backgrounds of the particular set of isolates under study but also to
produce a broader view of how the results of the different typing
methods are related. To achieve this goal, a framework of measures
for the quantitative comparison of typing methods results was developed
(Carric¸o et al., Illustration of a common framework for relating multiple
typing methods by application to macrolide-resistant Streptococcus
pyogenes, J. Clin. Microbiol. 2006) and is now implemented in a
free-access web-based interface, on which users can analyse their data
anonymously and retrieve the results.
Methods: To facilitate the use of the framework developed, a web-based
interface was implemented to provide researchers with a user-friendly
interface to compare their typing methods results. On the website,
we also provide a set of BionumericsTM scripts to allow the users to
implement the proposed analysis on their Bionumerics databases while
ofﬂine.
Results: The web-based interface and the Bionumerics scripts allow
for the calculation of several measures: Simpson’s index of diversity
with conﬁdence intervals for accessing the diversity of typing results
for different methods; Adjusted Rand and Wallace coefﬁcients for
bidirectional and unidirectional (respectively) comparison between the
results of two typing methods results. Based on these measures the
users can quantitatively evaluate the discriminatory power of the typing
methodologies used and their concordance.
Conclusion: The web-based interface and the Bionumerics scripts
provide users with the ability for a quantitative assessment of
correspondence between typing methods results. This can be used to
evaluate the predictive power of a typing methodology when compared
to another, which can guide the user in the choice of a ‘gold standard’
for clone deﬁnition. Furthermore, as new microbial typing methods are
proposed, this methodology allows for their comparison in terms of type
assignments with established methodologies.
O149 Multi-locus sequence typing for surveillance of Campylobacter
W. Sopwith, A. Fox, M. Regan, Q. Syed, E. Bolton, A. Birtles,
M. Matthews, S. Gee, K. Osborn (Liverpool, Manchester, Preston,
Warrington, UK)
Despite several case control studies and enhanced surveillance of
both human cases and animal environmental isolates, there is still
much unknown about the epidemiology of Campylobacter infection.
We describe a multi-agency project evaluating the utility of sequence
typing of human infection isolates to inform surveillance and distinguish
environmental sources of human infection.
Multi-locus sequence typing (MLST) developed for C. jejuni and C. coli
was applied to all human case isolates from four local authorities in
North West England, two largely rural and two largely urban, over
a continuous 3-year period. Isolates from drinking water supplies and
recreational surface waters were also sequence typed.
We describe here an analysis of the three year study data and steps
taken to adapt the methodology for use in routine surveillance settings.
The study has demonstrated several interesting correlations between
speciﬁc sequence types and a number of explanatory variables for
disease (eg month of infection, locality of residence, and travel abroad).
Other studies provide increasing evidence of host-association for speciﬁc
MLST types of campylobacter and these ﬁndings are related to the three
year dataset. In addition, many new types have been described in surface
waters from this project and there is evidence for a distinct water-borne
population that has not so far been described in human infection.
Tick-borne diseases
S154 Rickettsioses
D. Raoult (Marseilles, FR)
In recent years, the use of cell culture and molecular biology deeply
changed our knowledge on rickettsiae. As a matter of fact before 1990,
7 pathogenic rickettsial species were identiﬁed (Rickettsia prowazekii,
R. typhi, R. conorii, R. rickettsii, R. sibirica, R. australis, R. acari) and
since 1991, 10 new species were discovered (R. japonica, R. honei,
R. africae, R. slovaca, R. parkeri, R. helvetica, R. aechlimanii,
R. massiliae, R. heilongjanghensis transmitted by ticks and R. felis
transmitted by ﬂeas) and 2 new species (R. conorii caspia, R. sibirica
mongolotimonae).
New rickettsial diseases were found under 3 main conditions:
– In place where none was identiﬁed, typical rickettsial diseases
(including fever and a rash) were found (Japan, China).
– In some place typical rickettsioses could be caused by different
organisms. In such cases, the new Rickettsia was misdiagnosed with a
previously identiﬁed bacterium (such as R. massiliae with R. conorii).
– In some cases atypical clinical ﬁndings were found (no rash, no
fever) to be caused by Rickettsial organisms such as R. slovaca or
R. helvetica.
These ﬁndings challenge the old dogma postulating that of one tick borne
rickettsiosis was prevalent in one geographic area. For many years for
example, R. rickettsii, the agent of Rocky Mountain Spotted Fever, was
considered the only spotted fever group rickettsia in the USA and the
only tick-transmitted rickettsiosis in America. R. felis, a ﬂea-transmitted
spotted fever, and R. parkeri, a tick-transmitted spotted fever, have been
shown since to infect human beings in the USA and in Urugay. Moreover,
R. africae has been found in patients in West Indies.
Many Rickettsia have been identiﬁed in ticks but have not been currently
found in patients. These Rickettsiae should be considered potential
pathogens. These new ﬁndings should stimulate investigations to identify
new rickettsial diseases. Patients with atypical rash or fever after
arthropod bite should be targeted. Skin biopsies are the preferred samples
in this purpose. Molecular tests used for this purpose will be proposed.
Can pharmacokinetic–pharmacodynamic
parameters drive dosing regimens that are
less vulnerable to resistance?
S156 Can pharmacokinetic–pharmacodynamic parameters drive
dosing regimens that are less vulnerable to resistance? Pro
A. Novelli (Florence, IT)
In recent years, the rules for selection of antimicrobial agents have
been undergoing critical revision in terms of optimum dosing for
control of infectious diseases, with the goal of potentiating treatment
efﬁcacy and reducing the risk of selecting multidrug resistant pathogens.
The most important criterion for rational choice of an antimicrobial
agent is deﬁned by its pharmacodynamic (PD) characteristics, and
thus its antimicrobial activity which can be summarised as the
minimum inhibitory concentration (MIC) and minimum bactericidal
concentration (MBC). The second criterion for selecting an antibiotic
is due to its pharmacokinetic (PK) characteristics, since it has been
demonstrated that antibiotic concentrations at the infection site inﬂuence
the intensity and duration of the effect, and together with the PD
parameters, provide a general inter-relationship and contribute to deﬁning
the potential clinical efﬁcacy of a drug. Pharmacodynamics have been
upgraded in the last 10 years with in vitro and animal models which
have helped to identify fairly precise correlations with therapeutic
efﬁcacy of antibiotics. Moreover, the principles that link concentrations
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of antibiotics in humans and their effects have been outlined in
order to determine the optimal dosing interval. Antimicrobial drugs
with a concentration-dependent activity, i.e. the newer quinolones and
aminoglycosides, should be administered as a single daily dose to
maximise the peak serum concentration/MIC ratio. AUC/MIC ratio is
also an important parameter for PK/PD correlations. Existing data on
ﬂuoroquinolones suggest that a ratio of 100–125 correlates with high
bacterial eradication and optimal clinical outcome in infections due
to Gram-negative pathogens, while a ratio of 50 is associated with
a high probability of eradication of S. pneumoniae strains. For this
group of antibiotics the new concept of the so called mutant prevention
concentration (MPC) and mutant selection window (MSW) may be
helpful in restricting the enrichment of mutant subpopulations and
consequently, at least partially, in controlling the spread of resistance.
Beta-lactams, having time-dependent efﬁcacy, usually do not have great
post antibiotic effects (PAEs), and the parameter which seems to better
correlate PD with PK is the time duration with concentrations higher
than the MIC (T>MIC). These antibiotics need to be given with short
dosing intervals or even by continuous infusion to maintain plasma levels
exceeding the MIC for a sufﬁciently long period.
In summary, we can theoretically optimise the dosage regimen of
antibiotics (dose, administration route and interval between doses) in
clinical practice by correlating the PK and PD pertaining to each
antibiotic class, based on experimental animal studies and these PK/PD
parameters may contribute to the containment of resistance for all drug
classes and especially the most important ones used in serious infections
in intensive care patients.
Antibiotic resistance in developing countries:
a Pandora’s Box
S159 Surveillance of antimicrobial resistance in developing
countries: methods and strategies
A. Bartoloni (Florence, IT)
Antibiotics are the most commonly purchased class of drugs in low-
resource countries, where the infectious diseases are extremely frequent
and the bacterial infections are the major cause of death, especially
in childhood. The phenomenon of microbial drug resistance, which
represents a global public health problem, is particularly serious in
these countries, as resistance rates are even higher than in industrialised
countries and the therapeutic options are often unavailable or too
expensive. Surveillance of antibiotic susceptibility is a key element to
provide updated information on the magnitude and trends in resistance,
and to plan and monitor intervention strategies aimed at preserving the
therapeutic efﬁcacy of antibiotics. In low-resource countries, effective
surveillance programmes are difﬁcult to implement for a number of
reasons, including scarce ﬁnancial resources, lack of laboratory facilities
and, where laboratories do exist, lack of quality control, reliable reagents
and adequate supervision. In these settings, the development of reliable
and low-cost alternative methods could facilitate the implementation
of large-scale surveillance. There is an increasing agreement about the
importance of extending the surveillance of antibiotic resistance to the
commensal microbiota of humans and animals. This bacterial population,
although not being a speciﬁc target, is continuously exposed to the
selective pressure generated by antimicrobial chemotherapy and may
become a potential reservoir of resistant strains that can cause infections,
and of resistance determinants that can be transferred to pathogenic
bacteria. Therefore, surveillance of antibiotic-resistant bacteria carried
by healthy individuals is considered an indicator of the spread of
antibiotic resistance that could also be useful to predict the emergence
of resistance in pathogenic bacteria. In this perspective, resistance
patterns of some members of the commensal microbiota, such as the
faecal Escherichia coli, have been evaluated in various epidemiological
settings. For this purpose, different microbiological approaches have
been implemented and evaluated as useful tools to conduct large
scale resistance surveillance studies and to monitor resistance control
programmes in a cost-effective manner.
Does detection of extended-spectrum
b-lactamases matter?
S160 Does detection of extended-spectrum b-lactamases matter?
The No case
J. Turnidge (North Adelaide, AU)
The emergence of extended-spectrum b-lactamases (ESBLs) in Enter-
obacteriaceae in the 1980s marked an important turning point in routine
laboratory diagnostics. Soon after their discovery, phenotypic methods
were developed for their detection and conﬁrmation. Conﬁrmation
depended largely on the ability of clavulanate to inhibit the main culprit
enzymes at the time, the TEM and SHV variants. Later this technique
proved reliable for CTX-M type enzymes. Many susceptibility testing
methods recommended the use of ESBL screening and conﬁrmation
tests on a routine basis, including CLSI, BSAC, CA-SFM, and SRGA.
However, a number of issues have emerged with routine use over the
years:
1. The problem of deﬁning an adequate number of substrates to
ensure sufﬁciently sensitive screening. Ideally, one should include
a minimum of 4, namely cefpodoxime, ceftazidime, ceftriaxone or
cefotaxime, and aztreonam, and at concentrations that often differ
from those used for susceptibility breakpoints.
2. The lack of reliable phenotypic methods to detect ESBLs in species
with inducible AmpC b-lactamases. Some of these species have
been shown to be important reservoirs for ESBLs, and resistance to
extended-spectrum cephalosporins cannot solely attributed to stable
de-repression of AmpC.
3. The failure of current methods to provide advice on the interpretation
of a positive screening test but a negative conﬁrmation test, especially
if the isolates are “susceptible” to extended-spectrum cephalosporins
using method-recommended breakpoints. Such strains have been
shown to harbour OXA enzymes, inhibitor-resistant TEM enzymes, or
particularly plasmid-borne AmpC enzymes with signiﬁcant frequency.
Thus there is no current phenotypic or genotypic test that can be
practically and effectively applied in the routine laboratory with
sufﬁcient sensitivity to detect the emerging range of transmissible
enzymes.
However, we can rely to a great extent on the selection of or
change to appropriate susceptibility breakpoints. A range of recent
studies has suggested that failures of treatment with extended-
spectrum cephalosporins are likely when strains of Enterobacteriaceae
have MICs elevated above the wild-type. Further, application of
pharmacokinetic/pharmacodynamic (PK/PD) principles to the most
widely recommended dosing schedules of cephalosporins suggest that the
susceptibility breakpoints recommended by many methods are too high,
and should to lowered to values that fortunately coincide wild-type cut-
off values. Hence, lowering of susceptibility breakpoints for extended-
spectrum cephalosporins to those deﬁned by PK/PD will indicate the
presence of an ESBL or plasmid-borne AmpC enzyme with sufﬁciently
high likelihood to allow laboratories to report both resistance to these
agents and provide advice about appropriate infection control procedures.
Antibiotic usage
O164 A planned dramatic drop in trimethoprim consumption in
a 180,000 population did not result in a related decrease in
trimethoprim resistance in Escherichia coli
M. Sundqvist, M. Sjo¨lund, A. Runehagen, H. Cars, K. Abelson-Storby,
D.I. Andersson, O. Cars, G. Kahlmeter (Uppsala, Va¨xjo¨, SE)
Objectives: Since antibiotic resistance often is associated with a
biological ﬁtness cost for bacteria it is assumed that a reduction of
antibiotic use is followed by a reduction in resistance rates. Over the last
10 years trimethoprim (TRI) resistance in Escherichia coli has increased
in Sweden. In Kronoberg county the TRI resistance has increased from
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7% (1990) to 11% (2004). So far no prospective intervention in the
community has been carried out to investigate whether a substantial
decrease of the use of a single antibiotic will result in a corresponding
decrease in antibiotic resistance.
Method and Material: Physicians (n = 564) in county Kronoberg
(approx. 180,000 population), Sweden, were convinced, by personal
visits and mail, to cease their use of TRI and cotrimoxazole during two
years starting October 1st 2004. Monthly sales data for oral antibiotics
were retrieved from the National Corporation of Swedish Pharmacies
and made known to the physicians. All E. coli isolated from urinary
tract specimens at the Dept of Clin Microb, Va¨xjo¨, were included in
the analysis. The susceptibility testing methodology was stable since
1990 and the baseline consisted of quantitative data from 1990–2004.
In order to study the diversity among the isolates 2900 E. coli from the
period preceding and 1200 isolates from the end of the intervention were
phenotyped using the PhenePlateTM system.
Results: An immediate and sustained decrease of 85% in total use of
TRI was achieved. TRI use was in most cases replaced by mecillinam
(MEC), nitrofurantoin (NIT) and ciproﬂoxacin. The total decrease in
antibiotics used for UTI treatment was 4%. Resistance to TRI did not
decrease (10% and 12% in 2005 and 2006, respectively). Resistance
to NIT and MEC did not increase despite the substantial increase
in the use of these drugs, 31% and 69%, respectively. Resistance to
ﬂuoroquinolones (FQ) increased from 4% to 10% between 2000 and
2006. The phenotypic diversity index was 0.954 in the period prior to
the intervention, 0.964 during the ﬁrst 4 months and 0.949 during the
last 4 months of the intervention.
Conclusion: A substantial and sustained decrease in the use of TRI in
a 180,000 population did not result in any drastic changes in resistance
rates. Whether the increase in FQ-resistance was related to the increase
in use remains to be evaluated. The diversity index, based on E. coli
phenotypes, was stable indicating that the intervention did not favour
any certain clone to expand in the community.
O165 Sustained reduction of antibiotic use and low bacterial
resistance. A ten-year follow-up of the Swedish Strama
programme
S. Mo¨lstad, M. Erntell, H. Hanberger, E. Melander, C. Norman,
G. Skoog, C. Sta˚lsby Lundborg, A. So¨derstro¨m, E. Torell, O. Cars
(Jo¨nko¨ping, Halmstad, Linko¨ping, Lund, Stockholm, Gothenburg,
Uppsala, SE)
Objectives: Increasing use of antibiotics and spread of resistant
pneumococcal clones in the beginning of the 90ies alarmed the medical
profession and medical authorities in Sweden. A coordinated effort to
prevent further spread and preserve the effectiveness of antimicrobial
agents was therefore initiated
Methods: Strama (The Swedish strategic programme for the rational
use of antimicrobial agents and surveillance of resistance) was initiated
in 1994. The Strama network includes a broad representation of
medical disciplines, professional organisations and relevant authorities.
The programme includes surveillance of antibiotic use and resistance,
implementation of rational use of antibiotics and development of
new knowledge. The main goal is to preserve the effectiveness of
antimicrobial agents.
Results: Yearly validated data on antibiotic use and resistance were made
publicly available on a website. Multidisciplinary Strama-groups were
formed in each county to disseminate knowledge and implement rational
antibiotic use. Studies were performed on indications for antibiotic use
in out-patient care, hospital care and nursing homes.
Between 1995 and 2004 antibiotic use for out-patients decreased from
15.7 to 12.6 DDD/TID and from 536 to 410 prescriptions per 1000
inhabitants and year. The reduction was most prominent for children
5−14 years old (52%) and for macrolides (65%). During the period, the
number of hospital admissions for acute mastoiditis, rhinosinusitis and
quinsy was stable or declining. Although the epidemic spread in southern
Sweden of penicillin-resistant S. pneumoniae was curbed, the national
frequency increased from 4% to 6%. A hospital outbreak of MRSA could
be terminated using aggressive infection-control measures. Resistance
remained low in most other bacterial species during the period.
Conclusions: This multidisciplinary, coordinated programme has con-
tributed to the reduction of antibiotic use without measurable negative
consequences. Despite this, antibiotic resistance in several bacterial
species is slowly increasing which calls for continued sustained efforts to
preserve effectiveness of available antibiotics. Such efforts will include
interventions to further improve antibiotic use and to improve compliance
to basic hygiene precautions.
O166 ESAC II Hospital Care Subproject 2005–2007: patterns
of antibiotic use in relation to diagnoses in 19 European
hospitals in 2006, Point Prevalence Study
M. Erntell, F. Ansari, H. Goossens, P. Davey for the ESAC II HC
Subproject Working Group
Objectives: 19 European hospitals performed a descriptive pilot Point
Prevalence Study (PPS) of antimicrobial use in relation to diagnoses in
European hospitals.
Method: The protocol was designed to present demographic data as
well as the amounts and indications for antimicrobial agents against
bacteria. Treatments were recorded in relation to diagnoses, prophylactic
use, community acquired (CAI) and hospital acquired infection (HAI).
19 pre-deﬁned diagnosis groups were used. The previously presented
STRAMA protocol and web-based reporting system was used.
Results: 19 hospitals participated in the study. 3,398 patients treated
with antimicrobial agents were included out of 11,224 admitted. 30%
of the patients were treated with antimicrobials. 3,554 treatments
were recorded. 377 (10.6%) were given to children (<17 years)
and 47.6% to women. The indication for treatment was CAI in
15%, HAI in 9.2% and prophylaxis in 7.6%. For adults cultures
were taken before parenteral treatment in 57% and oral treatment
in 51%. The most commonly used antimicrobials for adults, in
DDD, in treatment and prophylaxis were penicillins with betalactamase
inhibitors (23%, 0−75, and 26%, 0−66), cephalosporins (14%, 4−38, and
30%, 0−60), ﬂuoroquinolones (14%, 8−31, and 11%, 0−52). The total
amount of antimicrobials used for adults was 52 DDD/100 admitted
patients (33−88). Two diagnosis groups were predominating; pneumonia
(19% of all therapies) and skin and soft tissue infections (13%).
Analysis of antibiotic usage in different countries shows countries having
mainly penicillins with betalactamase inhibitor or cephalosporins as
the predominating drug. Seven countries showed a more varied use of
drugs. The patterns of treatment and prophylactic usage were similar
in countries with heavy use of one ATC-class. Length of peri-operative
prophylaxis was dominated by >1 day in all surgical specialities; in
general surgery 59%, in orthopaedic surgery 52%, in urology 76% and in
ENT 89%. One-dose peri-operative prophylaxis ranged from 2% to 27%.
One-day prophylaxis was 34% in orthopaedic surgery.
Conclusions: The study describes wide differences (three fold) in
consumption between European hospitals. Peri-operative prophylaxis is
too long in all surgical specialities. There is limited variation in the
use of different antibiotic groups in most hospitals – a risk factor for
emergence of antibiotic resistance. Our web-based PPS provides a tool
for quality assessment of antibiotic prescribing in European hospitals.
O167 Attitudes, beliefs and knowledge concerning antibiotic use
and self-medication: a comparative European study
L. Grigoryan, J. Birkin, J. Burgerhof, J. Degener, R. Deschepper,
C. Sta˚lsby Lundborg, D. Monnet, E. Scicluna, F. Haaijer-Ruskamp,
A. Di Matteo, A. Tambi-Andrasevic, R. Andrajati, H. Edelstein,
R. Valinteliene, R. Mechtler, L. Deliens, G. Van der Kelen on behalf
of the SAR consortium
Introduction: Although the relevance of cultural factors for antibiotic
use is widely recognized, few studies exist in Europe. We compared
beliefs, attitudes and knowledge regarding antibiotic use and self-
medication between countries.
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Methods: Face to face structured interviews were conducted in 11
countries (Austria, The Netherlands, Sweden, UK, Belgium, Italy,
Malta, Israel, Czech Republic, Lithuania and Croatia). The study
population included respondents of our previous survey who agreed to
be interviewed. We aimed to recruit at least 100 respondents in each
country, including a group of users of self-medication and non-users.
Scales were grouped based on theoretical concepts and conﬁrmed by
factor analysis. The four scales were: attitudes towards appropriateness
of self-medication with antibiotics for bronchitis, beliefs about antibiotics
for minor ailments, attitudes towards situational use of antibiotics and
knowledge about antibiotics and viruses or bacteria. Knowledge of
antibiotic resistance was measured by an open-ended question. Analysis:
To deal with the possible confounding effect of both use of self-
medication and education, we performed stratiﬁed analyses, i.e., we
studied the differences between countries separately for users and
non-users of self-medication, and for respondents with high and low
education. The differences between countries were considered relevant
when regression coefﬁcients were signiﬁcant in all stratum-speciﬁc
analyses.
Results: In total, 1101 respondents participated. Respondents from the
UK, Malta, Italy, Czech Republic, Croatia, Israel and Lithuania had
signiﬁcantly less appropriate attitudes, beliefs or knowledge for at least
one of the dimensions. The Dutch, Austrian and Belgian respondents
did not differ from Swedish for any of the dimensions.
Conclusions: Our study showed clear cultural differences in levels of
public attitudes, beliefs and knowledge concerning antibiotic use, self-
medication and antibiotic resistance in 11 European countries. The levels
of misconceptions contributing to inappropriate use were the highest
in southern and eastern countries, indicating a strong need for public
education campaigns in these countries. Awareness about antibiotic
resistance was the lowest in countries reporting high prevalence of
resistance.
O168 Optimising use of ciproﬂoxacin in a large teaching hospital:
sustained effect of a prospective intervention study
B. van Hees, E. de Ruiter, E. Wiltink, B. de Jongh, M. Tersmette
(Nieuwegein, NL)
Objective: Antimicrobial resistance to ciproﬂoxacin, a valuable second-
line antibiotic, is increasing. To limit this increase the appropriate use of
ciproﬂoxacin should be encouraged. The objective of this study was to
reduce the number of inappropriate prescriptions and improve the quality
of ciproﬂoxacin prescriptions by way of educational intervention.
Methods: Five units (197 beds) of the departments of Internal Medicine,
Gastro-Enterology, Surgery, Urology and Pulmonary Diseases, selected
because of a high rate of ciproﬂoxacin prescription, participated in a
prospective intervention study. The study comprised three periods of
three months: 2 observation periods (phase 1 and 3) and an intervention
period (phase 2). A follow up of 3 months was done 9 months after start
of intervention. During the two observation periods all ciproﬂoxacin
prescriptions were registered and the quality of each ciproﬂoxacin
prescription was evaluated in a standardised manner by two experts
in infectious diseases independently. During the intervention period
physicians prescribing ciproﬂoxacin were interviewed by a medical
microbiologist, and educational presentations were given to physicians
of the participating units.
Results: During phase 1 491 prescriptions per 1000 admissions of
ciproﬂoxacin were written, declining to 184 prescriptions per 1000
admissions in phase 3, a reduction of 62.5%. The greatest reduction was
observed in units of the Departments of Surgery and Urology (83.9% and
75.6% respectively), mainly due to a reduction of erratic prophylactic
use. Unjustiﬁed prescriptions (no use of antibiotics indicated) decreased
with 25.9%. Inappropriate prescriptions (wrong choice of antibiotic or
duration of prescription) declined from 69.5% to 57.7%, mainly due to
the decrease of ciproﬂoxacin courses of too long duration. Appropriate
prescriptions increased with 33.5%. Nine months after intervention
136 prescriptions per 1000 admissions of ciproﬂoxacin were prescribed,
a total reduction of 72.3%.
Conclusion: Intervention by direct consultation of a medical microbi-
ologist and educational presentations led to signiﬁcant reduction of the
use of ciproﬂoxacin and improvement of the quality of ciproﬂoxacin
prescription. Nine months after the intervention the use of ciproﬂoxacin
had declined even further, indicating a sustained effect of the intervention
measures.
Rare fungal infections
O169 High-dose amphotericin B with ﬂucytosine for the treatment
of cryptococcal meningitis in HIV: a randomised study
T. Bicanic, G. Meintjes, R. Wood, K. Rebe, A. Brouwer, L-G. Bekker,
T. Harrison (London, UK; Cape Town, ZA; Nijmegen, NL)
Objectives: To determine the early fungicidal activity (EFA) and
toxicity of high dose amphotericin B (AmB, 1mg/kg/d) plus ﬂucytosine
(5FC) compared with standard dose amphotericin B (0.7mg/kg/d) plus
ﬂucytosine for the treatment of HIV-associated cryptococcal meningitis.
Methods: 64 HIV positive antiretroviral therapy naive patients,
presenting with a ﬁrst episode of cryptococcal meningitis in Cape
Town, South Africa from May 2005 to June 2006, were randomised to
receive either amphotericin B 0.7mg/kg/d plus ﬂucytosine 25mg/kg qds
(Group 1) or amphotericin B 1mg/kg/d plus ﬂucytosine 25mg/kg qds
(Group 2) for 2 weeks, followed by oral ﬂuconazole. EFA was evaluated
by the rate of reduction in CSF cryptococcal colony-forming units (CFU)
determined from serial quantitative CSF cultures on days 1, 3, 7, and 14
of treatment. Follow-up was 10 weeks.
Results: Median CD4 count was 38×106/L. 13% of patients had
abnormal mental status. Mean (SD) early fungicidal activity was
−0.56 (0.24) log CFU/mL CSF/d for AmB at 1mg/kg/d plus 5FC and
−0.45 (0.16) CFU/mL CSF/d for AmB at 0.7mg/kg/d plus 5FC. As
in prior studies, baseline count was associated with rate of clearance.
In a linear regression model including treatment group and baseline
count, EFA was signiﬁcantly greater for AmB at 1mg/kg/d plus 5FC
compared with AmB at 0.7mg/kg/d plus 5FC (difference 0.12 log CFU/d
[95%CI: 0.02−0.23], p = 0.02). There was a trend towards a greater rise
in creatinine in Group 2 versus Group 1: ﬁnal creatinine increased by
88% vs 52% from baseline (p = 0.08), which was reversible on stopping
study drug treatment. Mortality was 23% (15/64) at 10 weeks with no
difference between the two groups.
Conclusions: Amphotericin B at 1mg/kg/d with ﬂucytosine is more
rapidly fungicidal in the treatment of HIV-associated cryptococcal
meningitis compared to standard dose amphotericin B. Increasing the
dose of amphotericin B did not result in a clinically signiﬁcant increase
in nephrotoxicity.
O170 Clinical and epidemiological aspects of locally-acquired
Cryptococcus gattii human infections, an emerging fungal
pathogen in British Columbia, Canada
E. Galanis, L. MacDougall, M. Li, S. Kidd, M. Lee, M. Morshed
(Vancouver, CA)
Cryptococcus gattii emerged in the province of British Columbia
(BC), Canada in 1999. This study was undertaken to describe the
epidemiological and clinical features of locally-acquired C. gattii
infections in humans in BC.
Cases diagnosed by culture and conﬁrmed by restriction fragment
length polymorphism as C. gattii and HIV negative cases diagnosed by
serology and histopathology with no exposure to international endemic
areas were included. Cases reported to provincial authorities between
1999 and 2006 were interviewed to determine clinical presentation and
epidemiological characteristics. Frequencies were calculated based on
denominators available using SPSS® v14.0.
As of November 16 2006, 162 cases of locally-acquired cases of
C. gattii infection occurred in BC with an annual provincial average
of 6.3 cases/million population. Mean age was 59 years (2−92
years) and 56% were male. 16 cases (10%) were asymptomatic.
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142 (88%) had pulmonary, 28 (17%) had central nervous system and
2 (1%) had dermatological ﬁndings. Most common symptoms included
cough (46%), shortness of breath (44%), fever and night sweats (both
35%). Chest X-rays revealed nodules in 65 cases (66%) and inﬁltrates in
14 cases (14%). 19 cases (30%) were on oral steroids in the year prior
to diagnosis and 50 (49%) were current smokers. Only 5 (4%) were
HIV positive, 3 (3%) were organ transplant recipients, 30 (31%) had a
chronic lung disease and 26 (26%) had a history of cancer. 103 cases
(64%) were culture-conﬁrmed as C. gattii and 81 isolates (79%) were
genotyped as VGIIa. 4 cases (3%) died due to their C. gattii infection.
Most cases were treated with ﬂuconazole and amphotericin B for several
months. Most cases were exposed on Vancouver Island but the range of
the fungus has spread over the years and 4 recent cases were exposed
on the BC mainland.
Clinicians should be aware that C. gattii can be acquired in Canada and
that the epidemiological and clinical characteristics of this disease differ
from C. neoformans.
O171 A comparative study of treatment outcome in cryptococcal
meningitis in HIV-infected patients during period before
versus after implementation of treatment guidelines for
management of increased intracranial pressure
O. Putcharoen, W. Kulwichit, T. Tantawichien, M. Hanvanich,
C. Suankratay (Bangkok, TH)
Background: Cryptococcal meningitis is a common opportunistic
infections in HIV patients in Thailand, despite the expanded resources
for HIV treatment. Most patients had poor treatment outcome due to
poor control of severely increased intracranial pressure (ICP). This
complication may arise before, during or after the antifungal therapy.
Our study aimed to compare the treatment outcome in these patients
before and after implementation of the strategies particularly regarding
the management of severely elevated ICP.
Methods: We retrospectively reviewed the clinical data, treatment and
outcome of all adult HIV patients with cryptococcal meningitis who
were admitted at our tertiary care centre from 2002–2003 and 2004–
2005. The inclusion criteria included all patients who had meningitis
and either positive cerebrospinal ﬂuid (CSF) cultures for Cryptococcus
neoformans or cryptococcal antigen.
Results: There were 107 and 165 patients during the period before
and after the implementation of the guidelines. 250 (92%) had positive
cultures. No different baseline characteristics between the two groups
were observed. 52 (9.5%) patients had recurrent cryptococcal meningitis
despite ﬂuconazole prophylaxis. The mean age was of 37.4 years.
The median baseline CD4 cell counts was 55 cells/mm3. 39 (14%)
patients had received antiretroviral therapy. Most of the patients had
very high ICP. The mean and median CSF opening pressure (OP) were
34 and 38 cmH2O. 222 (85%) and 24 (14%) patients had OP of >20
and >40 cmH2O, respectively. CSF sterilisation could be achieved in
182 (70%) patients by amphotericin B treatment with a mean duration
of 18 days. Before adoption of guidelines, high ICP was treated by
the judgement made by individual primary care physicians. Strategies
for management of elevated ICP included 111 (42%) patients with
continuous once or twice daily lumbar punctures (LPs), 11 (4%) with
lumboperitoneal shunts, and 14 (5%) with ventriculoperitoneal shunts.
2 patients (0.7%) had emergency shunt surgery (impending visual acuity
loss or hearing loss). LP was performed in each patient for an average
of 12 times. The in-hospital mortality rate from cryptococcal meningitis
was signiﬁcantly reduced from (37/107) 35% to 23% (38/165) after
adoption of the guidelines (p< 0.05).
Conclusions: Mortality of HIV patients with severe cryptococcal
meningitis can be successfully reduced by prompt and aggressive
interventions for lowering the highly elevated ICP.
O172 Comparisons of Aspergillus galactomannan antigen levels
in human immnunodeﬁciency virus-infected patients with
Penicillium marneffei infection and cryptococcosis
Y.-T. Huang, C.-C. Hung, Y.-C. Chen, S.-C. Chang (Taipei, TW)
Objective: The levels of Aspergillus galactomannan (GM) antigen have
not been investigated in other endemic fungal infections in human
immunodeﬁciency virus (HIV)-infected patients before. This study
aimed to compare the levels of Aspergillus GM antigen in HIV-infected
patients with Penicillium marneffei infection and cryptococcosis.
Methods: Stored sera of 14 HIV-infected patients with P. marneffei
infection (9 [64.3%] with fungaemia and 7 [50%] with cavitary
lung lesions) and 22 HIV-infected patients with cryptococcosis
(14 [63.6%] with fungaemia and 8 [36.4%] with cavitary lung lesions)
diagnosed between January 2000 and October 2006 were subjected to
Aspergillus GM antigen testing using a commercial kit. Medical records
of those patients with invasive fungal infections were reviewed to exclude
the possibility of aspergillosis and concurrent use of antibiotics ever
reported to interfere the interpretation of GM antigen test. The median
time between diagnosis of invasive fungal infection and collection of
serum samples was 0 day (range, −7 to 6 days) for penicilliosis and
1 day (range, 0 to 6 days) for cryptococcosis.
Results: HIV-infected patients with penicilliosis had a statistically
signiﬁcantly higher optic density (O.D.) index of Aspergillus GM
antigen (median 3.19; range, 0.158–>20) than those with cryptococcosis
(median 0.247; range, 0.112−3.849) (p< 0.0001). Of the patients with
penicilliosis, patients with fungaemia had a statistically signiﬁcantly
higher O.D. index of Aspergillus GM antigen (median 10.48; range,
0.401–>20) compared with patients without fungaemia (median 0.378;
range, 0.158−4.419) (p< 0.0001). Of the patients with cavitary lung
lesions but without fungaemia, the median O.D. index of Aspergillus GM
antigen was also signiﬁcantly higher in penicilliosis than in crypto-
coccosis (1.009 [range, 0.247−4.419] vs 0.227 [range, 0.112−3.849];
p = 0.009).
Conclusion: Our study suggest that O.D. index of Aspergillus GM
antigen is elevated in HIV-patients with penicilliosis when compared
with those patients with cryptococcosis.
O173 Detection of zygomycete-speciﬁc biological markers in BAL
ﬂuid of patients with suspected invasive fungal infection
C.C. Van Leer, M.A.S.H. Mennink-Kersten, D. Ruegebrink, J.P. Donnelly,
N.M.A. Blijlevens, W. Melchers, P.E. Verweij (Nijmegen, NL)
Objectives: The incidence of invasive zygomycosis (IZ) appears to be
increasing, especially in patients treated for haematological malignancy.
Presently, no biological markers exsist that facilitate early diagnosis, and
one has to rely on conventional diagnostic methods, such as culture,
which lack sensitivity. We investigated the presence of zygomycete-
antigen (zAg) and zygomycete DNA in bronchoalveolar lavage ﬂuid
(BALF) of patients with documented IZ and of those at risk for this
disease.
Methods: BALF of 18 neutropaenic patients, who underwent a bron-
choscopy on suspicion of invasive fungal infection (IFI), was investigated
for the presence of water-soluble somatic zAg by immunoblotting
with a commercially available monoclonal antibody (anti-Rhizomucor,
Dakocytomation, Denmark). Five of 18 patients had proven IZ. Of the
remaining 13 patients without documented IZ, 8 had proven or probable
invasive aspergillosis (IA). BALF from 10 non-haematology patients was
used as control. BALF samples were also investigated for presence of
zygomycete DNA by PCR, using 18S primers.
Results: The BALF of the 5 patients with proven IZ were positive for
zAg. In the remaining 13 neutropaenic patients, zAg was detected in
BALF of 7. Four of these had probable or proven IA The number of
zAg positive BALF from neutropaenic patients with suspected IFI was
higher than in the control group (7 of 13 versus 1 of 10, P< 0.002).
Zygomycete DNA was detected in 11 of 12 BALF samples positive for
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zAG, and all BALF samples negative for zAg were also negative for
zygomycete DNA by PCR.
Conclusion: zAg and zygomycete DNA are present in BALF of patients
with IZ, and might be a useful tool for early diagnosis. The presence
of both markers in BALF samples from high-risk patients without a
clinically manifest disease might indicate the presence of colonisation
or subclinical infection.
Slime wars: an in-depth look at bioﬁlms
O174 Growth, adhesion and bioﬁlm formation of Pseudomonas
aeruginosa with antibiotic-induced morphological changes
under the inﬂuence of dynamic conditions
A.P. Fonseca, J.C. Sousa (Porto, PT)
Objectives: The aim of this study was to investigate the effect
of dynamic conditions and antibiotic-induced morphological changes
on growth, adhesion and bioﬁlm formation ability of Pseudomonas
aeruginosa.
Methods: A modiﬁed microtitre plate assay was used to quantify
adhesion, bioﬁlm formation and planktonic culture density of Pseu-
domonas aeruginosa ATCC 27853 under the effect of 0.5 Minimal
Inhibitory Concentration (MIC) of Piperacillin/Tazobactam, Imipenem
and Meropenem. Hydrodynamic conditions were obtained by orbital
shaking at 250 rpm with the presence of a glass bead in each microtitre
well.
Results: These conditions decreased the adhesion and bioﬁlm formation
abilities of bacteria with antibiotic-induced morphological changes
in comparison to static conditions. The planktonic culture density
signiﬁcantly correlates with adhesion but not with bioﬁlm formation.
Conclusion: Our results demonstrate the importance of using a
high-throughput dynamic model to assess the adhesion and bioﬁlm
formation deﬁcient behaviour of P. aeruginosa with antibiotic-induced
morphological changes and suggest the possible use of sub-MIC
antibiotics in clinical applications to prevent infections acquired by
haematogenous spread. This dynamic model contributes to a better
simulation of in vivo conditions of adhesion and bioﬁlm formation of
P. aeruginosa with altered morphologies induced by b-lactam antibiotics.
Acknowledgments: This study was supported by a grant from Fundac¸a˜o
Calouste Gulbenkian (Ref. 47273).
O175 Differences in bioﬁlm development by non-pigmented
rapidly growing mycobacteria using different culture media
J. Esteban, N. Zamora, R. Fernandez Roblas, I. Gadea, H. Adames,
T.J. Kinnari (Madrid, ES)
Objective: To evaluate the ability of different species of nonpigmented
rapidly growing mycobacteria to develop bioﬁlm in different culture
media using a microtiter plate assay.
Methods: Collection strains (Mycobacterium fortuitum ATCC 6841 and
ATCC 13756,M. chelonae ATCC 19235 and ATCC 35752,M. abscessus
DSM 44196, M. peregrinum ATCC 14467, M. mucogenicum DSM
44124, M. septicum ATCC 700731, M. immunogenum ATCC 700505,
M. mageritense ATCC 700351,M. porcinum ATCC 33776,M. elephantis
DSM 44368, M. smegmatis CECT 3032, CECT 3020 and CECT 3017,
M. goodii ATCC 700504, M. alvei CECT 3021, and M. brumae CECT
3022) of non-pigmented rapidly growing mycobacteria (NPRGM) were
inoculated in tissue culture-treated polystyrene microtiter plates and
incubated in Middlebrook 7H9, PBS-5% glucose or sterile tap water.
Plates were incubated at room temperature with rotation during 70
days, and media were changed each 4 days. One well for each strain
and medium was stained with Fuchsin, decoloured with ethanol, and
photographed to measure the bioﬁlm development the days 1, 4, 8, 12,
20, 27, 34, 41, 48, 55, 62 and 70. Calculation of the surface covered
by bacteria was performed analysing the photograps with the ImageJ
software for Windows.
Results: All the strains tested were able to form bioﬁlm in all the media
tested. However, differences were detected between the different media.
The isolates were able to form bioﬁlm faster in Middlebrook 7H9 (100%
of surface covered in day 28 for all the strains) than in tap water (100% of
surface covered in day 63 for all the strains). The day 70 none of strains
covered all the surface when using PBS-5% glucose. No difference was
found between species in bioﬁlm development.
Conclusions: All the NPRGM tested were able to develop bioﬁlm in all
tested media. The bioﬁlm development is dependent on the type of the
culture media, being faster when a rich media is used. No differences
were detected in bioﬁlm development among the different species.
Acknowledgments: T.J. Kinnari was funded by a grant from the
Academy of Finland. N. Zamora was funded by a grant from the
Fundacio´n Conchita Ra´bago de Jime´nez Dı´az (Madrid, Spain).
O176 Effect of Fe and glucose on the glycolysis and gluconeogenesis
in bioﬁlm-associated Staphylococcus epidermidis
C. Massonet, V. Pintens, R. Merckx, J. Van Eldere (Leuven, BE)
Objective: To determine the role of GapA (glycolysis) and GapB
(gluconeogenesis) in Staphylococcus epidermidis bioﬁlms.
Methods: A bioﬁlm-forming S. epidermidis strain from a proven
catheter-related infection was used. For in vitro studies, to examine
the inﬂuence of glucose, bacteria were grown overnight in BHI and
re-incubated in BHI (glucose-rich; Fe-rich) or 0.9% NaCl (glucose-
limited; Fe-rich). To examine the inﬂuence of iron (Fe) bacteria were
grown overnight in RPMI without Fe (fRPMI) and re-incubated in
fRPMI (glucose-rich; Fe-limited) or fRPMI with 25mM Fe (glucose-
rich; Fe-rich). For in vivo studies a subcutaneous rat model was used.
Quantiﬁcation of bacteria and gene expression through Taqman PCR
were performed as described by S. Vandecasteele et al. (Biochem.
Biophys. Res. Commun. 2002; 291: 528–534). Extracellular matrix and
bacteria were visualised through confocal laser scanning microscopy
(CLSM).
Results: In vitro, in a glucose-rich environment the expression of gapA
and gapB did not differ between planktonic and sessile bacteria and
stayed constant over time. Both in planktonic and sessile bacteria,
expression of gapA was up-regulated in comparison to gapB. In vitro,
in a glucose-limited environment, expression of gapA in sessile bacteria
decreased in comparison to its expression in planktonic bacteria and
expression of gapB in sessile bacteria increased to the expression level
of gapA in sessile bacteria.
In vitro, in sessile bacteria, gapB expression was high in a medium with a
low Fe content, irrespective of the glucose content. Simultaneously with
the increased expression of gapB, PIA production could be visualised
through CLSM in sessile bacteria in all media.
In vivo expression of gapA was high and remained constant over a period
of two weeks. The expression of gapB decreased during the initial phase
of implantation, but reached the expression level of gapA after two weeks
of implantation.
Conclusion: The persistent expression of gapA in sessile bacteria could
indicate a role in bioﬁlm formation, especially in the early stages, while
expression levels of gapB could indicate a role in the later phases of
bioﬁlm formation. Results of gene expression and CLSM indicate a link
between gapB and PIA production that is inﬂuenced by both Fe and
glucose.
O177 Bioﬁlm formation may be an independent virulence factor
in wild-type Staphylococcus saprophyticus strain 7108 in
contrast to wild-type strain CCM 883
F. Szabados, K. Strate, M. Kaase, T. Sakinc, A. Anders, S. Gatermann
(Bochum, DE)
S. saprophyticus is second only to E. coli the most important causative
organism of uncomplicated urinary tract infection in young female
outpatients. Compared to S. aureus and S. epidermidis only very
few virulence factors in S. saprophyticus have been described, for
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example Ssp, a surface-associated lipase, Aas, an autolysin adhesin,
SdrI, a collagen binding protein, and urease activity. Purportedly, the
uropathogenicity of S. saprophyticus can be attributed to its ability to
cope with the high range of variation in salt- and urea-concentration in
human urine. The aim of this study was to elucidate virulence factors of
uropathogenicity.
Methods: Bacterial growth was examined under different conditions
using a modiﬁed model of artiﬁcial urine as previously described.
Bacterial aggregation was observed in bright light and electron
micrographs. Bioﬁlm formation was tested using native polystyrene and
crystalline pre-coated microtiter plates.
Results: In S. saprophyticus strain CCM 883, in contrast to wild-type
strain 7108, generation-time was increased. In S. saprophyticus wild-type
strains 7108 and 9325, bacterial aggregation appeared near large crystal
structures in contrast to its urease negative derivative strain GJ1187 and
the wild type strain CCM 883. In native polystyrene and crystalline pre-
coated microtiter plates, bioﬁlm formation was observed in strain 7108
in contrast to strain CCM 883. The bioﬁlm formation in S. saprophyticus
seems independent of agr-, Ssp-, SdrI, since no difference between
knockout mutants to wild type strain was observed.
Conclusion: Bacterial aggregation could be due to increased adhesion.
The lipase activity may modulate hydrophobicity and Ca2+ binding.
Higher local Ca2+ concentration, as well as strengthened bacterial
aggregation, may lead to increased crystal formation. Bacteria may
adhere to crystals, additionally to the later mechanism due to bioﬁlm
formation. In crystallisation process, bacteria were embedded into the
crystal structure. This may be a new model of infectious stone genesis.
This study strongly suggest that S. saprophyticus wild-type strain CCM
883 lacks important virulence factors in contrast to wild-type strain 7108
and bioﬁlm formation may play an important role in S. saprophyticus
urinary tract infection.
O178 Production of an anti-bioﬁlm molecule by Candida albicans
yeasts growing as a bioﬁlm
E. Cateau, J. Berjeaud, M. Rodier, C. Imbert (Poitiers, FR)
Objectives: The inﬂuence of bioﬁlm formation in catheter-related
candidiasis has been established and it has been shown that the
development of bioﬁlm by the colonising yeasts confers resistance to
antifungals. The purpose of this work was to demonstrate the production,
by the Candida albicans yeasts growing as a bioﬁlm, of a molecule able
to reduce bioﬁlm growth.
Methods: An in vitro model of C. albicans bioﬁlm associated with 100%
silicone catheters was used. The supernatant medium recovered from
C. albicans (ATCC 3153) bioﬁlm aged of 24 hours was added during
the course of a new bioﬁlm formation made with 4 C. albicans strains
(182, 444, 2091 and ATCC 3153), and its inﬂuence was subsequently
evaluated with XTT method. Ultraﬁltration and puriﬁcation assays to
characterise the modulating fungal molecule responsible for the bioﬁlm
supernatant activity are presented in this study.
Results: The addition of the supernatant to adherent C. albicans cells
induced a signiﬁcant (p< 0.001) inhibition of the bioﬁlm growth. This
activity was not observed when the supernatant was added to preformed
bioﬁlms. Ultraﬁltration and puriﬁcation assays demonstrated that this
molecule is small (<3000Da) and hydrophilic.
Conclusions: These preliminary results suggest that this new molecule,
naturally produced within yeasts communities, could be a good candidate
for the prevention of bioﬁlms associated with indwelling medical
devices.
New diagnostic kits on the block
S179 Finding the niche of T cell assays in tuberculosis infection
and disease
P. Hill (Banjul, GM)
In 1994 the ﬁrst article describing an ‘early secreted’ antigen (esat-6)
from the culture ﬁltrate of M. tuberculosis was published. Three key
properties of this antigen are that it is highly immunogenic, it is not
found in BCG or many environmental mycobacteria, and it is a key
virulence factor. Its immunogenicity and speciﬁcity led to a series of
studies to assess its potential as a major component of new diagnostic
tests. Such tests have evolved into two major forms-a whole blood assay
marketed under the name Quantiferon and an ELISPOT assay marketed
under the name T-spot. New antigens have been assessed for improved
test performance, most notably CFP-10. Studies of in-house versions
of these assays, and more recently the commercial kits, have shown
encouraging results in TB cases for the diagnosis of disease and in
their close contacts for the diagnosis of M. tuberculosis infection. It
is clear that these tests are not confounded by prior BCG vaccination
and are probably not subject to boosting by injected tuberculin. Their
quantitative readouts may also provide important information with
respect to infectious load. However, some ﬁndings have caused concern:
disparity in test performance between temperate non-TB endemic and
tropical TB-endemic settings, evidence of relatively poor sensitivity to
the presence of certain M. tuberculosis strains (eg. M. africanum) and in
certain sub-groups (eg. Pulmonary TB, certain TB contacts), and rapid
unexplained test reversion. It is therefore becoming clear that T cell
assays may have a niche in the diagnosis of certain TB cases and in
certain individuals suspected of havingM. tuberculosis infection, but this
niche has not yet been fully deﬁned. More longitudinal studies, especially
following TB case contacts for the development of disease, are indicated.
Also more studies should be undertaken in TB endemic areas. Finally, if
these tests are to have any role in TB control globally they would need
to be much cheaper and more easy to use. Some advances with respect
to these two issues have already taken place.
Antiretroviral treatment
S184 New targets for innovative HIV treatment
G. Fa¨tkenheuer (Cologne, DE)
Over the last ten years unprecedented progress has been made in
the treatment of HIV infection by the application of combination
antiretroviral therapy (cART). Three classes of drugs have been
contributed to this success: the nucleoside (NRTI) and the non-
nucleoside (NNRTI) reverse transcriptase inhibitors, and the protease
inhibitors (PI). With the advent of the fusion inhibitor enfuvirtide (T20)
the ﬁeld has been opened for new classes of drugs. During the last
year a whole bundle of drugs with new targets has been studied in
humans. Among the most developed compounds are CCR5 antagonists
and integrase inhibitors. Other classes in earlier phases of clinical
development include attachment inhibitors and maturation inhibitors.
It is expected, that integrase inhibitors and CCR5- antagonists will
be introduced into clinical practice in 2007/2008. Both of these drug
classes have been ﬁrst studied in heavily treatment experienced patients
having failed NRTI, NNRTI and PI therapy. In preliminary analyses
the integrase inhibitor MK-0518 combined with optimised background
treatment (OBT) has shown clinical superiority over OBT alone. Up to
72% of patients treated with MK-0518 have reached complete viral
suppression (HIV-RNA <50 c/mL) after 16 weeks. Preliminary data also
suggest a high virological potency of the drug in treatment naı¨ve patients.
MK-0518 was applied bid and was well tolerated in both pretreated an
treatment naı¨ve patients.
Two CCR5 antagonists are currently studied in clinical trials, maraviroc
and vicriviroc. Vicriviroc together with OBT has shown superiority
over OBT alone in treatment experienced patients, but has failed in a
phase II study in treatment naı¨ve patients presumably due to matters of
dosing. Further studies to deﬁne the optimal dose (together with ritonavir
boosting) are underway. With maraviroc results of a study in treatment
experienced patients exhibiting dual tropic virus (R5/X4) are available.
In this population, maraviroc did not show additional virological efﬁcacy
over placebo, but lead to a greater increase of CD4 cells.
In conclusion, new drugs in new classes improve the treatment options
for patients with multi-resistant HIV considerably. Since these drugs
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seem to be very well tolerated there is also a potential for their use in
treatment naı¨ve patients in the future.
S185 Challenges in the management of adverse effects of long-term
ART
A.M. Geretti (London, UK)
Antiretroviral therapy is highly effective in controlling HIV replication,
inducing immune reconstitution and preventing AIDS-related morbidity
and mortality. Current antiretroviral regimens however cannot achieve
virus eradication and virological rebound virtually always occurs
after therapy discontinuation. Long-term highly active antiretroviral
therapy (HAART) is life saving, but poses several challenges. Potential
adverse events can be categorised as problems related to adherence,
pharmacokinetics, toxicity and drug resistance. Various interventions
have been explored to improve and maintain good adherence among
treated individuals, ranging from treatment simpliﬁcation strategies to
addressing mental health problems, and a major challenge is related to
the need for integrated biomedical, social and behavioural interventions.
Inadequate adherence however accounts for only a subset of sub-
therapeutic drug levels in clinical practice. There is a signiﬁcant degree
of inter-individual variability in absorption, metabolism and cellular
transport of antiretroviral drugs, with potential impact on both efﬁcacy
and toxicity of therapy. Important determinants include gender, age,
ethnic origin, and genetic polymorphisms. Although evidence of the
inﬂuence of pharmacogenomics is growing, there remain limited data
to guide clinical practice. Proton pump inhibitors are an example of
commonly prescribed medications that can affect antiretroviral drug
levels by reducing the absorption of certain protease inhibitors (PIs) and
increasing exposure to others. Herbal medicines such as St. John’s wort,
widely used by HIV patients, also have the potential to interact with
antiretroviral drugs. Thus, patient education and good communication
across care providers are paramount to prevent unfavourable drug–drug
interactions.
The risk of toxicity associated with long-term antiretroviral therapy is
difﬁcult to predict reliably in an aging population of HIV-infected per-
sons. Major examples of HAART-related toxicity include mitochondrial
damage and lipoatrophy associated with the use of nucleos(t)ide reverse
transcriptase inhibitors (NRTIs), and fat accumulation, dyslipidaemia and
insulin resistance associated with the protease inhibitors (PIs). The risk
of cardiovascular disease is a particular concern, due to the combined
effects on the cardiovascular system of HIV infection, HAART and life-
style related risk factors such as smoking which are common among HIV-
infected persons. In addition, renal, hepatic and bone toxicity represent
emerging side effects of long-term treatment.
Patients starting therapy on recommended ﬁrst-line regimens achieve a
high degree of virological and immunological success. However, drug
resistance continues to emerge as a result of problems with adherence and
tolerability. Furthermore, there remain a large number of HIV-infected
persons who have accumulated drug resistance through mono and dual
therapy in the pre-HAART era and the suboptimal use of therapy in the
early HAART era. In addition, a substantial proportion of newly infected
persons acquire drug-resistant virus.
New drugs and drug classes are required to optimise treatment among
drug-experienced persons and reduce the risk of side effects. Several
new compounds have recently entered clinical use that show improved
tolerability proﬁle or activity against drug resistant virus. Improved
methods for detecting and interpreting drug resistance are also being
developed to adequately guide treatment. In spite of these concerns
however, the beneﬁts of HAART far outweigh the risk of adverse events.
Clinical signiﬁcance of innate immune
defence
S188 Leishmania major induces secretion of inﬂammatory cytokines
and chemokines by keratinocytes via a TLR2 pathway
C. Ronet, S. Bakhiet, C. Pavlin, S. Akira, P. Launois (Epalinges, CH;
Osaka, JP)
Objectives: Some features of the cutaneous pathologies observed in
patients with cutaneous leishmaniasis can be reproduced in the murine
model of infection with L. major. After subcutaneous injection of
parasites in C57BL/6, mice are resistant to infection; in contrast BALB/c
mice are susceptible to infection. Resistance and susceptibility to the
infection were related to the development of polarised Th1 and Th2
response. Keratinocytes are the ﬁrst effector cells encountering parasites
during infection with L. major but their role in the initiation of the
immune response is mainly ignored. The aim of this study is to analyse
the role of the interaction between L. major and keratinocytes in the
subsequent immune response induced by infection with this parasite.
Methods: Cultured primary murine keratinocytes from neonatal
C57BL/6 and BALB/c mice (1−3 days old) were stimulated in vitro
by L. major LV39 strain (MHRO/Sv/59/P strain), and mRNA expression
and secretion of inﬂammatory cytokines (IL-1, IL-6 and TNF-a) and
chemokines (MIP-2) were analysed.
Results: Parasites adhere to keratinocytes through the ﬂagellar tip, the
ﬂagellar base or with the posterior pole in both strains of mice, but
they never infect keratinocytes. Whereas this interaction induces an up-
regulation of IL-1 and MIP-2 mRNA expression and secretion in both
BALB/c and C57BL/6 mice, IL-6 is produced in response to L. major
only in BALB/c mice. Furthermore, we demonstrated that TLR-2 −/−
mice are unable to produce MIP-2 in response to L. major stimulation.
Conclusion: The results strongly suggest that keratinocytes are able to
produce cytokines in response to L. major stimulation through in part-
TLR-2.
S189 Innate immunity and Aspergillus infections
L. Romani (Perugia, IT)
Aspergillus fumigatus, a termotolerant saprophyte, is associated with a
wide spectrum of diseases in humans, that includes saprophytic colonisa-
tion of preexisting cavities, allergic asthma, allergic bronchopulmonary
aspergillosis occurring as a complication of bronchial asthma or cystic
ﬁbrosis, and invasive aspergillosis in immunocompromised patients.
Immunocompetent and non-atopic subjects are relatively resistant to
A. fumigatus diseases and disease occurs in the setting of host
damage. The inherent resistance to diseases caused by A. fumigatus
suggests the occurrence of regulatory mechanisms that provide the
host with adequate defence without necessarily eliminating the fungus
or causing unacceptable levels of host damage. Respiratory tolerance
is mediated by plasmacytoid dendritic cells producing IL-10 and
inducing the development of CD4+ T regulatory cells expressing
FoxP3 and regulating inﬂammation and allergy through the indoleamine
2,3-dioxygenase (IDO)-dependent pathway. Thus, the IDO-dependent
pathway has a unique e central role in this process as it participates
in the effector and inductive phases of immunity and tolerance to the
fungus.
S190 Intracellular inhibitors of innate immunity encoded by
Vaccinia virus
G.L. Smith (London, UK)
Vaccinia virus (VACV) is the vaccine that was used to eradicate
smallpox. Like other poxviruses, VACV is a large DNA virus that
replicates in the cytoplasm, produces multiple infectious forms of
virus and encodes many virulence factors that are non-essential for
virus replication in cell culture. Many of these virulence factors are
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encoded in the terminal regions of the virus genome and are called
immunomodulators because they interfere with the host response to
infection. Some of these immunomodulators are present only within
infected cells and inhibit signalling pathways induced by ligand
engagement of cytokine, interferon or toll like receptors. Other molecules
inhibit pathways leading to the induction of apoptosis. This talk will
describe proteins from VACV that inhibit apoptosis or intracellular
signalling pathways leading to the induction of interferon or pro-
inﬂammatory cytokines. These studies will illustrate how studying the
structure and function of these molecules is increasing our understanding
of virus pathogenesis and cell biology.
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S191 European consensus on malaria chemoprophylaxis
C. Hatz (Basle, CH)
Every year several thousand malaria cases with a mortality around 1%
are reported in Europe. Visiting friends and Relatives (VFRs) are at
particular risk.
The complex situation of malaria transmission in various endemic areas
requires differentiated recommendations for malaria prophylaxis. Malaria
prophylaxis comprises of multiple components. Malaria risk can be
reduced by compliant exposure prevention, and with chemoprophylactic
drugs for travel to high risk areas are available.
Key points for malaria prevention and management include awareness
in endemic regions and after return, avoid mosquito bites, compliance
with chemoprophylaxis, and seeking immediate diagnosis and therapy
in case of fever.
The importance of exposure prophylaxis should be emphasized.
It is recommended to use mosquito repellents after dusk, espe-
cially if outdoor activities are performed. Light-coloured, loose-ﬁtting
insecticide-treated clothing with long trousers and long sleeves are
suggested. Sleeping under insecticide treated bed nets or in air-
conditioned rooms which are pre-treated with insecticides (knockdown
spray) is recommended.
Chemoprophylaxis is recommended in high risk areas. In most settings,
either meﬂoquine (Lariam®), atovaquone/proguanil (Malarone®) or
doxycycline (monohydrate) are used. In German speaking countries,
emergency treatment is recommended for trips to regions with low
or intermediate malaria risk. This strategy is recommended when the
infection risk is lower than the risk of severe drug side effects.
Good information by the consulting doctor and personal responsibility
of the traveller are essential for the correct handling of emergency-
self-treatment. Drugs used include artemether/lumefantrine (Riamet®),
atovaquone/proguanil (Malarone®) or meﬂoquine (Lariam®). The
guidelines for the application of the emergency-self-treatment should
be discussed thoroughly with the traveller, to make sure that in case of
fever the correct action will be taken:
1. In case of fever (sudden onset or rapidly progressive) – axillary
temperature >37.5ºC (oral, tympanal or rectal >38ºC) – a doctor
should be seen and a malaria blood test should be performed. A
working thermometer is essential in the tropics.
2. If no doctor can be seen within 24h and the traveller is in an endemic
region for at least 6 days, the fever should be lowered.
3. The malaria emergency medication should be taken with adequate
amounts of ﬂuid.
4. In every case, also after the intake of the malaria drug a doctor must
be consulted at the earliest possible time.
S193 Current trends in echinococcal diseases
P. Kern (Ulm, DE)
The term echinococcosis describes two diseases which markedly differ
in their presentation, behaviour and management: Alveolar echinococco-
sis (AE) is caused by the metacestode Echinococcus multilocularis and
cystic echinococcosis (CE) by E. granulosus. The larval growth of the
two bugs is very different and separates the “malignant” AE from the
“benign” CE. Thus, current trends are discussed separately.
AE: A recent European initiative (EchinoRisk) discovered a continuous
increase and spread of the parasite in the ﬁnal host (fox). In parallel,
human cases were observed in regions outside the known endemic areas,
such as in the Baltic States, in Hungary and Slowakia. Risk factors for
humans are farming and a long-standing, close contact to dogs. The
initially asymptomatic liver disease is still rare in Central Europe, and
diagnosis is often made at a late stage of the disease. An anatomical
classiﬁcation system has been used (PNM adapted from the TNM system
of tumours), allowing now a comparison of the disorder at the time
of ﬁrst diagnosis in different clinical settings. New foci have been
discovered in China/Tibet with a prevalence rate of up to 4% of the
affected population. Imaging techniques, such as Ultrasound, CT, MRI
and PET/CT contributed to a much better description of the lesions.
However, the expertise of the radiologist is often not available due to
the low incidence of AE. Serology is helpful, but may be misleading
due to non-standardised tests. Molecular tools have been developed, and
help histopathologists to clearly separate the two bugs by microscopy.
Radical surgery is curative and the ﬁrst choice of treatment. Due to the
potential “malignant” features of the disease palliative surgery and liver
transplantation should be strictly avoided. Instead continuous treatment
with benzimidazoles is the backbone of a lifelong management of AE.
CE: The disease, also known as hydatid disease, occurs worldwide.
Recent trends indicate a decreasing incidence throughout the Mediter-
ranean countries, whereas important new foci have been disclosed in
China/Tibet, and re-emergence is obvious in countries of the former So-
viet Union. For Central Europe it is believed that CE is an imported dis-
ease. However, autochthonous infections are being observed, and under-
line the fact that transmission is still possible. Based on molecular mark-
ers the species of E. granulosus was recently further subdivided accord-
ing to its main intermediate host in E. granulosus, E. ortleppi, E. equinus,
E. intermedius. In contrast to AE, the larva forms a single or several
ﬂuid-ﬁlled cyst(s), and induces a well-organised, compact capsule of host
origin. Serological diagnosis of the disease in humans is still unsatisfac-
tory, since young and unruptured cysts remain serologically negative. The
recently established WHO Classiﬁcation of hepatic cysts has much im-
proved the clinical management. Experiences with the PAIR/PEVAC pro-
cedure are encouraging, and have shown to be safe for hepatic hydatids.
Surgery is not anymore the treatment of choice. Instead many centres
apply short term cycles of benzimidazoles which act parasitocidal and
accelerate the degeneration of the cyst. Others favour the Watch and Wait
concept, and carefully observe the natural degeneration of the cyst(s).
S194 Current trends in ﬁlarial diseases
A. Hoerauf (Bonn, DE)
Filarial worm infections of humans cause morbidity and even death in
developing countries of the tropics. Current antiﬁlarial drug therapies
target only the ﬁrst stage larvae, requiring many years of annual/biannual
treatment. Another problem with controlling ﬁlarial infections is the
lack of any alternative drugs that can be used in the current mass
drug administration programmes should resistance develop. Wolbachia,
endosymbiotic bacteria that are found in most of the human ﬁlarial
worms are excellent targets for the discovery of new antiﬁlarial drugs
because of their requirement for worm embryogenesis, development
and adult survival. In both lymphatic ﬁlariasis and onchocerciasis,
administration of 6 weeks of doxycline at a dose of 200mg/day results
in a high macroﬁlaricidal effect of over 80% and 70%, respectively.
Targeting of Wolbachia with antirickettsial drugs has lead to the
recommendation of doxycycline for use on an individual basis and may
be recommended in areas where resistance to current drugs may develop.
Evidence that eliminating the endobacteria reduces adverse reactions
to current drug therapies and even reduces early stages of lymphatic
pathology is also accruing. Research is underway to discover new drugs,
preferably those already approved for use in humans, that have anti-
wolbachial activity and work in a shorter time and are widely applicable.
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Experimental models of infectious diseases
O195 Development of glycopeptide-intermediate resistance by
Staphylococcus aureus leads to attenuated infectivity in a
rat model of endocarditis
J. Entenza, P. Majcherczyk, M. Giddey, S. Piu, J. Vouillamoz,
P. Moreillon (Lausanne, CH)
Objectives: Whether S. aureus developing intermediate resistance to
glycopeptides, i.e. the GISA phenotype, are altered in their infectivity
is poorly documented. Here we used an isogenic pair of glycopeptide-
susceptible and -intermediate S. aureus (M1V2 and GISA M1V16;
vancomycin MIC: 2 and 16mg/l, respectively) to study their ability to
(i) adhere to ﬁbrinogen (Fg) and ﬁbronectin (Fn) in vitro, (ii) persist
in the bloodstream after intravenous inoculation, (iii) colonise aortic
vegetations in rats, (iv) multiply in situ thereafter, and (v) compete for
valve colonisation when inoculated in mixed cultures.
Methods: GISA M1V16 was selected by vancomycin exposure of
the glycopeptide-susceptible, methicillin-resistant S. aureus M1V2 (agr
type II) in the laboratory. The phenotypic expression of resistance
to vancomycin and the stability of the phenotype was analysed by
population analysis. Adherence was tested on immobilised Fg and
Fn. Rats with catheter-induced aortic vegetations were inoculated with
103−106 CFU of the test strains. Rats were killed after 24 h. Vegetations
and spleens were cultured and the lower inoculum infecting 90% of
vegetations (ID90) was recorded. Blood cultures were drawn within
the ﬁrst 60 min. Infectivity was also compared by co-inoculation with
10× the ID90 of M1V16 and a rifampin-resistant variant of the parent
M1V2, to discriminate them in organ cultures.
Results: The GISA M1V16 mutant grew on plates containing 16mg/l of
vancomycin and its resistance phenotype remained stable after 5 passages
on drug-free medium. Both GISA and parent strains adhered similarly
to Fg and Fn in vitro. In rats, the GISA M1V16 was cleared faster from
the blood (P< 0.005) and required 100× more bacteria than the parent
(106 versus 104 CFU) to infect 90% of animals. GISA M1V16 had also
100–1000× lower bacterial densities in vegetations and spleen. After
co-inoculation, M1V2 and GISA M1V16 produce similar vegetation
densities early after injection. However, while the vegetation counts of
the parent increased at 48, 72 and 120 h, the counts of GISA M1V16
remained stable.
Conclusions: GISA showed attenuated pathogenicity (ID90) and ﬁtness
(intra-vegetation growth) in rats with experimental endocarditis. Thus,
the GISA phenotype is globally detrimental to infectivity. This might
explain its clustering in immuno-compromised patients. Whether a very
prolonged exposure to glycopeptides might restore pathogenicity and
ﬁtness defects remains to be determined.
O196 Evaluation of moxiﬂoxacin and levoﬂoxacin against
S. pyogenes in various animal models
R. Endermann, K. Ehlert (Wuppertal, DE)
Objectives: Group A streptococci are frequently implicated in compli-
cated skin and skin structure infection (cSSSI). Moxiﬂoxacin (MXF)
has recently been approved for this indication. In this study, the
therapeutic efﬁcacy of MXF or levoﬂoxacin (LFX) against a clinical
isolate of S. pyogenes (6A47 wild-type) was investigated. We studied
both quinolones in a murine sepsis model and in two cSSSI models: the
granuloma pouch and the Gelfoam® implant model.
Methods: Sepsis model: bacteria were suspended in 5% mucin
in saline and inoculated intraperitoneally. Antibiotics were given
intravenously (i.v.) at 1, 4, 24 and 32 h post-infection (p.i.; 5
animals/group). Survival was monitored for 5 days. Granuloma pouch
model: pouches were formed by injecting 5mL of air and 0.5mL of
0.1% croton oil in olive oil under the skin of the back. After 72 h, the
air was replaced by 1mL of 0.25% agar in saline. A bacterial suspension
(0.5mL) was injected into the pouch after 48 h. Antibiotics were given
i.v. at 0.5, 4, 24 and 32 h p.i. (7 animals/group), and viable counts in
exudates were assessed at 48 h.
Gelfoam® model: a collagen piece was implanted under the skin of the
back. After 3 days, 50mL of bacterial suspension was injected into the
implant. Antibiotics were given i.v. for 3 days (b.i.d.), starting 2 h p.i.
(5 animals/group); implants were removed for bacterial cell counts 24 h
after treatment ended.
Results: Sepsis model: 100% survival was achieved with 25mg/kg MXF,
compared to 40% survival with 25mg/kg LFX. Granuloma pouch and
Gelfoam® models: the colony forming unit (CFU) reductions achieved
with MXF were greater than those achieved with LFX (Table).
CFU reduction (log10) in the granuloma pouch and Gelfoam® models
MXF LFX Pa
Granuloma pouch (log CFU reductionb)
50mg/kg −0.49 −0.18 0.48
75mg/kg −2.31 −0.30 0.009
Gelfoam® (log CFU reductionb)
25mg/kg −1.56 −0.92 0.19
50mg/kg −3.11 −1.38 0.03
aMann–Whitney test; bLog CFU reduction in relation to the untreated
control group.
Conclusion: In the murine sepsis model as well as in two models of
cSSSIs, MFX showed good antimicrobial activity against a recent clinical
isolate of S. pyogenes.
Research funding: Bayer HealthCare Pharmaceuticals
O197 Virulence and bioﬁlm formation of non-mucoid and mucoid
Pseudomonas aeruginosa strains in cystic ﬁbrosis: an animal
study
C. Moser, M. van Gennip, T. Bjarnsholt, H. Calum, P.Ø. Jensen,
B. Lee, O. Ciofu, M. Givskov, S. Molin, N. Høiby (Copenhagen, DK)
Most adult cystic ﬁbrosis (CF) patients are chronically infected with
P. aeruginosa in their lungs. Two major features of P. aeruginosa are the
abillities to form bioﬁlms and become mucoid. Recently, we reported a
time-dependent reduction in the ability to form bioﬁlm by non-mucoid
P. aeruginosa isolates from the same CF patient obtained over a period of
23 years. In order to investigate whether the declined ability of the PFGE-
identical isolates to form bioﬁlm in vitro correlated to pathogenicity
in vivo, 5 non-mucoid clones from 1980 and 1988 (early clones), and
1997, 1999 and 2003 (late clones) embedded in alginate were installed
in the lungs of ﬁve groups of BALB/c mice. Mice were sacriﬁced
after 5 days of infection. The experiment was evaluated by macroscopic
lung pathology, histopathology, quantitative bacteriology (CFU/lung) and
pulmonary cytokine production.
Survival was signiﬁcantly higher in mice infected with the late clones,
as compared to mice infected with the early clones (p< 0.025).
Macroscopic pathology was more disseminated in mice infected with
the early clones as compared to mice infected with the late clones
(p< 0.0015). Inﬂammation involving polymorphonuclear neutrophils
(PMN’s) was present more often in mice infected with the early clones
as compared to mice infected with the late clones (p< 0.05). In addition,
a higher degree of inﬂammation as well as more mice with athelectasis
was observed after infection with the early clones (p< 0.05). CFUs
were higher in mice infected with the early clones as compared to
mice infected with the later clones (p< 0.04). Pulmonary TNF-a, IL-10
and GM-CSF increased in mice infected with the late clones, whereas
the mobiliser of PMNs from the bonemarrow G-CSF and the PMN
chemoattractant MIP-2 decreased in mice infected with the late clones.
Mucoid PFGE-identical isolates from 1988, 1997 and 2003 from the
same patient were installed in the lungs of BALB/c mice. Survival
decreased signiﬁcantly in mice infected with the late clones from 1997
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(all 23 mice died) or 2003 (21 of 23 mice died) as compared to the clone
from 1988 (1 of 24 mice died) (p< 0.005).
In conclusion, non-mucoid P. aeruginosa lung infection is characterised
by a time-dependent correlation between the ability to form bioﬁlm,
the ability to establish lung infection, and the inﬂammatory responses.
In contrast, pathogenecity of the mucoid strains increases with time
supporting the importance of controlling this phenotype by all means.
O198 Reduction of pathogen shedding and alleviation of disease
signs in pigs challenged with Salmonella Typhimurium by
the application of a ﬁve-strain probiotic combination
P. Casey, G. Gardiner, N. Leonard, C. Stanton, P. Ross, G. Fitzgerald,
C. Hill (Cork, Fermoy, Dublin, IE)
Objectives: Infection with Salmonella spp. is a major cause of
gastroenteritis, with many thousands of cases reported every year. The
use of probiotics offers the potential to improve this situation. Here, we
investigate the effect of oral treatment of pigs with a deﬁned lactic acid
bacteria culture mixture on both clinical and microbiological signs of
Salmonella Typhimurium infection.
Methods: Fifteen weaned pigs blocked by gender and weight were
administered skimmed milk (as a control) or a mixture of ﬁve probiotic
strains (given as either a milk fermentate or milk suspension) for a
total of 30 days. The mixture comprised two strains of Lactobacillus
murinus and one strain each of Lb. salivarius ssp. salivarius, Lb. pentosus
and Pediococcus pentosaceus. Following probiotic administration for six
days, animals were orally challenged with Salmonella Typhimurium; the
health of the animals and the microbiological composition of their faeces
were monitored for 23 days post infection.
Results: Animals treated with probiotic displayed reduced incidence,
severity and duration of diarrhoea. These animals also gained weight at a
greater rate than control animals and mean faecal numbers of Salmonella
were signiﬁcantly reduced in probiotic-treated animals at 15 days post
infection.
Conclusions: The probiotic mixtures used lead to an amelioration of
clinical signs in Salmonella Typhimurium-infected pigs early in the
course of infection, and signiﬁcantly reduced pathogen shedding over
a longer timeframe. While the exact mechanism remains to be fully
elucidated, this demonstrates the validity of using commensal lactic acid
bacteria strains in the prevention of gastrointestinal infection. The in
vitro and in vivo procedures used to isolate and select the bacteria
are also validated. While the probiotics examined in this study are of
obvious interest to those involved in the pig production industry, the
similarities between the pig and human gastrointestinal tracts suggest
that the probiotics offer potential in cases of human salmonellosis, given
that the methodology used is also likely to be applicable to human disease
control.
O199 Efﬁcacy of linezolid in the treatment of bioﬁlm-associated
infection using a rabbit model of methicillin-resistant
Staphylococcus aureus catheter bioﬁlm
M. Ghannoum, L. Long, H. Kim, V. Rotondo, A. Cirino, D. Sheehan
(Cleveland, New York City, US)
Objectives: Catheter-related bioﬁlm infections (CRBI) are a major
cause of bloodstream infections in the USA. One of the most common
causes of CRBI related bloodstream infection is methicillin-resistant
Staphylococcus aureus (MRSA). Catheter removal has become an
integral part of the therapeutic approach to CRBI, however, it is
associated with increased medical costs, potential morbidity, and is not
always feasible in critically ill patients. Antibiotic lock therapy provides
the means for local delivery of high drug concentrations to overcome
resistance due to bacterial bioﬁlms that coat the catheter surface. In this
in vivo study, we compared the effectiveness of linezolid (LIN) versus
vancomycin (VAN) antibiotic lock therapy against MRSA CRBI.
Methods: In New Zealand White rabbits, silicone catheters were
tunneled subcutaneously and surgically placed in their jugular vein. The
catheter lumen was infected by locking 1×107 MRSA in the lumen for
24 h. To maintain catheter patency, heparin ﬂushes were performed daily.
Rabbits were randomised into three groups: untreated control, VAN 2mg,
and LIN 2mg. Each drug was locked in the catheter lumen for 8 h a day
for 7 days. After treatment, the animals were anaesthetised and peripheral
blood cultures were taken from the catheter. Animals were sacriﬁced,
catheter removed and divided into two pieces; one piece for quantitative
culture and the other for scanning electron microscopy (SEM).
Results: Bioﬁlms were conﬁrmed by blood culture showing MRSA
growth from the catheter 3 days post-infection. Catheters removed from
untreated controls yielded a higher fungal burden than LIN and VAN-
treated groups (2.59±0.76, 0.20±0.08, and 0.18±0.68, respectively). No
signiﬁcant difference was observed between LIN and VAN treatment
groups, (P value 0.8764). SEM of untreated control catheters revealed
patchy, abundant bioﬁlms while both LIN and VAN treated catheters had
almost completely cleared surfaces. VAN-treated catheters had small
patches of bacteria with damaged bioﬁlm matrix, while LIN-treated
catheters had scattered patches of bacteria with little or no surrounding
matrix.
Conclusion: Antibiotic lock therapy with LIN may be a useful treatment
strategy against MRSA in CRBI’s. A prospective, randomised clinical
trial evaluating LIN for the treatment of MRSA caused CRBI is
warranted.
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O200 Identiﬁcation of plasmid-mediated quinolone resistance in
Salmonella enterica isolated in England and Wales
E. Threlfall, K. Hopkins (London, UK)
Objectives: Plasmid-mediated quinolone resistance (qnr) genes have
been identiﬁed in enterobacteria from several countries. Such resistances
have frequently been associated with strains that produce extended-
spectrum b-lactamases (ESBLs). As Salmonella with resistance to
quinolone antimicrobials have become increasingly common in isolates
from humans in England and Wales, a study has been initiated to
investigate the occurrence of such genes in isolates from humans and
food, and to assess their importance for public health.
Methods: A panel of 118 isolates of S. enterica resistant to nalidixic
acid and with concomitant decreased susceptibility to ciproﬂoxacin
(MIC: 0.25−1.0mg/L), from cases of human infection and from foods
in England and Wales, were screened for the presence of qnrA, qnrB
and qnrS by PCR. Isolated qnr plasmid was tested by PCR genes and
for ESBL genes, and for 18 commonly occurring replicons. All strains
positive for qnr genes were further characterised by PFGE.
Results: All isolates were negative for qnrA and qnrB; 6 isolates
belonging to four serovars (S. Stanley, 2; S. Typhimurium, 1;
S. Virginia, 1; S. Virchow, 2) were positive for qnrS. Of these the isolates
of Stanley and Typhimurium were from patients infected abroad, the
isolate of Virginia was from a patient who had not travelled abroad, and
the two isolates of Virchow, one from imported frozen chicken and one
from a patient were associated with a series of infections in 2003/2004.
qnr plasmids were transferable either by conjugation or transformation;
their molecular masses ranged from 13.5 kb (S. Virginia) to >148 kb
(S. Stanley). Four of the six plasmids coded for additional resistance,
in two cases for resistance to 10 additional antimicrobials. The qnr
plasmids from the S. Virchow isolates were of similar size and conferred
a similar resistance phenotype as the ﬁrst qnr plasmid, identiﬁed in
Shigella ﬂexneri in Japan.
Conclusions: These results indicate that plasmidic quinolone resistance,
often linked to other resistances, has now appeared in S. enterica in
Britain. This is of particular concern for the treatment of infections with
invasive serovars such as S. Virchow.
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O201 Development of a low-cost and robust assay for the screening
of multiple genetic loci in Mycobacterium tuberculosis
I.L. Bergval, R.M. Anthony, E.R. Dalla Costa, A.R.J. Schuitema,
L. Oskam, P.R. Klatser (Amsterdam, NL; Rio de Janeiro, BR)
Objective: The rapid characterisation of (drug-resistant) Mycobacterium
tuberculosis (MTB) would be useful for the research and treatment
of tuberculosis (TB). Many important genetic markers of MTB have
been identiﬁed, notably for drug resistance, but also genotype, bacterial
lineage and adaptive potential. A single assay allowing identiﬁcation of
these markers would aid control efforts. Multiplex PCR is unsuitable
for simultaneous ampliﬁcation of several genetic loci in one reaction.
With Multiplex Ligation-dependent Probe Ampliﬁcation (MLPA) only
one primer-pair is used for the ampliﬁcation of multiple genetic targets.
We explored the utility of MLPA as a screening tool to rapidly
characterise MTB-strains
Method: MLPA can identify multiple single nucleotide polymorphisms
(SNPs) by ampliﬁcation of sequence-speciﬁc MLPA-probes, rather than
target DNA. A sensitive ligation-step ensures speciﬁcity of the assay. We
designed MLPA-probes speciﬁc for a range of discriminatory SNPs in
MTB. In addition, we selected three sequences of conserved regions to
use as internal controls and for quantitation. The size of MLPA-products
corresponds to the speciﬁc SNP they targeted.
Ampliﬁed MLPA-products were identiﬁed on an agarose-gel or by
fragment analysis, using capillary electrophoresis.
Results: Probes were initially validated on DNA from reference strains.
All probes were then combined in a single mixture and used to
characterise laboratory strains and a panel of clinical isolates from
Brazil, Peru and the Netherlands. To determine the predictive value of
MTB-speciﬁc MLPA, we screened DNA of MTB-strains with unknown
genotypes. Results were conﬁrmed by sequencing.
There was a very high correlation between sequencing results and results
obtained via MLPA. In addition, both the positive and the negative
predictive value were high. MLPA-products were clearly visible on an
agarose gel.
Conclusion:We have shown that with MTB-speciﬁc MLPA it is possible
to identify drug resistance associated mutations and MTB lineage
speciﬁc SNPs in a single assay. Depending on the application, probes
can be added to or removed from the probe-mix, making it a ﬂexible,
multi-purpose method. MLPA products can be easily identiﬁed on an
agarose-gel, making it especially suitable for screening of TB in the
less-developed world.
Based on our results we feel that in addition to using MLPA on DNA
extracted from culture, performing MLPA directly on DNA from sputum
samples is also feasible.
O202 Differences in mutation rate between phylogenetic groups
of Escherichia coli
D. Jonas, E. Meyer, F. Schwab, F. Daschner (Freiburg, Berlin, DE)
Objectives: The species Escherichia coli comprises four different
phylogenetic groups (A, B1, B2 and D). In general the majority of
infectious as well as colonising strains isolated from patients belong
to phylogenetic group B2. Yet, there is a known disparity between
ﬂuoroquinolone-susceptible and -resistant isolates, which it is assumed
has arisen from the susceptible population: Only a small proportion
of resistant isolates belong to group B2, while the majority belong
to group D. For a possible explanation of the disparate distribution
among phylogenetic groups this work analysed ciproﬂoxacin-susceptible
and -resistant ICU isolates in all phylogenetic groups for differences in
virulence factors (VF) and mutation frequencies.
Methods: Hundred and forty-six susceptible and 135 resistant isolates
were collected from patients in 27 ICUs. All strains were assigned to
phylogenetic groups by means of a triplex PCR protocol. In order to
compare isolates from different groups and susceptibilities, a similar
and as large a number as possible of susceptible and resistant strains
were chosen randomly from groups A (23; 27), B1 (7; 11), B2 (17; 9),
and D (15; 25). The occurrence of different VF was determined by use
of PCR and summarised for each isolate as a VF score. Moreover, the
mutation frequency was determined by plating on 100mg/L rifampicin
containing agar.
Results: Assignation to phylogenetic groups conﬁrmed differences
between susceptible and resistant isolates in the distribution among
phylogenetic groups: 82 out of 146 susceptible isolates belonged to
group B2, in contrast to just 9 out of 135 resistant isolates, with
a majority of 61 isolates belonging to group D. The VF score was
highest both in strains belonging to groups B2 and D without signiﬁcant
differences between susceptible and resistant isolates. However, there was
a small, but signiﬁcant difference in the median of the mutation rates
between the isolates of different groups, increasing in the order B2 < D <
B1 < A. The median mutation rate of B2 isolates (1.3×10−8) differed
signiﬁcantly (P< 0.05) from the remaining isolates as did, conversely,
that of the group A isolates (2.4×10−8).
Conclusion: Slightly, but signiﬁcantly reduced mutation rates in strains
of the deep rooted phylogenetic group B2 might be an explanation for
their rare occurrence among ﬂuoroquinolone-resistant isolates.
O203 Epidemiological surveillance and characterisation of TEM-,
SHV-, and CTX-M-type ESBLs in Russian nosocomial
strains of Enterobacteriaceae using real-time PCR and
melting-curve analysis techniques
M. Stepanova, A. Nikulin, M. Sukhorukova, M. Edelstein (Smolensk, RU)
Objectives: To determine the prevalence of major molecular class A
extended-spectrum b-lactamases (ESBLs) of TEM, SHV and CTX-M
families among nosocomial Enterobacteriaceae from Russian ICUs.
Methods: A total of 1373 consecutive nosocomial isolates of
Enterobacteriaceae collected as part of the national surveillance study
of antimicrobial resistance in ICUs of 32 Russian hospitals in 2002–
2004 were screened for ESBL production using the MIC and double-
disk synergy tests with cefotaxime, ceftazidime, cefepime and clavulanic
acid. All strains with ESBL phenotype were tested for the presence of
TEM, SHV and CTX-M ESBL-encoding genes using three real-time
PCR assays. Two of these assays employed postampliﬁcation melting
curve analysis with differentially labeled ﬂuorogenic probes to detect
all the known mutations associated with ESBL activity in blaTEM and
blaSHV genes, respectively. The third assay targeting blaCTX-M genes
utilised melting curve analysis with SYBR Green I to distinguish the
members of CTX-M-1, -2, -8, and -9 clusters according to melting
temperatures of PCR products generated with nested set of primers.
Strains producing penicillinases SHV-1, TEM-1, SHV ESBLs with aa
substitutions 146(V), 149(S), 156(D), 179(A,G,N), 238(A,S), 240(K),
TEM ESBLs with aa substitutions 104(K), 164(C,H,S), 237(T), 238(S),
240(K) and CTX-M enzymes (−2, −3, −5, −8, −9, −14, −15) representing
all four clusters were used as controls. Selected b-lactamase genes from
isolates with unusual real-time PCR melting proﬁles were cloned and
sequenced.
Results: ESBL phenotype was detected in 718 (52.3%) strains, members
of 10 genera, most commonly in Klebsiella pneumoniae (81.4%),
Escherichia coli (49.5%), Citrobacter spp. (59.3%) and Proteus
mirabilis (38.9%). The distribution of various ESBL types and their
combinations is summarised in the Table. In addition to the detection
of known ESBL types, real-time PCR and sequencing allowed the
identiﬁcation of new SHV variants, each containing one of the
following substitutions: 156D, 157E, 240K (alone), but lacking ESBL
activity.
Conclusions: This study demonstrates the usefulness and efﬁciency
of real-time PCR techniques for epidemiological typing of molecular
class A ESBLs. It reveals the extremely high incidence of ESBLs,
the dominance of CTX-M-1-cluster enzymes, frequent co-occurrence
of CTX-M and SHV ESBLs, and surprisingly low incidence of
TEM ESBLs among nosocomial Enterobacteriaceae isolated in Russian
ICUs.
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b-Lactamase types Number Percent in all
ESBL producers
TEM (His164) 1 0.1
SHV-2-like (Ser238) 18 2.5




CTX-M-1-cluster + SHV-2-like 44 6.1
CTX-M-1-cluster + SHV-5-like 98 13.6
CTX-M-2-cluster + SHV-2-like 3 0.4
CTX-M-2-cluster + SHV-5-like 1 0.1
CTX-M-9-cluster + SHV-5-like 8 1.1
Other ESBLs 7 1.0
Total TEMs/TEM ESBLs 373/1 51.9/0.1
Total SHVs/SHV ESBLs 425/250 59.3/34.8
Total CTX-M ESBLs 614 85.5
O204 Ceftazidime resistance evolution in ESBLs belonging to
CTX-M-1 cluster (CTX-M-1, CTX-M-3, CTX-M-10) in a
hypermutator background
A. Novais, R. Canto´n, R. Moreira, T.M. Coque, F. Baquero, J.C. Gala´n
(Madrid, ES; Oporto, PT)
Objectives: Resistance to ceftazidime (CAZ) has mostly emerged among
enzymes of CTX-M-1 lineage. The aim of this study was to understand
evolution of CAZ resistance among CAZ susceptible ESBL belonging
to this cluster by step-wise in vitro selection experiments.
Methods: blaCTX-M-1, blaCTX-M-3 and blaCTX-M-10 genes were
cloned into pBGS18 plasmid vector (KanR) using EcoRI and PstI
restriction enzymes. Recombinant plasmids were further transformed
into E. coli strain MI1443 (del-ampC, plasmid free) and its hypermutable
isogenic strain GB20 (mutS::Tn10 MI1443). GB20 transformants
corresponding to each ESBL were submitted to daily serial passages
with increased concentrations of CAZ (0.5−256 fold respect to MIC).
Plasmids containing mutants obtained at distinct concentrations were
transformed in MI1443 cells, selecting with CAZ (at 4× their
corresponding MIC). MICs to CAZ, cefotaxime (CTX), cefuroxime
(CXM), cefepime (FEP), and amoxicillin-clavulanate (AMX) were
determined in MI1443 carrying the different evolved and non-
evolved recombinant plasmids. blaCTX-M genes from strains containing
recombinant plasmids displaying reduced susceptibility to CAZ were
sequenced.
Results: A high frequency of CAZ mutants was detected (73%; 8/11
transformants tested) with signiﬁcant increments in CAZ resistance.
Interestingly, and with exception of two variants and CXM, a
concomitant loss of resistance to all other antibiotics tested (antagonistic
pleiotropy) was observed. All mutants contained new blaCTX-M
variants except blaCTX-M-52, which evolved from blaCTX-M-3. The
most frequent mutations found were D240G and P167S/T, the later
conferring higher resistance to CAZ than the former. However, D240G
change determined a lower decrease to FEP and CXM than P167S/T.
Additionally, two variants were recovered from the evolved blaCTX-
M-3 gene: P167S and P167S+A77V, found at 16 and 128mg/L of CAZ
respectively. The double mutant yielded higher resistance level to CAZ,
CTX and to a lesser extent to FEP than P167S variant. The A77V change
is one of the three polymorphisms between CTX-M-3 and CTX-M-1,
whose mutants obtained revealed the highest resistance levels to CAZ
and CTX in our study.
Conclusions: This work demonstrates an antagonistic relationship
between the susceptibility to CAZ and to other b-lactam antibiotics
tested. A77V could be a secondary mutation site affecting CAZ or could
be involved in re-equilibrium of CTXR/CAZR co-resistance.
O205 Fluoroquinolone-resistant group A Streptococcus in Belgium:
ﬁrst report of an emergence of high-level FQ resistance in
Emm6 GAS
S. Malhotra-Kumar, K. Haccuria, C. Lammens, S. Chapelle,
J. Piessens, M. Wijdooghe, H. Goossens (Antwerp, BE)
Objectives: Fluoroquinolone (FQ)-R group A Streptococcus (GAS)
worldwide are predominantly of the emm6 serotype. Emm6 GAS
are intrinsically low-level FQ-R due to a polymorphism in the FQ-
binding region in parC, which confers resistance to the older FQs like
ciproﬂoxacin (CIP). The new respiratory’s FQs, levoﬂoxacin (LEV) and
moxiﬂoxacin (MOX), retain their activity against these ﬁrst-step parC
mutants, although there are concerns that their widespread use might
select for second-step, high-level FQ-R mutants.
LEV and MOX were introduced into clinical use in 1999 and 2002,
respectively, in Belgium. We studied the prevalence and evolution of
FQ-R GAS recovered from tonsillopharyngitis and invasive infections in
Belgium during 2003–2005.
Methods: From a total of 3765 isolates collected from 10 provinces
during 2003−05, 261 (7%) isolates were resistant to CIP (MIC 
2mg/mL) and corroborated with MICs of 4 FQs in the presence
or absence of reserpine. Clonality was studied by pulsed-ﬁeld gel
electrophoresis (PFGE) and emm typing. Clonal isolates with CIP MIC
 2mg/mL were sequenced for mutations in the FQ binding regions of
parC, gyrA, gyrB, and parE.
Results: During 2003−05, FQ-R GAS increased from 2%, 5% to 16%.
The predominant emm type was emm6, which formed 76% of the
total FQ-R GAS during these three years. Emm6 and emm75 isolates
together constituted 92% of the FQ-R GAS. Isolates with CIP MICs
2−8mg/mL showed previously identiﬁed mutations in parC leading to
amino acid substitutions as S79A (emm6) and S79Yor S79F (emm75),
and no changes in gyrA, gyrB or parE. However, an emm6 throat
isolate, recovered from a 36-year old female in 2005, exhibited high-
level resistance to CIP (MIC 32mg/mL), full resistance to LEV (MIC
8mg/mL) and decreased susceptibility to MOX (MIC 1mg/mL). This
isolate also showed a second-step mutation in the FQ-binding region in
gyrA (predicted substitution S81Y). Reserpine-sensitive efﬂux was not
observed for any FQ-R GAS.
Conclusions: We report a dramatic increase in FQ-R GAS in 2005
in Belgium probably related to natural ﬂuctuations of the low-level
FQ-R emm6 clone. More importantly, we describe, for the ﬁrst time,
an emergence of high-level FQ resistance in a clinical emm6 isolate.
Although respiratory FQs are usually not a therapeutic option for GAS
infections, dissemination of this parC/gyrA double-mutant emm6 strain
needs close monitoring.
O206 Presence of family phage-like elements conferring
efﬂux-mediated macrolide resistance in group G streptococci
T.A. Figueiredo, M.D. Pinho, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objectives: Recently, we demonstrated that the prophage-like elements
belonging to the Tn1207.3/Phi10394.4 family in Streptococcus pyogenes
encode a DNA-modifying methyltransferase. In this study, the presence
of the Tn1207.3/Phi10394.4 family was evaluated in group G
streptococci (GGS) presenting the M phenotype.
Methods: Five GGS clinical isolates identiﬁed as Streptococcus
dysgalactiae ssp. equisimilis and expressing the M phenotype of
macrolide resistance were collected from 2002 to 2005 in Portugal. The
presence of the mef gene as well as it linkage with the msr(D) gene, both
involved in macrolide resistance, were investigated by PCR. The isolates
were also characterised by PFGE. To identify the general structure of
the mef genetic elements, the presence of phage-related ORFs belonging
to the Tn1207.3/Phi10394.4 family was investigated by PCR, including
the one encoding M.Spy10394I. Moreover, to discriminate between
these two genetic elements, the structure of the left insertion site in
the bacterial chromosome and a Phi10394.4-speciﬁc ORF, annotated as
encoding an R28-like protein were investigated.
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Results: The analysis of SmaI PFGE patterns showed that three of the
isolates were clonally related while one was not typable by PFGE, since
its DNA was resistant to SmaI digestion. All isolates showed the presence
and linkage of mef and msr(D) genes and four carried the mef(E) variant
while only one carried the mef(A) variant. Only the isolate, refractory to
SmaI digestion and positive for the mef(A) variant, was also positive for
all PCR reactions performed. The structure of the left insertion site of the
Tn1207.3/Phi10394.4 family in the chromosome of this isolate revealed
that in this streptococcal species the elements are inserted at the same
locus as in S. pyogenes. Moreover, the absence of a PCR product for the
ORF encoding the R28-like protein established Tn1207.3 as the element
present in this strain.
Conclusion: The data demonstrated the presence of an element of
the Tn1207.3/Phi10394.4 family in a GGS isolate. Resistance to SmaI
digestion in this M phenotype isolate is probably due to the expression of
the M.Spy10394I methylase, previously described in S. pyogenes. The
dissemination of the Tn1207.3/Phi10394.4 family among S. pyogenes
and GGS emphasize the important role of these related chimeric elements
and their associated prophage in the worldwide emergence of macrolide
resistant streptococci expressing the M phenotype.
O207 Plasmid-mediated quinolone resistance determinants, QnrA,
QnrB, and QnrS, among clinical isolates of Enterobacter
cloacae in a Taiwanese hospital
J. Yan, J. Wu, W. Ko, S. Tsai (Tainan, TW)
Objectives: A total of 526 nonreplicate clinical isolates of Enterobacter
cloacae collected in 2004 at a Taiwanese university hospital were
analysed to: (i) determine the prevalence of three plasmid-mediated
quinolone resistance determinants, QnrA, QnrB, and QnrS, and
(ii) investigate the association of the Qnr determinants and the IMP-8
metallo-b-lactamase.
Methods: The qnrA-, qnrB-, and qnrS-like genes were detected
by colony hybridisation and PCR-based experiments. Beta-lactamase
contents of qnr-positive were determined by isoelectric focusing and
PCR. Pulsed-ﬁeld gel electrophoresis was used for strain typing.
Restriction analysis of qnr-positive plasmids and blaIMP-8-positive
plasmids were performed after conjugation experiments.
Results: Eighty-six (16.3%) of all isolates were qnr-positive, and the
qnrA1-like, qnrB2-like, and qnrS1-like genes were detected alone or
in combination in 3 (0.6%), 53 (10.1%), and 34 (6.5%) isolates,
respectively. Among 149 putative extended-spectrum b-lactamase-
producing isolates, 59 (39.6%) isolates, all of which were SHV-12
producers, harboured qnrA (0.7%, 1 isolate), qnrB (28.9%, 43 isolates),
or qnrS (12.1%, 18 isolates). Forty-four (78.6%) of 56 IMP-8 producers
carried qnrB (58.9%, 33 isolates), qnrS (25.0%, 14 isolates), or both.
Conjugation experiments revealed coexistence of qnrB and blaIMP-8 on
the transferred plasmids and the absence of b-lactamase content on the
transferred qnrS-positive plasmids. The transferred blaIMP-8-positive
plasmids with and without qnrB had very similar restriction patterns.
Pulsed-ﬁeld gel electrophoresis showed 6 major patterns among the 44
qnr-positive IMP-8-producing isolates.
Conclusion: This study demonstrated the high prevalence of qnr among
E. cloacae isolates at a Taiwanese hospital. The extreme high prevalence
of qnr among metallo-b-lactamase-producing E. cloacae isolates may be
mainly due to intra-hospital spread of several clones and dissemination
of plasmids containing both qnrB and blaIMP-8.
O208 Biological ﬁtness of ﬂuoroquinolone-resistant invasive
clinical isolates of Streptococcus pneumoniae
C.B. Duesberg, T.T. Nguyen, T. Welte, M.W. Pletz (Hannover, DE)
Background: Resistance to ﬂuoroquinolones in pneumococci is
emerging globally. Biological ﬁtness of resistant strains in absence of
selective pressure is an important parameter determining the spread
and persistence of resistance. In vitro studies using isogenic isolates
have shown that most of the mutations in the quinolone resistance
determining regions are associated with a ﬁtness cost. In this study
resistant clinical isolates (LFX 8mg/L) were used to take into account
potential compensatory mutations.
Methods: Invasive isolates related to international multiresistant clones
deﬁned by the Pneumococcal Molecular Epidemiology Network (PMEN)
were analysed (Antimicrob Agents Chemother 2004; 48: 3491−7).
Because isogenic susceptible ancestors of resistant clinical strains can
not be obtained, the isolates studied were compared with their respective
ﬂuoroquinolone-susceptible PMEN reference clone.
Growth curves were determined in three independent experiments with
three replicates each by measuring optical density at 600 nm. Relative
ﬁtness was assessed comparing the slope of the curve of each isolate
with its respective reference clone by Mann–Whitney U test.
Results: Five clusters of isolates (Spain 23F-1: n = 8; Spain 9V-3:
n = 5; England 14−9: n = 5; Greece 6B-22: n = 5; Utah 35B-24: n = 3)
were examined. For the majority of isolates no signiﬁcant ﬁtness cost
was found when compared to their respective reference clone. In three
clusters (Spain 9V-3, England 14−9, Greece 6B-22) individual isolates
with a ﬁtness gain could be identiﬁed. Only in the Spain 23F-1 cluster, 3
of 8 isolates exhibited a ﬁtness cost which was associated with a serotype
switching from 23F to 19F.
Conclusion: We found notably few resistant clinical isolates with
a ﬁtness cost. Therefore even in the absence of selective pressure
(ﬂuoroquinolone usage), ﬂuoroquinolone-resistant strains may not be
replaced completely by susceptible strains.
O209 Large scale spa-typing of Staphylococcus aureus: a reference
centre’s view
B. Strommenger, C. Braulke, D. Heuck, W. Witte (Wernigerode, DE)
Objectives: In May 2006 we introduced spa-typing in our laboratory.
This method replaced phage typing in combination with SmaI-
macrorestriction analysis for routine S. aureus strain typing. This
study reviews typing results for six month with respect to typeability,
reproducibility, discriminatory power and concordance with alternative
typing methods.
Methods: A total of 1464 S. aureus isolates were characterised. The
polymorphic X-region of the protein A gene was sequenced and a spa
type was assigned using the Ridom StaphType software. The algorithm
BURP (based upon repeat patterns) was used to cluster resulting spa
types into different groups. To verify the results a subset of isolates was
subjected to SmaI-macrorestriction analysis and MLST.
Results: Among 1464 S. aureus isolates more than 200 different
spa-types were deﬁned. The twenty spa-types most frequently found
comprise more than 60% of all isolates and include most types linked
to predominant clonal lineages of MRSA in Central Europe, previously
deﬁned by phage typing and SmaI-macrorestriction analysis. Among
those clonal lineages distinct differences in spa-type variability were
seen; while some lineages (e. g. the Barnim epidemic MRSA, t032,
ST22) encompassed a variety of closely related spa-types, others (e. g. a
subclone of Rhine-Hesse epidemic MRSA, t003, ST225) are represented
only by a single type. For assessment of widely disseminated lineages
exhibiting only a single spa-type, additional markers must be applied.
More than one hundred spa-types were determined only once. For
these isolates BURP proved to be a valuable tool to assign them to
particular clonal groups. Thereby, results of BURP grouping were overall
concordant with those of SmaI-macrorestriction analysis and MLST.
Conclusion: spa-typing in combination with BURP based grouping
of isolates proved to be a valuable tool for strain typing with regard
to the demands of a national reference centre. The BURP algorithm
revealed extremely useful for grouping new and uncommon spa-types.
The increasing amount of typing data obtained from outbreak situations
enables comparison of closely related spa-types within BURP groups,
thus facilitating the deﬁnition of criteria for strain relatedness according
to those already deﬁned for SmaI-macrorestriction analysis. This will be
an important prerequisite for deﬁnition of isolates as identical, related
of different, which is essential for successful epidemiological outbreak
investigation.
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S218 Childhood bacterial respiratory tract infections in the
conjugate vaccination era
R. Dagan (Beer-Sheva, IL)
Although bacterial colonisation is common and mostly asymptomatic
in children, it frequently results in a wide spectrum of respiratory tract
infections (RTIs): acute otitis media (AOM), sinusitis, conjunctivitis,
pneumonia and other lower respiratory infections (LRIs). In children,
the majority of bacterial RTIs are caused by Streptococcus pneumoniae
(Pnc), Haemophilus inﬂuenzae (mostly nontypeable, NTHi) or both. In
AOM, NTHi and Pnc are equally common. Pnc is slightly more ‘ag-
gressive‘ than NTHi (i.e. higher temperature, higher polymorphonuclear
counts and complications are more frequent), but NTHi can still cause
signiﬁcant disease. The role of NTHi in recurrent and non-responsive
AOM in both infants and in older children is recognized, suggesting
different biological pathways compared with Pnc. In both acute and
subacute sinusitis, NTHi is found as commonly as Pnc. NTHi is the
most common causative agent of conjunctivitis and the most signiﬁcant
in relation to the co-presence of AOM and systemic symptoms and signs.
The role of NTHi in LRIs in general, and in pneumonia in particular, is
not yet clear. In cystic ﬁbrosis, however, NTHi is an important pathogen.
Although H. inﬂuenzae type b disease has practically been eliminated in
vaccinated populations, the picture with S. pneumoniae in the 7-valent
Pneumococcal Conjugate Vaccine (PCV7) era is much more complex
owing to its limited serotype coverage and some replacement with non-
vaccine serotypes. A vaccine with additional pneumococcal serotypes
and activity against NTHi would be a very welcome addition to our
vaccine armamentarium.
S219 The role of bacterial bioﬁlms in chronic and recurrent otitis
media
L.O. Bakaletz (Columbus, US)
Otitis media (OM) is a highly prevalent paediatric disease that is
associated with signiﬁcant morbidity and socioeconomic cost. OM
is caused by the synergistic interaction between upper respiratory
tract viruses and three predominant bacterial species, all of which
are members of the commensal ﬂora of the paediatric nasopharynx.
Despite their similar roles as opportunistic pathogens of the middle
ear, the pathogenic mechanisms utilised by these bacteria (nontypeable
Haemophilus inﬂuenzae, Streptococcus pneumoniae and Moraxella
catarrhalis) are unique. Thus, to date, most laboratories have investigated
the pathogenesis and prevention of disease caused by these microbes
individually. Recently, it has become appreciated that OM, and
particularly chronic and recurrent OM, is a disease that includes a bioﬁlm
component. By deﬁnition, bacteria resident within a bioﬁlm community
are inherently resistant to eradication due to their signiﬁcantly enhanced
ability to resist the action of antibodies as well as antibiotics. Moreover,
residence within a bioﬁlm promotes the bacterial exchange of DNA,
which confers resistance to antibiotics, and induces a markedly reduced
bacterial growth rate that commonly results in false-negative bacterial
cultures.
In the past few years it has been demonstrated that each of the
three predominant bacteria involved in OM can form a bioﬁlm in in
vitro assay systems and in animal models, and that they participate
in bioﬁlms formed on middle ear mucosa specimens recovered from
children with recurrent or chronic OM. This enhanced understanding of
the bioﬁlm component of middle ear infections is greatly inﬂuencing
the current approaches to both the management of OM and the design
of novel strategies to treat, or better to prevent, OM. It is particularly
intriguing that some of the paediatric middle ear mucosa-derived bioﬁlms
characterised were of mixed bacterial aetiology, suggesting that progress
made on single-microbe directed strategies for the treatment and/or
prevention of OM, while highly encouraging, are also likely to be
inadequate. Therefore, a signiﬁcantly greater understanding of how
microbial physiology relates to the involvement of bioﬁlms in OM is
required to identify points in the disease course that are perhaps more
amenable to treatment strategies, and also bioﬁlm-relevant antigenic
targets that would be helpful in the rational design of vaccine candidates
to prevent OM.
S220 Protein D of Haemophilus inﬂuenzae – the antigenic potential
of a carrier protein
A. Forsgren, K. Riesbeck, H. Janson (Malmo¨, SE)
Haemophilus inﬂuenzae (Hi) is a Gram-negative cocco-bacillus, which is
a common commensal in the nasopharnyx of healthy children. Hi exists
in encapsulated and non-encapsulated forms based on the expression of
capsular polysaccharide proteins. Six encapsulated strains are recognized
(a, b, c, d, e and f), while non-encapsulated strains are considered non-
typeable (referred to as NTHi).
Protein D (PD) is a highly conserved surface exposed 42 kDa lipoprotein
found in 100% of all NTHi and encapsulated Hi, and is highly
immunogenic in humans. Evidence suggests that PD is involved in the
pathogenesis of respiratory tract infections, and has been implicated in
NTHi adhesion and invasion of host cells.
An isogenic PD-deﬁcient NTHi-mutant, compared with the wild type
strain, had an approximately 100-fold lower capacity to cause acute otitis
media (OM) in rats and induced signiﬁcantly less impairment of ciliary
function in a human nasopharyngeal tissue culture model. The likely
mechanism of pathogenicity is that PD is an enzyme (glycerophospho-
diester phosphodiesterase, GlpQ) that releases phosphorylcholine (ChoP)
from host epithelial cells to the lipooligosaccharide (LOS) on NTHi.
LOS-ChoP interacts with platelet-activating factor receptors, inhibiting
ciliary beat frequency of human bronchial epithelial cells and activating
G protein-related pathways.
PD is also capable of inducing bactericidal anti-protein D antibodies
that protect against NTHi disease. PD-immunised rats cleared NTHi
signiﬁcantly better than non-immunised animals after middle ear and
pulmonary bacterial challenge. In addition, chinchillas, PD-immunised
or passively given anti-PD sera, showed protection against NTHi-
dependent OM.
PD was recently introduced as an antigenically active carrier protein
in an experimental 11-valent pneumococcal conjugate vaccine. In a
recent Phase III clinical trial with this experimental vaccine, signiﬁcant
protection was achieved against OM caused by pneumococci and/or
NTHi.
S221 The added value of measuring function of antibodies in
conjugate vaccine trials
H. Ka¨yhty (Helsinki, FI)
The currently licensed pneumococcal conjugate vaccine (PCV) has been
integrated into infant immunisation programmes of several industrialised
countries. New PCV candidates in development with wider serotype
coverage or new PCV formulations for both infants and adults will be
evaluated for efﬁcacy. Large efﬁcacy trials are not feasible any more, and
the acceptance of the new PCVs will rely on immunogenicity studies.
In the WHO guidelines (http://www.who.int/biologicals/publications/trs/
areas/vaccines/pneumo/en/index.html) the primary threshold for such
trials is the proportion of subjects with antibody concentration of
0.35mg/mL for all serotypes when measured via the WHO non-
22F ELISA. The protective functional mechanism of antibodies to
pneumococcal capsular polysaccharides resides in opsonophagocytosis
and the demonstration of the opsonophagocytic activity (OPA) has been
regarded as an important secondary threshold.
Thus far there are only few published PCV efﬁcacy trials that connect
with OPA data and their good correlation. Considering those data it
is becoming evident that measuring OPA has an added value when
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evaluating the vaccine efﬁcacy based on immunogenicity studies. In
general, the OPA titers and the antibody concentrations correlate well,
but different serotypes can show various OPA/EIA ratios meaning that
for certain serotypes (like 19F or 1) more antibodies are needed for
killing the bacteria than for the rest. Importantly, the elderly and HIV
positive patients seem to have antibodies of low functional activity, and
measuring OPA in studies in the elderly and HIV patients has been
considered important.
Various assays for determining OPA have been developed and some
laboratories have already performed extensive validation steps. A
multilaboratory standardisation of the OPA assay is imminent. Measuring
OPA with the classical killing assay consumes serum and time and thus
measuring OPA for large materials is not always feasible. However, the
development of multiplex and/or high throughput assays will end up in
wider use of this technology in the future clinical trials. This would be in
concordance with the guidelines for evaluation meningococcal conjugate
vaccines by serum bactericidal activity assay.
S222 A new protein conjugate vaccine for polymicrobial diseases:
a case study (POET)
W.P. Hausdorff (Rixensart, BE)
Bacterial respiratory tract infections are a leading cause of morbidity
and mortality in young children. Effective immunisation strategies
against these infections have to contend with both the multiplicity of
pathogens and a host of disease syndromes. Streptococcus pneumoniae
(pneumococcus), and both encapsulated and non-encapsulated forms of
Haemophilus inﬂuenzae (Hi), are the leading pathogens. More than
90 serotypes of pneumococci exist, but only 10 serogroups appear
to be responsible for 80–85% of invasive pneumococcal disease and
pneumococcal otitis media (OM) worldwide, ranging from the relatively
rare but clinically severe meningitis, to the more frequent infections of
the bloodstream and the lungs, such as pneumonia and ﬁnally to the
extremely common middle ear infections among young children.
Middle ear infections are often associated with diagnostic uncertainty,
frequent use and misuse of antibiotics, and recurrent and persistent
disease. Recurrent infections occur in as many as 10% of children
<3 years of age. Recurrent and persistence disease can lead to temporary
or even permanent hearing loss and surgery (tube placement). In order
to address these issues, preventive acute OM (AOM) strategies should
include a vaccine with broader pneumococcal serotype coverage as well
as protection against additional otopathogens.
This presentation describes a novel vaccine approach in which
polysaccharides from the 11 leading streptococcal paediatric serotypes
are conjugated to a carrier protein (protein D) derived from Hi. In
the Pneumococcal Otitis Media Efﬁcacy Trial (POET), conducted in
infants and young children in the Czech and Slovak Republics, this
approach resulted in substantial protection against pneumococcal and
Hi diseases. In this study, an 11-valent investigational conjugate vaccine
was concomitantly administered with diphtheria, tetanus, pertussis (DTP)
vaccines. The clinical diagnosis of AOM was conﬁrmed by both a
paediatrician and an otorhinolaryngologist, and tympanocentesis was
performed on children with conﬁrmed AOM. Vaccine efﬁcacy against
any AOM episode caused by vaccine-type pneumococci was 57.6%
(95%CI: 41.4−69.3%), and efﬁcacy against AOM caused by nontypeable
Hi was 35.3% (1.8−57.5%). Most strikingly, the overall impact of the
vaccine in this setting was to reduce all AOM by 33.6% (20.8−44.3%).
These results suggest that a vaccine that targets these two major groups
of bacterial pathogens would have a signiﬁcant public health impact.
Staphylococcal disease: from nose to morgue
S237 Staphylococcal components required for host–pathogen
interaction as vaccine targets
S. Foster (Shefﬁeld, UK)
The threat of multidrug resistant Staphylococcus aureus has renewed
efforts to develop a prophylactic vaccine and therapeutic/prophylactic
antibodies to combat this serious pathogen. A number of potential
vaccine components have been investigated including capsule, a surface
polysaccharide polymer and several surface proteins. However nothing
is available in the clinic at the moment. The search for vaccine
components has highlighted a number of proteins with important roles in
host:pathogen interaction. These include a family of proteins speciﬁcally
produced under conditions of iron limitation. A prominent member of
this family (IsdA) is required for nasal colonisation and vaccination with
IsdA prevents carriage.
The current status of vaccine development and how this has led to
interesting insights into interaction between S. aureus and its host will
be reviewed.
Presence and future of Clostridium difﬁcile
S238 Clostridium difﬁcile in Europe: results of the 2005
European-wide survey
F. Barbut, P. Mastrantonio, M. Delme´e, G. Ackermann, E. Bouza,
C. Balmelli, D. Drudy, E. Kuijper, H. Ladas, E. Nagy, H. Pituch,
M. Wullt, M. Yu¨cesoy, M. Rupnik, I. Poxton for the European Study
Group on Clostridium difﬁcile (ESGCD)
The recent emergence of the epidemic Clostridium difﬁcile strain 027
in Europe could lead to important changes in the epidemiology of
C. difﬁcile-associated diseases (CDAD) and requires an ongoing clinical
and molecular surveillance of CDAD.
A two-month prospective study on C. difﬁcile was conducted in
38 hospitals from 14 different European countries in order to get
an overview on the phenotypic and genotypic features of isolates in
2005. Strains were isolated from diarrheic patients with suspected
CDAD. They were characterised by toxinotyping and production of
toxins A and B. Binary toxin genes (cdtA and cdtB) were detected
by PCR. Minimal inhibition concentrations (MIC) of metronidazole,
vancomycin, erythromycin, clindamycin, moxiﬂoxacin and tetracycline
were determined using the Etest method. Epidemic 027 strain was
identiﬁed by PCR-ribotyping. Of 406 strains, 349 were toxigenic
of which 89 (25.5%) were toxin variant strains. Major toxinotypes
included toxinotype 0 (n = 260), V (n = 27), VIII (n = 22) and III (n = 22).
Resistance to erythromycin, clindamycin, moxiﬂoxacin and tetracycline
was found in 45.8%, 50.6%, 9.1% and 33.7%, respectively. All the strains
were fully susceptible to metronidazole and vancomycin. Resistance
to moxiﬂoxacin and erythromycin was tightly associated and MICs of
moxiﬂoxacin were signiﬁcantly higher in patients previously treated with
ﬂuoroquinolones. Prevalence of the 027 epidemic strain was 5.7%. It was
found in Ireland (n = 1), Netherlands (n = 8) and Belgium (n = 11). This
strain exhibits the same phenotypic and genotypic features as the NAP1
clone described in North America: it is positive for binary toxin genes,
it has an18-bp deletion in tcdC gene and it is resistant to erythromycin
and moxiﬂoxacin. Mean incidence of CDAD was 2.45 cases per
10,000 patient-days but it varied widely from one hospital to another.
Patients infected with 027 strain were likely to have a more severe
disease (RR= 1.72, 95%CI: 1.07−2.75, p = 0.048), to have received less
antimicrobials in the month preceding diarrhoea (RR= 0.76, 95%CI:
0.53−1.10, p = 0.05) and to have been more speciﬁcally treated by
metronidazole or vancomycin (RR= 1.32, 1.17−1.49, p = 0.02). On-going
epidemiologic surveillance of CDAD cases with periodic characterisation
of the strains is needed to timely detect clustering of cases and to monitor
the emergence of a speciﬁc hypervirulent clone.
S239 Novel insights into the molecular diagnostics and
epidemiology of C. difﬁcile
M. Rupnik (Maribor, SI)
The incidence and severity of nosocomial C. difﬁcile disease seems to
be increasing. Additionally, disease with community onset is becoming
more common than previously recognized and cases in groups with
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previously low risk have been reported. C. difﬁcile is also emerging
as an important animal pathogen in horses, calves and piglets.
Described changes correlate with changed populations of C. difﬁcile
present in humans. New type BI/NAP1/027 with increased virulence is
spreading since 2003, but only part of the recent increase in mortality and
morbidity caused by C. difﬁcile infections can be accounted for by this
new highly virulent type. The proportion of other binary toxin positive
types is also rising among human isolates. Such binary toxin positive
strains used to be more often associated with animal than human host
and early typing comparisons did not show many similarities between
human and animal strains. However, recent studies found a marked
overlap between isolates from calves and humans, including two of the
predominant outbreak types, 027 and 017. C. difﬁcile has also been
found in retail meat samples, suggesting that food could be involved in
the transmission of C. difﬁcile from animals to humans.
As a response to the new developments in C. difﬁcile epidemiology, new
diagnostic and typing methods are being developed aiming in quick and
sensitive detection of C. difﬁcile but also in quick recognition of strains
with higher virulence.
S240 Special challenges in C. difﬁcile infection control
E. Kuijper, R. Vonberg, M. Wilcox, P. Gastmeier (Leiden, NL; Leeds,
UK; Hannover, DE)
Clostridium difﬁcile is an anaerobic bacterium capable of forming
spores which confer resistance to heating, drying and chemical agents,
including disinfectants. Spores of CD may survive in the environment
for long periods and are resistant to alcohol. More than 150 PCR
ribotypes and 24 toxinotypes have been recognized; epidemic ribotypes
may have enhanced sporulation. The spectrum of C. difﬁcile-associated
disease ranges from asymptomatic carriage to fulminant, relapsing and
potentially fatal colitis. Since 2003, increasing rates of CDAD have been
reported in North America and Europe involving a more severe course,
higher mortality, increased risk of relapse and more complications. The
outbreaks are difﬁcult to control and require a multifaceted approach.
The most important infection control measures act on interruption of
transmission of spores to vulnerable patients from infected patients
and from the environment. Vulnerable patients are mainly patients
who receive antimicrobial treatment, and therefore fewer antibiotic
prescriptions should lead to less vulnerable patients. At present, no
sufﬁcient evidence exists to propagate the use of probiotics to vulnerable
patients for prevention of CDAD. Transmission of spores occurs mainly
via contact of contaminated healthcare workers to patients, directly by
patient-to-patient transmission or by transmission from the contaminated
environment to patients. There is no evidence that patients or healthcare
workers who are symptom-free but colonised with C. difﬁcile in the
intestinal tract are signiﬁcant sources of infection. Airborne transmission
of infection is unlikely to occur based on recent reviews of the literature.
Early diagnosis of CDAD, prompt isolation of symptomatic patients and
reducing antimicrobial treatment are essential ﬁrst steps. The infection
control measures include recommendations to isolate infected patient
on a single room with designated toilet, to apply proper hand hygiene
with soap and water, to use appropriate protective clothing (gloves and
aprons or gowns), to intensify environmental cleaning with a chlorine
containing disinfectant and to take speciﬁc precautions for the use of
devices (disposable or dedicated to individual patient). Patient isolation
must continue at least until diarrhoea has ceased. Each hospital should
have an appropriate surveillance system to recognize an increase of the
incidence of CDAD in an early stage. All infection control measures
should be written in a local protocol so that additional measures
can be carried out as soon as a problem with CDAD arises. When
outbreaks occur, additional recommendations include a reinforcement
of general and hand washing measures, intensifying of testing patients
with diarrhoea for C. difﬁcile, reinforcement of environmental cleaning,
information and education of healthcare workers, cleaning department
and visitors, cohorting of infected patients, and eventually closure of the
unit followed by intensive environmental cleaning. Restricted antibiotic
prescribing is also highly recommended to reduce polypharmacy and
duration of administration. Second and third generations cephalosporins,
clindamycin and more recently ﬂuoroquinolones have been identiﬁed
as potential risk factors. Although some hospitals report successes for
enhanced environmental cleaning with potentially effective agents such
as hydrogen peroxide vapour, the evidence is too scarce to consider this
as an evidence-based approach.
Acinetobacter – the Gram-negative MRSA?
S242 Global epidemiology of Acinetobacter
K.J. Towner (Nottingham, UK)
Members of the genus Acinetobacter, particularly Acinetobacter
baumannii, are now recognized as signiﬁcant nosocomial pathogens,
particularly for the subset of critically-ill patients requiring mechanical
ventilation in hospital intensive care units. However, Acinetobacter
infections can also be acquired outside the healthcare setting. Wound
infections caused by Acinetobacter are now common among trauma
patients in conﬂict zones or following natural disasters, and there have
also been reports of other community-acquired infections, mainly in
patients with some type of co-morbidity. Most of the latter reports
originate from tropical or sub-tropical areas, and may become more
common following ongoing changes in the global climate.
Strains of A. baumannii harbour inherent or acquired resistance
mechanisms against the vast majority of available antimicrobial agents,
including the carbapenems. These organisms also have a remarkable
capacity to persist in the hospital environment and to cause epidemic
outbreaks of infection in hospitals. A recent increase in the number of
carbapenem-resistant strains, particularly in eastern Europe, is currently
of great concern. The recent EU-funded ARPAC study revealed that
130 of 169 participating European hospitals in 32 European countries
had encountered carbapenem-resistant isolates of Acinetobacter, ranging
from very rare sporadic resistant isolates to an endemic/epidemic
situation. Certain multiresistant epidemic clones are currently spreading
worldwide, and epidemics of multiresistant A. baumannii infections have
occurred following the repatriation of casualties from the recent wars in
Kuwait, Iraq and Afghanistan to European and American hospitals.
In general, multiple isolates from a single hospital usually belong to the
same clone, but some hospitals yield isolates belonging to more than
one clone. Three ‘European Clones’ (lineages) have been identiﬁed in
hospitals throughout Europe, but numerous other, more localised, clones
have also been characterised, showing that the problem of A. baumannii
is not conﬁned solely to the widespread ‘European clones I, II and III’.
The reasons why certain A. baumannii lineages are more successful than
others are not understood at present.
Overall, the available epidemiological evidence suggests that A. bauman-
nii is becoming one of the most signiﬁcant microbial challenges of the
current era. Strains in some hospitals are already effectively untreatable,
and more scientiﬁc efforts and resources are urgently needed to further
elucidate the epidemiological and infection control issues related to these
infections.
S243 Current resistance trends and mechanisms in Acinetobacter
baumannii
P. Nordmann (Paris, FR)
Acinetobacter baumannii is an opportunistic pathogen that is mostly
involved in nosocomial infections in immunocompromised patients.
Whereas A. baumannii has itself a quite high level of naturally-
occurring antibiotic resistance, it may acquire additional resistance
traits as a source of multidrug resistance. These resistance mechanisms
may involve most of the antibiotic molecules, i.e. aminoglycosides,
b-lactams and ﬂuoroquinolones. Rate and spread of speciﬁc mechanisms
of resistance depends on each country. A similar trend between the
number of A. baumannii infections and antibiotic resistance may
be observed worldwide. Acquired resistance genes are located on
chromosome, plasmids, insertions sequences, transposons, integrons,
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and the recently described resistance island. One of the most worrying
antibiotic resistance problems in A. baumannii is the increasing trend of
carbapenem resistance since carbapenems are often used as antibiotics of
the last resort. Carbapenem resistance results from metallo-b-lactamases,
carbapenem-hydrolyzing oxacillinases and often combined mechanisms
of resistance.
Emerging infectious diseases
O246 Risk assessment and management of possible transmission
of Lassa virus during two ﬂights
T. Eckmanns, A. Gilsdorf, D. Reynders, D. Coulombier, F. Karcher,
G. Krause (Berlin, DE; Brussels, BE; Stockholm, SE; Luxembourg, LU)
Objectives: Since the emergence of Lassa fever, reports of about 25
patients who imported Lassa virus to Europe, USA or Canada have been
published. More than 1,200 contacts were ascertained in these events and
all remained pathogen free except one who showed a seroconversion. On
July 10th a person (patient) who ﬂew from Freetown (Sierra Leone) to
Frankfurt (Germany) via Brussels (Belgium) tested Lassa positive nine
days after arrival in Germany. A risk assessment was conducted to guide
the decision on a co-passenger trace back.
Methods: During the two ﬂights the patient had no cough but a urinary
tract catheter which was disconnected from the reservoir and released
relevant amounts of urine on the passenger’s seat. The patient’s urine
was tested positive for Lassa virus, which was taken into account for
the risk assessment and contributed to the decision to trace back co-
passengers potentially exposed.
The passengers at risk were deﬁned as those sitting in maximum three
rows distance from the patient. 57 additional persons from the airline
and the airport were exposed.
With the help of the airline the passenger’s lists of both ﬂights
were available within two days. 92 passengers from nine countries
were identiﬁed. Every country received a list with names and contact
telephone numbers of all passengers at risk who were allocated to the
country as well as a questionnaire about symptoms to be ﬁlled for traced
passengers. The trace back of the concerned staff was done by the airline
and the Belgian public health authorities.
Results: In EU countries 29 (66%) of 44 contact passengers, in European
non-EU countries 7 (68%) of 9 passengers were traceable and from non-
European countries 0 of 27 passengers were traceable. 100% of the staff
were traceable. Overall 62.4% of the contacts were traceable. Only one
of the traced contacts developed symptoms but revealed to be Lassa
negative.
Conclusion: In this investigation, the leakage from the urinary catheter
reservoir inﬂuenced the risk assessment and the decision for a
passenger trace back as Lassa fever is primarily transmitted by urine
of rats. Nevertheless, no contact passenger revealed Lassa virus. Our
investigation conﬁrms that the human to human transmission of Lassa
virus during ﬂights is unlikely if no haemorrhagic symptoms appear at
this time. Tracing back co-passengers remains a challenge internationally
and stresses the need for an early voluntary implementation of the revised
international health regulation.
O247 Comparison of oral ribavirin treatment in Crimean–Congo
haemorrhagic fever: a historical cohort study in Turkey
N. Elaldi, H. Bodur, A. Celikbas, Z. Ozkurt, H. Leblebicioglu,
M. Bakir, K. Aydin, N. Yilmaz, I. Dokmetas, M.A. Cevik, B. Dokuzoguz,
M.A. Tasyaran, R. Ozturk, H. Vahaboglu, A. Engin (Sivas, Ankara,
Erzurum, Samsun, Trabzon, Istanbul, Kocaeli, TR)
Objectives: To analyse the efﬁcacy of oral ribavirin treatment in
Crimean–Congo haemorrhagic fever (CCHF) patients and to compare
with a historical cohort.
Methods: In Turkey, patients admitted to four tertiary care hospitals
with a disease resembling CCHF were treated with oral ribavirin as
recommended by the World Health Organisation (WHO) between April
and September, 2004. Treated patients were compared with an untreated
historical cohort who admitted to the same hospitals in 2003. Sera
from suspected CCHF patients were obtained immediately following
hospitalisation. Whenever possible, a second sample was obtained at
least one week later. Serologic and virologic analyses were performed
in the CCHF reference laboratory of the RSH Institute of the Turkish
Ministry of Health. Only the patients that obtained a deﬁnitive diagnosis
of CCHF by means of clinical presentation and the presence of speciﬁc
IgM antibody against CCHF virus and/or viral RNA were included in
the study. Demographics of all patients, clinical and laboratory ﬁndings,
given blood and blood products, length of hospitalisation stay and
outcome were recorded.
Results: The treatment group and the historical cohort consisted of
126 and 92 conﬁrmed CCHF cases respectively. The mean age of
the treatment group was 44 and 41 years in the historical cohort
(p> 0.05). Among the given mean units of blood products, only the
amount of consumed fresh frozen plasma was signiﬁcantly lower than
the treatment group (median 4 vs 6.5 units; p< 0.05). Median length
of hospitalisation days was 8 in the treatment group and 9 days in the
historical cohort (p> 0.05). The case fatality rate in the treatment group
was not signiﬁcantly different than in the historical cohort (7.1% vs
11.9%; p> 0.05). A logistic regression analyse showed altered sensorium
and/or prolonged international normalised ratio (>1.4) were independent
predictors of mortality. These predictors discriminated fatal cases with
a sensitivity of 0.73 (14 of 19 fatal patients) and a speciﬁcity of 0.83
(156 of 186 non-fatal patients).
Conclusions: The results of this study showed that oral ribavirin
treatment failed to improve the survival rate in our conﬁrmed CCHF
cases. However, more controlled studies with oral ribavirin are needed
before more deﬁnite conclusion. We suggest the use of only the
parenteral form of ribavirin according to a risk assessment by the
predictors of mortality.
O248 Crimean–Congo haemorrhagic fever among children in
Southeast Iran (clinico-epidemiological feature and outcome
analysis)
B. Shariﬁ Mood, M. Mardani, H. Hatami, M. Metanat (Zahedan,
Shaheed, IR)
Background: Crimean–Congo haemorrhagic fever (CCHF) is a viral
haemorrhagic illness of the nairovirus group. Althought primarily it is
a zoonosis, sporadic cases and outbreaks of CCHF affecting humans
do occur. The disease is endemic in many countries in Africa, Eastern
Europe and Asia. During recent years, outbreaks have been reported
in South Africa, the Middle East and Iran. Despite the endemicity
of the disease especially in the Southeast of Iran, data on CCHF in
children from Iran are limited. This study was conducted to detect the
the risk factor and clinico-epidemiological feature and outcome analysis
regarding efﬁcacy of ribavirin in children with CCHF in Iran.
Patients and Method: Between 1999 and 2006, the study included
34 cases under the age of 18 years who were admitted to BooAli
hospital in Systan province of Iran. The diagnosis was conﬁrmed through
detection of IgM ELISA and/or genomic segment of PCR CCHFvirus.
Results: Out of 34 children with Crimean–Congo haemorrhagic fever
(23 male, 11 female) with age range of 5 to 18 years, 29 patients
(85%) were from rural areas and tick bite was determined as a
risk factor for 23.5% of affected children. The most observed symptoms
were fever (85.2%), myalgia (67.6%) and bleeding (61.7%). The most
common sites of bleeding were nasal and oropharyngeal mucosa,
with gastrointestinal tract ranking second. High fever (>38.5ºC) during
hospitalisation, confusion, bleeding from multiple sites, and presence
of petechia/echymosis occurred more often in those patients who died
than in surviving ones. (The presence of high fever during admission,
confusion, bleeding from multiple sites, and petechia/echymosis were
associated with higher mortality rate in admitted patients.) Additionally,
the mean values of ALT, AST, PTT, INR and urea were also higher, and
mean platelet count was lower in the patients who died. Nearly all of the
patients (except two) were treated with ribavirin. The recovery rate was
Emerging infectious diseases S49
higher in children whose treatment started during the initial 3 days of
illness in comparison to children whose treatment started after the ﬁrst
3 days (85.2% versus 24.8%).
Conclusion: In children who suffered from CCHF in southeast of Iran,
clinical features, factors inﬂuencing outcome of disease and risk factors
were similar to other outbreaks of this disease in adult patients in Iran.
Treatment with oral ribavirin can increase recovery rate in children as
well as adult patients.
O249 Clinical features of dengue infections, and predictors of
dengue haemorrhagic fever in Singapore
V. Lee, D. Lye, Y. Sun, G. Fernandez, A. Ong, Y.S. Leo (Singapore, SG)
Objectives: In 2004, Singapore experienced its worst dengue outbreak in
30 years with 9,459 notiﬁed cases, of which 80% were hospitalised. The
study objective was to explore the demographic, clinical and laboratory
features of dengue fever (DF) and dengue haemorrhagic fever (DHF)
upon presentation to the hospital, and to determine predictors of DHF
as a marker of severity.
Methods: A retrospective study was conducted on all laboratory-
diagnosed dengue cases admitted from 1 Jan to 31 Dec 2004 to Tan
Tock Seng Hospital (TTSH), the main dengue treatment hospital in
Singapore. Demographic, clinical, and laboratory data were collected
from the hospital’s emergency department and standardised dengue
clinical pathway during admission. Using data throughout the admission,
cases were classiﬁed as DF or DHF according to the World Health
Organisation classiﬁcation. Data on presentation was then used to
determine the predictors of subsequent development of DHF.
Results: The study included 2,144 laboratory-diagnosed dengue cases.
Of these, 140 (6.5%) were classiﬁed as DHF, with one death. On
presentation, the mean age among DF and DHF patients were not
signiﬁcantly different (35.1 years compared to 32.3 years respectively).
However, there were more male DHF patients (74.3%) compared
to DF patients (63.2%, p< 0.01). DHF patients had more frequent
dehydration on admission (20.7%), compared to DF patients (2.9%,
p< 0.01). DHF patients also had more co-morbid medical condi-
tions (27.9%) compared to DF patients (10.4%, p< 0.001). For the
laboratory results, DHF patients had lower mean white cell count
(2.99×103/uL) compared to DF patients (3.65×103/uL, p< 0.01),
and lower total protein levels (2.95 g/dL) compared to DF patients
(6.32 g/dL, p< 0.01). Mean prothrombin and partial thromboplastin
times, and atypical lymphocytes counts were also signiﬁcantly lower
in DHF compared to DF patients. From the multivariate analysis,
males [odds ratio (OR) = 1.61], dehydration (OR= 6.06), white cell count
(OR= 0.86), total protein levels (OR= 0.96), and atypical lymphocyte
counts (OR= 0.95) were independently and signiﬁcantly associated with
DHF.
Conclusions: A few key routine demographic, clinical, and laboratory
variables collected on admission may be used to predict DHF. These
variables can be used by clinicians to determine the likelihood of DHF
occurring during the admission, and may also be used as a marker to
determine the need for admission or close monitoring.
O250 Transmission potential of Chikungunya fever in a two-wave
epidemic in Reunion Island
P.Y. Boe¨lle, E. Vergu, A.J. Valleron, A. Flahault, G. Thomas (Paris,
Jouy en Josas, FR)
Background: A Chikungunya fever epidemic, transmitted by Aedes
albopictus mosquitoes, has swept Reunion Island (Indian Ocean),
causing 3000 cases in a ﬁrst wave (April–May 2005) then 260,000
cases in a second wave (December 2005–May 2006). The reason for this
dramatic increase between the two seasons is unknown, but it has been
suggested that molecular changes may have increased the transmission
potential.
Methods: We assessed the transmission potential through determining
the reproduction number R (i.e. average number of secondary cases per
index case) during the course of the epidemic. R values larger than 1
correspond to an epidemic outbreak. The method uses the epidemic
curve and the generation interval distribution (time from symptoms
in the index case to symptoms in a secondary case). The generation
interval distribution was reconstructed by composing the latent, viremic
and incubation period in humans, as well as the bite rate and mortality
in mosquitoes.
Results: R was larger than 1 during 6 weeks in the 2005 epidemic
(average 2.3), and during 20 weeks in the 2005/2006 epidemic
(average 1.7). In all cases, the magnitude of the reproduction number
was comparable between the two waves. Our best estimate for the
initial reproduction number (R0) was 3.7, although it could range from
2 to 11 depending on assumptions regarding incubation and lifespan in
mosquitoes. In the best ﬁtting case, each infected individual may have
contaminated 3 mosquitoes at most, and each mosquito contaminated
1.4 persons on average. Using data from the ﬁrst season alone, model-
based extrapolations suggested that epidemic outbreaks were possible as
long as more than one third of the population remained susceptible.
Conclusion: Despite a thousand-fold change in incidence between
the two seasons, the transmission characteristics of Chikungunya were
similar; therefore there is no epidemiological evidence for an increase in
virulence between seasons. At a time when information systems make
it easier to monitor the course of emerging diseases, methods for timely
and efﬁcient analysis of the data must also be developed.
O251 Seroprevalence and reservoirs of leptospirosis in Conakry
(Guinea)
S. Zimmermann, A. ter Meulen, E. Calvet, L. Koivogui, O. Sylla,
M. Goris, R. Hartskeerl, J. ter Meulen (Heidelberg, Frankfurt, DE;
Paris, FR; Conakry, GN; Amsterdam, Leiden, NL)
Objectives: From September to December 2001, an urban outbreak of
febrile jaundice revealed 107 cases in Conakry. Among them, 16 were
diagnosed with acute leptospirosis. Because this disease is probably
underdiagnosed in this country, a pilot study was undertaken in 2004 in
Conakry, with an investigation of both humans and small mammals. Sera
from 1200 human subjects were screened for leptospirosis antibodies to
estimate the incidence of the infection during the past rainy season and
identify risk factors for transmission. In parallel, rodents were trapped
in households to identify the reservoir animals of the disease.
Methods: A cross-sectional serologic survey was carried out in 5
resource-poor urban neighbourhoods in Conakry, Guinea. A detailed
standardised questionnaire was completed to document demographic and
environmental risk factors of transmission. Leptospirosis speciﬁc IgM
and IgG levels were detected by ELISA and conﬁrmed with MAT testing.
The trapped rodents were taxonomically identiﬁed and one kidney was
collected for detection of leptospires by culture and PCR testing. A
nested PCR with a high sensitivity was performed, non-pathogenic
leptospires (e.g. L. biﬂexa) were excluded by primer design. PCR positive
samples were conﬁrmed using different typing PCRs.
Results: Approximately 7 percent of study subjects were positive for
leptospira antibodies. Preliminary epidemiological analysis revealed as
risk factors for leptospira IgM antibodies: (i) living in a neighbourhood
from which leptospirosis cases were reported in 2001; (ii) use of
tap water for washing and bathing; (iii) living close to a waste pipe;
(iv) history of hospitalisation during the past rainy season
330 rodents were trapped within the 5 neighbourhoods. Rattus rattus
and Mus musculus were the most frequent species, but in addition some
Crocidura and Mastomys spp. were identiﬁed. In ﬁve of the kidney
samples leptospiral DNA was detected by nested PCR. In three cases
speciﬁc molecular typing revealed L. kirschneri.
Conclusion: This survey shows that a signiﬁcant percentage of the
population of Conakry, a city with ~2 Million inhabitants, is exposed
to leptospirosis during the rainy season. Transmission probably occurs
through leptospira infested water on the domestic compounds, with
rodents as one possible reservoir. As the outbreak in 2001 shows, there
is an urgent need for further identiﬁcation of the main reservoir(s) of
the disease and environmental control measures.
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O252 Majority of the clinical Yersinia enterocolitica isolates in
Finland belong to biotype 1A
L.M. Sihvonen, M. Kuusi, S. Hallanvuo, E. Huovinen, K. Haukka,
A. Siitonen (Helsinki, FI)
Objectives: Zoonotic Yersinia enterocolitica is a more common cause
of gastroenteritis in Finland than domestic salmonellae. Annually,
more than 500 Y. enterocolitica infections are notiﬁed in the register
for infectious diseases. Most of the cases seem to be sporadic
but occasionally outbreaks emerge, pigs being a common reservoir.
Y. enterocolitica diagnostics is challenging since among the strains
pathogenity varies. In addition, strains of other Yersinia species can
resemble pathogenic Y. enterocolitica strains in their biotypic and
serotypic reactions. Our purpose was to collect an extensive number
of clinical strains, study their detailed phenotypic and genotypic
characteristics, and interview the patients to assess the clinical
signiﬁcance of the different Yersinia strains.
Methods: We collected all Yersinia strains from10 Finnish clinical
microbiological laboratories in the year 2006. The strains were examined
by biotyping, serotyping, and by several genotypic methods, such as gene
sequencing and pulsed-ﬁeld gel electrophoresis. The patients were asked
e.g. about onset and symptoms of illness, and food consumed. We then
combined the data collected from bacterial strains with the information
gathered from patients. To study the appearance of Y. enterocolitica
in healthy population, we also studied stool samples of 200 healthy
individuals.
Results: Approximately 40 Yersinia strains per month were received
from the clinical laboratories. The majority of all strains, approxi-
mately 70%, belonged to Y. enterocolitica biotype (BT) 1A and 15% of
the strains were of bio-/serotype 4/O:3 or 2−3/O:9. The remaining 15%
consisted of other Yersinia species. The use of cold-enrichment increased
the number of BT 1A ﬁndings. The symptoms of the patients with either
a BT 1A or 4/O:3 ﬁnding were rather similar concerning abdominal
pain and diarrhoea, but there was a statistically signiﬁcant difference in
appearance of fever in the patients with the 4/O:3 ﬁnding. Less than a
one percent of the healthy individuals had Y. enterocolitica in their stool
samples.
Conclusion: Majority of the Finnish clinical Y. enterocolitica ﬁndings
were BT 1A strains that have traditionally been considered as non-
pathogenic strains since they do not possess pYV virulence plasmid.
However, according to the preliminary analyses of the patients’
interviews some of the BT 1A strains were associated with severe
gastrointestinal symptoms.
O253 Epidemiology of Haemophilus inﬂuenzae serotype A from
2000–2005, an emerging pathogen in Northern Canada and
Alaska
M. Bruce, S. Deeks, T. Cottle, C. Palacios, C. Case, C. Hemsley,
M. Lovgren, I. Sobol, A. Corriveau, B. Larke, T. Hennessy, C. Debyle,
M. Harker-Jones, D. Hurlburt, H. Peters, A. Parkinson (Anchorage,
US; Toronto, CA; Iqaluit, Yellowknife, Whitehorse, Edmonton, CA)
Background: Prior to introduction of the Haemophilus inﬂuenzae type b
(Hib) conjugate vaccines, rates of Hib disease among aboriginal people
living in Alaska (AK) and Northern Canada (NCan) were among the
highest reported in the world. Routine vaccination has reduced these
rates to very low levels; however, serotype replacement with non-type b
strains may result in a reemergence of invasive disease in children.
Methods: We reviewed population-based data on invasive Hi disease
in AK and NCan collected from 2000–2005 through the International
Circumpolar Surveillance (ICS) network. Chart reviews were conducted
on laboratory-conﬁrmed cases using standardised forms to verify illness
episode information. All Hia isolates were characterised using pulsed-
ﬁeld gel electrophoresis (PFGE). AK and NCan estimated populations
as of 2005 were 655,435 and 132,956 respectively; aboriginal peoples
comprised 19% of the population in AK and 59% in NCan.
Results: During the study period, a total of 138 cases of invasive
Hi disease were reported from AK (76) and NCan (62). Among
the 88 (67%) invasive Hi cases with serotype information available,
42 (48%) were serotype a, 27 (31%) were serotype b, 12 (14%) were
serotype f. Among Hia isolates, 35 (83%) occurred in aboriginal
peoples; median age was 1.1 years (range 3mo to 74 years); 62% were
male. Two Hia cases (1 adult/1 child) were fatal. Common clinical
presentations included: meningitis (33%), pneumonia (29%), and septic
arthritis (12%). There were no cases of epiglotittis. Overall annual Hia
incidence was 0.9 cases per 100,000 population. Annual incidence rates
in aboriginals in AK and NCan were 1.1 and 4.6 per 100,000 persons,
respectively; rates in aboriginal children <2 years of age were 22 and
101 cases per 100,000 persons, respectively. PFGE analysis revealed
genetically similar Hia strains in both AK and NCan.
Conclusions: Serotype a is now the most common Hi serotype seen in
the North American Arctic, with the highest rates among indigenous
children. Further research is needed to determine sequelae, risk factors,
outbreak potential, and the utility of chemoprophylaxis for this disease.
O254 Mediterranean spotted fever: a reemerging rickettsiosis?
New trends in epidemiology, ecology and clinical presentation
C. Rovery, N. Mouffok, P-E. Fournier, P. Brouqui, D. Raoult
(Marseilles, FR)
Objectives: In recent years, rickettsial disease had undergone important
evolution, particularly in the ﬁeld of molecular genetics. In parallel,
important changes in our comprehension of Mediterranean spotted fever
(MSF) had occurred in the ﬁeld of ecology, epidemiology, occurrence
of severe forms. The objective of this study is to determine new trends
in Mediterranean spotted fever.
Methods: We disposed of the data from the ‘Unite´ des Rickettsies’ from
1982 until today and of the data from 1993 to 2005 in Oran. We reviewed
the literature from the ﬁrst description of MSF to September 2006 on
the subject to determine incidence of the disease, incidence of severe
cases, risk factors of severity, changes in clinical description. We also
reviewed literature on the state of knowledge about factors inﬂuencing
the incidence of MSF, the vector and reservoir of R. conorii.
Results: First clinical descriptions based only on serology surely
included infections related to multiple species of Rickettsiae and do not
correspond to only one clinico-etiologic entity. Now, with more accurate
technique of identiﬁcation of rickettsial disease, we can differentiate
different clinical presentation according to the species. Incidence of
Mediterranean fever has known important variations with a peak in the
1980’s. Incidence of severe form is also ﬂuctuating; in Beja district,
Portugal, the case fatality rate in hospitalised patients with MSF was
32.3%, the highest ever obtained there; in France, peak of incidence
of MSF with 30 cases and of severe form (30%) was noted in 2004,
one year after the canicule. The possible factors include an increased
number of ticks, increased human contact with the habitat of infected
ticks and climatic factors, such as the increase in temperature and the
lack of rainfall. Multiple eschars are now recognized in MSF. In our unit,
in 2004, 9 patients had a conﬁrmed diagnosis of MSF either by PCR
or culture of the eschar or blood culture. Among them, 3 had multiple
eschars and 2/3 had a severe form of MSF. It is noteworthy that 6/9 of
these patients had a severe form of MSF. In Oran, multiple eschars are
not a risk factor for severe MSF.
Conclusion: MSF shows evolving features in epidemiology, clinical
presentation and one hundred years after its ﬁrst description, we better
know the disease. However areas of uncertainty persist, such as what is
the real vector and reservoir of MSF.
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O255 Is Echinococcus multilocularis increasing in prevalence in
the Western European border line?
J. van der Giessen, M. Vervaeke, A. de Vries, M. Chu, L. Brochier,
B. Losson, P. Teunis, K. Takumi (Bilthoven, NL; Antwerp, Brussels,
Liege, BE)
Objectives: Alveolar echinococcosis is one of the most pathogenic
parasitic zoonoses in central Europe, caused after oral uptake of eggs of
Echinococcus multilocularis, shed by infected foxes. At present, there
seems to be a trend towards increased parasite density in central Europe
and spread in western Europe, although it cannot be decided whether
E. multilocularis recently has extended its habitat or whether the parasite
has simply remained undetected until now in marginal regions. We
analysed red fox data from an area close to the westernmost margin
of E. multilocularis habitat in Europe, Belgium and a neighbouring
province (Limburg) in The Netherlands (NL), with the aim of studying
the emergence of the parasite in this area.
Methods: A total of 1202 foxes has been analysed (1018 in Belgium,
184 in NL) with 179 infected (164 in Belgium, 15 in NL) using mucosal
scrapings. Spatial coordinates of the locations of infected and uninfected
foxes have been determined by GPS. In addition, additional data in
southern Europe were analysed using GIS and modeling to study changes
in distrinution and prevalence.
Results: The large scale spatial distribution of the prevalence of infection
among sampled foxes has been modeled as an ellipsoidal gradient,
demonstrating increasing prevalence in southeastern direction that means
towards the endemic area in central Europe. Using this gradient, the
spatial pattern of E. multilocularis infection in Belgium and a contiguous
region in NL could be shown to have a continuous distribution across
national borders. Part of the Belgian data allowed investigation of the
temporal changes in spatial distribution of E. multilocularis, revealing
spreading into northwestern direction. A mathematical model describing
the parasite population dynamics both in time and in space was ﬁtted
to the worm burdens of foxes sampled between 1996 and 2006 in NL.
We found a strong indication that the parasite’s reproduction number R0
is greater than 1 and that the parasite is spreading to a wider region in
Limburg. Based on the R0 derived from the mathematical model of the
parasite’s transmission, we explore the effect of public health measures
aimed to eradicate the infection.
Conclusion: Increased infection pressure of E. multilocularis in north-
western Europe is most likely to occur at present. In Belgium human
alveolar echinococcosis had been absent in the past, but 3 human cases
have been reported in 2004.
Novel resistance mechanisms and quinolone
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O256 Telavancin targets the bacterial membrane of Staphylococcus
aureus: analysis of membrane effects by ﬂow cytometry
C. Lunde, M. Renelli, J. Janc, M. Mammen, P. Humphrey, B. Benton
(South San Francisco, US)
Objectives: Telavancin is a novel, multivalent, lipoglycopeptide antibi-
otic that exerts rapid bactericidal activity against a broad range of Gram-
positive pathogens. Telavancin has a unique multifunctional mechanism
of action that includes both inhibition of bacterial cell wall synthesis
and disruption of bacterial membrane function. Previous studies
with methicillin-resistant Staphylococcus aureus (MRSA) revealed that
telavancin increases cell membrane permeability and causes rapid
dissipation of the bacterial membrane potential. This study aimed to
further characterise the effects of telavancin on the functional integrity
of the MRSA cell membrane using ﬂow cytometry.
Methods: Cell membrane potential and membrane permeability were
studied in telavancin-treated S. aureus ATCC 33591 (MRSA) cells. The
ﬂuorescent dyes, DiOC2(3) and propidium iodide, were used to assess
membrane potential and permeability, respectively. Flow cytometry was
used to analyse uptake of these dyes in telavancin-treated cells.
Results: Telavancin (MIC, 0.5mg/mL) caused a concentration- and
time-dependent dissipation of the membrane potential in MRSA cells.
After 60 minutes’ exposure to telavancin, 67% of the bacterial
population was depolarised at 8 mg/mL (approximate human plasma
trough concentration), while 32mg/mL resulted in 95% depolarisation.
Membrane permeability was also concentration- and time-dependent,
as seen when cells were exposed to telavancin concentrations ranging
from 2 to 64mg/mL, with 32 and 64mg/mL yielding rapid, >90%
permeabilisation of the cell population.
Conclusion: Exposure of MRSA cells to telavancin initiated
concentration- and time-dependent membrane depolarisation and in-
creases in permeability, further demonstrating that telavancin interferes
with bacterial cell membrane function. These effects were observed
at telavancin concentrations that are achieved clinically with 10mg/kg
intravenous dosing, and further highlight the therapeutic relevance of
telavancin’s multifunctional mechanism of action.
O257 Relationship between antibiotic exposure and overproduction
of MexXY efﬂux pump in Pseudomonas aeruginosa
D. Hocquet, A. Muller, K. Blanc, P. Ple´siat, D. Talon, D. Monnet,
X. Bertrand (Besanc¸on, FR; Copenhagen, DK; Vandoeuvre, FR)
Objectives: Overproduction of the MexXY efﬂux pump results in
increased resistance to aminoglycosides (AGs), ﬂuoroquinolones (FQs)
and cefepime (FEP) in Pseudomonas aeruginosa (PA). This mechanism
is very prevalent (up to 40%) in the clinical isolates. However, the
conditions that favour the emergence of MexXY-overproducing mutants
(PA/XY+) in the hospital setting remain unclear. We therefore analysed
the temporal relationship between the prevalence of PA/XY+ and
antibiotic use, and then compared the results to in vitro selection
experiments.
Methods: The incidence of PA/XY+ per 1000 patient-days was
determined between 2001 and 2004 (3,800 isolates) from the laboratory
susceptibility database (% of isolates with a low-level resistance to all
the tested AGs). We conducted time-series analysis of monthly incidence
of PA/XY+ and monthly consumption of various antibiotic classes in
our hospital. In parallel, the ability of antibiotics at 1 or 2 MICs to
select for PA/XY+ mutants was determined in vitro with reference strain
PAO1. Detection of PA/XY+ was done by replicating resistant clones
on MH plates containing gentamicin (5mg/L) or FEP (5mg/L). The
PA/XY+ in vitro mutants were further characterised phenotypically and
genotypically.
Results: The adjusted Linear Transfer Function model showed a
signiﬁcant relationship between the AGs and the FQs use series and the
PA/XY+ series. This was observed for contemporaneous data and with
a lag of several months. Conversely a negative correlation was found
between third generation cephalosporins (cefotaxime and ceftriaxone) or
anti-pseudomonal penicillins use series and PA/XY+ series. There was
no correlation between the FEP use, which is very low in our hospital
(<0.5 DDD/100 PD), and PA/XY+ series. The model explained 70.1%
of the variability of the resistance series (adjusted r-squared = 0.701). In
vitro, PA/XY+ were readily selected by all the tested FQs (n = 4), AGs
(n = 3) and FEP at a frequency of 3×10−7 to 5×10−6.
Conclusion: This study strongly suggests that PA/XY+ are selected by
AGs and FQs in the hospital setting. The broad-spectrum resistance of
these mutants could reduce the efﬁcacy of combination therapy involving
substrates of the MexXY efﬂux pump (i.e. FEP, AGs and FQs).
O258 Telavancin inhibits peptidoglycan biosynthesis through
preferential targeting of transglycosylation: evidence for a
multivalent interaction between telavancin and lipid II
B. Benton, E. Breukink, I. Visscher, D. Debabov, C. Lunde, J. Janc,
M. Mammen, P. Humphrey (South San Francisco, US; Utrecht, NL)
Objectives: Telavancin (TLV) is a novel, rapidly bactericidal lipo-
glycopeptide with activity against methicillin-resistant Staphylococcus
aureus (MRSA). TLV possesses a unique, multivalent, multifunctional
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mechanism that contributes to enhanced activity and includes inhibition
of cell wall peptidoglycan (PG) biosynthesis and disruption of bacterial
membrane barrier function. In vitro studies suggest that TLV exhibits
superior antibacterial potency relative to vancomycin (VAN); this may
be due to the lipophilic decylaminoethyl side chain that targets TLV to
the bacterial cell membrane. The objective of this study was to elucidate
the mechanistic basis for the enhanced antibacterial action of TLV.
Methods: Isothermal titration calorimetry was used to determine afﬁni-
ties of TLV to 3-lipid II (a water soluble lipid II analogue), and wild-type
lipid II embedded in model membrane vesicles made of 1,2-dioleoyl-sn-
glycero-3-phosphocholine. PG biosynthesis was evaluated in methicillin-
susceptible, methicillin-resistant, and vancomycin-intermediate isolates
of S. aureus. Formation of immature (polymerised, non-cross-linked
transglycosylation product) or mature (polymerised, cross-linked, the
product of transglycosylation then transpeptidation) PG was assayed
in intact cells by measuring incorporation of [14C]-GlcNAc into 5%
trichloroacetic acid-insoluble material in the presence of penicillin G
(immature PG), or into hot 4% sodium dodecylsulphate-insoluble
material (mature PG).
Results: The afﬁnity of TLV for the water-soluble lipid II variant was
4.7±0.5×105 M−1; a nearly 35-fold increase in afﬁnity was observed
with membrane-bound, wild-type lipid II. Inhibition patterns of immature
and mature PG by TLV were distinct from those of VAN. VAN
preferentially inhibited the formation of mature PG (transpeptidation
reaction product), requiring ~10-fold higher concentration to inhibit
transglycosylation. In contrast, TLV appeared to preferentially inhibit
the transglycosylation reaction.
Conclusion: TLV inhibits PG polymerisation and cross-linking steps in
bacterial cell wall synthesis. The higher afﬁnity of TLV for membrane-
bound lipid II (vs the soluble analogue) is consistent with the concept
that TLV selectively binds to the bacterial cell membrane. The superior
inhibitory potency of TLV toward PG biosynthesis may derive from its
membrane-anchoring properties which confer increased binding afﬁnity
for the transglycosylase substrate, lipid II.
O259 Risk for selection by clindamycin of resistant mutants from
Staphylococcus aureus inducibly resistant to erythromycin:
erm(A) and erm(C) genes are not similar
C. Daurel, C. Huet, A. Dhalluin, M. Bes, J. Etienne, R. Leclercq (Caen,
Cherbourg, Lyon, FR)
Objectives: S. aureus isolates inducibly resistant to erythromycin by
production of ErmA or ErmC methylases are still susceptible to
clindamycin. However, constitutive mutants resistant to clindamycin may
be selected in vitro or in vivo in the presence of this antibiotic. The risk
for selection may depend on several factors including the frequency
of mutation to resistance, the bacterial inoculum size and the type of
infection. Our objective was to compare the clindamycin mutation rate
of clinical isolates of S. aureus containing an erm(C) or an erm(A) gene.
Methods: 28 isolates of S. aureus bearing erm(C) (n = 18) or erm(A)
(n = 10), originating from various countries and including 12 community-
acquired methicillin resistant strains representative of different clones,
were studied. For determination of mutation frequencies, cells from
an overnight broth culture were plated onto trypticase-soy agar plates
supplemented with 20mg/L of clindamycin. After 48 h of incubation
at 37ºC, colonies were counted and the mutation frequencies were
determined relative to the total count of viable organisms plated. Each
experiment was repeated three times. Two erythromycin-susceptible
S. aureus and 4 S. aureus with the efﬂux gene msr(A) were included
as controls. Susceptibility to oleandomycin was determined by the disk
diffusion method.
Results: S. aureus erm(C) displayed a 14-fold higher mean frequency of
mutation to clindamycin [range: 1.7×10−6 to 4.4×10−8; mean: 4.7×10−7
(±5.5×10−7)] than the S. aureus erm(A) strains [range: 7.3×10−10 to
1.8×10−8; mean: 3.4×10−8 (±2.4×10−8)]. The frequencies of mutations
for the erm(A) isolates were similar to those for the controls [range:
1.3×10−9 to 1×10−8; mean: 1.1×10−8 (±6.4×10−9)].
All isolates with the erm(A) gene were susceptible to oleandomycin
whereas no inhibition zone was observed for the isolates with the erm(C)
gene.
Conclusion: S. aureus with the erm(C) gene are more readily susceptible
to develop constitutive resistance to clindamycin than those with
the erm(A) gene, regardless methicillin resistance. Susceptibility or
inducible resistance to oleandomycin was associated with the presence of
an inducible erm(A) or erm(C) gene, respectively and might constitute
markers of these genes. The risk analysis for the clindamycin use in
therapy of infections due to S. aureus inducibly resistant to erythromycin
might include the nature of the resistance gene.
O260 Multidrug-resistant Escherichia coli mutants selected with
diazepam or lomeﬂoxacin overexpressing soxS, sdiA, acrAB,
TolC and PBP3
M.M. Tavı´o, V. Aquili, A. Fa´brega, Z. Gonza´lez-Lama, J.B. Poveda,
J. Vila (Las Palmas De G.C., Barcelona, ES)
Objectives: Multiple resistance of Escherichia coli to distinct classes of
antimicrobials is usually attributed to simultaneous increased expression
of AcrAB-TolC efﬂux system and loss of porin F generated by
transcriptional activators marA, soxS or rob. AcrAB-TolC is also up-
regulated by SdiA, an E. coli protein that regulates cell division.
In this study, multidrug resistant mutants selected in vitro with diazepam
(DZ) and lomeﬂoxacin (LOM) from two E. coli susceptible clinical
isolates were characterised.
Methods: Mutants were selected with DZ or LOM at 2, 3, 4 or 6×
the MIC. Tolerance of strains to 10% cyclohexane was measured in
liquid medium. Inner and outer membrane proteins (IMP and OMP)
were analysed by electrophoresis on polyacrylamide gels. Penicillin-
Binding-Proteins (PBPs) were detected with Bocillin FL and Imperial
Protein Stain. Active efﬂux was evidenced by 0.05mM carbonyl cyanide
m-chlorophenylhydrazone (CCCP). The expression of the acrA, acrB,
marA, soxS, rob and sdiA genes was studied by reverse transcription of
total RNA and PCR of cDNA (RT-PCR), using gapA gene as internal
control of expression. PCR products were separated on polyacrylamide
gels and detected using silver staining. Ag100 strain (induced or non-
induced with 5mM salicylate or 0.2mM paraquat) was the control strain.
Results: Nine different clones were selected with DZ or LOM. Selection
frequencies were around 10−9 to 10−8. The nine mutants increased
resistance to quinolones, chloramphenicol and b-lactams (2−8 fold
ceftazidime, cefpirome and aztreonam MICs). The presence of CCCP
increased the susceptibility of mutants to antimicrobial agents. The OMP
TolC increased in mutants, coinciding with their increased cyclohexane
tolerance. Mutants and parent strains showed a high expression of acrA
and acrB genes. Nevertheless, only mutants showed overexpression of
sdiA and soxS and OmpF decrease. Neither parent strains nor mutants
showed marA or rob overexpression. Increased PBP3 expression was
detected in only the mutants selected with 6× MIC of DZ or LOM.
Conclusions:
i. DZ (a non-antimicrobial drug) and LOM selected multiple antibiotic
resistant mutants that overexpressed the same transcriptional regula-
tors, soxS and sdiA, resulting in TolC increased expression in mutants.
ii. The OmpF decrease, which was generated by soxS overexpression,
and increased TolC and PBP3 expression contributed to 2−8-fold
increment in ceftazidime, aztreonam and cefpirome MICs in mutants.
O261 Role of the pentapeptidic proteins from Gram-positive
bacteria as a possible source of Qnr-like quinolone resistance
determinants
J. Rodriguez-Martinez, C. Velasco, I. Garcia, M. Conejo, A. Pascual
(Seville, ES)
Objectives: To study the role of Qnr-like pentapeptidic proteins of
several Gram-positive species in resistance to quinolones in vitro.
Methods: Enterococcus faecalis V583 homologue QnrA protein
sequence was used to search pentapeptidic proteins with different levels
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of aminoacidic identity in the NCBI database. A PCR-based strategy was
used to clone and express the genes coding for Qnr-like pentapeptidic
proteins of E. faecalis ATCC 29212, E. faecalis V583, E. faecium
BM4147, Listeria monocytogenes 868 (clinical isolate), Clostridium
perfringens 455 (clinical isolate) and Bacillus cereus ATCC 11778 in
pPCR-Script vector (Stratagene) in Escherichia coli DH10B. According
to CLSI guidelines, MICs of nalidixic acid, oﬂoxacin, norﬂoxacin,
ciproﬂoxacin, levoﬂoxacin and moxiﬂoxacin were determined for clinical
strains, reference strains and Escherichia coli DH10B harbouring
recombinant plasmids containing genes coding for the pentapeptidic
proteins.
Results: The aminoacidic identity of Qnr-like pentapeptidic proteins
of the Gram-positive strains compared to those of plasmid-mediated
QnrA1, QnrB1 or QnrS1 quinolone resistance proteins ranged from
20% to 27%. When compared to the homologue of QnrA in E. faecalis
V583, the aminoacidic identity ranged from 30% to 35%. All the clones
obtained in E. coli DH10B expressing a pentapentidic protein from the
Gram positives strains conferred reduced susceptibility to quinolones.
The recombinant plasmids expressing pentapentidic proteins in E. coli
DH10B increased the MICs from 4 to 12 folds for nalidixic acid, from
6 to 24 folds for oﬂoxacin, from 2 to 47 folds for norﬂoxacin, from 12 to
32 folds for ciproﬂoxacin, from 4 to 21 folds for levoﬂoxacin, and from
4 to 32 folds for moxiﬂoxacin.
Conclusions: The pentapeptidic proteins analysed confer reduced
susceptibility phenotype in E. coli. These data could provide further
evidence about the possible role of pentapeptidic proteins of different
Gram-positive species in their natural resistance to quinolones. These
Gram positives species could constitute a reservoir of Qnr-like quinolone
resistance proteins.
O262 The mode of action of daptomycin against Staphylococcus
aureus
J. Hobbs, K. Miller, N. Read, I. Chopra (Leeds, UK)
Objectives: The Silverman model for the mode of action of daptomycin
(DAP) is based on the leakage of potassium ions (K+), membrane de-
energisation and subsequent cell death without lysis. However, it is
unknown whether loss of K+ is sufﬁcient to cause cell death. In this
study we determined the kinetics of both cell death and lysis of S. aureus
treated with DAP to establish any relationships between the two.
Methods: Time-kill experiments were performed at various concentra-
tions of DAP to determine the kinetics of cell death and samples were
taken and prepared for scanning and transmission electron microscopy
(EM). Culture samples were taken at intervals and the extracellular
and intracellular amounts of ATP determined. The extracellular and
intracellular levels of b-galactosidase (b-gal) in a S. aureus strain
expressing b-gal in its cytoplasm were also measured.
Results: The time-kill experiments show DAP to be rapidly bactericidal
at 32mg/L. DAP at 4mg/L shows a bacteriostatic effect for the ﬁrst
60min and then becomes slowly bactericidal. There is evidence for dose-
dependent leakage of ATP and b-gal from cells treated with DAP, but
this leakage occurs at very different rates. After 30min of treatment
with DAP at 32mg/L, 90% of the total ATP has been released but only
a negligible amount of b-gal. The percentage of b-gal released increases
steadily over a period of hours, reaching 40% after 6 h and 90% after
24 h. After 30min of treatment with DAP at 4mg/L, 50% of the total
ATP has been released and this amount continues to increase steadily.
The leakage of b-gal is less apparent and after 24 h the cells have released
less than 30%. The EM images show some cellular disruption in the ﬁrst
hour after DAP treatment, with this damage becoming more apparent and
widespread over the following hours. The images clearly show that the
rate and extent of cellular lysis is dose-dependent.
Conclusion: Our ﬁndings support the Silverman model for the mode
of action of DAP and the hypothesis that it can cause rapid cell death
without whole cell lysis. We have, however, shown that cell lysis does
occur over time, through both EM images and the leakage of large
amounts of b-gal. Our ﬁndings, while upholding the Silverman model,
suggest that it is too simple to conclude that cell death is due only to
loss of K+ and membrane de-energisation. The rapid loss of ATP would
be an equally likely cause of cell death.
O263 The correlation between resistance phenotype and expression
levels of efﬂux pumps of Pseudomonas aeruginosa
X.J. Lu (Chengdu, CN)
Objective: To study the effects of efﬂux pump inhibitors (CCCP
and PAbN) on carbapenems in P. aeruginosa (Pa); to investigate the
correlation between the resistance phenotypes and expression levels of
efﬂux pumps of Pa and discuss the mechanism of different phenotypes
in resistant Pa.
Methods: MICs of imipenem (IMP) or meropenem (MEP) combined
with efﬂux pump inhibitors against IMP resistant strains were determined
by agar dilution method. For 32 strains with different resistant
phenotypes to IMP and MEP, the mRNA expression levels of three
efﬂux pump genes (mexA, mexD, mexF) were quantiﬁed by real time
ﬂuorescent quantitative PCR.
Results: The resistance rate of IMP and MEP descended gently after
combined with efﬂux pump inhibitors. The strains with sustained MICs
reached over 50%. MICs of only 8 strains descended to 1/4 original MIC
values. The amount of mRNA of efﬂux pump genes in ATCC27853 was
deﬁned as 1. The amounts of mexA in susceptible strains were from
0.0003 to 0.99, those of mexD were from 0.0001 to 1.11, and those of
mexF were from 0.013 to 0.31. The amounts of mexA in IMP resistant
but MEP strains were from 0.28 to 4.48, mexD were from 0.37 to 20.06
and mexF were from 0.44 to 5.56. The amounts of mexA in both resistant
strains were from 1.42 to 138.25, mexD were from 0.1 to 16.66 and
mexF were from 0.22 to 12.61. That appeared overexpressions of efﬂux
pumps accounted for 88.89% in 27 strains resistant to carbapenems.
The statistic result showed the expression levels of three efﬂux pumps
of strains resistant to carbapenems were much higher than susceptible
strains.
Conclusions: When CCCP was incorporated in the Mueller-Hinton agar
at a concentration of 5mg/mL and PAbN was 20mg/mL in vitro they
could not obviously decrease the carbapenems resistance of Pa in this
study, and there were rare relativity between the amount of mRNA of
efﬂux pump genes and effects on MICs of carbapenems with efﬂux
pump inhibitors. Overexpression of efﬂux pumps were the main reason
for the resistance to carbapenems of Pa in our hospital. A phenomenon
that manifold efﬂux pumps co-existed in a Pa isolate was common. It
demonstrated that overexpression of MexAB-OprM plays an important
role in resistance differences between IMP and MEP. Overexpressions of
MexCD-OprJ and MexEF-OprN played important roles for carbapenems
resistance in Pa, but had fewer effects on resistance difference between
IMP and MEP.
O264 Natural variation within Staphylococcus aureus populations
determines concentration and time-dependent phenotypic
daptomycin resistance
M. Morosini, M. Garcı´a-Castillo, R. Canto´n, B. Levin, F. Baquero
(Madrid, ES; Atlanta, US)
Daptomycin (DAP) is a rapid-killing lipopeptide antibiotic acting on
MSSA, MRSA, and GISA strains. However, we have seen that, after
killing, extended incubation with 8×MIC DAP concentrations results in a
slow but sustained increase (from 24 h to 5 days) in viable staphylococcal
cells. Such increase occurs in the presence of non-degraded DAP, and
sub-cultivation of viable cells renders only DAP-susceptible organisms,
suggesting heterogeneous phenotypic DAP-resistance.
Objective: To determine whether heterogeneous phenotypic DAP-
resistance occurs as a result of natural variation in S. aureus populations
before DAP exposure.
Methods: Time kill studies (in triplicate) with DAP 8×MIC were
performed in 10ml-tubes inoculated with 5×105 CFU/mL of 4 S. aureus
ATCC strains (29213, 25923, 43300, and 700789) and incubated along
5 days. Natural variation in propensity to DAP-killing was studied with
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the ATCC 25923 strain using the Luria-Delbru¨ck ﬂuctuation test (in
duplicate) at 2×, 4×, and 8× DAP concentration (using both 3ml-
and 10ml-tubes) along 6 days of incubation. Non-degraded DAP was
determined by a microbioassay.
Results: In time kill studies, DAP displayed bactericidal activity against
all ATCC strains at 3 hours. However, an after-killing increase (re-
growth) of DAP-susceptible viable cells was observed along prolonged
incubation despite of no DAP degradation over time. Fluctuation
test indicates that natural phenotypic variation in propensity to DAP
killing is generated at random before DAP exposure. The frequency
of DAP-phenotypic resistant variants is inversely proportional to DAP
concentration and time of exposure. Bacterial densities of 3×105 contain
variants able to re-grow in 4 out of 6 tubes at 72 h after exposure to
2×MIC, only in 1/6 tubes at 4×MIC, and none (0/6 tubes) at 8×MIC.
On the contrary, 1×106 bacterial density contains variants able to grow
in all tubes at 2×, 4× and 8×MIC at 24 h. However, after 6 days of
exposure, bacteria from 4 out of 6 tubes were killed.
Conclusions: A stochastic phenotypic variability in propensity to being
killed by DAP occurs in S. aureus. The number of phenotypically
resistant variants able to persist and re-grow in the presence of DAP
is inversely proportional to drug concentration and time of exposure.
Studies on putative implication of physiological, reversible heterogeneity
in cytoplasmic membrane in this behaviour are awaited to interpret these
ﬁndings.
O265 Worldwide dissemination of expanded-spectrum b-lactamase
VEB-1 and quinolone resistance determinant QnrA1
through acquisition of IncA/C2 plasmids
L. Poirel, L. Villa, A. Bertini, J. Pitout, P. Nordmann, A. Carattoli
(Le Kremlin Bicetre, FR; Rome, IT; Calgary, CA)
Purpose: To trace the plasmid co-dissemination of extended-spectrum
b-lactamase gene blaVEB-1 and quinolone resistance gene qnrA by using
the replicon typing method.
Material and Methods: Seventeen non-repetitive VEB-1 and/or QnrA-
positive isolates (mostly transconjugants) have been included in the
study. They had been collected from 1999 to 2005 from patients
hospitalised in different parts of the world scattered on four continents.
PCR-based replicon typing (PBRT) method including eighteen primer
pairs was used, allowing to recognize FIA, FIB, FIC, HI1, HI2, I1-Ig,
L/M, N, P, W, T, A/C, K, B/O, X, Y, and FII replicons. Plasmid restriction
analysis followed by Southern hybridisation was performed to compare
their structures.
Results: PBRT results showed that the thirteen blaVEB-1-positive
plasmids (including eleven qnrA1-positive) were positive for the A/C-
type replicon and sequencing identiﬁed the A/C2 replicon in all cases.
By contrast, all the qnrA1-positive but blaVEB-1-negative isolates were
negative for the A/C2 replicon. These results clearly indicated that
the genes encoding QnrA1 and VEB-1, when identiﬁed concomitantly
in a given isolate, were always located on plasmids belonging to the
same IncA/C2-incompatibility group that may vary in size and digestion
pattern. In addition, plasmids carrying the blaVEB-1 gene but lacking
qnrA1 were also of the A/C2 type. On the opposite, plasmids that
were qnrA1-positive but blaVEB-1-negative were of distinct replicon
types, suggesting independent acquisition of the qnrA gene on different
plasmids.
Restriction pattern analysis of plasmid DNAs performed using the PstI
endonuclease revealed that the blaVEB-1-positive plasmids exhibited
different restriction proﬁles but also sharing common bands, likely
corresponding to a common plasmid backbone. Hybridisation performed
with an A/C2-speciﬁc probe showed an identical signal revealing that
the bands carrying the replication control region of the plasmids were
of identical size, as expected with plasmids from the same lineage.
Conclusion: It is shown here that the IncA/C2 plasmid may be the main
vehicle of the blaVEB-1 gene on which the QnrA1 determinant may be
added.
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O266 Risk factors for invasive group A streptococcal infections in
Europe
T. Lamagni, T. Siljander, J. Darenberg, B. Luca, A. Bouvet,
R. Creti, A. Efstratiou, K. Ekelund, B. Henriques Normark, A. Jasir,
M. Koliou, N. Legakis, R. Reinert, C. Schalen, L. Strakova, M. Straut,
J. Vuopio-Varkila for the Strep-EURO group
Objectives: Data on invasive group A streptococcal (iGAS) infections
collected by 11 European countries were analysed to identify the
frequency of factors predisposing individuals to infection.
Methods: Prospective surveillance of iGAS disease diagnosed between
1st January 2003 and 31st December 2004 was undertaken across Europe
as part of the EU FP-5 funded Strep-EURO project (Cyprus, Czech
Republic, Denmark, Finland, France, Germany, Greece, Italy, Romania,
Sweden, UK). Each participant undertook enhanced surveillance of
iGAS disease using a standardised case deﬁnition: isolation of GAS
from a sterile site or from a non-sterile site in patients with clinical signs
of streptococcal toxic-shock syndrome (STSS). Rates of iGAS disease
were calculated for all countries with deﬁnable catchment populations
(Cyprus, Czech Republic, Denmark, Finland, Romania, Sweden, UK).
Results: During 2003−04, 5538 iGAS cases were identiﬁed across the
eleven countries. Cases were concentrated in the elderly and to a lesser
extent in infants, with rates being higher in males than females in all
countries except Denmark, where rates were non-signiﬁcantly higher
in females (RR= 1.16; 95%CI: 0.91−1.49). The age distribution of
cases in the UK was unusual in having relatively high rates in young
adults (3.35/100,000 in 20−39 year olds) compared to other countries, a
reﬂection of the high proportion of UK cases being injecting drug users
(21%). Seasonal patterns of iGAS infection were evident, with marked
peaks in March/April in both years and an additional peak in January
2004. Considerable congruence in the timing of seasonal peaks and
troughs was evident between countries. Eight per cent of infections
were healthcare-associated, 63% of these post-surgical. Skin lesions/
wounds were the most common predisposing factor, reported in 23% of
cases. Four per cent of cases presented with puerperal sepsis, with the
emm28 strain being strongly associated with these infections compared
to other presentations (33% vs 10%; Chi2(1df) = 52.90; p< 0.001).
Eighteen per cent of cases were reported as not having any predisposing
factors for iGAS infection.
Conclusion: Comparison of data from participating countries within
the Strep-EURO programme is yielding interesting new perspectives
on risk factors for iGAS disease which warrant further exploration.
Understanding these patterns will help to identify potential targets for
public health intervention.
O267 Incidence and management of group B streptococci colonised
women in labour
E. Edwards, P. Milner, J. Gray, J. Daniels, L. Magill (Birmingham, UK)
Objectives: Controversy still surrounds the indications for intrapartum
antibiotic prophylaxis (IAP) against group B streptococci (GBS) for
women in labour, with arguments for and against the two recognized
care pathways; antenatal screening and risk factor assessment.
Using data obtained from a large test accuracy study into rapid
detection of intrapartum GBS colonisation, the aims were to de-
termine (1) the prevalence of vaginal and rectal GBS in labouring
women, comparing standard culture to enrichment culture techniques;
(2) what proportion of women present with different risk factors; (3) how
both culture positivity and risk factors correlate with the frequency of
IAP administration; (4) baby colonisation rates with regard to maternal
colonisation site and whether or not IAP was given.
Methods: Vaginal and rectal swabs collected from 1185 women in labour
for direct culture on streptococcal selective agar (CNA) and enrichment
culture (LIM broth). 1125 ear swabs from neonates were collected within
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1 hour of birth for enrichment culture. Data on risk factors and antibiotic
therapy collected prospectively.
Results:
1. Enriched culture gave an overall (vaginal and/or rectal) colonisation
rate of 21% compared to 10% with standard culture.
2. 32% of women studied had at least one risk factor, most commonly
prolonged rupture of membranes (49%).
3. 50% of women with any risk factor did not receive IAP (Table 1).
4. Only 21% of GBS carriers received IAP, whilst 67% of women who
received IAP were GBS-negative (Table 2).
5. The baby colonisation rate was 8% (90/1125). Positive vaginal culture
identiﬁed 78% of the positive babies; positive rectal culture 89% and
both rectal and vaginal positive culture combined 93%.
Table 1










1. The prevalence of GBS in labouring women was higher than in many
previous European studies.
2. Our data conﬁrms that the need for enrichment culture of vaginal and
rectal swabs for maximum diagnostic yield.
3. There was a large percentage of women with risk factors who did not
receive IAP, whilst only one third of women carrying GBS received
IAP.
4. Rectal culture performs better than vaginal, although ideally they
should be combined.
O268 An outbreak of pneumonia caused by S. pneumoniae at a
military training facility in Finland in 2006
A. Vainio, O. Lyytika¨inen, R. Skytta¨, T. Kaijalainen, A. Virolainen
(Helsinki, Oulu, FI)
Objectives: A cluster of pneumonia cases occurred among military
recruits following a one-week hard encampment in Eastern Finland in
the summer of 2006; several recruits were hospitalised and some had
positive blood cultures for S. pneumoniae. To assess the extent of the
outbreak and the carriage rate and microbiological characteristics of
S. pneumoniae, all recruits who had participated in the encampment
were screened for nasopharyngeal carriage of aerobic ﬂora.
Methods: Nasopharyngeal cultures were taken from all 43 recruits who
had participated in the military encampment and blood cultures were
taken from all hospitalised recruits. All S. pneumoniae isolates were
studied for antibiotic susceptibility, serotyped by latex agglutination
and/or counterimmunoelectrophoresis, CIEP, and genotyped by multi
locus sequence typing, MLST. Medical records of the hospitalised
recruits were reviewed and all recruits were interviewed regarding the
preceding symptoms, medical history, medication, and smoking habits.
Results: Of the 43 military recruits, ﬁve (12%) were hospitalised with
pneumonia and two (5%) of them were positive for S. pneumoniae
by blood culture. These two isolates were both of serotype 7F and
ST2331. Eighteen (42%) of the 43 men were detected positive for
S. pneumoniae by nasopharyngeal culture. All the 18 pneumococcal
isolates were susceptible to penicillin and other commonly used
antibiotics. Nine (50%) of the 18 isolates were of serotype 7F, ﬁve (28%)
were of serotype 9N, three (17%) were of serotype 23F, and one (6%)
was of serotype 16. MLST results corresponded with serotype results:
all 7F serotypes were of ST2331, the 9N serotypes were of ST525,
the 23F serotypes were of ST36, and the serotype 16 was of ST30.
Three of the 18 pneumococcal carriers had no preceding symptoms while
15 presented with fever, rhinitis or sore throat. None had any underlying
conditions known to be a risk factor for invasive pneumococcal disease.
Conclusions: Pneumococcal serotype 7F, ST2331, was clearly associated
with the outbreak of pneumonia and nasopharyngeal carriage in this
military encampment. Outbreaks of invasive pneumococcal disease can
occur in a crowded environment such as military training facility even
among previously healthy young men.
O269 Methicillin-resistant Staphylococcus aureus producing
Panton-Valentine leukocidin: a cause of acute osteomyelitis
in children
V. Chini, G. Sdougkos, D.A. Papanastasiou, G. Christodoulou,
D. Garantziotou, A. Vris, G. Dimitracopoulos, I. Spiliopoulou (Patras,
GR)
Objectives: Staphylococcus aureus remains the prevalent bacterium
causing acute osteomyelitis in children. The involvement of methicillin-
resistant S. aureus (MRSA) as a cause of acute childhood osteomyelitis
was investigated.
Methods: Included in the study were all children treated for acute
osteomyelitis due to S. aureus in Western Greece from January 2005 until
August 2006. Bone scan, MRI and X-rays were performed in order to
ascertain the diagnosis and to assess the severity of the disease. S. aureus
was isolated from blood and/or bone tissue when surgical drainage
was necessary. The Staphylococcal Cassette Chromosome (SCCmec)
type and Panton-Valentine leukocidin (PVL) genes (lukS-PV and lukF-
PV) were detected by PCRs. MRSA clones were deﬁned by PFGE
of SmaI DNA digests. Signs, symptoms and laboratory ﬁndings were
prospectively registered and statistically evaluated (Mann-Whitney-U
test) in all patients until cessation of activity of the disease.
Results: Nineteen patients, 12 males and 7 females, median age 11 years,
range 2−13 years, were diagnosed as having acute staphylococcal
osteomyelitis. Three children had a suspected site of bacterial entrance
(injury, burn, insect bite). S. aureus was isolated from the blood of nine
patients, from the tissue of nine more patients and from both clinical
specimens in one patient. In ﬁve children community-acquired MRSA
(CA-MRSA) carrying SCCmec type IV and PVL was identiﬁed. Among
the 14 MSSA isolated from the remaining patients, two were PVL-
positive. The maximal ESR and CRP values as well as the time necessary
for normalisation of ESR and CRP differed statistically signiﬁcantly in
patients with PVL positive stains (MRSA and MSSA) compared to PVL-
negative MSSA (p< 0.05). Surgical drainage was more often necessary
among patients with PVL-positive stains.
Conclusions: PVL-positive CA-MRSA are recovered not only from
patients with superﬁcial but also with invasive musculoskeletal
infections. The production of PVL seems to be the main factor that
contributes to the course of acute osteomyelitis.
O270 Methicillin-resistant Staphylococcus aureus clones producing
toxic shock syndrome toxin 1: ﬁrst case of intrafamily
transmission
C. Francois, X. Lemaire, L. Legout, E. Senneville, E. Beltrand,
M. Caillaux, G. Lina, J. Etienne, Y. Yazdanpanah (Tourcoing, Lyon, FR)
Background: in the past decade, new strains of MRSA have emerged in
the community, causing aggressive infections in young, otherwise healthy
people. Most of community MRSA (C-MRSA) isolates expressed
Panton-Valentine leukocidin (PVL), a highly potent toxin previously
implicated in theses types of infections. Recently, a new clone of
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C-MRSA producing toxic shock syndrome toxin 1 (tsst1) have been
isolated [Durand G et al., J Clin Microbiol 2006]. Here, we describe
the ﬁrst report of family transmission of C-MRSA PVL-, tsst1+, in a
patient (pt) with osteomyelitis.
Case report: In October 2006, a 29-year-old alcoholic man with no
medical history was admitted in our department of infectious diseases
for acromioclavicular osteoarthritis. He was married and had two
children (6 and 8 year-old). In 2005 he had a traumatic dislocation
of the right acromioclavicular joint and was operated one year later
for tendons refection using homogenic graft. Two weeks after surgery,
a purulent discharge from the post-operative wound was noted, and
MRSA was cultured from swabs. The strain was resistant to oxacillin,
kanamycin, tobramycin, and susceptible to oﬂoxacin, trimethoprim-
sulfamethoxazole, pristinamycin, clindamycin, vancomycin, and was
intermediate to fusidic acid. He was given oral pristinamycin (1 g tid
for 8 weeks). One week after the end of treatment, in October 2006,
he was admitted for a right acromioclavicular osteoarthritis which
required surgical debridement and intravenous vancomycin treatment.
A C-MRSA strain PVL− tsst1+ grew from intra-operative samples.
The family carriage screening (including the pt) showed that the
pt’s children were colonised with the same MRSA strain according to the
antibiotic susceptibility proﬁle (PVL and tsst 1 detection still in process).
The members of the pt’s family had no healthcare associated risk
factors for C-MRSA. Vancomycin was switched to oral trimethoprim-
sulfamethoxazole and rifampicin combination for 3 months.
Discussion: In 2002, a new type of MRSA producing tsst1 has been
described in France and Switzerland. To the best of our knowledge,
family transmission of C-MRSA PVL-, tsst1+ strain has never been
reported. In the present case report, a cross contamination between the
pt and his family is highly suspected.
Conclusion: the present case shows that C-MRSA PVL-, tsst 1 might
be associated with family transmission.
O271 Legionella spp. causing community-acquired pneumonia
in Germany. Data from the Competence Network for
Community-Acquired Pneumonia (CAPNETZ)
H. von Baum, R. Marre, S. Gonschior, T. Welte, C. Lu¨ck (Ulm,
Hannover, Dresden, DE)
Objectives: Prevalence, clinical data and outcome of Legionella
pneumonia (LP) in 2503 patients from ten clinical centres with
community acquired pneumonia (CAP), participating in the German
multicentre study of the Competence Network for Community Acquired
Pneumonia (CAPNETZ) were analysed.
Methods: All demographic, clinical and diagnostic data of the patients
were recorded using standardised web-based data sheets. Work up of
respiratory samples included identiﬁcation of bacterial microorganisms
as well as PCR for C. pneumoniae, M. pneumoniae, Legionella spp. and
viral pathogens. Urine was tested for the presence of S. pneumoniae
and L. pneumophila antigen. Relevant results from serologic tests were
considered.
Results: Legionella spp. was diagnosed in 105 (4.2%) patients and thus
represented after S. pneumoniae the second most frequent identiﬁed
pathogen causing pneumonia. Patients with LP were predominantly older
men, suffered more often from diabetes, were heavier smokers and
produced more often respiratory samples, which were less often purulent.
They received more often antibiotic substances with activity against
atypical bacteria. Although 85% of the patients had a CRB 65 score
of 0 or 1, respectively, 14 patients (13.3%) with LP expired.
Conclusion: Legionella spp. is a relevant pathogen causing CAP in
Germany and is associated with a serious clinical course.
O272 Pathogenic Yersinia enterocolitica widely distributed in
ﬁnishing pigs at slaughter in Switzerland
M. Fredriksson-Ahomaa, A. Stolle, R. Stephan (Oberschleissheim,
DE; Zurich, CH)
Objectives: Yersiniosis is a common human infection, which is a
reportable disease since 2001 in Germany. Y. enterocolitica 4/O:3 is
the third most frequently isolated pathogen from patients with enteric
disease after Campylobacter and Salmonella. The isolation rates of
Yersinia enterocolitica of bioserotype 4/O:3 in German pig tonsils
has shown to be high (56−67%). Only very few data are available
for Switzerland. This work was conducted to study the prevalence
of pathogenic Y. enterocolitica in Swiss pig tonsils. Furthermore, the
isolates were characterised by pheno- and genotypic methods to get more
epidemiological information to the current situation
Methods: Tonsils of 212 ﬁnishing pigs were sampled from a
slaughterhouse in Switzerland during February and March 2006.
Seventeen to 35 samples were collected from at least two different
herds at 8 different days. The culture method included direct plating
on a selective CIN plate, overnight enrichment in non-selective CASO
bouillon and selective enrichment in ITC bouillon. The Y. enterocolitica
isolates were bio- and serotyped. The pathogenicity was conﬁrmed with
pheno-and genotypic methods. ail-Positive Y. enterocolitica was detected
with real-time PCR after overnight enrichment in CASO. At least one
isolate per sample was characterised with PFGE using NotI enzyme.
Results: The prevalence of ail-positive Y. enterocolitica was 84% with
PCR. The prevalence varied from 61% to 100% between the sampling
days. The isolation rate was only 34% and varied between 18% and 82%.
Bioserotype 4/O:3 was found in 96% of the culture-positive tonsils. Only
10% of the samples were biotype 2/O:9 positive. Six genotypes were
obtained among bioserotype 4/O:3 isolates and 3 among bioserotype
2/O:9 isolates. Two genotypes (GT 1 and 2) of bioserotype 4/O:3 were
dominant. Genotypes 1 and 2 were found on 6 and 5 out of 8 sampling
days, respectively.
Conclusions: The prevalence of pathogenic Y. enterocolitica in Swiss
pigs was high using PCR, however, the isolation rate was clearly lower
than in German pigs. Most of the Swiss pigs were infected with
bioserotype 4/O:3, which is the most common type found among human
Y. enterolitica gastroenteritis in German and Switzerland and is the only
type isolated from German slaughter pigs. Pig was also shown to be a
reservoir for bioserotype 2/O:9 in Switzerland. The genetic diversity of
ail-positive Y. enterocolitica in the pig tonsils collected from one Swiss
slaughterhouse was limited.
O273 Risk factors, including antibiotic use, at hospital level for
outbreaks with Clostridium difﬁcile PCR ribotype 027
T. van der Kooi, M. Koningstein, D.W. Notermans, E.J. Kuijper,
P.M.G. Filius, A. Lindemans, S. van den Hof (Bilthoven, Leiden,
Rotterdam, NL)
Objectives: After reports on outbreaks of severe Clostridium difﬁcile-
associated disease (CDAD) in Canada, the USA and the UK, epidemics
of this strain (PCR ribotype 027, toxinotype III) were ﬁrst reported in
The Netherlands in June 2005. National surveillance and typing of strains
was started. Fluoroquinolone use has been recognized in several studies
as an important risk factor at patient level for CDAD due to type 027.
This study aimed at identifying risk factors at hospital level for outbreaks
with type 027.
Methods: Data from 7 hospitals with known transmission of type 027
(group A), 5 hospitals with sporadic cases (group B) and 12 hospitals
from a random selection without known type 027 (group C) were
included. Quarterly data for 2004–2005 were collected on CDAD-
incidence, inpatient antibiotic use (penicillins with extended spec-
trum and with b-lactamase inhibitors, cephalosporins, carbapenems,
macrolides, clindamycin and ﬂuoroquinolones) and hygienic and other
preventive measures. The ﬁrst 6 quarters were deemed the ‘pre-epidemic’
phase. In the last 2 quarters of 2005, the ‘epidemic’ phase, almost all
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027 outbreaks took place. The association of AB use and hygiene policy
with the incidence was analysed with multilevel linear regression.
Results: Mean pre-epidemic incidence in affected hospitals was 3.6 per
10,000 patient days, in group B 3.2 and in group C 2.3. During the
epidemic phase this was 5.4, 3.3 and 2.8, respectively.
Pre-epidemically the unaffected hospitals had a signiﬁcantly higher
total use of the investigated AB [3776 DDD/10,000 patient days (pd)]
than the A and B hospitals (3291 and 3325). In the epidemic phase,
group A hospitals had signiﬁcantly reduced their use of ﬂuoroquinolones
(from 615 to 416) whereas this rose in group C from 791 to 994
DDD/10,000 pd.
In multivariate analysis giving special instructions to visitors of diarrhoea
patients (regression coefﬁcient [r.c.] −1.9), wearing an apron when caring
for diarrhoea patients (r.c. −2.7) and being an academic hospital (r.c. 1.6)
were signiﬁcantly associated with the CDAD incidence.
Conclusion: Hospital-wide use of most antibiotics known to be a
risk factor for CDAD at patient level, such as ﬂuoroquinolones, are
not associated at institution level with higher incidences of type 027-
associated CDAD. Possibly, investigation at ward-level might correlate
better. Wearing an apron and giving special instructions to visitors in
case of diarrhoea appeared to be protective.
O274 Amoebae as a second host for Vibrio cholerae
G. Sandstro¨m, A. Saeed, B. Edvinsson, A. Weintraub, H. Abd
(Stockholm, SE)
Objectives: Acanthamoebae have been reported to represent the
environmental host of several human pathogens. Vibrio cholerae requires
108 to 109 cells to cause cholera, and accordingly it needs an
environmental host to enhance its growth. Our studies have shown that
extracellular V. cholerae O1 and O139 have grown and survived in
Acanthamoeba castellanii. The aim of this study is to examine the ability
of A. castellanii to protect V. cholerae and to enhance its growth to be
able to infect humans.
Methods: V. cholerae producing green ﬂuorescent protein was co-
cultivated with A. castellanii. An antibiotic assay used to examine ability
of amoeba to protect intracellular bacteria and to differentiate between
extracellular and intracellular bacteria.
A. castellanii cultivated with V. cholerae for one week. After
gentamicin killing and washing of extracellular V. cholerae, the
number of intracellular bacteria was found to be 2×105 cells/mL. The
amoebae harbouring V. cholerae were re-cultivated and growth of the
microorganisms examined by viable counts during 2 weeks.
Results: Gentamicin killed only the extracellular bacteria, while
ciproﬂoxacin killed both, thus, the amoeba protected the intracellular
V. cholerae from gentamicin. The antibiotic assay differentiated between
extracellular bacteria that killed by gentamicin and intracellular bacteria
that killed only by ciproﬂoxacin, which could diffuse into amoeba cells.
Re-cultivation of A. castellanii harbouring intracellular V. cholerae
resulted in enhanced growth of V. cholerae to 2×1011 CFU/mL and
the bacteria survived for more than two weeks. Thus, amoeba acted
as a biological incubator in which intracellular growth of the bacteria
occurred to increase their number a million fold and maintained their
overall viability. Existence of V. cholerae extracellularly as well as
intracellularly in culture medium conﬁrmed its facultative intracellular
behaviour, which enhanced its growth and survival.
Conclusions: The utilised antibiotic assay differentiates between
extracellular and intracellular bacteria. Free-living amoeba is a possible
biological factor, which protects and enhances growth of V. cholerae to
exceed its infections dose and to supports the idea of amoeba as a second
host to the bacterium in nature besides man.
O275 Microbiology of thrombotic microangiopathies in Scotland,
2003–2006
K. Pollock, M. Locking, J. Cowden (Glasgow, UK)
Without current surveillance of thrombotic microangiopathies such as
HUS, neither prevalence nor outcomes are established in either adults
or children. This study seeks to identify both health outcomes and
existing management strategies. It comprises clinically driven enhanced
surveillance of HUS and TTP and also further investigates the links
between these syndromes and factors, which have been implicated in
the etiology of HUS and TTP including infections, vascular procedures,
chemotherapeutic agents and immuno-suppressants.
Cases were ascertained prospectively by active, national surveillance
during 2003 to 2006. Consultants in haematology, infectious diseases,
microbiology, nephrology, paediatrics and public health medicine, were
sent a monthly e-mail with case deﬁnition and asked to indicate
whether they had a ‘case to report’ or ‘nil return’. Questionnaires,
information sheets and consent forms were then sent to the relevant
clinicians/consultants by post. All completed forms and questionnaires
were returned to HPS and entered into a database for statistical analyses.
From 2003 to October 2006, 145 reports of thrombotic microangiopathy
were notiﬁed to HPS of which 103 were clinically designated HUS and
42 as TTP. There were 10 fatalities, 22 cases had some form of renal
impairment and of those, 14 became dialysis dependent. Of 103 reports
of HUS, 85 (83%) were caused by verotoxin-producing E. coli (VTEC)
(82 were due to serotype O157). The non-O157 organisms were
designated as serotypes O145, O177 and O-unidentiﬁable. Two atypical
HUS cases were reported. One was preceded by parvovirus B19
infection/MMR immunisation and the other was due to infection with
Streptococcus pneumoniae. The list of predisposing infections for
development of TTP was more varied and included infection with
coagulase-negative Staphylococcus aureus, Klebsiella pneumoniae and
Clostridium difﬁcile but development of TTP was signiﬁcantly associated
with severe sepsis. The study clearly demonstrates that development
of HUS or TTP has serious and sometimes fatal consequences and
that infection is a major predisposing factor in development of such
syndromes.
The medico-dental health interface –
Paradigm shifts and advances in oral health
for populations (Symposium organised by
Colgate-Palmolive)
S279 Relationship between periodontal infections and systemic
disease – the oral systemic connection
G.J. Seymour (Dunedin, NZ)
Common oral conditions, such as gingivitis and chronic periodontitis, are
found world-wide and are among the most widely prevalent microbial
diseases of mankind. A primary trigger for these conditions is the
complex microbiota found as dental plaque, a complex microbial bioﬁlm.
Despite 3000 years of history demonstrating the inﬂuence of oral status
on general health, recent decades have seen an accelerated effort for
the prevention and management of these conditions through ground-
breaking advances. One outcome of these advances is the realisation
that periodontal diseases are associated with systemic conditions such
as coronary heart disease and stroke; higher risk for preterm, low birth
weight babies and pose threats to those with chronic disease: diabetes,
respiratory diseases and osteoporosis. This presentation will highlight
recent research associating periodontal disease with systemic diseases.
The relationship between oral infections and systemic disease represents
a paradigm shift in current research.
A portion of this lecture will be devoted to examining the role of chronic
infections and their association with cardiovascular diseases (CVD).
These infections include Helicobacter pylori, Chlamydophila pneumo-
niae, Cytomegalovirus (CMV), and, more recently, periodontopathic
bacteria including Porphyromonas gingivalis. Although a number of
potential mechanisms have been postulated, the mechanism by which
these infections are associated with CVD is still unclear. The various
hypotheses concerning this relationship include common susceptibility,
inﬂammation via increased circulating cytokines and inﬂammatory
mediators, direct infection of the blood vessels and ﬁnally the possibility
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of cross-reactivity or molecular mimicry between bacterial and self
antigens. The evidence for each of these mechanisms will be presented
and the clinical implications for medical and dental practitioners
discussed. This introductory lecture will set the stage for subsequent
speakers highlighting the medico-dental interface as a required shift in
health practices for the future.
S280 The importance of dentistry and medicine collaboration for
the improvement of oral and general health
C. Migliorati (Fort Lauderdale, US)
While both medicine and dentistry are healthcare professions devoted to
patient care, the interaction between the two disciplines remains limited.
It is rare for dental professionals to be integral members of medical
teams or hospital/healthcare settings. While referrals between the two
professions occur, improved communications between professionals are
required to optimise treatment options. This is increasingly required to
capitalise on recent advances in health sciences for the management of
chronic diseases that have reduced morbidity. Improvements in longevity
have resulted in unique populations with special oral care needs and
include those with cancer of the head and neck, immunocompromised,
HIV/AIDS, geriatrics, residents of long-term care facilities, patients with
lifelong conditions, after organ transplantation and those on prescription
medications like those for blood-pressure control or anticoagulation
therapy. This session will highlight the unique oral care needs for our
changing patient population, and how oral health can be improved when
dentists and physicians work together.
The role of prescription medications to treat medical conditions and their
adverse reactions in the oral cavity will form a separate another area for
discussion. Many medications, for instance, are xerostomic. Patients with
xerostomia are at increased risk for tooth decay and periodontal disease.
The need for increased collaboration between dentists and physicians to
prevent or reduce complications by maintaining better oral and medical
health will form a core theme for this session. It cannot be any longer
ignored that oral health and medical health professionals must unite for
optimal management of patient health.
S281 Common therapeutic approaches for the control of oral
bioﬁlms: microbiological safety and efﬁcacy
P. Gilbert (Manchester, UK)
A primary step to improve oral health is the routine control of dental
plaque, a natural bioﬁlm. Oral hygiene formulations with signiﬁcant
effects on the dental bioﬁlm augment ineffective practices of routine
prophylaxis. Chlorhexidine and triclosan formulated in oral hygiene
formulations have an extensive history of clinically proven efﬁcacy and
safety. An overview of clinically effective oral hygiene formulations
and their role as therapeutic strategies will commence this presentation.
With triclosan serving as a case-study, the talk will bring together recent
advances in the assessment of oral bioﬁlms, analyses of clinical strains
including susceptibility to demonstrate the microbiological safety and
efﬁcacy of oral hygiene formulations.
The past three decades have witnessed no general reduction in the
effectiveness of triclosan for its target bacteria including periodontal
bacteria. Whilst triclosan is not noted for its activity against enteric
bacteria and pseudomonads, laboratory studies demonstrated that chronic
sub-lethal exposure of Escherichia coli can select mutant clones with
signiﬁcantly reduced susceptibility. These mutants are either mutated
in an enzyme (FabI) associated with fatty-acid biosynthesis or over-
express multi-drug efﬂux pumps. Initial concern that mutations in FabI
might be capable of horizontal transfer between environmental bacteria
and noscomial pathogens or that parallel processes might occur directly
in Gram-positive pathogens have subsided. Similarly, concern about
possible selection of resistance towards third-party agents (antibiotics)
that might share the FabI gene target has proven unfounded. Selection of
efﬂux-on mutants, whilst demonstrated in the laboratory is not supported
by analyses of isolates from the hospital or domestic environment where
agents such as triclosan have been widely deployed. Evidence suggests
that efﬂux-on mutants are unable to compete in natural microbial
communities.
Whilst there is insufﬁcient evidence to suggest that the uncontrolled use
of triclosan in domestic products is totally free of risk, its deployment
for oral hygiene, especially where such use might limit the number
of refractory infections and their possible complications contributes
ultimately to a reduction in antibiotic use is encouraged.
Collectively, there is no evidence that the long-term application of
triclosan formulations to the oral cavity or skin selects for triclosan-
resistant bacterial populations.
S282 Clinical efﬁcacy of triclosan/copolymer and other common
therapeutic approaches
R. Davies (Manchester, UK)
As the increasing elderly population retain more of their natural teeth
into later life periodontal disease will pose an increasing problem both
for the dentition and potentially general health. The maintenance of an
effective level of oral hygiene is the cornerstone of all attempts to prevent
and control periodontal diseases and yet the widespread prevalence of
these diseases indicates the inability of most people to achieve a level of
plaque control commensurate with periodontal health. The inclusion of
antibacterial agents, such as chlorhexidine and triclosan/copolymer, into
oral care products has provided the consumer with the means to improve
their oral health. Randomised controlled clinical trials have demonstrated
that a dentifrice containing triclosan/copolymer signiﬁcantly improves
gingival health, prevents the onset of periodontitis and furthermore
reduces the progression of the disease. These beneﬁts were initially
attributed to the antibacterial action of triclosan but evidence now
suggests that it is also an anti-inﬂammatory agent. The delivery of such
beneﬁts is considerable with implications for the maintenance of oral
and general health and the costs of dental care.
Current trends in treating continuously
evolving Gram-negative infections
(Symposium organised by Janssen Cilag)
S286 Treatments for serious Gram-negative infections
J. Rello (Tarragona, ES)
The emergence of multidrug resistance (MDR) in pathogens such as
Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobac-
teriaceae that produce extended-spectrum beta-lactamases (ESBLs) is
alarming. Increasing MDR in patients treated for nosocomial infections
is causing an increase in costs, morbidity, and mortality. Traditionally,
a narrow-spectrum drug was used ﬁrst, and the most potent drugs were
reserved for subsequent use. Unfortunately, the traditional approach
increases the chance of treatment failure and the emergence of multidrug-
resistant strains. In fact, the inappropriate choice of antibiotics is the most
important independent risk factor for death.
ESBL producers are resistant to most penicillins and cephalosporins
and are often cross-resistant to aminoglycosides and ﬂuoroquinolones
as well. Carbapenems have been shown to provide superior outcomes
compared with other agents for infections caused by ESBL producers.
Consequently, the ﬁrst-line use of carbapenems is optimal for serious
infections in which ESBL pathogens are suspected.
The major non-fermentative Gram-negative pathogen of concern is
P. aeruginosa. P. aeruginosa is a common cause of nosocomial infections
and the leading cause of ventilator-associated pneumonia. Initial therapy
should include an antipseudomonal b-lactam, such as piperacillin-
tazobactam, an antipseudomonal carbapenem, or an antipseudomonal
cephalosporin, plus an aminoglycoside or a ﬂuoroquinolone. A. bauman-
nii generally is susceptible to carbapenems, aminoglycosides, sulbactam,
colistin, or tigecycline. Carbapenems are one of the few classes that
remain an excellent choice for both nonfermenters. Doripenem is a
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new broad-spectrum carbapenem with activity superior to that of other
carbapenems against P. aeruginosa and similar to other carbapenems
against A. baumannii.
As antibiotic resistance increases, empiric therapy for severe infections
should be based on local pathogen etiology and resistance patterns. A
new approach is to start with a high-dose, broad-spectrum antibiotic
and then tailor the individual therapy based on microbiological results.
Carbapenems are likely to remain an important option for serious Gram-
negative infections for the foreseeable future. Since the number of new
intravenous agents with activity against Gram-negative organisms is
extremely limited, the development of a new carbapenem may help
to reduce the mortality, morbidity, and cost of serious nosocomial
infections.
S287 Should all carbapenems be viewed the same?
D. Livermore (London, UK)
The widely marketed carbapenems long comprised imipenem (launched
1985) and meropenem (1996), but the family is now growing, with
ertapenem (2002), doripenem (anticipated 2007/2008), and CS-023 (in
development). Use is also growing, driven by the spread of extended-
spectrum b-lactamases (ESBLs).
The carbapenems have much in common with each other, with broader
activity and better stability to ESBLs and AmpC enzymes than other
b-lactams, but with lability to metallo- and KPC b-lactamases and to
the OXA carbapenemases of Acinetobacter clones. Three carbapenem
groups nevertheless can be deﬁned.
Group 1 agents lack activity versus non-fermenters; they are represented
by ertapenem and perhaps in the future also by oral analogues. Er-
tapenem’s utility lies in the treatment of community-acquired infections,
where ESBL producers are likely or proven; it has convenient, once-
daily, dosing but is the most vulnerable carbapenem to combinations of
ESBL or AmpC plus impermeability.
Group 2 comprises imipenem, meropenem, and doripenem, plus
analogues available only in East Asia; they are active versus most
non-fermenters and are appropriate in nosocomial settings where these
pathogens are likely. Doripenem and meropenem are very similar,
but with doripenem circa two-fold more active versus most species;
imipenem is slightly less active against Gram-negative bacteria except
Acinetobacter but is the sole carbapenem active versus Enterococcus
faecalis. Doripenem and meropenem need two mutations – loss
of OprD and up-regulated efﬂux – for resistance in Pseudomonas
aeruginosa. Imipenem resistance arises by loss of OprD alone and can
be selected in therapy; nevertheless, imipenem is unique in evading
pseudomonal efﬂux. Meropenem and doripenem are relatively stable to
renal dehydropeptidase, but imipenem needs protection with cilastatin;
doripenem and meropenem are chemically stable, allowing prolonged
infusion, whereas imipenem is not; doripenem and meropenem have
little seizure potential (meropenem is licensed for meningitis), but CNS
side-effects limit imipenem dosage.
Group 3, comprising analogues active versus MRSA, is represented by
the developmental agent CS-023; its minimum inhibitory concentrations
for MRSA are more widely distributed than those of anti-MRSA
cephalosporins, but it has the wider spectrum typical of a carbapenem.
As carbapenem usage expands, it is critical to understand these
differences, so that the most appropriate analogues can be selected.
S288 Optimising utility of the carbapenem class
A. MacGowan (Bristol, UK)
Increasing antibiotic resistance and a lack of new drug classes in
development are driving the need to optimise use of currently available
drugs. The goal of antimicrobial chemotherapy is to optimise the
combined pharmacokinetic (PK) and pharmacodynamic (PD) proﬁle of
a drug so that the greatest percentage of patients achieves the PD target
associated with a favourable outcome, while minimising the development
of resistant organisms. Integration of population PK, a PD target, and
microbiologic surveillance data by Monte Carlo simulations can generate
an empirical dosing strategy that maximises the likelihood that an
antibiotic regimen achieves the desired PD end point (exposure target).
For b-lactams, the exposure target is the percentage of time that free drug
levels are above the minimum inhibitory concentration (T>MIC). For
carbapenems, the T>MIC requirement is lower than for other b-lactams.
By extending the infusion period to achieve the necessary T>MIC,
a lower dose can achieve the same efﬁcacy as a higher dose, while
lowering cost and potential toxicity. For example, a recent publication
showed that a 1-g 0.5-h infusion of meropenem has a 77.1% rate of target
attainment against Pseudomonas aeruginosa isolated from hospitals in
Hungary, whereas a 3-h infusion of 0.5 g meropenem would have an
83.8% rate of target attainment. In a retrospective study that compared
0.5 h piperacillin/tazobactam infusions (3.375 g, q6h) with 4-h infusions
(3.375 g, q8h) in patients infected with P. aeruginosa, the 4-h infusions
reduced 14-day mortality from 31.6% to 12.2% (P = 0.02) and median
length of stay from 38 to 21 days in patients with APACHE II scores
17 (P = 0.02).
Doripenem is more stable upon reconstitution than other carbapenems,
potentially making it more convenient and easier to use as an extended
infusion. Furthermore, the study design for the doripenem ventilator-
associated pneumonia phase 3 trial includes an extended infusion
regimen (0.5 g over 4 h).
In conclusion, the same dose of an antibiotic has the capacity to increase
efﬁcacy for more resistant infections if infused over an extended period.
Extended infusion of a lower dose of antibiotic may produce efﬁcacy
equivalent to shorter, higher-dose infusions while reducing both toxicity
and the emergence of resistance. Extended infusion of a carbapenem,
such as doripenem, that has neither seizure potential nor high resistance
selection is a particularly promising strategy for serious infections.
S289 Doripenem: a new, potent, broad-spectrum treatment for
serious Gram-negative infections
K. Naber (Munich, DE)
Doripenem is an investigational carbapenem that has completed
phase 3 multi-national trials for complicated urinary tract infections
(cUTIs), complicated intra-abdominal infections (cIAIs), hospital-
acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).
Doripenem’s advantages over other carbapenems include: enhanced
activity against Pseudomonas aeruginosa (with a low propensity for
resistance), the lowest potential for seizures in the carbapenem class,
and the greatest stability after reconstitution.
Two randomised, double-blind phase 3 cIAI trials compared intra-
venous (IV) doripenem (500mg q8h) with IV meropenem (500mg
q8h), with an option to switch to amoxicillin/clavulanate for both
treatment arms after 9 doses of IV study drug therapy. Results
from the cIAI trials showed that doripenem (500mg q8h) is well-
tolerated and non-inferior to meropenem (1 g q8h). Doripenem was
microbiologically effective against major causative organisms of cIAIs,
including Enterobacteriaceae and Bacteroides spp. Adverse events (AEs)
occurring in 3% of subjects in either treatment arm were nausea and
vomiting. No seizures were reported.
A randomised, double-blind phase 3 cUTI trial compared IV doripenem
(500mg q8h) with IV levoﬂoxacin (250mg q24h), with an option to
switch to oral levoﬂoxacin for both treatment arms. Results from this trial
showed that doripenem is well-tolerated and non-inferior to levoﬂoxacin.
Doripenem was effective against major causative organisms of cUTIs,
including Escherichia coli, Proteus mirabilis and Klebsiella pneumoniae.
Doripenem had greater efﬁcacy in patients who remained on intravenous
therapy and in patients with levoﬂoxacin-resistant E. coli. Fewer
pathogens had a 4-fold increase in minimum inhibitory concentration
during therapy with doripenem than with levoﬂoxacin. AEs occurring in
3% of subjects in either treatment arm were headache, diarrhoea, and
phlebitis. No serious study drug-related AEs were reported. Urine from
patients was obtained and evaluated to assess urine bactericidal titers.
Serum and urine drug concentration data collected in Phase 1, 2, and 3
studies will also be discussed.
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Doripenem also completed a phase 3 trial versus piperacillin/tazobactam
for HAP (including early-onset VAP), and a phase 3 trial versus
imipenem for VAP (early and late onset). Doripenem’s superior stability
allowed the VAP trial to utilise an extended infusion (4-h) regimen for
doripenem that may maximise for these difﬁcult infections.
Keynote lectures
K290 Immune reactions to Mycobacterium tuberculosis –
implications for new vaccines
S. Kaufmann (Berlin, DE)
Tuberculosis is a major health threat with 9 million new cases and 2
million deaths annually. The available vaccine, BCG, protects newborns
from miliary tuberculosis, but fails to prevent the most prevalent
form of disease, pulmonary tuberculosis in adults. One third of the
world population is infected with the etiologic agent, Mycobacterium
tuberculosis. Hence: (i) M. tuberculosis can be controlled (though
not eradicated) by the immune response induced by natural infection;
(ii) BCG fails to induce a protective immune response at least in those
individuals who are susceptible to tuberculosis.
Current vaccination strategies have to consider both pre-exposure and
post-exposure vaccines. Acquired immunity against tuberculosis is a
T cell-dependent phenomenon. The T cell system comprises distinct
populations. CD4 T cells are undoubtedly of central importance for
acquired resistance against tuberculosis. Antigens of M. tuberculosis
also stimulate CD8 T cells, probably through crosspriming. In addition,
unconventional T cells also seem to participate in immunity against
tuberculosis. What can we learn for rational vaccine design? Novel
vaccination strategies either focus on subunit vaccines or viable
attenuated vaccines. Subunit vaccination strategies are based on the
assumption that one or few antigens sufﬁce for an efﬁcient immune
response. Hence, the identiﬁcation of protective antigens represents
an essential prerequisite for the success of this type of vaccines.
Subunit vaccines come in three forms: Protein/adjuvant formulations,
recombinant heterologous carriers or naked DNA constructs. Viable
attenuated vaccines are based on the assumption that multiple antigens
are required for efﬁcacious protection. Two major strategies are
being pursued: Knockout mutants of M. tuberculosis and improved
recombinant (r)-BCG vaccines. Improved r-BCG should ﬁrst be endowed
with a higher immunogenicity and second may need a broader antigenic
repertoire. Rational vaccination strategies performed in the laboratory
of the author focus on improved BCG. A r-BCG strain which expresses
listeriolysin induces better protection than wild-type BCG. It is tempting
to speculate that a prime/boost scheme comprising prime with improved
r-BCG and boost with the most efﬁcacious subunit vaccine candidate
will provide optimal protection. Identiﬁcation of a biosignature that
allows distinction between infection/protection and infection/disease in
tuberculosis could speed up efﬁcacy testing of vaccines in clinical trials.
The Grand Challenge 6 of the Bill & Melinda Gates Foundation aims at
identifying such biosignatures.
Taking advantage of our increasing knowledge about the immune
response to M. tuberculosis will facilitate rational design of novel
vaccines against one of the most frightening threats in the world,
tuberculosis. The following years will witness the transformation of
vaccine candidates from preclinical to clinical trials requiring intensive
coordination in order to identify the most appropriate candidate(s).
Recommended reading:
– Kaufmann SHE. Nat. Rev. Immunol. 6: 699–704 (2006).
– Kaufmann SHE. Trends Immunol. 26: 660–667 (2005).
– Kaufmann SHE, McMichael A. Nat. Med. 11: S33-S44 (2005).
– Baumann S, et al. Curr. Opin. Immunol. 18: 438–448 (2006).
K291 Clinical implications of PK/PD
J. Mouton (Nijmegen, NL)
One of the most important characteristics that separate antimicrobials
from other drugs used in clinical medicine is that their target (the
receptor of the drug) is part of the microbe, and not of men. The
activity of the antimicrobial can therefore be studied both in vitro and
in model systems, such as animal models, and a relationship between
exposure and effect established. The exposure is primarily determined
by the pharmacokinetic characteristics of the drug, while the effect is
determined by the concentration–effect relationship of the antimicrobial
and the micro-organism. However, in most clinical settings, it is the
potency of the antimicrobial that is measured in terms of the MIC and
not the concentration–effect relationship itself. Therefore, a relationship
needs to be ascertained between the MIC, exposure of the drug and
effect. Over the last decade, these pharmacokinetic/pharmacodynamic
(PK/PD) relationships of antimicrobials have been established for most
classes of drugs. The two major indices describing these relationships are
the time the concentration of the antimicrobial remains above the MIC
(T >MIC) as a fraction of the dosing interval and the Area under the
Time Concentration curve over 24 hours divided by the MIC (AUC/MIC
ratio). The Peak/MIC ratio correlates with effect for a number of drugs,
but it in many, if not all, cases the effect can not be clearly distinguished
from the AUC/MIC effect. Importantly, for virtually all antimicrobials,
it is the exposure of the free non-protein bound fraction of the drug
that best correlates with efﬁcacy, and is of particular signiﬁcance when
drugs are compared with each other within a class and/or across species,
including men.
From these PK/PD relationships, a number of issues have come forward.
Importantly, it has been shown in a number of clinical trials – now
exceeding 10 – including several classes of drugs, that the PK/PD
relationships that do exist in animals are, as expected, similar to those
in men. Moreover, it has been shown that the quantitative relationships
are remarkably similar. In other words, exposures in infected animals
result in the same effect as exposures in infected humans under
similar conditions. A second, perhaps even more important topic is
that these relationships – once well established – can be used to
optimise therapy in patients by optimising exposure of the drug. In a
relatively simple approach, these relationships are used in daily clinical
practice in the use of clinical breakpoints. These MIC values are
used to discriminate between high and low probabilities of successful
outcome of treatment (S and R, respectively) based on the PK/PD
relationships of the antimicrobial together with the clinical setting.
For instance, lower exposures to obtain the same effect are needed in
the immunocompetent host because of the contribution of the immune
system. More sophisticated, these relationships are used to adjust dosing
regimens once the MICs of the infectious micro-organisms are known,
and thus provide an integrated approach to the individual patient.
Finally, PK/PD relationships are used in the development phase of
the drug in determining the optimal dose for the indication sought.
Alternatively, once dosing regimens are established, they can be used to
form an opinion on the possible indications for various clinical treatment
modalities.
Dissemination and reversal of antibiotic
resistance
S293 Dissemination of resistance unrelated to antimicrobial
consumption
G.M. Rossolini (Siena, IT)
Dissemination of microbial drug resistance observed in the antibiotic
era is clearly related to the selective pressure generated by the use of
antibiotics in clinical, veterinary and agricultural practices. This notion
is universally acknowledged and supported by the several studies that
have correlated the emergence and dissemination of resistance with the
use of new antibiotics, and by documentation of the absence of acquired
resistance in clinical isolates from the pre-antibiotic era.
However, the presence of antibiotic-resistant bacteria has recently been
reported also in humans and in wild animals living in remote areas where
antibiotic exposure has been absent or minimal [1−3]. This unexpected
ﬁnding raises a question on the mechanisms responsible for spreading
and maintenance of antibiotic resistance in similar settings, and could
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have important implications for the design of strategies addressed at
controlling bacterial resistance based on antibiotic restriction policies.
Results of studies on antibiotic resistance in settings of minimal
antibiotic exposure (including investigations recently carried out in very
remote human communities living in the Bolivian Chaco and in the
Alto Amazonas jungle of South America, and among wild reptiles
(land iguanas) from a remote and protected island of the Gala´pagos
archipelago with no documented sources of antibiotic exposure and
minimum human contacts) will be critically reviewed in this presentation,
and the mechanisms potentially involved in the dissemination of resistant
strains and resistance genes unrelated to antimicrobial consumption
will be discussed. Results from the characterisation of resistance
determinants carried by bacterial isolates from these settings pointed
to their likely origin from antibiotic-exposed areas rather than to
a local and independent resistance selection process. However, the
mechanisms responsible for this ﬂow of resistance genes and for their
maintenance and spread in absence of sustained antibiotic use remain
elusive.
Reference(s)
[1] Gilliver M et al. Antibiotic resistance found in wild rodents. Nature
1999; 401: 233-4.
[2] Bartoloni A et al. High prevalence of acquired antimicrobial
resistance unrelated to heavy antimicrobial consumption. J Infect
Dis 2004; 189: 1291-94.
[3] Grenet K et al. Antibacterial resistance, Wayampis Ameridians,
French Guyana. Emerg Infect Dis 2004; 10: 1150-3.
P. aeruginosa pathogenesis and
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O295 Alveolar macrophage phagocytosis and respiratory burst
activity is regulated by Lyn–PI3Kinase–Akt pathway
S. Kannan, A. Audet, H. Huang, M. Wu (Grand Forks, US)
Introduction: Alveolar macrophages (AM) form the ﬁrst line of defence
in the lung alveoli. Pseudomonas aeruginosa (PA) is a common hospital-
acquired infectious agent that can cause life-threatening infections in
susceptible individuals. We hypothesise AM to have important function
in early stages of PA infection.
Rationale: Recently, we have shown that Lyn tyrosine kinase is critically
involved in alveolar epithelial cell invasion with PA through lipid raft
mechanism. Lyn is known to be involved in mast cell motility and
generation of superoxide free radicals in neutrophils. Thus we propose
a role for Lyn in AM function during PA infection.
Methods: Akt activity was detected by immunoblotting with phospho
Akt (Ser 473) antibody and by in vitro kinase assay. Lyn, PI3Kinase
and Akt protein interactions were analysed by co-immunoprecipitation
and Lyn-GST pull down assays. Phagosome formation and localisation
of signaling proteins were studied by immunostaining with ﬂuorescent
antibodies followed by confocal microscopy. Lyn-YFP and PH-Akt-
GFP co-transfected MHS cells were used for studying spatio-temporal
association of Lyn and Akt during PA phagocytosis by live cell confocal
microscopy. Phagosomes from infected cells were isolated by sucrose
density gradient centrifugation for biochemical characterisation.
Results: PA-infection induced Akt activity in MHS cells depends
on Lyn function. Lyn, PI3Kinase and Akt were actively recruited to
phagosome fractions in PA-infected cells. Both Lyn-YFP and PH-Akt-
GFP were found to colocalise in the lamellipodium and phagocytic cup
of PA-infected MHS cells from live cell imaging studies. GST pull down
assay conﬁrmed Lyn–Akt interaction. Respiratory burst activity depends
on Lyn function.
Conclusions: Our data indicates that Lyn–PI3Kinase–Akt pathway is
crucial for regulating phagocytosis and respiratory burst activity of AM.
Figure 1. Co-immunoprecipitation analysis shows that Lyn interacts
with PI3Kinase (B) and Akt (A) upon PAO1 infection of MHS cells.
This interaction is signiﬁcantly affected by pretreatment with PP2 (Lyn
inhibition) or LY2094002 (PI3Kinase inhibitor) (B,C). (D) Lyn dominant
negative transfection decreases Lyn and Akt association. GSK3b is a
downstream effector of Akt.
O296 EF-Tu, a novel phosphorylcholine-containing protein
involved in the interaction of chronic infectious Pseudomonas
aeruginosa isolates with the airway epithelial cells
M. Barbier, L. Garcı´a, A. Oliver, J.B. Goldberg, S. Albertı´ (Palma
de Mallorca, ES; Charlottesville, US)
Pseudomonas aeruginosa PAO1 grown at 22ºC expresses a 43-kDa
protein that contains a phosphorylcholine (ChoP) epitope. In other
respiratory pathogens, like Streptococcus pneumoniae and Haemophilus
inﬂuenzae, this motif interacts with the airway epithelial cells via Platelet
Activating Factor Receptor (PAFr).
Objective: The objective of this study was to identify the 43-kDa
ChoP containing protein and characterise its function in the virulence of
P. aeruginosa.
Methods: To identify the ChoP containing protein, bacterial cell
fractions were separated by FPLC. Fractions were analysed by Western
blot using speciﬁc monoclonal anti-ChoP antibodies and those that
contained the ChoP epitope were further puriﬁed by SDS-PAGE. A
43-kDa protein containing the ChoP epitope was cut out of the gel,
trypsinised, and subjected to capillary LC-MS and MS/MS.
ChoP epitope expression of whole cell extracts of 92 genetic unrelated
P. aeruginosa isolates (46 from chronic infections and 46 from
acute infections) was analysed by Western blot analysis using speciﬁc
monoclonal anti-ChoP antibody. ChoP epitope expression was also
analysed by ﬂow cytometry and immunoﬂuorescent microscopy on intact
cells of P. aeruginosa.
To determine whether the ChoP epitope was involved in the interaction
of the P. aeruginosa isolates with the respiratory epithelial cells, standard
invasion assays were performed using 16HBE14- bronchoepithelial cells,
either treated or untreated with a PAFr antagonist.
Results: The 43-kDa ChoP containing protein was shown to be the
elongation factor Tu (EF-Tu). The expression of the ChoP epitope at
37ºC was signiﬁcantly more frequent in P. aeruginosa strains isolated
from chronic infections (70%) than from acute infections (28%). The
ChoP epitope was shown to be expressed on the outer surface of
the bacterial cell and bacterial invasion was signiﬁcantly inhibited by
treatment with the PAFr antagonist compared to controls.
Conclusions: We have demonstrated that in P. aeruginosa, the
ChoP epitope is associated with EF-Tu. A high percentage of the isolates
from chronic infections, in comparison with those from acute infections,
express this epitope at 37ºC. This epitope is present on the cell surface
and mediates the invasion of the airway epithelial cells via PAFr.
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O297 Development of recombinant antibody therapeutics for the
treatment of bacterial infections
I.D. Broadbent, K.A. Charlton, G. Strachan, S.J. Williams, J. Steven,
J. Park, C.J. Barelle, D.P. McGregor, A.J.R. Porter (Aberdeen, UK)
Objectives: We aim to develop novel therapies for the treatment of
Gram-negative bacterial infections, by isolating monoclonal antibodies
that are capable of binding to signal molecules involved in bacterial
quorum sensing. Signalling blockade was hypothesised to prevent the
production of virulence factors and so allow the host immune system to
eliminate the infection.
Methods: As Gram-negative bacterial signaling molecules are typically
of low molecular weight (less than 500Da) they have been considered
intractable to standard antibody discovery methodologies. Therefore
we have used a novel suite of antibody discovery processes termed
Haptomics® to isolate a panel of human antibodies capable of binding
to signal molecules produced by Gram-negative bacteria.
Results: We have demonstrated the abilities of the antibodies to bind
bacterial signaling molecules using a range of in vitro experiments,
and we have also evaluated the antibodies using in vivo models
of Pseudomonas aeruginosa infection. Results will be presented
demonstrating the efﬁcacy of our fully human recombinant antibody
fragments and whole IgG molecules in the treatment of Gram-negative
bacterial infections.
Conclusion: Our approach offers the exciting prospect of using powerful
immunological reagents to combat bacterial infection. By targeting the
signal molecules, rather than the bacteria themselves, we believe that
resistance is considerably less likely to develop to these antibody-based
therapeutics. We are currently broadening our approach to develop
antibodies capable of disrupting quorum sensing in Gram-positive
organisms.
O298 Pseudomonas aeruginosa utilises its type III secretion system
to kill the free-living amoeba Acanthamoeba castellanii
A. Saeed, H. Abd, B. Wretlind, G. Sandstro¨m (Stockholm, SE)
Objectives: Pseudomonas aeruginosa is a free-living, extracellular and a
common environmental bacterium. It is an opportunistic and nosocomial
pathogen causing serious health problems. To compete its predators
such as macrophages and environmental phagocytes it utilises different
survival strategies such as bioﬁlm and formation of micro-colonies. It
also develops resistance mechanisms and produces virulence factors such
as lipopolysaccharide, alginate as well as extracellular, quorum sensing
regulated enzymes and toxins and type III secretion system (TTSS). The
aim of this study is to examine the interaction between P. aeruginosa
PA103 and Acanthamoeba castellanii.
Methods: Bacteria and amoebae were co-culture and the interaction
was examined between P. aeruginosa PA103 and A. castellanii by co-
cultivation, viable count, eosin staining, electron microscopy, apoptosis
assay and statistical analysis.
Results: The results showed that P. aeruginosa PA103 induced necrosis
and apoptosis to kill A. castellanii by the effects of TTSS proteins
ExoU, ExoS, ExoT, and ExoY. In comparison, growth of Acanthamoeba
cultured alone and co-cultured with TTSS mutant strain was not affected.
Conclusions: The results conﬁrm the nature of P. aeruginosa as a strict
extracellular bacterium that needs TTSS to survive in the environment
since this system is able to kill its eukaryotic predators such as
Acanthamoebae.
O299 Triggering receptor expressed on myeloid cells-1 is
involved in the pathogenesis of experimental sepsis by
multidrug-resistant Pseudomonas aeruginosa
I. Tzepi, E. Spyridaki, C. Kranidioti, I. Vaki, V. Karagianni,
H. Giamarellou, E. Giamarellos-Bourboulis (Athens, GR)
Objective: To deﬁne the contribution of TREM-1 (triggering receptor
expressed on myeloid cells-1) in the pathogenesis of sepsis by multidrug-
resistant P. aeruginosa (MDRPA).
Methods: An inoculum of 7 log10 cfu/g of one MDRPA isolate was
injected intraperitoneally in 35 B6C57 male mice. Survival was recorded
in 10; the other mice were sacriﬁced at consecutive time intervals and
blood was drawn from their inferior vena cava. Expression of TREM-1
was estimated after staining of white blood cells with anti-TREM-1 PE
and ﬂow cytometric analysis withgating for neutrophils. Tumour necrosis
factor (TNF)-alpha and interleukin (IL)-6 were measured by ELISA.
Results: All animals died within 36 hours. Median expression of
TREM-1 on neutrophils and median concentrations of TNFalpha and
IL-6 after bacterial challenge are given in the Table.
Time (hrs) TREM-1 (%) TNF (pg/mL) IL-6 (pg/mL)
2 19.00 37.39 288.43
3 16.15 NP NP
4 17.85 39.31 222.87
5 21.17 NP NP
6 48.47 31.25 145.74
NP: not performed.
Conclusions: Increase of the expression of TREM-1 on neutrophils is
observed after that of pro-inﬂammatory cytokines. As a consequence,
induction of TREM-1 might be an independent pathway in the
pathogenesis of experimental sepsis by MDRPA.
Antibacterial susceptibility testing
O300 Evaluation of the Merlin MICRONAUT system for rapid
direct susceptibility testing of Gram-positive cocci and
Gram-negative bacilli from positive blood cultures
N. Wellinghausen, T. Pietzcker, S. Poppert, S. Belak, N. Fieser,
M. Bartel, A. Essig (Ulm, DE)
Objectives: Bloodstream infections are life-threatening conditions which
require timely initiation of appropriate antimicrobial therapy. We
evaluated the automated Merlin MICRONAUT system for rapid direct
microtiter broth antimicrobial susceptibility testing (AST) of Gram-
positive cocci and Gram-negative bacilli from positive BACTEC 9240
blood culture bottles in comparison to the standard method on the Merlin
MICRONAUT system.
Methods: This prospective study was conducted under routine working
conditions during a 9-month period. Altogether, 504 isolates and 11,819
organism–antibiotic combinations from 409 patients were evaluable for
comparison of direct and standard AST on the Merlin MICRONAUT
system.
Results: Concerning Gram-negative bacilli, direct and standard AST was
evaluated in 110 isolates and MIC agreement was found in 98.1% of
2,637 organism–antibiotic combinations. Category (SIR) agreement was
found in 99.0%, with 0.04% very major, 0.2% major, and 0.8% minor
errors. Concerning Gram-positive cocci, 373 isolates were evaluated
and MIC agreement was found in 95.6% of 8,951 organism–antibiotic
combinations. SIR agreement was found in 98.8%, with 0.3% very
major, 0.4% major, and 0.5% minor errors. In addition, for the ﬁrst time
direct and standard AST were evaluated on 21 blood cultures positive
with Streptococcus spp. MIC agreement and SIR agreement was found
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in 96.5% and 97.8%, with 1.7% very major, 0% major, and 0.4% minor
errors.
Conclusion: Direct AST of Gram-negative bacilli and Gram-positive
cocci from positive blood cultures on the MICRONAUT system is a
reliable technique that allows omitting repeat testing of subcultured
isolates. Thereby, it signiﬁcantly shortens the time to result of blood
culture testing and has a positive impact on patient care.
O301 Detection of heteroresistant vancomycin intermediate
Staphylococcus aureus in bloodstream infection
Y. Harigaya, V. Huang, J. Mylotte, A. Lesse, B. Tsuji (Buffalo, Atlanta,
US)
Objectives: Poor clinical outcomes have been attributable to hVISA
infection. Traditional methods using broth microdilution (BMD) seldom
detect hVISA, and the optimal method to detect hVISA has not been
clearly deﬁned. We examined the prevalence of hVISA among 220
clinical S. aureus (SA) bloodstream isolates by Etest and population
analysis proﬁles (PAP).
Methods: 220 SA bloodstream isolates from Buffalo VAMC (2003) were
examined, which included 101 methicillin-susceptible SA (MSSA) and
119 methicillin-resistant SA (MRSA) isolates. SA strain ATCC 29213
was used as a control strain of vancomycin (VAN) susceptible. VAN
MICs were determined by BMD according to CLSI. Etest was used
as initial screening of hVISA, and PAP were performed for SA strains
considered as hVISA. hVISA was deﬁned as isolates which contained
resistant subpopulations, but MICs of the parent strains were within
the susceptible range (1−2mg/mL). A modiﬁed starting inoculum was
utilised (1010 CFU/mL) for PAP. Cultures were serially diluted and plated
on BHI agar on VAN concentrations of 0.5−16mg/mL (Wootton et al.
JAC 48(1): 161).
Results: VAN MICs for 220 SA isolates ranged from 0.25 to 2mg/mL
in BMD; 12.3% (MIC 0.5mg/mL), 72.3% (MIC 1mg/mL), 15.4%
(MIC 2mg/mL). MIC90 for MRSA=2, MSSA= 1mg/mL. Etest detected
13 isolates (5.9%) as hVISA, which were classiﬁed as susceptible per
BMD. hVISA isolates were detected in 10.3% (10/97) of MRSA and
in 2.44% (3/123) of MSSA (P = 0.014). All hVISA isolates detected by
Etest were also classiﬁed as hVISA by PAP. Using PAP, 100% (13/13) of
hVISA isolates displayed intermediately resistant subpopulations which
grew on 4mg/mL VAN BHI agar, 7.6% (1/13) grew on 6 mg/mL VAN
BHI agar, and 0% on 8 or 16mg/mL VAN BHI agar. Using a standard
starting inoculum (108 CFU/mL) PAP detected only 11/13 (85%) hVISA
isolates.
Conclusions: All SA strains were classiﬁed as VAN susceptible by
BMD, but 5.9% of isolates were categorised as hVISA both by PAP
and Etest. hVISA isolates were detected signiﬁcantly more among
MRSA than among MSSA. Starting inoculum was an important factor
to detect resistant subpopulations. Our results suggest that Etest is a
reliable method to screen for hVISA. This ﬁnding will have important
implications on hVISA detection in clinical setting.
O302 New immunometric concept for rapid MRSA screening
without pure-culture
J. Koskinen, T. Stenholm, J. Vaarno, A. Soini (Turku, FI)
Objectives: Most of the MRSA (methicillin-resistant Staphylococcus
aureus) screening methods currently in clinical use, including PCR,
require pure culturing prior to the MRSA testing. The pure culturing
causes two days delay between the sampling and the result. We
present a new phenotypical technique for antimicrobial susceptibility
testing. The new technique combines microbial culturing and speciﬁc
immunometric detection in a single separation-free process, and allows
on-line monitoring of microbe-speciﬁc growth.
Methods: A sample is incubated in growth medium, which contains
antibody coated microspheres, ﬂuorescent antibody reagent, and an
antimicrobial agent in varying concentrations. As a result of the
immunometric binding reaction, ﬂuorescent cell-microsphere clusters are
formed, which are then detected without separation steps by ArcDia TPX
ﬂuorescence detection technique (ﬁgure). The new MRSA screening
technique applies dry-chemistry approach, where reagents are dispensed
into the assay wells in the manufacturing process of the kits. Thus, only
sample addition and incubation is needed prior to analysis. In order to
demonstrate the performance of the technique for rapid MRSA screening
several strains of Staphylococcus were tested.
Microspheres used as solid-phase reaction carriers for bioafﬁnity assay.
Three-component immunocomplexes are formed on the solid-phase
surface in proportion to the analyte concentration.
Results: The results show that the new technique enables antimicrobial
susceptibility testing of MRSA in a time scale of 6−8 hours. Tolerance
of the new technique to competing microbes was demonstrated by
supplementing S. aureus samples with up to 400-fold excess of a
competing microbe (S. epidermidis). Although competing-microbes
lowered signal levels, the assay result remained the same. Presence of
immunoreagents in the growth medium did not affect microbe growth.
Conclusion: In contrast to other genotypic or phenotypic methods,
the new technique does not require pure culturing. This tolerance
to competing microbes is a unique feature of the new technique.
The results suggest that the new technique allows rapid detection of
MRSA and antimicrobial susceptibility testing directly from clinical
samples within 6−8 hours. This time is signiﬁcantly shorter compared
to methods that are currently in clinical use. Such a rapid and simple
screening methodology would be valuable tool in clinical microbiology,
since it shortens turn-around-times of microbiological analyses, and
reduces empirical use of antibiotics. This improves cost-efﬁciency of
antimicrobial resistance management.
O303 Evaluation of ﬁve commercially available rapid ESBL detec-
tion methods in a routine clinical microbiology laboratory
J. Lo-Ten-Foe, M. Hendriks-Franssen, A. Buiting (Tilburg, NL)
Objectives: We evaluated ﬁve commercially available easy-to-perform
phenotypic tests designed for ESBL detection in our routine clinical
microbiology laboratory.
Methods: We compared the E-test (Biotest), two different disk
diffusion systems (supplied by Becton Dickinson and Oxoid), VITEK2
susceptibility testing cards (AST-N020, AST-N048) lacking an ESBL
test in combination with the Advanced Expert System (bioMe´rieux), and
VITEK2 susceptibility testing cards (AST-N041, EXT-N04) containing
an ESBL test (bioMe´rieux). Both clinical isolates (Escherichia coli and
Klebsiella species) from our laboratory and genotypically characterised
ESBL-producing isolates were tested using the different phenotypic
testing methods.
Results: A high sensitivity (87.5–100%) was observed for all tested
phenotypic ESBL detection methods in the clinical isolates and in the
genotypically characterised ESBL-producing isolates. The speciﬁcity for
the two disk diffusion systems, E-test and VITEK2 susceptibility testing
cards containing an ESBL test was also high (80–100%). However, the
speciﬁcity for the VITEK2 susceptibility testing cards lacking an ESBL
test was low (21−25%).
Conclusion: VITEK2 susceptibility testing cards lacking an ESBL test
are suitable for initial screening for ESBL production since they display
high sensitivity. The E-test and the two tested disk diffusion methods
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reliably detect ESBL-producing isolates. In general, the E-test and the
disk diffusion methods are used to conﬁrm ESBL production in a speciﬁc
isolate. More time is required to perform these extra conﬁrmation
tests following initial screening tests for ESBL production. However,
the ESBL test containing VITEK2 susceptibility testing cards make
it possible to do both the screening and the conﬁrmation in one test,
allowing for faster and reliable ESBL detection.
O304 What system for the glycopeptides and oxazolidinone
susceptibility testing among Enterococcus faecium isolates?
G. Raponi, M.C. Ghezzi, G. Gherardi, G. Dicuonzo (Rome, IT)
Objectives: The performances of three widely diffused, commercially
available, methods for the susceptibility testing of glycopeptides and of
oxazolinidone were compared against clinical isolates of E. faecium
Methods: Thirty strains of E. faecium were consecutively isolated
from clinical specimens of patients hospitalised during the year 2005
at the “Azienda Policlinico Umberto I” Academic Hospital of Rome,
Italy. Strain identiﬁcation was performed with both VITEK2® and
Phoenix® automated systems. The antimicrobial susceptibility testing
for teicoplanin, vancomycin, and linezolid, was performed by the
VITEK2, by the Phoenix and by the E-test® method, according to
the manufacturers’ instructions. Detection of 23S rRNA gene G2576T
mutation was carried out by PCR-RFLP using speciﬁc primers.
Results: The automated systems fully agreed in the strain identiﬁcation.
MIC values for teicoplanin 16 ug/mL were detected in 6, 16, and
17 isolates by the VITEK2, the Phoenix, and the E-test respectively.
Furthermore, differences >2 twofold dilutions were observed for 11
strains between the VITEK2 and the Phoenix, for 17 strains between
VITEK2 and E-test, and for three strains between Phoenix and E-test.
For vancomycin, both VITEK2 and Phoenix evidenced MIC values
16 ug/mL in 25 strains, agreed in three susceptible strains, while in two
cases they showed discordant results. The E-test showed MIC values for
vancomycin 16 ug/mL in 22 strains, in six isolates displayed results
discordant with the automated systems, while agreed in two cases of
susceptible strains. In all instances but one, the three methods agreed
in the susceptibility testing for linezolid. The only strain carrying 23S
rRNA mutation showed MIC values for linezolid 4 ug/mL when tested
with the Phoenix and with the E-test, while with the VITEK2 displayed
a MIC> 8 ug/mL.
Conclusions: Glycopeptide resistance of Enterococci poses serious
therapeutic problems and an accurate microbiological diagnosis is
fundamental for the treatment. Our results evidenced a high rate of
discrepancies in the detection of glycopeptide resistance by three widely
diffused susceptibility testing methods. Furthermore, some limits were
observed in the detection of linezolid resistance that prospectively could
reduce the therapeutic options.
The emerging b-lactam resistance in
Escherichia coli
S309 Emerging broad-spectrum b-lactamases in Escherichia coli:
latest ESBLs and carbapenemases
L. Poirel (Paris, FR)
Increasing b-lactam resistance in E. coli has become a worrying
threat worldwide. In that species, most of the mechanisms involved in
the b-lactam resistance are linked to the production of b-lactamases,
including clavulanic-acid inhibited expanded-spectrum b-lactamases
(ESBLs) and carbapenemases which are the most powerful enzymes
able to degradate most b-lactams. Besides the most common ESBLs
circulating in Enterobacteriaceae (TEM-, SHV, and CTX-M-types), there
are other emerging enzymes which are mostly plasmid-encoded and are
distributed in a large variety of species. The ESBL VEB-1 is known
to be largerly distributed in South-East Asia, PER-1 in Turkey, Italy,
Korea, and also South America, and GES/IBC-type enzymes in Greece
and Japan mostly. All these ESBLs are known to efﬁciently hydrolyze
expanded-spectrum b-lactams, and some variants of the GES family are
also hydrolysing imipenem at a low level. Other enzymes of the KPC
family have been also reported in E. coli. KPC-2 has been shown to be
prevalent in E. coli in Israel and KPC-3 has been reportyed sporadically
in the USA. These latter enzymes are considered as ESBLs since they
are inhibited by clavulanic acid and their hydrolytic efﬁciencies toward
imipenem are very high, thus giving rise to high level resistance to
carbapenems in those E. coli isolates.
In addition to these ESBL determinants, metallo-b-lactamases (MBL)
have been identiﬁed in E. coli. These enzymes which are not inhibited
by clavulanic acid and hydrolyse carbapenems very efﬁciently are of the
IMP and VIM groups. In E. coli, IMP-1 has been identiﬁed in Japan and
VIM-2 in Greece, but the most worrying observation is that related to the
spread of VIM-1 in Greece. Indeed, this determinant has been identiﬁed
in clinical isolates also harbouring ESBL encoding genes, thus leading
to panresistance in those strains.
Noteworthy, most of the ESBL and MBL encoding genes encountered
in E. coli are vehiculed by plasmids and located into class 1 integron
structures, thus facilitating the occurrence of multidrug resistance via
the co-localisation of other antibiotic resistance genes.
A particular attention will be needed in the next future to trace the
isolates harbouring these worrying determinants, and also to trace the
corresponding plasmids which are powerful tools for such dissemination.
Surrogate markers of disease severity and
for guidance of antimicrobial therapy
S311 Monitoring severe sepsis and therapy
E. Bergomi, M. Antonelli (Milan, Rome, IT)
Severe sepsis is a serious syndrome with organ failure that may affect a
large proportion of the patients admitted to the intensive care unit and
whose prediction is often difﬁcult [1]. The Surviving Sepsis Campaign
(SSC) is a global programme to reduce mortality rates in severe sepsis,
endorsed by 11 International Medical Societies. This Campaign produced
the guidelines for management of severe sepsis and septic shock [2].
These recommendations were reviewed during the annual meeting of
the Society of Critical Care Medicine held in January 2006.
The Campaign has taken an action to create National and International
networks to collect data and monitor interventions. In Italy the network
was settled in September 2006. But, can we monitor therapy for severe
sepsis if concepts, tools, ideas and attitudes differ largely between
centres? With the aim of answering this crucial question, we conducted a
survey on the perception of Severe Sepsis, its diagnosis and monitoring
through the national network for the Italian Chapter of the SSC.
Twenty-three participating centres (10 community and 13 teaching
hospitals) responded to our survey, for a total number of 261 ICU/critical
care beds. When the participants were asked to describe the methodology
currently used for implementation of data in their institution, 70% of the
respondents adopted a continuous data collection methodology and the
other 30% a “before and after event” design.
On the question whether an educational tool was used to sensitise people
to the campaign, 13% of the respondents declared that no speciﬁc
tool was used and the other 87% (20 centres) stated that they used
different educative means (mostly chart documentations and department
conferences).
When asked when data collection for the diagnosis of sepsis usually
takes place, thirteen respondents said that their collection occurred within
24 hours from the diagnosis, only 2 contemporary, and 8 retrospectively.
On the question how data were collected 9 institutions out of 23 (39%)
answered that the SSC paper tool or database were used, 11 (47%) a
combination of the two, and 3 (23%) other systems.
In 17 of the 23 centres the responsibility of data collection is assigned
to the attending physician; in the remaining 5 cases residents, nurses
or students collect the data, but same centres allow the simultaneous
collaboration of more ﬁgures.
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Partnership between ICUs and other departments to approach Sepsis
in the spirit of the SSC is unfortunately scarce: only 4 (17%) of the
respondents have a form of collaboration with other units. The effect of
this mentality is that only 6 (26%) of the interviewed hospitals currently
apply a screening for severe sepsis in the ward.
One main concept that illustrates the spirit of the SSC is the idea of
an early intervention to apply the different recommendations. Again,
in checking how the time of presentation of sepsis is conceived in the
emergency department, in the ward and in the ICU we obtained answers
that were quite diverse. Of the 23 participating institutions, 16 responded.
Only 50% of physicians in the Emergency Department identiﬁed the
“presentation time” of severe sepsis with the moment of triage or hospital
admission. The remaining 50% had a sort of “a posteriori” diagnosis,
losing the possibility of an early approach. Things are much worse
looking at the ward, where in 80% of cases the moment of severe sepsis
presentation corresponded to the identiﬁcation of symptoms from the
“a posteriori” reviews of the medical notes, the arrival of a critical care
consultant or ICU admission. Surprisingly, in the ICU still 30% of the
cases is usually diagnosed through the review of the medical reports.
Conclusions: At present, despite the tremendous effort made by the
International Intensive Care Community to standardise the therapy for
severe sepsis, predicating the comandements of the SSC and boundles,
a large variability exists in the concept of time, tool availability, and
logistics.
Reference(s)
[1] Alberti C, Brun-Buisson C, Chevret S, et al.; European Sepsis Study
Group. Systemic inﬂammatory response and progression to severe
sepsis in critically ill infected patients. Am J Respir Crit Care Med
2005 Mar 1;171(5): 461−8. Epub 2004 Nov 5. IF 8.689.
[2] Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign
guidelines for management of severe sepsis and septic shock.
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Fungal diagnostics
S312 Antifungal susceptibility testing
J.L. Rodriguez Tudela (Majadahonda, ES)
The EUCAST Subcommittee on Antifungal Susceptibility Testing
(EUCAST-AFST) has recently published a standard for determining
the susceptibility of fermentative yeasts to antifungals. Besides,
another standard related with the susceptibility of ﬁlamentous fungi
to antifungals will be published very soon. The EUCAST General
Committee has recently published guidelines for harmonisation of
breakpoints for antimicrobials and therefore the Antifungal Susceptibility
Testing Subcommittee of EUCAST has adopted it. In order, to prove that
breakpoints for antifungals can be obtained, EUCAST-AFST decided to
make a proof of concept with ﬂuconazole. All the requirements raised
for EUCAST committee to obtain break points for antimicrobials have
been addressed and ﬂuconazole break points have been attained. The
data obtained through the revision system to obtain break points for
ﬂuconazole will be discussed. Also the discrepancies of EUCAST and
CLSI break points will be examined and analysed. In the near future,
it is intention of EUCAST AFST develop break points to all licensed
antifungals.
Epidemiology of nosocomial infections
in the ICU
O318 Bloodstream infections due to Klebsiella pneumoniae in an
intensive care unit in Greece: susceptibility patterns and
clinical characteristics
J. Pavleas, A. Skiada, K. Salatas, K. Koufakos, A. Rigas, N. Archontoulis,
P. Vernikos, A. Mega, G. Thomopoulos, K. Rigas (Athens, GR)
Objectives: In recent years K. pneumoniae has been shown to
have increasing resistance, due to production of extended-spectrum
b-lactamases (ESBLs) or metallo-b-lactamases (MBLs). The aim of this
study was to record the bacteraemias due to K. pneumoniae in our ICU,
to analyse the patterns of resistance, as well as the clinical characteristics
of the ensuing infections.
Methods: Prospective observational study in patients who were
hospitalised in the ICU, from September 2004 to October 2006. The
demographic characteristics of all patients admitted were recorded, as
well as the underlying diseases, disease severity as estimated by the
APACHE II score and possible factors predisposing to infections, such
as previous consumption of antibiotics. Susceptibility testing of culture
isolates was performed by MicroScan autoSCAN4. The outcome of all
bacteraemias was recorded. Statistical analysis was done with ESPSS
v.12.
Results: During the study period 290 patients were admitted to the
ICU and 160 episodes of bacteraemia were recorded. Of these, 29
(18%) were due to K. pneumoniae. The isolates were resistant as
follows: 100% to ampicillin, 72% to b-lactamase inhibitors, 90% to
3rd-generation cephalosporins, 41% to imipenem (MIC> 4mg/L),
41% to aztreonam, 86% to quinolones and 31% to aminoglycosides. All
isolates were susceptible to colistin (MIC 2mg/L). The carbapenem-
resistant isolates (CRKP) were also resistant to all other antibiotics
tested, except aztreonam and gentamicin (75% and 58% sensitive
respectively). The bacteria were isolated in 23 patients (mean age
67 years, 69% male) of whom 56% were surgical. Their mean
APACHE II score was 19. Ten bacteraemias were primary, 5 secondary
to ventilator-associated pneumonia and 14 catheter-related. The 14-
days mortality of patients with bacteraemia due to CRKP was 53%,
while in those with sensitive strains it was 28% (p = 0.2). Outcome
was signiﬁcantly related to the APACHE II score (p = 0.02). Of the
patients who had bacteraemia due to CRKP, 77% had been previously
receiving a carbapenem. Of those who had a carbapenem-sensitive
isolate, 35% had been receiving a carbapenem (p = 0.4)
Conclusions: Infections due to K. pneumoniae resistant to carbapenems
represent a serious clinical problem in our ICU and are associated with
a high mortality rate. It seems that previous use of carbapenems leads
to increased resistance. Larger studies are needed in order to obtain
statistically signiﬁcant results.
O319 Epidemiologic surveillance of nosocomial infections in the
intensive care unit: role of risk factors, emerging pathogens
and cross-transmission
A. Agodi, M. Barchitta, R. Cipresso, L. Giaquinta, M. Romeo,
C. Denaro (Catania, IT)
Objectives: Nosocomial infections surveillance was performed in
an Italian ICU in order to pretest the HELICS protocol before
its nationwide implementation, and to evaluate the impact and the
routes of acquisition of three emerging multiresistant pathogens, Pseu-
domonas aeruginosa, Acinetobacter baumannii and Stenotrophomonas
maltophilia by determining: (i) the occurrence of carriage on admission;
(ii) the microrganism-speciﬁc ICU-acquired infection rates, by site;
(iii) the impact of cross-transmission using molecular typing data, and
(iv) the individual risk factors for infection.
Methods: A six-months surveillance survey was performed at the
ICU of an Italian Hospital, in accordance with the HELICS protocol,
excluding patients staying less than three days. An electronic data form,
was designed using the SPSS Data Entry Enterprise Server (SPSS
Inc.). Clonality was determined by macrorestriction analysis using well
established criteria, and the presence of two indistinguishable strains in
two patients was considered one episode of cross-transmission.
Results: During the study period, 121 patients were enrolled into the
survey for a total of 2165 days. The ICU-acquired infection rate was
82.6% patients and the incidence density was 46.2‰ patient-days. The
occurrence of P. aeruginosa carriage on admission was 1.6% patients. No
episode of A. baumannii or S. maltophilia carriage was identiﬁed. The
ICU-acquired P. aeruginosa, A. baumannii and S. maltophilia associated
infection rates were respectively: 35.9%, 13.0% and 12.4% patients.
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The incidence density were respectively 19.4‰, 7.4‰, 6.9‰ patient-
days. ICU-acquired pneumonia was conﬁrmed to be the ﬁrst infection
type (30.0%), followed by bloodstream infections (BSIs) (25.0%),
local CVC-related infections (23.0%), urinary tract infections (13.0%),
CVC-related BSI (8.0%), and surgical site infections (1.0%). Eighteen
P. aeruginosa, one A. baumannii and four S. maltophilia distinct clones
were identiﬁed by macrorestriction analysis over a total of 162 isolates.
The impact of cross-transmission was estimated to be at least 52.4%, thus
deﬁning the preventable proportion of all cross-transmission episodes.
Two major risk factors were identiﬁed: inappropriate management of
invasive devices and of antimicrobial usage.
Conclusion: Our study conﬁrms the essential role of epidemiologic
surveillance to provide advanced risk-adjusted infection rates as a
measure of quality of care.
O320 European surveillance of ICU-acquired infections
(HELICS-ICU), 2004–2005: ICU-acquired pneumonia
C. Suetens, A. Savey, M. Palomar, M. Hiesmayr, A. Lepape, I. Morales,
P. Gastmeier, J.C. Schmit, R. Valinteliene, J. Fabry for the HELICS-ICU
Data Centre, Scientiﬁc Institute of Public Health, Brussels
Objective: To describe the 2004–2005 results of the European
surveillance of ICU-acquired pneumonia in the HELICS-ICU (HI)
network (http://helics.univ-lyon1.fr).
Methods: Six patient-based networks (Austria, Belgium, France, Spain,
Luxemburg and Lithuania), 2 piloting countries (Norway, Slovakia) and 1
unit-based (Germany) surveillance networks contributed data on 15,161
episodes of ICU-acquired pneumonia (PN) from 721 ICUs between
Jan 2004 and Dec 2005. Since the HI protocol excludes patients with
a length of stay (LOS) of <3 days in the ICU, data from Germany (no
denominator data for patients staying >2 days) were excluded for the
calculation of indicators, but included for the description of infections.
Table 1. Relative frequency of 10 most frequent isolated micro-organisms in ICU-
acquired pneumonia, HELICS-ICU, 2004–2005
AT BE DE ES FR LT LU Total
No. of ICUs 43 33 329 112 185 12 7 721
No. of isolates in PN 2087 1587 6074 1279 4385 97 58 15,567
S. aureus 12.8% 12.0% 21.9% 20.4% 22.4% 17.5% 8.6% 19.6%
%MRSA/SA 38.8% 38.2% 34.5% 38.4% 44.8% NA NA 38.7%
P. aeruginosa 22.2% 18.8% 14.6% 17.7% 23.0% 23.7% 22.4% 18.8%
Escherichia coli 6.4% 8.8% 9.9% 6.4% 8.1% 3.1% 12.1% 8.5%
Klebsiella spp. 7.7% 7.6% 10.7% 6.4% 5.6% 2.1% 10.3% 8.1%
Enterobacter spp. 6.5% 11.7% 7.9% 5.6% 6.7% 1.0% 8.6% 7.5%
Candida spp. 12.5% 3.3% 4.8% 2.3% 2.5% 0.0% 5.2% 4.8%
Haemophilus spp. 2.4% 5.6% 3.3% 6.4% 5.3% 14.4% 3.4% 4.3%
Enterococcus spp. 7.4% 1.6% 5.0% 1.6% 1.0% 1.0% 5.2% 3.6%
Streptococcus spp. 3.2% 2.8% 2.2% 3.8% 5.6% 9.3% 0.0% 3.5%
Acinetobacter spp. 3.1% 1.1% 2.5% 10.2% 3.1% 14.4% 0.0% 3.3%
Results: Of 87,353 patients staying more than 2 days in the ICU,
8.7% acquired a PN (intubator-associated 89.9%). The median incidence
density varied from 3.3 PN episodes per 1000 patient-days (pd)
(distribution ICUs P25 0.0; P75 7.7) in ICUs with less than 30%
patients intubated, to 6.4 (P25 3.1; P75 10.4) in ICUs with 30−59%
patients intubated and 9.4 (P25 4.8; P75 13.9) in ICUs with 60% of
patients intubated. The incidence was higher in polyvalent ICUs (P50 7.6
PN/1000 patient-days) than in surgical (P50 4.4) and medical (P50 5.7)
ICUs. The most frequently reported micro-organism was S. aureus
(19.6%) with an average MRSA/SA percentage resistance of 38.7%.
There were marked differences in the relative frequency of isolated
micro-organisms between countries (table).
The diagnosis of PN was conﬁrmed by quantitative culture (HELICS
deﬁnition PN1 or PN2) in 79% in FR, 54% in ES, 32% in AT, 21% in BE,
15% in LT and 7% in LU. In the piloting countries (limited numbers),
71% was conﬁrmed in Norway and 0% in Slovakia.
Conclusion: Although underlying differences in diagnostic practices
persist, the compatibility with the HI protocol is increasing. The
level 1 (unit-based) data presented here provide sufﬁcient indicators for
continuous follow-up of infection rates within the ICU and limited risk-
adjusted inter-ICU comparisons with a low workload.
O321 REA-RAISIN: National surveillance network of
ICU-acquired infections, France, 2005
A. Savey, B. Tressieres, A. Lepape, N. Garreau, T. Lavigne, F. L’heriteau,
P. Parneix, J. Fabry, B. Coignard on behalf of the National Nosocomial
Infection Alert, Investigation & Surveillance Network (RAISIN), France
Background: The objective of nosocomial infections (NI) surveillance
in intensive care units (ICU) is to assess and compare rates over time
and amongst ICUs, in order to provide an evidence-based approach for
improving infection control practices.
Methods: In France, regional ICU surveillance networks have been
implemented since 1994. In 2004, surveillance methods were standard-
ised through a national surveillance project (RAISIN). The national
REA-RAISIN network conducts 6 months a year a patient-based NI
surveillance in ICU. On a voluntary basis and using a standardised
methodology, participating ICUs collect data for each patient staying
more than 2 days in the unit. Surveillance focuses on device related-
infections, providing the units with incidence rates of ventilator-
associated pneumonia (PNE), urinary tract infections (UTI), central
venous catheter colonisation (COL) with or without catheter-associated
infections (CRI) and nosocomial bacteraemia (BAC).
Results: From January to June 2005, 151 ICUs included 20,632 patients.
– Patient characteristics: mean age 61.7 yrs, gender ratio 1.62, type
of admission (medical 68%, scheduled surgical 17%, emergency
surgical 15%), trauma 9%, impaired immunity 12%, patient origin
(home 54%, acute care 38%, LTCF 4%, other ICU 3%), antibiotic
treatment at admission 52%, mean SAPS II 40.1, mean length of stay
11.2 days.
– Exposure to invasive devices: intubation/tracheotomy 60.5%, central
venous catheter (CVC) 57.6% and indwelling urinary catheter
(UC) 79.2% (device utilisation ratio = 58.1%, 62.0% and 74.2%
respectively).
– A total of 5,159 nosocomial events were documented concerning 2,569
patients (12.4%).
– Overall incidence rates were calculated: 17.6 PNE/1,000 intubation-
days, 5.5 COL/1,000 CVC-days (or 2.2 CRI/1,000 CVC-days), 3.3
BAC/1,000 hosp.-days and 7.9 UTI/1,000 UC-days.
– Unit distributions were performed with great variations concerning
patient/unit characteristics and rates. Further analyses are planned,
using a multivariate model (standardised incidence ratios) in order to
improve benchmarking possibilities.
Conclusion: This report on NI surveillance in ICU from a large sample
of French hospitals will serve as a national reference and will allow
describing, evaluating and monitoring NI in ICUs. Feedback to ICUs
provides them with relevant information to monitor and target infection
control policies.
http://www.invs.sante.fr/raisin/
O322 Nosocomial invasive pneumococcal disease in Toronto,
Canada, 1995−2005
K. Green, D. Low, A. McGeer (Toronto, CA)
Background: Recently, several outbreaks of antibiotic resistant noso-
comial invasive pneumococcal disease (IPD) have been reported. We
review the occurrence of nosocomial IPD in Toronto, Canada from 1995
to 2006.
Methods: Population based surveillance for IPD in residents of
metropolitan Toronto and Peel region, Ontario, Canada (popula-
tion 3.9M) has been on-going since 1995, and surveillance for disease
associated with respiratory isolates of S. pneumoniae (SPN) since 2002.
Nosocomial disease is deﬁned using US NNISS criteria.
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Results: From 1995 to 2005, 4,836 episodes of IPD have been
identiﬁed of which 208 were nosocomially acquired. The overall
average incidence of nosocomial IPD was 0.53/100,000/y. There was
no change in incidence over time although the incidence of community-
acquired IPD decreased from 13.5 to 7.9/100,000/y during the same
period. The median age of patients was 68 yr (range 0.12−97 yr);
34 (16%) were children. 125 (60%) were male, 179 (86%) had
chronic illness qualifying them for receipt of pneumococcal vaccine
[most commonly: cancer (80, 38%), cardiac disease (73, 35%), lung
disease (50, 24%), diabetes mellitus (48, 23%)]. The most common
serotypes causing disease were 6B (21), 23F (20), 6A (16) and
22F (14). Overall resistance was: erythromycin 13.6%, penicillin 5.7%,
ceftriaxone 2.5%, levoﬂoxacin 3.7%, moxiﬂoxacin 0%. From 2002 to
2006, 391 patients with respiratory isolates of SPN were identiﬁed;
103 episodes met criteria for non-bacteraemic pneumococcal pneumonia
(NBPP). Median age of patients was 65 yr, 73% were male, 83% had a
qualifying chronic underlying illness. The most common serotypes
were 19F (67), 6A (31), 6B (25), and 3 (24). Resistance rates were:
erythromycin 21%, penicillin 6.3%, ceftriaxone 4.2%, levoﬂoxacin 1.8%,
moxiﬂoxacin 1.1%. The case fatality rate was 29% in NBPP, and
45% in IPD. In IPD episodes, levoﬂoxacin resistance (LEVR) increased
from 0 in 1995/8 to 9.5% in 2001 (P = 0.25). From 2002 to 2005, LEVR
decreased in both IPD and non-invasive isolates, from 8.8% (2001) to
1.4% (2006) (P = 0.01). Examination of cases for clustering in time and
space revealed clusters of 2−5 cases each comprising 38/599 (6.3%)
cases.
Conclusion: Nosocomial pneumococcal disease is uncommon, but
associated with a high case fatality rate. Most disease is sporadic. In
Toronto, levoﬂoxacin resistance is decreasing in nosocomial isolates
while remaining stable in the community: this may be due to changes in
hospital antibiotic use.
Mycobacterium tuberculosis: cell biology and
molecular pathogenesis
O323 Execution of macrophage apoptosis by PE_PGRS33 of
Mycobacterium tuberculosis
S. Basu, Suschil Pathak, A. Banerjee, Shresh Pathak, A. Bhattacharyya,
Z. Yang, S. Talarico, M. Kundu, J. Basu (Calcutta, IN; Ann Arbor, US)
Objectives: The role of the multi-gene PE family of proteins unique
to mycobacteria, in the pathogenesis of tuberculosis is still poorly
understood. Tumour necrosis factor-alpha (TNF-a) is essential for
successfully combatting tuberculosis. Our objective was to understand
how PE_PGRS33, a surface-exposed protein known to undergo variation
among strains, inﬂuences TNF-a release from macrophages, and how
this is linked to apoptosis of macrophages.
Methods: Recombinant PE_PGRS33 was tested for its ability to release
TNF-a from the macrophage cell line RAW264.7 as well as from
human monocyte-derived macrophages. Its binding to cell surface TLR2
was analysed by ﬂow cytometry and the role of TLR2 was studied
by transfecting cells with dominant-negative TLR2 prior to analysing
PE_PGRS33-induced TNF-a release. The signaling pathways activated
were studied by assaying for the mitogen-activated protein kinase
(MAPK) kinase kinase ASK1 and downstream MAPKs. Cell death was
analysed using histone ELISA and also by assaying surface-associated
annexin-FITC.
Results: PE_PGRS33, a surface exposed protein, elicits TNF-a
release from macrophages in a Toll-like receptor 2 (TLR2)-dependent
manner. Apoptosis signal-regulating kinase 1 (ASK1) is activated
downstream of TLR2. ASK1 activates the mitogen-activated protein
kinases (MAPKs) p38 and JNK. PE_PGRS33-induced signaling leads
to enhanced expression of TNF-a and TNF receptor I (TNFRI) genes.
Mycobacterium smegmatis expressing PE_PGRS33 elicits the same
effects as puriﬁed PE_PGRS33. Neutralising TNF-a antibodies showed
that release of TNF-a is required for triggering apoptosis in macrophages
challenged with PE_PGRS33. The death receptor-dependent signals are
ampliﬁed through classical caspase 8-dependent mitochondrial release
of cytochrome c, leading to the activation of caspases 9 and 3.
Conclusions: The important aspect of our ﬁndings is that deletions
within the PGRS domain (simulating those occurring in clinical strains)
attenuate the TNF-a-inducing ability of PE_PGRS33. These results
provide the ﬁrst evidence that variations in the polymorphic repeats of
the PGRS domain modulate the innate immune response.
O324 Cytokine secretion, phagosomal maturation and killing
capacity of human neutrophils is differentially inﬂuenced by
virulent and avirulent strains of Mycobacterium avium
P. Hartmann, F. Sperl, N. Robinson, C. Franzen, J. Rybniker, G. Plum
(Cologne, Regensburg, DE)
Objective: Polymorphonuclear neutrophils (PMNs) have been impli-
cated in the early inﬂammatory response against mycobacteria besides
monocytes/macrophages. Whereas virulent mycobacteria manage to
survive inside macrophages (MF) for a prolonged period of time by
blocking the phagosome from fusion with late endosomes and lysosomes,
little is known about the potential of mycobacteria to alter the basic
biologic behaviour of PMNs. We studied the inﬂuence of virulence of
different M. avium strains on killing capacity, cytokine production and
phagosomal maturation of PMNs.
Methods: PMNs isolated from 20 healthy donors were infected with
M. avium (2 virulent and 2 avirulent strains) and incubated at 37ºC
for deﬁned time periods. Neutrophil killing activity: dilution series of
released intracellular bacteria (SDS lysis) were plated on 7H10 agar.
Colony forming units (CFUs) were counted after 7 days. Cytokines in
the supernatant were measured by ELISA. FITC labeled M. avium were
simultaneously visualised with Alexa-Fluor® antibody staining of early
endosomal and lysosomal markers respectively (Rab5 and LAMP-1) by
ﬂuorescence microscopy. Statistical signiﬁcance of data was calculated
by Student’s t-test except CFU-values and killing index respectively were
analysed by variance analysis. Post hoc pairwise comparisons were done
using Scheffes’ test.
Results: At 2 h 53.73±7.73% of virulentM. avium initially phagocytised
were killed, whereas killing was virtually complete, 96.58±0.71%, for
avirulent strains. IL-8 and MIP-1a in supernatants of PMNs infected
with avirulent M. avium strains were signiﬁcantly higher (p = 0.004) than
in PMNs infected with virulent M. avium strains. IL-1b secretion of
PMNs was independent of virulence of M. avium. However the receptor
antagonist of IL-1, IL-1ra, was signiﬁcantly higher in supernatants
of PMNs infected with virulent strains. At 1 h 83.8±12.9% of the
membranes of all cell-associated avirulent, but only 27±6.3% of virulent,
M. avium strains stained positive for LAMP-1. In contrast 78.96±10.7%
of virulent, but only 35.8±7.5% of avirulent, strains stained positive for
rab5.
Conclusion: Virulent strains of M. avium escape early host defence
by inhibition of proinﬂammatory cytokines and blocking of phagosome
maturation of PMNs. Thus PMNs may serve as a trojan horse for virulent
mycobacteria. The latter, once released from PMNs, are then capable of
infecting new host cells such as macrophages.
O325 Characterisation of polyphosphate kinase 1 of mycobacteria
and its role in persistence
K. Sureka, S. Dey, P. Datta, A. Singh, A. Dasgupta, J. Basu, M. Kundu
(Calcutta, IN)
Objectives: Polyphosphate kinase (PPK1) is the principal enzyme
required for the synthesis of inorganic polyphosphate (polyP), a
polymer of tens or hundreds of Pi residues linked by high energy
phosphoanhydride bonds. It plays an important role in long term bacterial
survival in stationary phase, against nutritional, oxidative, osmotic and
thermal stress, and is associated with virulence of several pathogens.
Mycobacterium tuberculosis, the causative agent of tuberculosis, survives
inside host macrophages in a nutritionally starved and stressed condition.
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Our objective was to understand the role of PPK1 in bacterial survival
under stress.
Methods: To evaluate the role of PPK1 in mycobacterial survival,
the gene encoding PPK1 was disrupted in M. smegmatis through
homologous recombination. The effect of stress on the wild type and
the mutant were then analysed. ppk1 was also silenced by antisensing in
M. tuberculosis.
Results: The PPK1-deleted strain of M. smegmatis exhibited signiﬁ-
cantly reduced intracellular survival in murine RAW264.7 macrophages
compared to the survival of its wild type counterpart. It exhibited an
extended lag phase of growth when shifted to a low phosphate-containing
medium, was unable to grow in nitrogen-depleted medium and impaired
in its ability to survive in anaerobic conditions. It showed decreased
transcription of the stringent response regulator relA. M. tuberculosis
ppk1 could complement the mutant. Antisensing of the ppk1 gene in
M. tuberculosis also showed reduced levels of relA transcription. The
ppk1 mutant was defective in its ability to form bioﬁlms.
Conclusion: ppk1 likely plays a role in mycobacterial persistence and
is a potential target for drug development.
O326 Cholesterol oxidase as a virulence factor of Mycobacterium
tuberculosis
A. Brzostek, B. Dziadek, J. Pawelczyk, A. Rumijowska-Galewicz,
J. Dziadek (Lodz, PL)
Objectives: The objective of this study was to evaluate cholesterol
oxidase (ChoD) as a putative virulence factor of Mycobacterium
tuberculosis.
Methods: A two-step recombination protocol was used to replace the
cholesterol oxidase gene with a non-functional copy. The pathogenicity
of resultant strains was analysed in vitro using peritoneal macrophages
and in vivo by mice infection.
Results: Cholesterol oxidase is known to be a key enzyme initiating
cholesterol degradation processes in many soil bacteria, including fast
growing mycobacteria. Pathogenic mycobacteria accumulate cholesterol
without its utilisation and express cholesterol oxidase as an extracellular
enzyme. A homologous recombination was used to construct an
M. tuberculosis strain with an unmarked deletion within the choD gene.
The wild type M. tuberculosis strain (Mt-wt), choD-mutant (mut-
choD) and mutant complemented with choD gene controlled by a heat
shock protein promoter (mut-choD-PhspchoD) were used to study the
function of cholesterol oxidase in mycobacterial pathogenesis. Peritoneal
macrophages (106/well) were infected with Mt-wt, mut-choD and mut-
choD-PhspchoDM. tuberculosis strains (105/well) and incubated for four
and six days. The numbers of Mt-wt and mut-choD-PhspchoD viable
bacteria recovered from macrophages were at least an order of magnitude
higher compared to mut-cho strain as revealed by cfu analysis. The same
strains were used for infection of mice. Ten weeks post infection, lungs
and spleens were isolated from euthanised mice. The numbers of viable
bacteria in each organ were detected by cfu. Analysing at least 10 mice
of each group, the strong attenuation of choD mutants was observed
compared to wild type and complementation strains.
Conclusion: Cholesterol oxidase is an important virulence factor during
infection by M. tuberculosis.
This work was supported with KBN grant: contract no. 3P05A14024
O327 Ex vivo proﬁling of cytokines/chemokines in patients with
tuberculosis and latent tuberculosis infection
T. Bodmer, D. Grandgirard, S. Bigler, C. Daubenberger, S. Leib
(Berne, Basle, CH)
Objectives: While in most cases infection with Mycobacterium
tuberculosis (Mtb) is contained (latent Mtb infection; LTBI), it
progresses to overt disease (TB) in a small proportion of those infected.
We studied the cytokine/chemokine proﬁles associated with LTBI and
TB in order to gain insight into ongoing immune activation events in
Mtb-infection.
Methods: Blood was obtained from patients with culture-conﬁrmed
TB (n = 4), with recently acquired LTBI (n = 3), and from healthcare
workers without Mtb exposure (n = 6). Interferon-gamma (IFN-g) that
was released from sensitised lymphocytes upon ex vivo stimulation with
Mtb-speciﬁc antigens was determined using the QuantiFERON-TB®
Gold In Tube assay as recommended by the manufacturer (Cellestis Ltd.,
Carnegie, Australia). Microsphere-based multiplex assays (Lincoplex®,
Linco Research Inc., St Charles, MA, USA) were used to assess
the plasma concentrations of IFN-g, TNF-a, IL-2, IL-4, IL-5, IL-6,
IL-8, IL-10, IL-12p40, IL-12p70 IL-13, IL-15, Fraktalkine, GM-CSF,
MCP-1, and IP-10 before (NIL) and after (TbAg) ex vivo stimulation.
Values were determined using Bio-Plex Manager (Bio-Rad Laboratories,
Hercules, CA, USA). The limit of detection was 3.2 pg/mL. Statistical
analysis was performed using Prism 4.1 (GraphPad Software Inc., San
Diego, CA, USA). The Kruskal-Wallis test was used for multiple group
comparison, and the Mann-Whitney test for group to group comparison.
Results: IFN-g, IP-10, IL-2, GM-CSF, IL-13 concentrations were
signiﬁcantly higher in patients with TB and LTBI as compared to controls
(Table).
DTb Ag − NIL, median (range), pg/mL] ANOVA Mann−Whitney






IFN-g −0.2[−3.0 − 2.0] 175.3 [131.0 − 238.6] 115.9 [2.2 − 185.4] P< 0.02 P< 0.03 P< 0.03
IP-10 212.0 [126.0 − 1409] 18,188 [3,806 − 46,279] 12,996 [1,809 − 24,112] P< 0.02 P< 0.01 P< 0.03
IL-2 0.47 [−4.6 − 59.9] 630.5 [404.5 − 5,871] 413.5 [280.1 − 887.5] P< 0.02 P< 0.01 P< 0.03
GM-CSF −2.3 [−12.9 − 11.0] 27.6 [2.9 − 481.2] 20.8 [16.6 − 59.1] P< 0.02 P< 0.02 P< 0.03
IL-13 −2.8 [−34.6 − 14.2] 61.6 [0.2 − 144.2] 57.6 [2.9 − 59.5] P< 0.04 P< 0.04 P< 0.05
Conclusions: Mean plasma concentrations of IP-10 were 50 to 90-fold
higher than those of IFN-g, both in patients with active TB and LTBI.
Assessment of IP-10 might substantially increase the sensitivity of IFN-g
release assays (IGRA) for detecting Mtb infection. Ex vivo proﬁling of
cytokines/chemokines using IGRA in combination with ﬂow-cytometer
multiplex assays identiﬁed additional candidate parameters to conﬁrm
Mtb infection and will improve our understanding of TB pathogenesis.
Clostridium difﬁcile
O328 Community rather than hospital factors promote increase of
Clostridium difﬁcile associated diseases in Northern Bavaria
S. Borgmann, A. Kick, T. Jakobiak, B. Schulte, M. Hamann, R. Busch,
C. von Eichel-Streiber, O. Hasselmayer (Weiden, Tu¨bingen, Erlangen,
Mainz, DE)
Objectives: Recently, the number of C. difﬁcile associated diseases
(CDAD) has increased. Prevalence data of CDAD particularly resulted
from analyses performed at university hospitals, etc. In our lab
we perform microbiological analyses for more than 3500 facilities
comprising more than 40 hospitals in Northern Bavaria allowing
examination of C. difﬁcile prevalence in the local region.
Methods: Stool samples were analysed by ELISA detecting toxins
A and B of C. difﬁcile (Cdt). The total number of ELISA performed in
2004, 2005, and 2006 and the number of positive results was determined
by hybase analysis. All C. difﬁcile positive patients identiﬁed in 2005
were documented. Analysis of toxin genes IStron types integrated into
the genome (C. difﬁcile integration proﬁles) was performed on C. difﬁcile
cultured from stool samples of 17 patients treated at 2 hospitals.
Results: The number of Cdt positive stools samples increased from
372 in 2004 to 515 (2005) and 642 (Jan–Sept 2006). From October 2005
to January 2006 there was a marked increase from 31 to 103
Cdt positive stool samples per month. High numbers were also observed
in the subsequent period until June 2006 (median 84/month). In July
this number decreased to 39. When this analysis was performed on
Cdt positive ﬁndings of patients from 4 harvested hospitals (I, II, III, IV)
courses of each facility was very similar to that of the total collective
suggesting that increase of CDAD in particular depended on community
factors and secondarily on hygiene of certain hospitals. Typing analysis
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results suggested that all isolates from patients of hospitals I and II were
identical. No transmissions of patients from hospital I to hospital II
had been found and vice versa indicating prevalence of one prevailing
C. difﬁcile strain in the local region. Binary toxin was not found in these
isolates indicating the strain neither NAP 1 nor 027.
Conclusion: One C. difﬁcile strain seems to be predominating in
Northern Bavaria CDAD patients. The increased number of CDAD cases
was probably promoted by common events, e.g. increased antibiotic
use due respiratory infects in winter. Therefore, infection control
programmes to restrict spread of C. difﬁcile should not be restricted
to hospitals but also should imply other healthcare facilities (nursing
homes, house doctors).
O329 High incidence of Clostridium difﬁcile associated diarrhoea
with a community onset in a hyperendemic region in
Germany
H.P. Weil, U. Fischer-Brugge, C. Harmanus, F. Mattner, P. Gastmeier,
E.J. Kuijper (Nordhorn, DE; Leiden, NL; Hannover, DE)
Background: Recent studies from UK and USA suggest an increase
of community-acquired CDAD, possible associated with use of proton
pump inhibitors (PPI).
Objectives: To investigate the incidence of CDAD among patients
with diarrhoea visiting the general practitioner and using the proposed
deﬁnitions of European Center of Disease Control and Prevention.
Methods: All faeces samples of patients with diarrhoea submitted
by general practitioners were investigated for CDAD by an enzyme-
immunoassay for C. difﬁcile toxin A/B. Positive samples were cultured
for the presence of C. difﬁcile. Isolates were typed by PCR ribotyping.
Standardised questionnaires were used to obtain clinical data and patient
information using ICD-10 classiﬁcation.
Results: Of 703 faeces samples submitted in a 6 months period in 2006,
34 (4.8%) contained Salmonella enteritica and 21 (3%) Campylobacter.
Giardia lamblia and Yersinia enterocolitica were isolated in 2 and 1
patients, respectively. C. difﬁcile was detected in 66 (9.3%) of all
faeces samples; 13 (26%) patients had moderate–severe diarrhoea
and 53 (74%) suffered from mild diarrhoea. Of 66 patients with
community-onset CDAD, 31 (47%) were healthcare-associated (onset
of symptoms within 48 h following admission or within 4 weeks after
discharge) and 53% were community-associated. The mean age of 66
patients (24 males and 41 females) with CDAD was 66 years. The
most frequent underlying diseases were cardiovascular disease (41%),
urogenital disease (20%), lung disease (14%), diabetes mellitus (11%)
and malignancy (9%). Recent antibiotic use was reported by 34 (52%)
patients with cephalosporins (33%) and ﬂuoroquinolones (33%) as most
frequently. Of 66 patients, 19 (29%) received a PPI and 17 (26%)
NSAID. Preliminary results of typing of 14 strains revealed 8 different
types with type 001 (21%) and type 015 (14%) as the predominant types.
Conclusion: Clostridium difﬁcile was the most frequent cause of
diarrhoea in a population of patients who visited the GP because of
diarrhoea, but 47% was healthcare-associated.
O330 Predicting Clostridium difﬁcile toxin in hospitalised patients
with antibiotic-associated diarrhoea
J. Bishara, N. Peled, Z. Samra, S. Pitlik (Petah-Tiqva, IL)
Objectives: Clostridium difﬁcile infection is implicated in 20−30% of
cases of antibiotic-associated diarrhoea. Few studies have evaluated risk
factors for the development of C. difﬁcile-associated diarrhoea (CDAD)
in patients with antibiotic-associated diarrhoea. Our objective was to
compare clinical characteristics of hospitalised patients who received
antibiotics and developed CDAD with hospitalised patients who received
antibiotics and developed diarrhoea with negative C. difﬁcile toxin assay
in their stool.
Methods: A prospective cohort study of hospitalised patients who had
received antibiotics and developed diarrhoea were included. CDAD
patients were deﬁned as patients who had diarrhoea and was associated
with a positive stool toxin A/B enzyme immunoassay test. Univariate
and stepwise logistic regression analyses were used for prediction
of C. difﬁcile toxin. The predictive capability of the model was
demonstrated by a receiver operator characteristic (ROC) curve.
Results: Fifty-two (24%) out of 217 patients were found to be positive
for C. difﬁcile toxin A/B in their stool. The logistic regression model
included impaired functional capacity, watery diarrhoea, use of a proton
pump inhibitor, use of a histamine receptor blocker, leukocytosis, and
hypoalbuminaemia. The area under the receiver operator characteristic
curve for the model as predictor to positive stool toxin assay was
0.896 [95%CI: 0.661–1.00; p< 0.001], with a 95% speciﬁcity and
68% sensitivity.
Conclusions: Our results may help clinicians predict the risk of
CDAD in hospitalised patients with antibiotic-associated diarrhoea,
guide careful antibiotic prescription and early attention to infection
control issues.
O331 Metronidazole and vancomycin outcomes for Clostridium
difﬁcile-associated diarrhoea in a US hospital database
B.J. Lahue, D.M. Davidson (Cambridge, Waltham, US)
Objective: Clostridium difﬁcile-associated diarrhoea (CDAD) treatment
guidelines recommend metronidazole (MET) ﬁrst-line and vancomycin
(VANC) second, but few studies compare outcomes. The objective of
this study is to compare hospital outcomes for identiﬁed CDAD patients
treated ﬁrst with MET versus VANC therapy.
Methods: CDAD cases (ICD-9 008.45) January 2004 to June 2005
were identiﬁed in a national US hospital database (Premier Perspective).
Inpatient cases receiving oral MET or VANC were analysed, and
initial dual therapy cases were excluded. Groups were compared
on demographics, prior CDAD admissions, and comorbidity proxy
measures, the APR-DRG Severity of Illness (SOI) and Risk of Mortality
(ROM). Length of stay (LOS), in-hospital mortality, ICU stay, colon
resection deﬁned case outcomes. Chi-square and t-tests produced
p-values.
Results:We identiﬁed 32,325 CDAD cases treated ﬁrst with MET (89%)
or VANC (11%). Cases were similar in age (mean 70 years, p = 0.38).
Fewer (p< 0.0001) MET than VANC cases were female (58% vs 64%),
had a principal CDAD diagnosis (19% vs 31%), prior CDAD admission
(10% vs 31%) or prior acid suppressive therapy (42% vs 53%). Higher
SOI and ROM were observed in MET vs VANC (p< 0.0001), with
30% MET and 24% VANC rated extreme SOI. During hospitalisation,
15% VANC cases subsequently received MET, and 12% MET received
VANC; 9% MET and 11% VANC received IV MET (unknown if
speciﬁcally for CDAD), and 1.5% MET and 3.1% VANC received
rifampin. MET vs VANC had increased LOS (12.8 vs 11.5 days,
p< 0.0001), in-hospital death (7.9% vs 6.8%, p< 0.02), and ICU stay
(23.2 vs 17.7 days, p< 0.0001). There was no difference in colectomy
(1.0% MET vs 0.8% VANC, p = 0.37). Despite lower costs of MET vs
VANC therapy, total pharmacy costs were similar ($2,439 vs $2,492,
p = 0.52), while total hospitalisation costs were higher ($16,953 vs
$14,718, p< 0.0001).
Conclusion: Most CDAD patients received MET, and modiﬁcation to
initial therapy occurred in similar proportions of MET and VANC cases.
Compared to initial VANC therapy, those treated with MET had higher
rates of poor discharge outcomes and greater resource use, however
comparisons do not adjust for acute comorbidities.
O332 Successful combat against Clostridium difﬁcile
PCR-ribotype 027 at a regional outbreak from 2003–2006
in the Netherlands
D. Veenendaal, E. Kuijper (Haarlem, Leiden, NL)
Background: Since 2003 severe cases of Clostridium difﬁcile (CD)
associated diarrhoea (CDAD) have been reported in hospitals in North
America and Europe caused by a hypervirulent strain CD ribotype 027,
toxinotype III. This ribotype is also detected in The Netherlands.
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Objective: A descriptive study to the incidence of CDAD after the
introduction of speciﬁc infection control measures in a region with
outbreaks due to type 027.
Methods: A case of CDAD was deﬁned as a patient with diarrhoea
and a positive toxin test on a faeces sample (ICTAB, Meridian). Strains
isolated from positive faeces samples were further investigated by PCR
ribotyping.
Results: The Public Health Laboratory Haarlem, The Netherlands,
services an area with 440,000 inhabitants including nursing homes
and three hospitals (A, B and C). Monthly admission rates of the
latter are 1,050, 1,300 and 1,600, respectively; overall admission rate
47,000 yearly. Retrospective evaluation of laboratory data showed short
episodes of CDAD outbreaks in hospital A in October 2002 (incidence
62/10,000 admissions) and June 2003 (121/10,000); in hospital C in
December 2003 (50/10,000) and April 2004 (44/10,000). The highest
CDAD increase was found in hospital B in August 2004 (>130/10,000).
The latter episode was found to be the start of a long-term increase
of CDAD with incidence peaks of >100/10,000 admissions per month
in all hospitals as well as one nursing home to which hospital patients
were transferred. In the 3rd quarter of 2005, 67% of 30 CD strains from
hospitalised patients belonged to the hypervirulent ribotype 027. Speciﬁc
measures against CDAD were introduced in all hospitals and nursing
homes: strict barrier precautions as private room, glove use, gowns
and hand washing, environmental cleaning with bleach and restrictive
use of ﬂuoroquinolones. Also a laboratory algorithm was introduced to
investigate all faecal samples from hospitalised patients with diarrhoea.
Subsequently, during the 4th part of 2005 until the 3rd part of 2006,
CDAD incidence decreased to a mean of 21/10,000 (range 30−13/
/10,000) admissions, corresponding with the national incidence. The
percentage type 027 strains decreased from 67% to 36% and 8% in
the 3rd 05, 1st 06 and 3rd 06 period, respectively.
Conclusion: Speciﬁc hygienic measures in combination with restrictions
of antibiotic prescriptions and intensiﬁed laboratory surveillance are
successful to overcome CD 027 outbreaks.
Bacterial phylogeny and complete genome
sequences
S335 Identiﬁcation of bacterial lineages using multi-strain whole
genome microarrays
J.A. Lindsay (London, UK)
Whole-genome multi-strain bacterial microarrays can be used to take
a rapid snapshot of gene presence or absence in unsequenced bacterial
genomes, and allow large bacterial populations to be interogated for
genetic markers of phenotypic, clinical or evolutionary behaviour.
We have designed and built a seven-strain Staphylococcus aureus
microarray, and used it to compare S. aureus isolates from nasal carriage,
community- and hospital-acquired disease. We found the S. aureus
genome consists of three parts, core, core variable (CV) and mobile
genetic elements (MGE).
About 70% of the genes in a S. aureus genome are common to all
strains and called core. Surprisingly, about 12% of genes are CV, their
presence, absence or variabity can be used to classify an isolate into one
of about ten human lineages. This classiﬁcation matches well with multi-
locus sequence typing clonal complexes. Many CV genes are regulators
of virulence genes, or known or predicted to be expressed on the
bacterial surface and to interact with the host during nasal colonisation
and infection. Since each lineage carries a unique combination of CV
genes scattered throughout the chromosome, there was likely to be
a common S. aureus ancestor but early evolutionary divergence of
lineages, with possible selection in the nose. MGE often carry key
resistance and virulence genes, and show substantial variation within and
between lineages, indicating frequent horizontal transfer. Interestingly,
we have been unable to identify any markers that differ between carriage
and typical invasive community isolates (not CA-MRSA), suggesting
community-acquired invasive disease is strongly dependent on host
factors.
We have also discovered the likely mechanism controlling the
independent evolution of lineages. A restriction modiﬁcation pathway
found in all S. aureus called Sau1 can block horizontal transfer of DNA
between isolates, and the speciﬁcity of the system varies according
to lineage. Thus DNA from one lineage is recognized as foreign and
digested by other lineages, but as self by isolates of the same lineage. Not
only does this explain independent lineage evolution, but has important
implications for how S. aureus continues to evolve, and in particular
to acquire MGE leading to increasingly antibiotic resistant and virulent
strains.
Infectious disease challenges in international
settings
S337 Baseline laboratory facilities on remote sites in Africa:
too much/too little?
A. de Frey (Johannesburg, ZA)
The provision of medical care to privately funded, isolated populations
in geographically and socio-economically remote areas of the world pose
the challenge of providing maximum laboratory support to medical and
para-medical personnel in the most cost effective way.
This requires a pragmatic approach based on a knowledge of the
clinically most signiﬁcant diseases in the area, either due to a high and
clinically signiﬁcant incidence or a high risk of signiﬁcant morbidity
and or mortality due to disease, the outcome of which may require or
may beneﬁt from reliable, affordable and readily available laboratory
diagnostics.
The author provides a perspective on this challenge based on the
provision of medical services to multinational companies operating in
remote areas of Africa on a limited budget over a ten year period.
In a setting in which a relatively small number of expatriate and national
employees are taken care of with limited funding, the healthcare provider
needs to be aware of the health risk proﬁle of the region in which the
service is rendered, the likely exposure of the population served to the
prevalent diseases and the availability of laboratory tests that could or
would make a signiﬁcant difference to clinical disease management if
available
The main limiting factor in the provision of laboratory support to a
medical service is funding.
Laboratory equipment may vary from a number of simple dry chemistry
based kits to sophisticated spectrophotometer and other technology based
analysers.
A number of factors impact on this including ease of operation of
the provided tests, sensitivity and speciﬁcity, quality assurance and
sustainability.
The absence of trained laboratory personnel is most often a signiﬁcant
determinant in the decision making process regarding the level of
sophistication that can be achieved.
On the African continent the advent of rapid malaria antigen test kits
have had a major impact on suspected malaria case management in the
absence of trained miscroscopists.
Long standing main stays of side-room diagnostics such as blood and
urine test kits capable of detecting a number of metabolic and other
diseases prove to be cost effective, regularly useful, affordable and
sustainable whilst sophisticated dry chemistry analysis machines ﬁnd
a very limited application on a remote site with limited medical and
other infra-structure.
Dry chemistry tests that may be useful in this setting are superﬂuous in
a setting in which a patient who requires, e.g., regular kidney function
monitoring needs to be evacuated due to the overall limitations beset by
the area.
S338 Medical challenges in migrants
T. Jelinek (Berlin, DE)
Migrants and other mobile individuals, such as migrant workers
and asylum seekers, are an expanding global population of growing
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social, demographic and political importance. Often, grave disparities
exist between place of origin and destination, in particular with
relation to health determinants. The effects of those disparities can
be observed at both individual and population levels. Migration
inﬂuences the epidemiology of many diseases globally and in nations
receiving migrants. Speciﬁc disease-based outcomes may vary between
migrant group and location. Traditionally, migration health activities
have been designed for national application and lack an integrated
international perspective. Present and future health challenges related
to migration may be more effectively addressed through collaborative
global undertakings. The epidemiological relationships resulting from
health disparities in migration are reviewed and the growing role of
migration and population mobility in global disease epidemiology is
highlighted. Implications for national and international health policy and
programme planning are presented.
S340 Emerging viral diseases: ﬁghting an uphill battle
S.K. Lam (Kuala Lumpur, MY)
In the last decade, Southeast Asia has become the epicentre of a number
of new disease outbreaks with the potential for global spread. Nipah virus
encephalitis ﬁrst occurred in Malaysia in 1998 and there is serological
evidence that the virus has spread to Cambodia, Thailand, China and
India. In Bangladesh, Nipah virus or one closely related to it has
caused several outbreaks in Bangladesh with a high mortality rate. The
outbreak of severe acute respiratory syndrome (SARS) followed by avian
inﬂuenza H5N1 in China and their subsequent spread led to fear of global
pandemics. Many factors accounting for the emergence of new infections
must be in place prior to such outbreaks. The convergence of a number
of these factors in Southeast Asia makes this region a hotspot for their
emergence.
In order to mount a programme to ﬁght emerging viral diseases, it
is important to have adequate funds and political commitments. The
key to a comprehensive programme includes good surveillance, clinical
hospital management, preventing disease spread, strong laboratory
support, research and evaluation, and a well-tested national preparedness
plan. Surveillance is complicated in the case of a zoonotic disease
such as avian inﬂuenza H5N1. Hospitals are ill-equipped to cater to
large numbers of severely ill patients as in the Nipah virus outbreak
in Malaysia. Preventing disease spread in an era of globalisation
poses tremendous challenges in developing countries that depend on
international trade and tourism. Research and evaluation are greatly
hampered by lack of manpower and infrastructure, including the lack
of high security laboratories. Although there are guidelines available for
pandemic preparedness as in the case of avian inﬂuenza, national plans
are totally inadequate and do not measure up to expectation.
Despite these inadequacies, developing countries in Southeast Asia are
making contingency plans in the event of unexpected viral emergence.
There is no doubt that this will be an uphill battle but certain measures
initiated in the region will hopefully reduce the spread of emerging viral
diseases.
Antimicrobial drug discovery: the road is
long . . . (Symposium arranged with the
ICAAC Program Committee)
S345 What’s in the pipeline? Cell wall inhibitors/
miscellaneous metabolism inhibitors
K. Bush (Raritan, US)
Cell wall inhibitors have traditionally provided the infectious disease
community with safe and efﬁcacious agents to treat serious bacterial
infections. In addition, metabolism inhibitors, singly or in combination,
have continued to provide coverage for some of the more resistant
pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).
Of the cell wall inhibitors in the pipeline, b-lactams have been a
major component of antibiotic discovery programmes, but lagged in
development as multidrug-resistant Gram-positive bacteria, such as
MRSA, and cephalosporin-resistant Gram-negative organisms emerged
as prevalent nosocomial pathogens. Compounds in late stage de-
velopment include anti-MRSA b-lactams such as ceftobiprole, the
broad-spectrum cephalosporin that has successfully completed two
Phase III trials in complicated skin and skin structure infections
(cSSSI). Following are two investigational anti-MRSA b-lactams, the
anti-MRSA cephalosporin, ceftaroline, that has completed a Phase II
cSSSI trial and the carbapenem CS-023/RO-4908463 with in vitro
activity against MRSA and cephalosporin-resistant Enterobacteriaceae.
Also in development are two additional carbapenems, ME1036, in
Phase I studies, with activity against MRSA as well as against most
Enterobacteriaceae, and SMP-601/PZ-601 that has demonstrated in vitro
activity against many multidrug-resistant Gram-positive and Gram-
negative bacteria in preclinical studies.
Other b-lactam agents in development include doripenem, a carbapenem
with enhanced activity against Pseudomonas aeruginosa; doripenem has
recently completed clinical trials for complicated urinary tract infections
and intra-abdominal infections. FR264205 is an unusual preclinical
cephalosporin with promising in vitro activity against Helicobacter
pylori and AmpC-hyperproducing P. aeruginosa.
Additional cell wall active agents include lipoglycopeptide inhibitors
that are active against most Gram-positive bacteria. Telavancin and
dalbavancin are in late-stage regulatory reviews, and are characterised by
long half lives in humans, with a proposed once-weekly dosing regimen
for dalbavancin.
Iclaprim, a dihydrofolate reductase inhibitor that is the most advanced
metabolism inhibitor with completion of a Phase III cSSSI clinical
trial, demonstrates in vitro antibacterial activity against MRSA,
penicillin-resistant pneumococci and other respiratory pathogens. Other
metabolism inhibitors that have been described in early development
include peptide deformylase inhibitors and inhibitors of fatty acid
biosynthesis. However, none of these early metabolism inhibitors have
proceeded to proof-of-concept therapeutic studies at this time.
S346 The compound bank approach: complementing to increase
the chance of success
T. Trust (Waltham, US)
Since the publication of the ﬁrst complete bacterial genome in 1995,
the genome-derived target based approach to discover new classes of
antibacterial drugs with novel mechanisms of action has been employed
widely. The literature shows that the success rate of both biochemical
screening of individual antibacterial targets, and whole-cell antibacterial
screening has been disappointing. In retrospect, this is not surprising
given the historical content of the chemical collections that companies
employed in their early high throughput screening campaigns. Most
companies have engaged in “cleaning-up” their compound libraries
in recent years and have increased the molecular diversity of their
collection in efforts to increase the chance of success, regardless of
therapeutic area. Efforts have also been made to create focussed chemical
libraries that are better suited to ﬁnding antibacterial compounds. By
complementing the screening of diverse, drug-like, infection-friendly
compound collections against drugable targets, and early application
of structure-based approaches, we should see breakthroughs in the
discovery of antibacterial drugs with novel mechanisms of action.
S347 The natural product approach: advances over the last
10 years that make it an attractive approach again
S. Pelzer (Berlin, DE)
There is an urgent medical need to discover and develop new antibiotics,
since resistance to antibiotics is becoming an increasingly frequent
problem and current development pipelines are lacking innovative, novel
antibiotic classes. In the past natural products dominated the ﬁeld
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of antibiotics and have had a signiﬁcant role in the discovery and
development of commercially successful drugs of all classes. Over 75%
of the antibacterial new chemical entities (NCEs) introduced worldwide
between 1981 and 2002 were based on natural products. The unmatched
chemical diversity and complexity of natural products is one reason for
their success over those obtained by pure chemical synthesis. Another
reason for their superiority can be explained by the fact that their
synthesis evolved naturally in response to needs and challenges of the
natural environment generating compounds which are pre-selected for
activity. Despite these facts, natural product research has recently gone
through a phase of reduced interest. Big pharmaceutical companies in
particular have downgraded or even stopped this kind of research. The
reasons for this development may be that natural products are often
produced in low quantities and as mixtures of similar compounds, the
rediscovery of known compounds and the challenge of natural product
derivatisation using classical chemical means.
The past few years have witnessed major developments in the use of
innovative natural product related technologies, such as fermentation
optimisation, separation, structure elucidation and dereplication allowing
much faster access to sufﬁcient quantities of pure natural compounds.
The application of modern medicinal chemistry adapted to the special
needs of natural products is also an efﬁcient way to revisit and recycle
old antibiotic classes. The use of modern Genome-based technologies,
established in the past few years, offers the opportunity to increase the
attractiveness of natural products. Genome-based screening technologies
provide fast access to the enormous genetic potential of Actinomycetes,
soil bacteria known to represent one of the most important sources for
bioactive metabolites. Additionally, genetic engineering technologies will
help to overcome two of the main hurdles connected to natural products,
the difﬁculty in derivatising complex structures and the quantitative
improvement of the production yield.
By focussing on examples in the ﬁeld of genome based screening and
genetic engineering this presentation will give an overview of major
improvements that may lead to a rediscovery of natural product based
drugs to meet the urgent need for new antibiotics.
Respiratory pathogens and vaccination
O348 Clinical evaluation of a new ID-Tag RVP assay for the
detection of 20 respiratory viruses
J. Mahony, S. Chong (Hamilton, CA)
Objectives: To evaluate the performance of the ID-Tag RVP test for the
detection of respiratory viruses.
Methods: NP specimens [N= 227] were collected from symptomatic
patients under ERB approval and were tested by the ID-Tag RVP
test (TmBioscience Corp’n, Toronto, Canada) and conventional DFA
plus culture. The RVP test is a new test for the detection of
20 respiratory viruses that uses multiplex PCR, a Universal Array
of oligonucleotides (TmBioscience), and a ﬂuidic microbead array
(Luminex X-Map). The test detects Inﬂuenza A (subtypes H1, H3,
and H5 Asian lineage), Inﬂuenza B, Parainﬂuenza types 1, 2, 3, 4, RSV
types A and B, Adenovirus, Metapneumovirus, Rhinovirus/Enterovirus,
Coronavirus 229E, OC43, NL63, HKU1, and (SARS-CoV). The ID-
Tag RVP test was performed according to manufacturer’s instructions.
Brieﬂy, viral nucleic acid was ampliﬁed by a multiplex PCR followed a
multiplex Target Speciﬁc Primer Extension (TSPE) reaction and sorting
of TSPE products using the Luminex X-Map system. DFA and culture
were performed using MCabs and R-Mix shell vials (Diagnostic Hybrids
Inc.). For discordants and RVP positives where the targets were not tested
by DFA/culture, a second PCR (unique primers) and sequencing was
performed as the comparator test.
Results: Twenty-two of 227 specimens (9.7%) failed to give a signal for
the internal control indicating extraction failure or was called equivocal
for at least one target. Of the 206 specimens analysed, 135 were
RVP+ DFA/culture+ and 37 were RVP− DFA/culture− concordant. There
were 7 RVP− DFA/culture+ and 27 RVP+ DFA/culture− discordants.
After resolution of discordants RVP had a sensitivity of 95.8% (138/144)
compared with 93.7% (135/144) for DFA/culture. RVP detected an
additional 26 conﬁrmed positives including 22 Rhino/Entero, 1 NL63,
and 3 HKU1 that are not routinely tested by DFA or culture and
4 additional Flu B positives that were missed by DFA/culture.
Conclusion: The ID-Tag RVP test is more sensitive than DFA/culture
and detects a number of respiratory viruses not routinely tested for.
Overall 22.5% additional positive specimens were detected that were
either missed by DFA/culture or not tested for. The ID-Tag RVP test
should improve the ability of hospital and public health laboratories to
diagnose viral RTIs in a hospital or community outbreak situation.
O349 Molecular epidemiology, genotypes and recombination of
coronavirus HKU1, a novel human coronavirus associated
with respiratory tract infections
P.C.Y. Woo, S.K.P. Lau, C.C.Y. Yip, Y. Huang, H.W. Tsoi, R.W.S. Poon,
B.H.L. Wong, K.H. Chan, K.Y. Yuen (Hong Kong, HK)
Objectives: Recently, we described the discovery of a novel group 2
coronavirus, coronavirus HKU1 (CoV-HKU1), from a patient with
pneumonia. In this study, we examined the molecular epidemiology,
genotype distribution and recombination in CoV-HKU1.
Methods: We collected nasopharyngeal aspirates of patients with
respiratory tract infections over a two-year period. The complete
genomes of a total of 22 strains of CoV-HKU1 were sequenced
and compared. Genotypes and possible sites of recombination were
determined.
Results: Phylogenetic analysis of 24 putative proteins and polypeptides
showed that the 22 CoV-HKU1 strains fell into three clusters
(genotype A, 13 strains; genotype B, three strains and genotype C, six
strains). However, different phylogenetic relationships among the three
clusters were observed in different regions of their genomes. From nsp4
to nsp6, the genotype A strains were clustered with the genotype B
strains. For nsp7 and nsp8, and from nsp10 to nsp16, the genotype A
strains were clustered with the genotype C strains. From hemagglutinin
esterase (HE) to nucleocapsid (N), the genotype B strains were clustered
closely with the genotype C strains. Bootscan analysis showed possible
recombination between genotypes B and C from nucleotide positions
11500 to 13000, corresponding to the nsp6/nsp7 junction, giving rise to
genotype A; and between genotypes A and B from nucleotide positions
21500 to 22500, corresponding to the nsp16/HE junction, giving rise to
genotype C. Multiple alignments further narrowed the sites of cross-over
to a 143-bp region between nucleotide positions 11750 and 11892, and
a 29-bp region between nucleotide positions 21502 and 21530. Genome
analysis also revealed variable numbers of tandem copies of a perfect
30-base acidic tandem repeat which encodes NDDEDVVTGD and
variable numbers and sequences of imperfect repeats in the N-terminal
of nsp3 inside the acidic domain upstream of papain-like protease 1
among the 22 genomes. All 10 CoV-HKU1 with incomplete imperfect
repeats (1.4 and 4.4) belonged to genotype A.
Conclusions: Three genotypes, genotype A, genotype B and genotype C,
exist in CoV-HKU1. Analysis of a single gene is not sufﬁcient
for genotyping of CoV-HKU1, but would require ampliﬁcation and
sequencing of at least two gene loci, one from nsp10 to nsp16 (e.g.
pol or helicase) and another from HE to N (e.g. spike or N).
O350 Epidemiology and diagnosis of epidemic and avian inﬂuenza
in Australia
C. Baleriola, S. Stelzer, R. Escott, P. Kirkland, P. Robertson,
W. Rawlinson (Randwick, North Ryde, Candem, AU)
Inﬂuenza activity in temperate regions of Australia typically occurs
between May and September, whereas in tropical regions inﬂuenza can
occur any time throughout the year.
The main purpose of this presentation is to outline the epidemiology
of human inﬂuenza during 2001–2006 in NSW. The second purpose
is to report a quality assurance programme for laboratory diagnosis of
inﬂuenza throughout Australia, including avian inﬂuenza.
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Epidemiological data from NSW, Prince of Wales Hospital (Sydney)
shows that Respiratory syncytial virus (RSV) is the ﬁrst respiratory
virus emerging in the winter season. Inﬂuenza A infections typically
last for 4−5 weeks during August and September. Infections with
other respiratory viruses such as Parainﬂuenza virus 3 and human
metapneumovirus occur from June to late November and December.
Summary data from the last 5 years will be presented.
Inﬂuenza data from 2001 to 2006 indicate that the ﬁrst ones affected
early in the season are children and young adults, whereas during peak
season the majority are between 20 and 50 years of age. There is an
even distribution between the number of inﬂuenza attacks among males
and females (51% and 49% respectively). From a total of 500 specimens
tested for respiratory viruses during 2001–2006, 51% were true inﬂuenza
cases, 10% RSV and 17% rhinovirus. Data collected from the Prince
of Wales Hospital is submitted on a weekly basis to the New South
Wales Department of Health as part of the NSW Inﬂuenza Surveillance
Program.
During 2006 we have undertaken a Quality Assurance Program aiming
to improve detection and diagnosis of HPAI H5N1 among Australian
and Asian Laboratories in collaboration with the Royal College of
Pathologists Australia (RCPA) and the Elizabeth MacArthur Agricultural
Institute, integrating human and veterinary health laboratories. The
project assesses H5 diagnosis accuracy using serological and molecular
techniques, utilising a new avian inﬂuenza module within the Serology
Quality Assurance Program (SQAP). The report from the ﬁrst Nucleic
acid testing panel is already available to the 30 participant laboratories.
The results suggest that testing laboratories around Australia and Asia
generally utilise accurate and sensitive methods for detection of H5N1,
although some laboratories are only testing for Inﬂuenza A and are
currently not performing speciﬁc H5N1 tests.
O351 Model-based pandemic inﬂuenza preparedness planning
M. Schwehm, H. Duerr, S. Brockmann, M. Eichner (Tu¨bingen,
Stuttgart, DE)
Objectives: Inﬂuenza pandemic preparedness plans are currently being
developed on national and international levels. Planning public health
responses rely on predictive models by which the impact of different
intervention strategies can be evaluated. Previous research has rather
focused on producing predictions for certain localities or under speciﬁc
conditions and on the administration of antiviral drugs. The effectiveness
of these interventions depends on various factors which must be
explored by sensitivity analyses, based on mathematical models. We
investigate how pharmaceutical and non-pharmaceutical interventions
can mitigate an inﬂuenza pandemic and examine how intervention
schedules, restricted stockpiles and contact reduction (social distancing
measures and partial isolation of cases) determine the course of a
pandemic wave and the success of interventions.
Methods:We provide the freely available planning tool InﬂuSim (ﬁgure),
a deterministic compartment model, which is based on a system of
over 1,000 differential equations and designed to operate with an optimal
combination of the competing requirements of precision, realism and
generality. It allows for producing time courses and cumulative numbers
of inﬂuenza cases, outpatient visits, applied antiviral treatment doses,
hospitalisations, deaths and work days lost due to sickness, all of which
may be associated with economic aspects.
Results: The model shows that a timely application of antiviral drugs
combined with a quick implementation of contact reduction measures
is required to substantially protract the peak of an inﬂuenza epidemic
and reduce its height. Delays in the initiation of antiviral treatment (e.g.
because of parsimonious use of a limited stockpile) result in much more
pessimistic outcomes and can even lead to the paradoxical effect that the
stockpile is depleted earlier compared to early distribution of antiviral
drugs.
Conclusion: InﬂuSim efﬁciently assists public health planners in de-
signing optimal interventions against pandemic inﬂuenza. It reproduces
the infection dynamics of pandemic inﬂuenza like complex computer
simulations while offering at the same time reproducibility, higher
computational performance and better operability. When controlling
pandemic inﬂuenza, pharmaceutical and non-pharmaceutical measures
should not be used exclusively. Contact reduction measures must be part
of mitigation strategies and have the advantage to be not limited per se.
O352 Evaluation of the antibody responses induced by the
2006–2007 inﬂuenza vaccine
Y.-J. Chan, S.-J. Hwang, J.-C. Lin, C.-H. Tsai, C.-Y. Liu, S.-D. Lee,
D.M. Ho, C.-H. Lee (Taipei, TW)
Objectives: Although inﬂuenza (Flu) is an old infectious disease, it
will cause pandemics and requires global cooperation for control and
prevention. In addition to the avoidance of exposure during the inﬂuenza
season vaccination has been the most effective modality for preventing
inﬂuenza epidemics. However, due to the genetic variability of the
inﬂuenza it requires vaccination every year. Our Department of Health
supported free inﬂuenza vaccination for aged people (>65 year-old) for
years and the host antibody responses are evaluated.
Methods: A total of 89 paired sera was collected before and 3 weeks
after the vaccination with one dose of a commercial trivalent inﬂuenza
vaccine for 2006–2007. The paired samples were tested for inﬂuenza
A and B antibodies by complement ﬁxation (CF) and quantitative
enzyme-linked immunosorbent assay (ELISA). In addition, 83 paired
sera were tested by haemagglutination inhibition (HI) using an A/New
Caledonia/20/99-like strain. There were 49 males and 34 females, and
47 people were older than 65.
Results: Our results indicated that the CF response rates (deﬁned as
4-fold titer increase of the paired sera) for both inﬂuenza A and B
were low (33.7% and 15.7%, respectively). However, the pre-immunised
ELISA titers for both inﬂuenza A and B were much higher than
normal (average 98.3±45.6 RU/mL for Flu A and 176±57.5 RU/mL
for Flu B; normal <22RU/mL). The overall response rate for HI was
32.5% (27/83), but the response rate of the aged (>65 year-old) was
lower (27.7%, 13/47) than people <65 year-old (38.9%, 14/36). However,
the rate of pre-immunised sera with protective HI titer (HI 40) was
80.7% (67/83).
Conclusion: The antibody responses induced by the 2006–2007
inﬂuenza vaccine were low, but the pre-immunised antibody positive
rates and titers were high. The phenomenon might reﬂect the quality of
the vaccine and the consequences of previous vaccination.
O353 Perception of adverse-effect risks and receipt of inﬂuenza
vaccination among hospital personnel
B.P. Ehrenstein, F. Hanses, S. Blaas, F. Mandraka, F. Audebert,
B. Salzberger (Regensburg, DE)
Objectives: Hospital personnel (HP) are at risk for contracting inﬂuenza
and may transmit inﬂuenza to patients. Although, inﬂuenza vaccination
of HP signiﬁcantly reduces the overall mortality of patients, vaccination
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rates in many hospitals remain low. Surveys among HP delineated fear of
adverse effects (AE) as an important reason for HP not to get vaccinated.
We surveyed HP to delineate their appraisal of inﬂuenza vaccine AE rates
and to correlate correct knowledge of AE rates with the receipt of
inﬂuenza vaccination.
Methods: In February 2006, we distributed anonymous self-
administered, multiple-choice paper questionnaires to the 637 physicians
and ﬁnal-year medical students (FYMS), 994 nurses, and 267
hospital administrators at a university tertiary care hospital. Questions
pertained to the incidence and complication rates of inﬂuenza, to the
general knowledge about, and the indications for inﬂuenza vaccination,
and to the rates of twelve possible inﬂuenza-vaccination AE. We also
retrieved demographic data, the receipt of inﬂuenza vaccination in the
current season (2005/2006), and the most important reason to get or not
get vaccinated.
Results: 647/1898 (34%) surveys were returned. 345/647 (53%)
respondents had received inﬂuenza vaccination in 2005/2006. 127/302
(42%) 2005/06 non-vaccinated HP stated that vaccine AE were the
most important reason not to get vaccinated. Overall, respondents
underestimated the incidence rates of non-severe AE (headache, muscle
aches, fever, chills, painful injection site, and >2 days absenteeism) and
overestimated severe AE rates (skin necrosis, severe hepatitis, acute renal
failure, encephalitis, Guillain-Barre´ syndrome, permanent neurological
damage). In a multivariate analysis among physicians and FYMS, receipt
of inﬂuenza vaccination 2005/06 was independently associated with
above-average knowledge about inﬂuenza vaccine (OR 2.4) and correct
appraisal of severe AE rates (OR 3.7), among nurses with above-average
knowledge about the inﬂuenza vaccine (OR 2.1) and an underestimation
of non-severe AE rates (OR 3.6).
Conclusion: HP overestimated the severe AE rates and underestimated
the non-severe AE rates of inﬂuenza vaccination. The appraisal of these
AE rates appears to be very important in the decision of HP to get
vaccinated. A better mediation of the actual very low rates of severe
adverse effects may improve the inﬂuenza-vaccination rates among HP.
O354 Cross-subtype immunity against avian inﬂuenza in humans
recently vaccinated for the inﬂuenza season
C. Castilletti, C. Gioia, L. Bordi, C. Agrati, M. Tempestilli,
R. Chiappini, P. Piacentini, S. Squarcione, G. Ippolito, M. Capobianchi,
F. Poccia (Rome, IT)
Objectives: Avian H5N1 inﬂuenza viruses could be transmitted to
humans, resulting in severe or fatal disease. Aim of this study was to
evaluate the immune cross-reactivity between human and avian (H5N1)
inﬂuenza strains in healthy donors vaccinated for seasonal H1N1/H3N2
inﬂuenza A.
Methods: Healthcare workers wishing to receive seasonal inﬂuenza
vaccination at the Spallanzani Institute were enrolled. Blood samples for
the assessment of humoral and cell-mediated responses were obtained
before and 30 days after vaccination. The frequency of circulating
antigen-speciﬁc CD4 and/or CD8 T-cells in healthy donors enrolled in
the study were analysed by ﬂow cytometry, using intracellular cytokine
staining assay after the expansion of effector-cells in vitro. Human sera
from the same donors were tested for their HA-inhibition activity against
vaccine preparation and neutralisation activity against H5N1 virus.
Results: Our data indicate that vaccination may boost cross-subtype
cellular and/or humoral immunity against H5N1 inﬂuenza. Speciﬁcally,
H5N1-speciﬁc CD4 T-cell frequency was signiﬁcantly higher in pluri-
vaccinated versus ﬁrst ﬂu-vaccinated donors. The main target for
cross-reactivity between H5N1 and H3N2/H1N1 strains was N1. No
correlation between inﬂuenza-speciﬁc CD4 T-cells and humoral response
was observed, suggesting that this response was mainly CD4 T-cell-
independent. Differently, CD4 T-cells may help for anti-inﬂuenza
CD8 T-cell response. Furthermore, human sera from the same donors,
tested for their HA-inhibition activity against vaccine preparation,
showed a signiﬁcant rise (73.7%) after vaccination. The same sera were
tested for their H5N1 neutralisation activity and 34.2% of subjects
was able to show anti-H5N1 antibody rise after seasonal inﬂuenza
vaccination, showing the existence of an antibody-dependent cross-type
immunity. No correlation between inﬂuenza speciﬁc CD4 T-cells and
humoral responses were observed, suggesting that this type of antibody
response was mainly CD4 T-cell independent.
Conclusion: In this study, we demonstrated that vaccination against
seasonal inﬂuenza might induce both cellular and humoral cross-reactive
immunity against H5N1 avian inﬂuenza. This cross-type immunity may
represent an important component of the immune response against novel
inﬂuenza A infections.
O355 Potential impact of pneumococcal vaccination in Denmark
Z.B. Harboe, P. Valentiner-Branth, T. Hjuler, J.J. Christensen,
L. Lambertsen, K. Mølbak, H.B. Konradsen (Copenhagen, DK)
Background: Since 2000, the pneumococcal 7-valent protein-conjugate
vaccine (PCV-7) has been implemented in the childhood vaccination
programme in several countries. In Denmark (DK), the PCV-7 is only
recommended for children in high-risk groups.
Objective: To describe incidence and antibiotic resistance of invasive
pneumococcal disease (IPD) and estimate the direct and indirect effect
of PCV introduction in DK.
Methods: Review of demographic and laboratory data from IPD
cases between 2000 and 2005. Data on pneumococcal meningitis were
obtained from the Notiﬁable Infectious Disease Register. Considering
the local serotype distribution, the direct effect of PCV-7, -10, and -13
was estimated in children under 5 years (<5 y), assuming a 90%
vaccination coverage and a 97% effectiveness in reducing IPD caused
by vaccine-serotypes. Herd immunity effect was estimated assuming a
40% reduction of IPD caused by vaccine-serotypes.
Results: (1) Incidence: The total incidence remained stable throughout
the period, ~20/100,000 population, whereas the incidence in <5 y
increased from 25 to 34. The highest incidence was observed among
adults >65 years, ~69 per 100,000. 92% of cases presented as
bacteraemia. Approx. 100 cases of pneumococcal meningitis were
registered annually, with an overall mortality of 20%. (2) Vaccine
effectiveness: The overall serotype coverage among IPD< 5 y was
estimated as: 64% (PCV-7), 82% (PCV-10), and 91% (PCV-13). With
an annual average of 86 cases of IPD< 5 y the number of vaccine-
preventable cases would be: 48 (PCV-7), 61 (PCV-10) and 68 (PCV-13).
The annual number of IPD> 5 y protected by herd immunity would be:
144 (PCV-7), 237 (PCV-10) and 277 (PCV-13). In terms of mortality,
2.1 children <5 y die annually. Introduction of PCV would prevent
1.2 deaths (PCV-7), 1.5 (PCV-10) and 1.7 (PCV-13). The annual
number of deaths among IPD> 5 y is 199; 30 fatal cases would be
prevented by PCV-7, 46 by PCV-10 and 55 by PCV-13. (3) Antibiotic
resistance: 2.5% of the isolates tested for penicillin susceptibility had
MIC> 0.125 ug/mL, none had MIC> 2 ug/mL. 5% of isolates presented
erythromycin MIC> 1.5 ug/mL.
Conclusions: The incidence of IPD< 5 y increased during 2000–2005 in
DK. The PCV-10 and -13 would provide higher protection than PCV-7
based on the serotype distribution, mainly due to presence of serotype 1.
Monitoring serotypes, resistance, and mortality related to IPD is essential
in order to evaluate the effect of vaccine introduction.
O356 Comparison of immunogenecity of pneumococcal polysaccha-
ride vaccine with protein conjugate vaccine in Korean adults
S.Y. Lim, H.J. Lee, S.Y. Woo, J.Y. Seoh, K-H. Kim (Seoul, KR)
Objective: To compare the immunogenicity of a 7-valent pneumococcal
conjugate vaccine (PCV) to a 23-valent polysaccharide pneumococcal
vaccine (PPV) in Korean adults.
Methods: Twenty-seven and 20 healthy adults were immunised with
either a PCV or a PPV intramuscularly. Sera were obtained before and
at 4 weeks after immunisation to determine IgG pneumococcal antibody
titers by enzyme-linked immunosorbent assay and opsonisation tier by
opsonophagocytic killing assay to the 7 serotypes represented in the PCV.
Results: Antibody titers and opsonisation titers to 7 pneumococcal
serotypes were signiﬁcantly increased after immunisation in PCV and
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PPV groups. Post-immune antibody titers to serotype 4, 18C and 23F
were signiﬁcantly higher in PCV groups than in those in PPV group. Also
PCV elicited signiﬁcantly higher fold rise of opsonisation titer compared
with PPV in serotype 4, 18C and 23F. Antibody titers and opsonisation
titers to 7 serotypes have good correlation in pre-immune sera as well
as post-immuue sera in both groups. More than 95% of subjects in both
groups have antibody titer 1mg/mL to 7 serotypes after immunisation.
Serotype Vaccine EIA (mg/mL) OPKA (opsonisation titer)
Pre-im Post-im Fold incr Pre-im Post-im Fold incr
Pn 4 PPV 0.43 2.21* 4.83 17 1275* 73
PCV 0.48 6.56*# 13.60# 8 1656* 212#
Pn 6B PPV 1.06 6.17* 5.36 350 5958* 17
PCV 2.88 13.34* 4.63 73 3766* 52
Pn 9V PPV 1.08 6.05* 5.27 464 4424* 10
PCV 1.14 7.91* 6.94 59 3686* 63
Pn 14 PPV 3.02 18.70* 4.91 237 4846* 20
PCV 2.82 26.76* 9.49 48 2311* 48
Pn 18C PPV 1.1 5.80* 4.58 636 5583* 9
PCV 1.4 12.99*# 11.29# 12 2199* 184#
Pn 19F PPV 3.28 8.42* 2.25 40 2035* 51
PCV 3.66 12.60* 3.44 31 1142* 37
Pn 23F PPV 0.6 3.22* 4.81 478 2840* 6
PCV 1.15 10.92*# 9.48# 21 1280* 60#
aPre-im, pre-immune; Post-im, post-immune; Fold incr, fold increase.
Conclusions: Quantitative and qualitative antibody responses to PCV
and PPV are good in Korean adults. PCV is more immunogenic than
PPV to serotype 4, 18C and 23F.
O357 Differential propensity of serotype groups to switch and
acquire multidrug-resistance after the introduction of the
pneumococcal conjugate vaccine in the USA
R.M. Mera, L.A. Miller, H.A. Madsen, M.A. Pentella, T.R. Fritsche,
R.N. Jones (Durham, Upper Providence, Iowa City, North Liberty, US)
Objectives: The S. pneumoniae heptavalent conjugate vaccine, intro-
duced in February 2000, covered 73% of the US paediatric population in
2004. Changes over time in serotype prevalence and multidrug-resistance
(MR) to antibiotics were evaluated using results from a longitudinal
surveillance programme (SENTRY).
Methods: The study included 704 isolates: 301 from years before the
introduction of the vaccine (1998–1999) and 298 post-release (2003–
2004). Key demographic data, serotype and resistance proﬁles for
5 antimicrobial classes were analysed. Strains displaying resistance
(deﬁned as non-susceptibility based on CLSI breakpoints) to >2 classes
were considered MR. Statistical analysis was carried out using linear
mixed effects models for repeated measures.
Results: After adjusting for age, invasive status and region, a multivariate
logistic regression model showed that non-vaccine (NV) isolates are
1.9 times (1.3−2.7, p = 0.03) more likely to be MR in the post-vaccine
release period. When serotypes are divided into groups according to
the prevalence of multiple resistance and their propensity to expand
(i.e. become more prevalent after introduction of the vaccine), we
found that the serotype 19 not F was 4.4 times more likely to expand
(2.1−9.1) than other NV serotypes (p< 0.0001). A group formed by
serotypes [11, 15, 33, 35] is also more likely to increase in prevalence,
OR 2.4, 1.3−4.5, p = 0.01) than other NV serotypes. Details in resistance
prevalence and proportions at each point in time are shown in the table.
Conclusion: Groups of both vaccine and non-vaccine serotypes can
be categorised according to their propensity to expand and to acquire
MR. Serotype 19F slightly decreases in prevalence but increases in
MR rate, while serotype 19 not F both increases in prevalence and
acquires resistance at a rate that is proportional to the expansion process.
About half of the NV serotypes rapidly increased both in prevalence and
resistance. Vaccine serotypes (excluding 19F) decreased in prevalence
but not in resistance.
Serotypesa Prevalence Multiple resistance
Before After n Before After p
PCV7
19F 20.7% 17.6%~ 135 58.9% 80.6% ↑ 0.009
14, 6B, 9V 31.0% 8.2% ↓ 138 56.0% 72.0%~ NS
23F, 18C, 4 16.8% 3.4% ↓ 71 33.3% 50.7%~ NS
NV
11, 15, 33, 35 5.4% 19.6% ↑ 88 0% 20.3% ↑ 0.032
19 not F 3.1% 20.5% ↑ 83 27.3% 72.2% ↑ 0.003
6 not B 8.2% 8.8%~ 60 58.1% 55%~ NS
Other NV 14.8% 21.9% ↑ 129 15.4% 7.8%~ NS
aPCV7: vaccine serotypes; NV: non-vaccine serotypes.
↑ : Signiﬁcant increase: ↓ : Signiﬁcant decrease; ~. no signiﬁcant
change.
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O358 Increasing resistance to quinolones and expanded-spectrum
cephalosporins in commensal Escherichia coli from children
living in urban areas of Latin America: a report from the
ANTRES research project
A. Bartoloni, L. Pallecchi, C. Fiorelli, T. Di Maggio, C. Fernandez,
Y. Vallejos, E. Guzman, A. Villagran, A. Mantella, F. Bartalesi,
M. Strohmeyer, A. Bechini, H. Gamboa, H. Rodriguez, T. Falkenberg,
G. Kronvall, E. Gotuzzo, F. Paradisi, G. Rossolini for the ANTRES
study group
Objectives: ANTRES is a research project aimed at describing
antimicrobial use and resistance in low-resource countries of Latin
America. In this project, dissemination of microbial drug resistance
is monitored in commensal Escherichia coli, which has largely been
exploited as an indicator for similar studies. In the baseline study, carried
out in 2002, we observed a high rate of faecal carriage of E. coli with
acquired resistance to several antimicrobial agents. Here we report the
results of a second cross-sectional study conducted in 2005 to evaluate
the evolution of antimicrobial resistance rates in the studied areas.
Methods: Rectal swabs were collected from 3,193 healthy children
aged 6−72 months, living in 4 urban areas (2 in Bolivia and
2 in Peru). Samples were processed by a rapid screening method which
allowed detecting of E. coli resistant to ampicillin (AMP), ceftriaxone
(CRO), tetracycline (TET), chloramphenicol (CHL), kanamycin (KAN),
gentamicin (GEN), amikacin (AMK), streptomycin (STR), trimethoprim-
sulphamethoxazole (SXT), nalidixic acid (NAL), and ciproﬂoxacin
(CIP). Sampling strategy and microbiological processes were the same
as in the baseline study.
Results: The data from the 2005 survey conﬁrmed the high resistance
rates for AMP (96% vs. 95%), SXT (94% vs. 94%), TET (93% vs. 93%)
and CHL (69% vs. 70%) observed in the baseline study, and showed a
remarkably increase in the resistance rates to quinolones (57% vs. 35%
for NAL and 33% vs. 18% for CIP) and CRO (1.7% vs. 0.1%).
A signiﬁcant increasing trend was also observed for STR and GEN
(92% vs. 82% and 27% vs. 21%, respectively).
Conclusion: The results of this study conﬁrmed the magnitude of the
problem of antimicrobial resistance in these low-resource countries and
evidenced an alarming increase in the resistance rates to quinolones and
to expanded-spectrum cephalosporins.
ANTRES project, supported by EU INCO-DEV, ICA4-CT-2001–10014
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O359 Is the ratio of associated Escherichia coli resistance
comparable over Europe?
N. van de Sande-Bruinsma, G. Kahlmeter, M. de Kraker, E. Tiemersma,
J. Monen, H. Grundmann and EARSS participants
Introduction: The EARSS database discloses increasing levels of
antimicrobial resistance in Escherichia coli in most parts of Europe. We
investigated the levels of associated resistance in the E. coli database.
Methods: Invasive E. coli susceptibility results to aminopeni-
cillin (AMP), 3rd-gen cephalosporins (3CP), ﬂuoroquinolones (FQ)
and aminoglycosides (AG) from 2005 were extracted for 7 countries
representing different geographic areas and levels of antimicrobial
resistance: the Czech Republic (CZ), Germany (DE), Ireland (IE),
Finland (FI), France (FR), Slovenia (SI) and Spain (ES). Associated
resistance was deﬁned as “resistance to one drug in the presence of
resistance of another drug”. The levels of associated resistance were
determined. For each drug the levels of resistance was determined for
isolates susceptible and resistant to the other drugs.
Table. Minimum (min) and maximum (max) % resistance reported per
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aInterpretation: “In Finland 36% of E. coli were resistant to AMP; in these
resistance to 3CP was 7% as compared to 0% in the 64% not resistant to AMP.”
Results: Overall, most if not all resistance to a drug was in the presence
of resistance to one or more of the other drugs. More than half of the
isolates resistant to 3CP were resistant to FQ. Whereas only 3−10% of
all isolates were resistant to AG, similarly almost all isolates resistant to
AG were also resistant to FQ (82−91%) as compared to the much lower
rates in those sensitive to AG (6−22%). Large differences were observed
between countries in antimicrobial resistance rates, whereas the levels of
associated resistance among the group of resistant isolates did not vary
to the same extent (Table).
Conclusions: (i) The level of associated resistance for the isolates
resistant to the different antimicrobial groups under EARSS study
seemed comparable between countries, irrespective of their differences
in overall resistance proportions. (ii) The group of isolates resistant
to one group of antibiotics was more likely to be resistant to other
antimicrobial groups (under EARSS surveillance) compared to their
susceptible counterparts.
The observation that most resistance is associated with other types of
resistance and that the level of associated resistance seems comparable
between countries would suggest that the overall reduction of the
antibiotic use is probably more important in the society as a whole
than targeted reduction of single drugs. Our analysis suggest that efforts
should be focused on these ‘multi’ resistant strains.
O360 Multidrug-resistance among invasive Klebsiella pneumoniae
in Europe in 2005, the ﬁrst full year of EARSS reporting
J. Monen, N. van de Sande-Bruinsma, E. Tiemersma, M. de Kraker,
H. Grundmann and EARSS participants
Objectives: We explore the resistance to important antibiotic groups
of invasive Klebsiella pneumoniae isolates reported to the European
Antimicrobial Resistance Surveillance System (EARSS) by participating
laboratories.
Methods: Participating laboratories carry out routine antimicrobial
susceptibility testing (AST) for invasive K. pneumoniae isolates. The
EARSS protocol includes aminoglycosides, ﬂuoroquinolones and third-
generation cephalosporins, but results on carbapenems are also accepted.
EARSS accepts the interpretations as deﬁned by the guidelines used by
the participating laboratories. Data are collected at the national level and
forwarded to EARSS at the National Institute for Public Health and the
Environment (RIVM) in Bilthoven, The Netherlands.
Results: In the year 2005, 23 countries reported AST results for 4,929
K. pneumoniae isolates. Of these, 4,597 isolates were tested for all
classes in the protocol. Six countries reported proportion of less than 1%
for the combined resistance against aminoglycosides, ﬂuoroquinolones
and third-generation cephalosporins, 7 reported between 1% and 5%,
one country between 5% and 10%, 7 between 10% and 25% and 2
more than 25% (see ﬁgure). The resistance to carbapenems was <1%
in all countries but one, the exception being Greece that reported
25% combined resistance to all 4 groups.
Klebsiella pneumoniae. Combined resistance to aminoglycosides, ﬂuoro-
quinolones and third-generation cephalosporins.
Conclusion: Our data suggest that multidrug resistance among
K. pneumoniae is high in many European countries, but that carbapenems
can still be used in most of them. The data from Greece predominantly
reﬂect the situation among ICU patients (for which more blood-
culture results were available). It must be kept in mind that most
guidelines (including CLSI) use breakpoints which are not designed to
detect metallo-b-lactamases and that therefore the dissemination of this
important resistance trait cannot be deduced from the EARSS data at
present.
O361 The prevalence and genetic relatedness of KPC-possessing
Klebsiella pneumoniae isolates from a United States hospital
R. Tibbetts, W.M. Dunne (St. Louis, US)
Background: Carbapenem resistance due to KPC-possessing Klebsiella
pneumoniae is a major healthcare concern. KPC-1 was ﬁrst identiﬁed
in South Carolina in 2001 and since then KPC-1 and the KPC-2 and
KPC-3 derivations have been identiﬁed throughout the USA, Southeast
Resistance in clinical isolates S77
Asia, and Europe. Following the identiﬁcation of the ﬁrst imipenem-
resistant, KPC-positive Klebsiella pneumoniae isolate in our institution,
we initiated a prospective study from August 2006 to November 2006
of 108 consecutive isolates of this organism to determine the prevalence
and genetic relatedness of KPC-positive strains.
Methods: KPC-speciﬁc polymerase chain reaction was performed
on total DNA and plasmid DNA from 108 consecutive Klebsiella
pneumoniae isolates. Repetitive sequence PCR was performed on all
KPC-positive isolates to determine genetic relatedness
Results: Of the 108 isolates collected over the four-month period,
13 (12.0%) were shown to harbour the KPC ORF by PCR. Six of the 13
isolates were identiﬁed from three patients, while each of the remaining
seven came from individual patients. Eight of the eleven isolates were
resistant to imipenem by disk diffusion testing while three of the isolates
were fully susceptible. Plasmids containing the KPC gene were isolated
and veriﬁed by PCR from the 8 imipenem-resistant isolates. In contrast,
we were unable to isolate any plasmids from the 3 imipenem-sensitive
strains; however, they were positive for the KPC ORF using PCR on total
genomic DNA. Two distinct clusters of Klebsiella pneumoniae were seen
following repetitive sequence PCR. The ﬁrst cluster of 7 isolates was
86.0% identical suggesting a clonal expansion while the other 5 isolates
were unrelated. As expected, multiple isolates from single patients were
between 94.8% and 97.4% identical.
Conclusions: The prevalence of KPC-possessing Klebsiella pneumoniae
in our institution has risen to 9.2% in 4 months thereby compromising
empiric treatment options for patients infected with Klebsiella pneumo-
niae. Both a clonal expansion and horizontal plasmid transfer appear to
be involved in KPC dissemination. In addition, these data suggest that
the KPC ORF may reside in the chromosome and is not expressed until
the proper inducing agent is present or that the KPC ORF may reside
on a transposable element that is not expressed until transferred into a
plasmid.
O362 Pseudomonas aeruginosa resistance rates in association with
level of hospital care: data from the EARSS
E.W. Tiemersma, N. van de Sande, G. Kahlmeter, M. de Kraker,
J. Monen, H. Grundmann and EARSS participants
Objective: Pseudomonas aeruginosa (PAE) is known to cause problems
mainly in severely immunocompressed patients. This frequently involves
multiresistance phenotypes. PAE resistance rates can reach levels of
over 10%. Since July 2005, EARSS has been collecting antimicrobial
susceptibility testing (AST) data from invasive PAE isolates. Here, we
report for the ﬁrst time the data for 2006 and relate these to hospital
characteristics. We investigated the potential importance of levels of
hospital care.
Methods: Participating laboratories carry out routine AST for invasive
PAE isolates. Data are collected at national level and are forwarded to the
EARSS database. AST data and information on hospital characteristics
were available for 2,316 isolates from 262 hospitals in 20 countries.
AST data included aminopenicillins, ceftazidim, ﬂuoroquinolones,
aminoglycosides and carbapenems. Multiple drug resistance was deﬁned
as resistance to all 5 drug classes. A logistic model was used to test the
association between resistance and hospital characteristics (two-sided
p-value <0.05). Hospital characteristics included were type (university/
teaching, general/secondary and other), presence of (neonatal) intensive
care units (ICUs), and transplants, burns and heamatology units, number
of beds, and number of ICU beds.
Results: A signiﬁcant proportion of isolates was resistant against
piperacillin (± tazobactam) (14.5%), ceftazidim (13.6%), ﬂuoro-
quinolones (25.0%), aminoglycosides (19.7%) and/or carbapen-
ems (16.7%). Multiple drug resistance occurred in 4.7% of all isolates,
although proportions varied between countries. All multiple drug
resistant isolates originated from hospitals with ICUs, although not all
isolates originated from patients being treated at ICUs. Resistance rates
in hospitals were associated with the number of intensive-care beds and
presence of a neonatal ICU (p< 0.0001) only. None of the other hospital
characteristics inﬂuenced the resistance rates.
Conclusions: An important proportion of PAE isolates was found
resistant to multiple drugs. The proportion of multiple drug resistance
was associated with the number of ICU beds and presence of a neonatal
ICU. Hospital types (university, general, other) were not associated to
PAE resistance, which might reﬂect differences in deﬁnition of hospital
type.
O363 Resistance in Pseudomonas aeruginosa and Acinetobacter spp.
from blood in the UK and Ireland, 2001−2005
R. Reynolds, R. Hope on behalf of BSAC Working Party on Bacteraemia
Resistance Surveillance
Objective: The BSAC Bacteraemia Resistance Surveillance Programme
monitors resistance to established and developmental antibiotics among
the pathogens of bacteraemia in the UK and Ireland.
Methods: Between 2001 and 2005, 29 laboratories sent 1,014
P. aeruginosa and 200 Acinetobacter spp. for central MIC testing by
BSAC methods. Ceftazidime, ciproﬂoxacin, gentamicin, imipenem and
piperacillin-tazobactam (CAZ, CIP, GEN, IPM and TZP) were tested
throughout. Tetracycline, minocycline and tigecycline (TET, MIN and
TGC) were tested from 2002, ceftobiprole (BPR) from 2004, and
doripenem (DOR) from 2005. Results were compared with LabBase2,
a voluntary system taking routine results for blood isolates from nearly
400 centres in England, Wales and (from 2002) N. Ireland.
Results: Non-susceptibility in P. aeruginosa was 3% for CAZ,
7% for GEN, IPM and TZP and 19% for CIP; 8/1,014 (1%) were
non-susceptible to all 5 agents, and 8% non-susceptible to 2 classes
of agents. LabBase2 results differed for CAZ and CIP (both 6% non-
susceptible). For CIP, a lower breakpoint (set in 2005, and used for all
BSAC isolates, but not in LabBase) explained the difference. Factors
independently associated with increased risk of non-susceptibility to
1 of these agents in P. aeruginosa were intensive care, young age,
>48 hours prior hospitalisation, and infections arising from skin/soft
tissue and lines.
Among Acinetobacter, resistance was concentrated in A. baumannii:
2/110 (2%) of A. baumannii were non-susceptible to all 5 agents, and
36% to 2 classes of agents. Overall, 5% of Acinetobacter were non-
susceptible to GEN and IPM, and 17%, 27% and 63% to TZP, CIP and
CAZ respectively. Numbers were too small to assess trend, predictors or
agreement with LabBase2.
MIN and TGC largely overcame TET resistance in Acinetobacter, with
maximum MICs of 8 and 4mg/L respectively. DOR MICs were closely
related to IPM, on average 2.8 dilutions lower for P. aeruginosa and
0.5 dilutions higher for Acinetobacter. BPR MICs were on average
1.2 dilutions higher than CAZ for P. aeruginosa and 2 dilutions lower
for Acinetobacter.
Drug Pseudomonas aeruginosa Acinetobacter spp.
N MIC
mode
MIC90 %NS (MIC) N MIC
mode
MIC90 %NS (MIC)
CAZ 1,014 1 4 3% (>8) 200 4 16 63% (>2)
CIP 1,014 0.25 4 19% (>0.5) 200 0.12 64 27% (>0.5)
GEN 1,014 1 4 7% (>4) 200 0.12 16 5% (>4)
IPM 1,014 1 4 7% (>16) 200 0.06 0.25 2% (>4)
TZP 1,014 4 16 7% (>16) 200 0.5 512 17% (>16)
TET Not tested – inherently resistant 156 2 256 n/a
MIN Not tested – inherently resistant 156 0.06 2 n/a
TGC Not tested – inherently resistant 156 0.25 2 n/a
BPR 442 2 8 n/a 81 0.5 32 n/a
DOR 226 0.06 0.5 n/a 35 0.06 0.5 n/a
MICs in mg/L. NS = non-susceptible (MICs in the range deﬁned in brackets).
Conclusion: Most bloodstream P. aeruginosa in the UK and Ireland
remain susceptible to relevant antibiotics. Carbapenem-resistant Acine-
tobacter, although widely referred to the HPA specialist laboratory from
other infection sites, are rare in bacteraemia. TGC may be useful for
Acinetobacter infections and BPR for P. aeruginosa; DOR has good
activity against both species.
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O364 Multidrug-resistant bacteria surveillance, France, 2002–2005
A. Carbonne, I. Arnaud, B. Coignard, D. Trystram, N. Marty,
S. Maugat, T. Fosse, A. Savey, C. Dumartin, H. Senechal, X. Bertrand,
O. Bajolet, P. Astagneau, V. Jarlier (Paris, St Maurice, Bordeaux,
Lyon, Rennes, Nancy, FR)
Background: The prevalence rate of multidrug resistant bacteria
(MDRB) in French hospitals is one of the highest among European
countries. Since the mid-1990s, control of MDRB patient-to-patient
transmission has becoming a main priority for the national infection
control programme. In 1998, hospitals were advised to strengthen MDRB
surveillance and prevention based on deﬁned national guidelines.
Methods: To assess the impact of the control programme, a national
coordination of MDRB surveillance networks was set up in 2002:
data were collected three months a year from volunteer hospital
laboratories. All diagnosis specimens (a strain with the same antibiotype
per patient) of methicillin-resistant Staphylococcus aureus (MRSA), and
Enterobacteriaceae producing extended-spectrum b-lactamase (ESBLE)
were prospectively included. The incidence rate per 1000 patient–
days (pd) was estimated for MRSA and ESBLE. Incidence between
2002 and 2005 was compared using the Poisson conﬁdence interval.
Results: The number of participating laboratories has increased from
478 in 2002 to 589 in 2005. The incidence per 1000 pd was the
highest in intensive care unit (2.24), compared to 0.76 in acute care and
0.39 in long-term care facilities. When all care units were considered, the
incidence of MRSA decreased signiﬁcantly from 0.63 in 2002 to 0.58 per
1000 pd in 2005. The decrease was observed mostly in acute care and
intensive care units. The incidence of ESBLE increased signiﬁcantly
from 0.13 to 0.16 per 1000 pd. This increase was observed in all type
of care facilities. Enterobacter aerogenes was the most frequent ESBLE
(36%), in 2002 and Escherichia coli (39%) in 2005.
Conclusion: These results demonstrates the positive impact of the
national prevention programme on hospital-acquired MRSA rates.
However, the incidence remains high and efforts have to be sustained. In
contrast, incidence of ESBLE is increasing, especially ESBL Escherichia
coli, which could be a threat for the community.
O365 10 years of surveillance of bloodstream infections in
European medical centres by the SENTRY Antimicrobial
Surveillance Program (1997–2006)
H. Sader, T. Fritsche, M. Stilwell, R. Jones (North Liberty, US)
Objectives: We assessed the frequency of occurrence and antimicrobial
susceptibility (S) of pathogens causing bloodstream infection (BSI) in
European (EU) medical centres participating in the SENTRY Program.
Methods: The ﬁrst 20 unique and clinically relevant BSI isolates were
collected from 44 medical centres (10−31/year) located in 16 EU
countries, Turkey and Israel and sent to a central monitor each month.
Isolates were tested for S by broth microdilution methods and results
interpreted according to the 2006 CLSI M100-S16 document. S rates by
country and variations over time were analysed.
Results: A total of 47,621 strains were processed. The antimicrobial
S rates of the most common Gram-negative bacilli are shown
in the table. The most common Gram-positive cocci were (rank
order among all/no. of isolates/%of total): Staphylococcus aureus
(2/9,291/19.5%) > coagulase-negative staphylococci (3/6,202/13.0%) >
Enterococcus spp. (4/3,598/7.6%). The rank order and the frequencies
were stable over the interval. MRSA rates varied from 0.7% in Sweden to
47.5% in the UK and 48.2% in Israel, but remained very stable over time;
while VRE rates varied from <1.0% in France and Spain to >14% in
Ireland and UK. In general, VRE increased from 3.2% in the 2001–
2002 to 7.2% in the 2005–2006 period. ESBL phenotypes varied from
0.8% in Sweden to 24.0% in Turkey among Escherichia coli (5.2%, all
EU), and from 1.0% in Switzerland to 40.6% in Israel and >50% in
Greece among Klebsiella spp. (KSP; 21.9%, all EU). ESBL phenotypes
among E. coli and KSP increased from 3.7 and 19.8% in 1997–1998 to
6.8 and 23.7% in 2005–2006, respectively; while S to ciproﬂoxacin (CIP)
among E. coli and KSP decreased from 91.9% and 94.4% in 1997–1998
to only 80.3% and 84.6% in 2005–2006, respectively. Decreased S to
imipenem (IMI; MIC 8mg/L) varied from <3% in Sweden and UK
to 32.2% in Turkey and 37.9% in Greece among P. aeruginosa, and
from 0% in Germany, Sweden and Switzerland to 40.3% in Greece and
48.2% in Turkey among Acinetobacter spp. In general, S to IMI dropped
from 84.8% and 80.3% in 1997–1998 to 79.0% and 66.7% in 2005–2006
among PSA and ASP, respectively, due to metallo-b-lactamases.
Rank Organism MIC90 /% Susceptible





4 / 85.6 2 / 94.1 0.12 / 98.2 0.5 />99.9
5 Klebsiella spp.
(3,470 / 17.3)
2 / 89.2 >8 / 85.2 8 / 91.4 0.5 / 99.5
6 P. aeruginosa
(2,965 / 6.2)
>4 / 71.1 >8 / 72.3 >16 / 76.1 >8 / 79.7
7 Enterobacter spp.
(2,038 / 4.3)
>4 / 82.5 8 / 89.1 4 / 96.2 1 / 99.2
9 Acinetobacter spp.
(1,203 / 2.5)
>4 / 39.9 >8 / 41.3 >16 / 48.1 >8 / 73.0
12 Proteus mirabilis
(892 / 1.9)
>4 / 81.4 >8 / 85.2 0.25 / 95.7 2 / 99.7
Conclusions: The following R phenotypes showed signiﬁcant increase
during the study period: VRE, ESBL and CIP R among E. coli and
KSP, and IMI R among PSA and ASP. A wide geographic variation was
observed; with higher R rates being more frequent in UK, Ireland and
southeastern countries and lower rates in Sweden and Switzerland.
O366 Plasmid-mediated quinolone resistance in non-typhi
serotypes of Salmonella enterica in Ireland in 2001−May 2006
J. O’Connor, D. Morris, N. DeLappe, G. Doran, M. Cormican
(Galway, IE)
Objectives: To screen non-typhoid Salmonella enterica isolates for
plasmid encoded quinolone resistance determinant qnrA, qnrB and qnrS.
Methods: All 5340 isolates of non-typhoid Salmonella enterica received
from humans and animals between 2001 and May 2006 were included.
Susceptibility to nalidixic acid and ciproﬂoxacin was performed in
accordance with the disk diffusion methods of the Clinical Laboratory
Standards Institute. Ciproﬂoxacin MICs were determined by Etest for all
nalidixic acid resistant isolates, and isolates with an MIC of >0.25 ug/mL
were screened for the presence of qnrA, qnrB and qnrS by PCR using
speciﬁc primers previously described. A positive control for qnrA was
included and all samples were conﬁrmed as ampliﬁable using universal
primers for 16SrRNA.
Results: Eighty-one (1.5%) isolates had a ciproﬂoxacin MIC> 0.25
ug/mL. The qnrA positive isolate yielded a product of expected size. All
isolates tested were negative for the qnrA gene. One isolate of Salmonella
enterica ssp. houtenae (IV or 4) tested positive for qnrB on PCR and
sequencing conﬁrmed a qnrB 5. The qnrS gene was identiﬁed in 9
salmonella isolates. Of these, 4 were serovar (S.) Corvallis, 2 S. Virchow,
1 S. Typhimurium, 1 S. Enteritidis and 1 S. Schwarzengrund. Sequences
for 8 isolates were 100% homologous to published sequences for qnrS1
and 1 isolate (S. Virchow) differed from the published qnrS sequence
by a single nucleotide. A history of foreign travel was reported for one
isolate (the S. Schwarzengrund).
Conclusion: The plasmid mediated quinolone resistance determinants
qnrB (1) and qnrS (9) were identiﬁed in 10 of 81 Salmonella enterica
isolates with raised ciproﬂoxacin MICs. S. Corvallis is an uncommon
serovar in our experience (0.2% of all isolates) and is remarkable that
this serovar represents a high proportion of all qnrS positive isolates
detected. There is no evidence of an epidemiological link between the
S. Corvallis isolates.
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O367 Signiﬁcant increase in isolation of ESBL-producing and
ciproﬂoxacin-resistant non-typhoidal Salmonellae from
Pakistan
K. Jabeen, A. Zafar, E. Khan, S. Irfan, R. Hasan (Karachi, PK)
Introduction: Increasing antimicrobial resistance in non typhoidal
Salmonellae (NTS) is a global challenge. Data regarding quinolone
and 3rd-generation cephalosporin resistance in NTS is limited from
developing countries.
Material and Methods: This descriptive study was conducted from
1990 to 2006 at Aga Khan University, Karachi. All clinical samples
yielding the growth of NTS were retrieved from computerised data base
and included in the study. Duplicate samples from the same patient were
excluded. During the study period NTS were isolated and identiﬁed using
standard microbiological techniques. Antimicrobial susceptibility testing
was performed by Kirby Bauer method according to Clinical Laboratory
Standard Institute (CLSI). Extended spectrum b-lactamase production
(ESBL) was detected using combined disc method according to CLSI.
Sensitivity to ciproﬂoxacin was detected by nalidixic acid screening
method. Minimum inhibitory concentration (MIC) of ciproﬂoxacin was
determined by agar dilution method according to CLSI. Statistical
analysis was performed using SPSS version 13.
Result: During the study period of 16 years 1,651 NTS were
isolated. Out of these 1,519 (92%) were from stool and 114 (8%)
were from blood and sterile sites. Most prevalent were Salmonella
group B (579), followed by non-typeable Salmonella spp. (709). Isolation
of NTS was high in children less than 5 years of age (58.5%).
Ciproﬂoxacin-resistant NTS (MIC 0.25) increased from 29% in 2002
to 49% in 2006. Ceftriaxone-resistant NTS increased from 2% in 2000
to 9% in 2006. ESBL production was seen in 98.5% (n = 68) of
the ceftriaxone-resistant NTS. ESBL positive isolates exhibit high
resistance against amoxicillin clavulanic acid (57%), gentamicin (58%)
and amikacin (23%). No resistance was seen to piperacillin tazobactam
and imipenem. Interestingly resistance against the ﬁrst-line drugs
remained stable over the years. Rather resistance against chloramphenicol
decreased from 26% in 1990 to 2% in 2006. Similarly resistance against
cotrimoxazole and ampicillin remained static with minimum variations.
Moreover multidrug resistant NTS strains decreased from 26% in 2002
to 0% in 2006.
Conclusion: Increase in drug resitant NTS is a serious threat to public
health and it necessitates continuous surveillance and use of appropriate
screening tests for laboratory detection. Decrease in antimicrobial
resistance against ﬁrst line agents suggests decrease utilisation of these
drugs in the community.
The role of rapid diagnostics for patient
screening: new tools in the ﬁght against
Staphylococcus aureus and MRSA
S372 A surgeons perspective on staphylococcal infection
R. Morgan-Jones, J. Kluytmans, M. Bonten (Cardiff, UK; Breda,
Utrecht, NL)
Orthopaedic and Trauma surgery is an implant specialty where surgical
success is related to the insertion of prosthetic joints (e.g. knee, hip and
shoulder replacements) and reconstructive metalwork following trauma
(e.g. intra-medullary nails, plates and screws).
The worst complication is infection which results in multiple additional
operations, extended hospitalisation, prolonged morbidity and poor func-
tional outcomes. Infection rates are low, ideally between 0.5% and 2%.
The most common infective organism is Staphylococcus aureus which
accounts for 50−70% of cases. Methicillin-resistant coagulase-negative
staphylococci are of growing importance but numerically less signiﬁcant.
The clinical presentation, surgical techniques and pre/post operative
morbidity of chronic osteomyelitis and infected joint replacement will
be discussed to project the patients’ perspective of S. aureus.
S373 Staphylococcus aureus: effect of perioperative eradication of
carriage
J. Kluytmans (Breda, NL)
Staphylococcus aureus is the leading nosocomial pathogen in hospitals
all over the world. It is associated with substantial morbidity and
mortality that is increasing due to the widespread dissemination of
methicillin-resistant S. aureus. It is important to prevent infections with
S. aureus. Control of S. aureus infection has been based traditionally on
the prevention of cross-infection. However, in recent years it has been
shown repeatedly that the majority of nosocomial S. aureus infections
originate from the patients’ own ﬂora. Nasal carriage of S. aureus at
admittance to the hospital is now considered a well-deﬁned risk factor
for subsequent infection in various groups of patients, including patients
undergoing surgical procedures. The relative risk of carriers to develop a
surgical site infection is approximately 8 times higher than non-carriers.
Also, when carriers of S. aureus develop an infection after surgery,
the strains from the infection are identical to the strains carried before
surgery in more than 80% of the cases.
Based on these ﬁndings several intervention studies have been
performed. Although the results were promising, ﬁnal conclusions could
not always be made due to methodological deﬁciencies. Most studies
used historic control groups and included both carriers and non-carriers.
Subsequently, a number of randomised controlled trials were performed.
In general, the results of these studies were showing a trend towards a
beneﬁcial effect of mupirocin but failed to produce signiﬁcant results.
Proposed explanations are mainly: (1) the infection rates in the placebo
groups were lower than anticipated. Therefore, the sample size was too
low. (2) Due to the duration before the results of culture are available,
carriers could not be identiﬁed before inclusion. Therefore both carriers
and non-carriers were included resulting in a dilution of the effect.
A systematic review was performed to determine the effect on the
S. aureus infection rate of treating identiﬁed carriers of S. aureus with
mupirocin nasal ointment. Only prospective and adequately controlled
trials were included. The literature search resulted in eleven hits. Only
three articles met the inclusion criteria. Among the 556 mupirocin-
treated surgical patients with S. aureus nasal carriage there were
20 S. aureus infections (3.6%), as compared with 7.5% (42/559) in
the controls (nasal carriers without mupirocin treatment) [p = 0.006;
Number Needed to Treat (NNT) = 25]. Prophylactic intranasal mupirocin
signiﬁcantly reduced the rate of S. aureus infections among surgical
patients who were S. aureus carriers. Prospective studies in carriers only
are needed to determine the overall effectiveness of mupirocin in surgical
patients.
S374 Modelling of MRSA: the potential beneﬁts of rapid
diagnostic testing
M. Bonten (Utrecht, NL)
Mathematical modelling is a tool to describe the complex dynamics
of MRSA epidemiology. A recently published model (Bootsma et al.
PNAS 2006) will be presented. In this model the effects of the individual
components of the Dutch ‘Search & Destroy’ policy are evaluated, both
in settings of low and high MRSA-endemicity. A consequence of this
policy is the pre-emptive isolation of patients suspected of MRSA-
colonisation. With conventional cultures it can take up to 5 days before
colonisation can be ruled out. The effects of rapid diagnostic testing (with
different test characteristics) on the number of isolation days needed will
be presented.
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S390 Emerging pathogens and host species barriers
T. Kuiken (Rotterdam, NL)
Emerging infectious diseases have a major impact on public and animal
health, the economy, and the environment (Science 309: 1680). Human
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mortality from recently emerged diseases varies, ranging from less
than 200 people thus far for H5N1 avian inﬂuenza to about 20 million for
AIDS. Livestock production has been negatively affected by the direct
mortality of animals from emerging infections and depopulation policies
to protect the safety of international trade and to control the spread of
pathogens. The environmental impact of emerging infections is of special
concern for endangered wild animal populations, which can be pushed
to the brink of extinction by such events. Animals, and particularly wild
animals, are thought to be the source of more than 70% of all emerging
infections (Philos Trans R Soc London B 356: 983). Understanding how
some infectious agents have breached the barriers that normally limit
this interspecies transmission is important. However, these barriers are
poorly characterised. The host species barrier for infection can be deﬁned
as an interaction of factors that collectively limits the transmission of
an infection from one host species (the donor species) to another (the
recipient species) (Science 312: 394). Such limiting factors may occur at
different levels, of which the functional components are organism, tissue,
and cell. At the organism level, barriers limiting contact between two
host species, and thus preventing transmission of an infection, may be
geographical, environmental, or behavioural. Because of the rapid growth
of both human populations and their consumption patterns, these barriers
are often breached. Even if two host species share the same geographical
area and habitat, pathogen transmission may not occur due to behavioural
restrictions. At the tissue level, an emerging pathogen, in particular a
virus, needs to gain access to the appropriate tissue or tissues in order to
replicate. First it must invade the host through a portal of entry. It may
then remain localised and replicate in a tissue near the original portal
of entry, or may generate a systemic infection, using various pathways
to spread to more distant target tissues in the host. Release of progeny
virus from the infected host typically occurs through dissemination by
respiratory, enteric, or urogenital secretions, or by an arthropod vector
that has ingested blood from a viremic host. There are barriers at each
stage of this process that may prevent the virus from developing a
productive infection. At the cellular level, a virus needs to enter, replicate
in, and exit from the appropriate cell type, simultaneously dealing with
any host response to infection. Understanding how a pathogen is able to
breach the constraints of the host species barrier and become established
in a new host species will help us to detect and control the emergence
of zoonotic infections.
S391 The domestic animal revolution and inﬂuenza
B. Olsen (Kalmar, SE)
In humans, inﬂuenza A virus causes yearly seasonal inﬂuenza epidemics
of respiratory disease resulting in high morbidity. There are many
different subtypes of inﬂuenza virus which are characterised according to
two surface structures – the hemagglutinin (H1−H16) and neuraminidase
(N1−N9). These subtypes have the ability to recombine, thereby creating
new variants, for example H5N1. If a subtype that humans have not
encountered starts to spread it can result in a pandemic. Pandemic
outbreaks have occurred at irregular intervals and have had a devastating
impact on mankind. The Spanish inﬂuenza pandemic of 1918 is thought
to have killed about 50 million people. In particular dabbling ducks
are believed to constitute the main reservoir for inﬂuenza A virus.
In ducks, the virus causes sub-clinical gastrointestinal infection. By a
meta-analysis on all published screening data of wild birds and data
from a four-year screening of ducks caught and sampled in Sweden
we found that the prevalence of inﬂuenza A virus in the western
Eurasian duck population shows a different temporal pattern compared to
North America. The prevalence in western Eurasian ducks is high from
August to December and also rises in the spring. These ﬁndings are of
importance for the understanding of how inﬂuenza virus is perpetuated
in nature. Of concern is the presence of H5 and H7 subtypes that are
prone to change into highly pathogenic variants in poultry. Many of the
strains isolated in our study are prototypes that have caused inﬂuenza
outbreaks in poultry in Europe during recent years. This indicates that
wild bird surveillance for inﬂuenza A virus can be of value as a sentinel
system to prevent outbreaks in domestic poultry.
A result of the domestic animal revolution is that there has never before
in history been so much poultry as today. This fact, in combination with
a growing number of humans, creates an arena where domestic animals,
humans and ﬁnally zoonotic pathogens can interact. Inﬂuenza A virus
is the ultimate actor in this play where some subtypes may change into
highly pathogenic forms. These may be transmitted directly to man.
Another worrying scenario is that an avian inﬂuenza virus will reassort
with a circulating human inﬂuenza. A genetic trait might then readily
go from the human to the bird virus so that avian inﬂuenza acquires
the capacity to pass from person to person. With this risk in mind, it
would advisable to consider any method to reduce the probability of this
happening. Contingency planning should take into account the known
evolutionary potential of animal viruses and other pathogens to adapt to
the environment of humans and domestic animals.
S392 Wildlife hosts of SARS-coronavirus and related viruses
L-F. Wang (East Geelong, AU)
Severe acute respiratory syndrome (SARS) represents the ﬁrst pandemic
transmissible disease of previously unknown aetiology in the 21st cen-
tury. The pandemic started in November 2002 in Guangdong, China and
was brought under control in July 2003, after it had spread to 33 countries
on 5 continents resulting in more than 8000 infections and close to
800 deaths. The outbreak was caused by a newly emerged coronavirus,
now known as the SARS coronavirus (SARS-CoV). A closely related
virus was detected in masked palm civets from a live animal market in
Guangdong during the outbreaks. In late 2003 and early 2004, sporadic
outbreaks were reported in the same region of China where the 2002/3
outbreaks originated. This time, civets were identiﬁed as the direct source
of the virus responsible for human infections. However, a large-scale
survey in China failed to ﬁnd any evidence of infection of farmed or
wild civets with SARS-CoV. It appears that the infection of civets was
limited to animals present in the live animal markets only. The role of
civets as a natural reservoir of SARS-CoV was hence never conﬁrmed.
Molecular epidemiological studies revealed that the viruses responsible
for the 2003/4 outbreaks were not the same as those isolated during the
2002/3 outbreaks, indicating independent species-crossing events. These
ﬁndings indicate that a SARS epidemic may recur in the future and that
SARS-like coronaviruses (SARS-like-CoVs) originating from different
reservoir host populations may lead to epidemics at different times and
in different regions depending on the distribution of the reservoirs and
transmitting hosts. This notion was supported by the later discovery of a
group of diverse SARS-like-CoVs in bats. At least ﬁve different SARS-
like coronaviruses have been identiﬁed in different species of horseshoe
bats in the genus Rhiolophus. Sequences of four complete genomes were
determined and the overall nucleotide sequence identity between bat
SARS-like coronaviruses and SARS-CoV was 87−92%. Although the
exact host species for the SARS-CoV has not been identiﬁed, the great
genetic diversity of bat coronaviruses highly suggests that a different
horseshoe bat or a closely related bat species is the most likely natural
reservoir of the SARS-CoV responsible for the 2002–2004 outbreaks.
S393 Bats: important hosts of emerging viruses
C. Calisher (Fort Collins, US)
Bats (order Chiroptera, suborders Megachiroptera and Microchiroptera)
are abundant, diverse, and geographically widespread. Bats represent
about 20% of the approximately 4,600 species of mammals. The
megachiropterans include 166 species and the microchiropterans
759 species. Bats provide us with resources but their importance is
minimised and many of their populations and species are at risk, even
threatened or endangered. Some of their characteristics (what they eat,
whether they are colonial or solitary, how their populations are structured,
that they can ﬂy, that they migrate seasonally and may move daily,
that they enter torpor and/or hibernate, that they are able to live for
many years, that they have peculiar roosting behaviours, that they can
echolocate, and that they have various virus susceptibilities) make them
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exquisitely suitable hosts of viruses and other disease agents. Bats of
certain species are well recognized as being capable of transmitting
Rabies virus but recent observations of outbreaks and epidemics of newly
recognized human and livestock diseases caused by viruses transmitted
by various megachiropteran (“ﬂying foxes”) and microchiropteran bats
have drawn attention anew to these remarkable mammals. This pre-
sentation summarises information regarding chiropteran characteristics
and information regarding 66 viruses [at the time of preparation of this
abstract] that have been isolated from bats. It is clear that we do not
know enough about bat biology, that we are doing too little in terms of
bat conservation, and that there remain a multitude of questions regarding
their role in disease emergence. Recent observations have proven these
points and will be discussed.
Controversies in fungal disease
S395 Challenges and progressions in antifungal susceptibility
testing
S. Arikan (Ankara, TR)
Development of standard antifungal susceptibility testing (AFST) assays
has been one of the most important progressions in the ﬁeld of
medical mycology. CLSI (Clinical and Laboratory Standards Institute)
microdilution and disk diffusion methods as well as AFST-EUCAST
(European Committee for Antimicrobial Susceptibility Testing –
Antifungal Susceptibility Testing Subcommittee) microdilution reference
methodology are the currently used standard assays. Recent progressions
have further expanded the knowledge on application and clinical utility
of AFST. Among these are validation of the previously documented CLSI
ﬂuconazole MIC breakpoints and dose-dependent susceptibility concept
for ﬂuconazole vs. Candida, and documentation of MIC breakpoints and
disk diffusion inhibition zone interpretive parameters for voriconazole
vs. Candida. The use of ﬂuconazole susceptibility proﬁle as a surrogate
marker for prediction of voriconazole susceptibility has also been
proposed recently. In addition, based on the modiﬁcations of the CLSI
M38-A reference method, new guidelines for in vitro susceptibility
testing of antifungal agents against Aspergillus spp. have been developed
by AFST-EUCAST. A standard assay for testing antifungal agents
against dermatophytes is also under development. Further investigations
address the applicability of other methods, which are more practical
and/or require shorter incubation periods. Among these are Etest,
colorimetric methods, ﬂow cytometry, and ergosterol quantitation. Utility
of ﬂow cytometry for AFST of yeasts and moulds is being currently
studied and appears promising. Assessment of metabolic activity by
using XTT colorimetric assay is also being investigated as a novel
approach, particularly for determination of quantitative endpoints for
testing caspofungin against Aspergillus, and for susceptibility testing of
Zygomycetes. Despite these progressions, utility of AFST in direction
of antifungal therapy and prediction of clinical outcome is still limited.
While in vitro triazole (particularly ﬂuconazole) susceptibility results for
Candida appear to be optimally correlated with clinical outcome, data are
either limited and investigational or fail to demonstrate any signiﬁcant
in vitro–in vivo correlation for most of the remaining fungus–antifungal
drug combinations. Importantly and conclusively, the results obtained
by AFST constitute one of the several factors that inﬂuence clinical
outcome. Optimisation of test methodologies and parameters for routine
use and expanded in vitro-in vivo correlation studies may further enhance
the role of AFST as an adjunct in direction of antifungal therapy.
Harmonising expert rules and interpretive
reading for antimicrobial susceptibility
testing in Europe
S398 The concept of interpretative reading of the antibiogramme
P. Courvalin (Paris, FR)
In recent years, there has been important progress in our knowledge
of bacterial resistance to antibiotics. The availability of a large
number of antibiotics has allowed precise individualisation of resistance
phenotypes, and enzyme inhibitors have provided clues concerning
certain mechanisms of resistance. Detailed analysis of the bacteriostatic
and bactericidal activity of antibiotics, alone or in combination, has
indicated the limits of in vitro antimicrobial susceptibility tests in
the detection of resistance resulting in clinical failure. The goal of
combined molecular and therapeutic interpretation of susceptibility
tests is to provide an improved logical basis for decision-making
in antibiotic therapy by taking into account the recent progress
in the understanding of bacterial resistance. The molecular analysis
and therapeutic interpretation, designated “interpretative reading”, of
the in vitro antibiotic susceptibility tests consists of three steps:
(1) characterisation of the resistance phenotype with a judicious
assortment of antibiotics belonging to the same class; (2) deduction from
the observed phenotype of the corresponding biochemical mechanism
of resistance; and (3) inference from the deduced mechanism of the
predicted resistance phenotype. In vitro antibiotic susceptibility tests,
like other tests in biology, should provide objective quantitative data,
e.g. MICs. For various historical reasons, they also provide subjective
interpretation of the data such as clinical categories. Interpretative
reading of antimicrobial susceptibility tests is an attempt to reconcile
these two notions by basing interpretation on the most recent knowledge
in the ﬁeld of antibiotic study, in particular that of mechanisms of
resistance. The best that one can ask of antibiotic susceptibility testing
is detection of resistance, in particular of low-level resistance. This
can be achieved by improved interpretation of the results of in vitro
sensitivity tests or by the design of certain genotypic approaches. The
goal of the proposed approach is to provide the clinician with the
necessary results for judicious decision-making in antibiotic therapy
utilising available information and to draw his or her attention to the
combinations of bacterium and antibiotic for which there is a therapeutic
risk.
S401 Expert rules for aminoglycosides, macrolides and
lincosamides
R. Leclercq (Caen, FR)
Resistance to aminoglycosides is mostly related to production of
modifying enzymes, phosphorylases, nucleotidyltransferases or acetyl-
transferases. The enzymes vary in their substrate ranges which are
often broad and each enzyme is characterised by a particular proﬁle
of resistance which allows its putative identiﬁcation from the conferred
phenotype. The enzymes from Gram-positive cocci generally differ
from the enzymes detected in Gram-negative bacteria. Generally, the
presence of an enzyme confers to the host frank resistance to the
antibiotics modiﬁed in vitro. However, there are some exceptions, both
in Gram-negative and in Gram-positive bacteria. For instance, resistance
of Gram-positive organisms to the kanamycin–neomycin group of
antibiotics is due to the synthesis of an APH(3′)-III enzyme. The enzyme
catalyzes efﬁcient phosphorylation of amikacin in cell-free extracts
but does not always determine resistance to this antibiotic. However,
bactericidal synergism of amikacin with b-lactams or vancomycin is
always abolished. Therefore, the test of kanamycin better predicts the
activity of amikacin against Gram-positive organisms. In this case
and several others, interpretive reading of susceptibility tests based on
identiﬁcation of resistance phenotypes may help to identify impaired
activity of aminoglycosides.
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Interpretive reading may also allow to identify some pitfalls in
the detection of resistance to macrolide and lincosamide antibiotics.
Staphylococci may be resistant to macrolides by production of a
ribosomal methylase encoded by erm genes conferring the MLSB
phenotype or by production of an efﬂux pump encoded by the msr(A)
gene. In case of inducible MLSB resistance, clindamycin that is not
an inducer remains active. However, constitutively resistant mutants
can be selected by clindamycin and clinical failure during treatment
by clindamycin have been reported in a few occasions. The use of
clindamycin is probably best avoided in severe infections or infections
with heavy bacterial inocula. In case of resistance by efﬂux, clindamycin
is not substrate for the pump and the risk for selection of resistant
mutants is not greater than that for erythromycin-susceptible isolates. By
a disk diffusion test, the inducible MLSB phenotype can be identiﬁed
by the ﬂattening of the clindamycin zone facing the erythromycin disk.
Challenges in infection control
S404 Pseudomonas aeruginosa: don’t go near the water
M. Dettenkofer (Freiburg, DE)
P. aeruginosa is amongst the most problematic nosocomial pathogens,
especially in intensive care settings. The organism has a predilection
for moist environments (“don’t go near the water” – subtitle of an
editorial by M. Bonten and R. Weinstein in Crit Care Med 30, 2002):
aqueous solutions, e.g. soaps, irrigation ﬂuids, eye drops, and dialysis
ﬂuids, may become contaminated with P. aeruginosa. It is frequently
detected in faucet aerators and traps of sinks and in case of inadequate
reprocessing even in respiratory therapy equipment. P. aeruginosa may
contaminate bronchoscopes leading to severe outbreaks. In case of long
or artiﬁcial ﬁngernails, healthcare personnel may harbour P. aeruginosa
which may be associated with outbreaks caused by P. aeruginosa. Finally,
the organism may be found on the surface of raw fruits or vegetables.
Within hospital settings, colonised patients, especially those frequently
treated with broad-spectrum antibiotics, are important reservoirs.
The relative importance of the contaminated inanimate environment
is discussed controversially: Whereas outbreaks due to environmental
sources have been described repeatedly, its role as a source for endemic
colonisation (and, as a consequence, infection) in intensive care patients
has not been ﬁrmly established. More recent data show that in an ICU, a
high ﬁgure of 35% of all cases of P. aeruginosa acquisition may originate
from contaminated tap water (clonal relationship between isolates) and
that retrograde contamination of faucets by patients may occur in 15%.
However, surveillance of intestinal colonisation (which plays a relevant
role in the epidemiology of P. aeruginosa) was not undertaken. The
majority of colonised patients is already colonised on admission, with
preceding antibiotic exposure being responsible for the majority of cases
of acquired respiratory tract colonisation.
With regard to infection control, adequate hand hygiene is essential,
whereas ‘sterilisation’ of sinks or routine use of water ﬁlters seems
impractical. Alcohol-based handrubs, via dispensers near the bedside
or in coat pockets, should be preferred in most situations over hand
washing with soap and water. All open water sources including sinks
may be a potential habitat of pathogens like P. aeruginosa, and the use
of tap water for critically ill or immuno-compromised patients must be
restricted.
Nosocomial urinary tract infection
S406 Nosocomial urinary tract infections in urology sections. Data
from the PEP and PEAP-studies
T. Bjerklund Johansen, M. Cek, K. Naber, M. Grabe, P. Tenke on
behalf of the European Society for Infection in Urology
Introduction and Objectives: We wanted to study the etiology,
prevalence and diagnostic practice related to nosocomially acquired
urinary tract infections (NAUTI) in urology departments. The results
are presented on behalf of the PEP and PEAP-study investigators.
Material and Methods: Two internet based prevalence registrations
were carried out in November 2003 and 2004 respectively. 152 hospitals
from Europe and Asia took part and 6033 hospitalised urology patients
were screened for NAUTI. Detailed information on 727 patients with
NAUTI were provided.
Results: The most common pathogen was Escherichia coli accounting
for 33% followed by Pseudomonas sp. in 14% and Enterococcus in 11%.
A second pathogen was reported in 65% of patients and Candida sp.
was seen in 14%. There were signiﬁcant regional variations in the
distribution of pathogens and the number of culture tests taken (0−5.9
cultures per patient admission). The principal pathogen was resistant to
the most commonly used antibiotics in 60−90% of cases. The prevalence
of asymptomatic bacteriuria was about 30% in most regions, while the
prevalence of urosepsis varied between 2−27% in the regions studied.
Conclusions: Urology sections should be encouraged to monitor the
susceptibility of pathogens causing NAUTI in order to tailor a better
empirical antibiotic treatment. Urologists need to work out guidelines
on when to take blood cultures after urological surgery to obtain a more
uniform reporting of urosepsis between regions. The high prevalence of
urosepsis after urological surgery is a cause of concern.
S407 Pathogens and resistance
T. Matsumoto (Kitakyushu, JP)
Escherichia coli accounted for about 80% of organisms in uncomplicated
UTIs. In contrast, in complicated UTI many kinds of enterobacteriaceae
isolates, staphylococci, enterococci, Pseudomonas aeruginosa, and the
other glucose-nonfermentable Gram-negative rod (NFGNR) are isolated.
Almost nosocomial UTI (NUTI) is complicated UTI. In the 2003 GPIU
study (formerly PEP study), NUTI prevalence rate was 9.4% (326/3350).
In the 2003 GPIU study, E. coli was the most frequent pathogen,
accounting for about 30% of all pathogens isolated. Pseudomonas (13%),
Klebsiella (10%), Enterococcus (9%), and Proteus (7%) were isolated
frequently. In our hospital, Enterococcus faecalis was the most
frequent of all isolated organisms, accounting for 24%. The other
enterococci (12%), S. marcescens (12%), P. aeruginosa (9%), the other
NFGNR (9%), E. coli (6%), Staphylococcus epidermidis (6%) were
isolated frequently. It is considered that these differences occurred by
the difference of patients’ background.
The ﬂuoroquinolone- and cephem-resistant enterobacteriaceae isolates
from patients with NUTI are increasing. Most of the cephem-resistant
isolates of E. coli, K. pneumoniae and P. mirabilis are producing
Extended-Spectrum b-lactamases (ESBLs). ESBLs are plasmid-mediated
broad-spectrum b-lactamases. The ratios of ESBL producers in E. coli
and K. pneumoniae are quite different in each country (less than 5% to
more than 80%). Most of the nosocomial ESBL producers have acquired
resistance to non-b-lactams, such as ﬂuoroquinolones, phosphomycin,
co-trimoxazole. Some of the multi-drug resistant isolates have no
effective oral antibiotics. According to the 2003–2004 GISP study,
the ratios of ﬂuoroquinolone resistance of E. coli and K. pneumoniae
accounted for about 20%, respectively, that of enterococci accounted
for more than 60%. Mechanisms of resistance to quinolones are mainly
target mutations, especially GyrA and ParC. Qnr that is plasmid encoded
quinolone resistance reported in 2002. The emergence of qnr also
alerts us to the potential rapid dissemination of quinolone-resistant
determinants. Qnr shows quinolone speciﬁc resistance, but the qnr-
plasmids reported are integron-associated and carry multiple resistance
determinants providing resistance to several classes of antimicrobials
including b-lactams and aminoglycosides.
Multi-drug resistant isolates cause nosocomial spread easily. There are
many reports about nosocomial spread of multi-drug resistant ESBL
producers. To prevent prevalence of antimicrobial-resistant isolates
appropriate antimicrobial selection is needed. Geographic variations
in pathogen occurrence and susceptibility proﬁles require monitoring
continuously, and it is important to update treatment guidelines based
on susceptibility proﬁle and the results of clinical trials.
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S409 Treatment options in nosocomial urosepsis
F. Wagenlehner (Straubing, DE)
Urosepsis accounts for approximately 25% of all sepsis cases and
may develop from a community or nosocomial acquired urinary tract
infection (UTI). The underlying UTI is almost exclusively a complicated
one with involvement of the parenchymatous urogenital organs (e.g.
kidneys, prostate) and mostly associated with any kind of obstructive
uropathy. If urosepsis originates from a nosocomial infection, a broad
spectrum of Gram-negative and Gram-positive pathogens have to be
expected which are often multiresistant.
In urosepsis, as in other types of sepsis, the severity of sepsis depends
mostly upon the host response. The treatment of urosepsis follows the
generally accepted rules of the Surviving Sepsis Campaign Guidelines.
Early normalisation of blood pressure and early adequate empiric
antibiotic therapy with optimised dosing are equally important to meet
the requirements of early goal directed therapy. In most cases of
urosepsis an early control of the infectious focus is possible and as
important. Optimal supportive measures need to follow the early phase
of resuscitation.
Although most antibiotics achieve high urinary concentrations there are
several unique properties in complicated UTI, and thus in urosepsis,
that inﬂuence the activity of the antibiotic substances: (i) The renal
pharmacokinetics in unilateral and bilateral renal impairment and in
unilateral and bilateral renal obstruction differ. (ii) Varations in pH
may inﬂuence the activity of certain antibiotics. (iii) Bioﬁlm infection
is frequently found under these conditions, which may increase the
minimal inhibitory concentrations (MIC) of the antimicrobials at the
site of infection by several 100-folds. In order to assess the antibiotic
pharmacodynamic properties in such situations not only the MIC as
determined in vitro and the plasma concentrations of the free (unbound)
drug, which are the guiding principle for many infections, but also the
actual renal excretion and the urinary bactericidal activity of an antibiotic
substance should be taken into account. In the treatment of urosepsis it is
important to achieve optimal exposure to antimicrobials both in plasma
and in the urinary tract. The role of drugs with low renal excretion rate
is therefore limited.
Since urosepsis originates quite often from catheter associated UTI
and after urological interventions, optimal catheter care and optimal
strategies to prevent nosocomial UTI may be able to reduce the frequency
of urosepsis.
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O410 Role of “atypical” respiratory pathogens in patients with
exacerbations of chronic obstructive pulmonary disease
B. Diederen, P. van der Valk, C. de Jong, M. Peeters, R. Hendrix
(Tilburg, Enschede, NL)
Objectives: The term “atypical pathogen” commonly refers to M. pneu-
moniae, C. pneumoniae and L. pneumophila. Serological studies suggest
that these pathogens may play a role in acute exacerbations of chronic
obstructive pulmonary disease (AECOPD). We investigated the presence
of atypical pathogens in sputum samples in patients with stable COPD
and those with AECOPD using real-time PCR.
Methods: From May 1999 through March 2000, COPD patients (GOLD
stage I and II) were recruited from the outpatient pulmonary clinic of the
Medisch Spectrum Twente, a 1150-bed teaching hospital in Enschede,
The Netherlands. Sputum samples were retrieved from patients with
stable disease and during exacerbation. Sputum was processed with
the NucliSens® easyMAGTM platform, (bioMe´rieux) and DNA was
stored at −20ºC until processing was performed. For the detection of
M. pneumoniae an assay based on the the PI adhesin gene was used. For
the detection of C. pneumoniae an assay based on the ompA gene of
C. pneumoniae was used. For the detection of Legionella two assays were
used, targeted at speciﬁc regions within the 5S rRNA and the mip gene.
Results: A total of 248 sputum samples from 104 patients were analysed
(mean age 63 years; range 45−75 years; 86 men, 18 women). In
total, 122 stable-state sputa and 126 exacerbation sputa were available
for testing. Of the stable-state sputa, all samples were negative for
M. pneumoniae and C. pneumoniae DNA, whereas one sample was
positive for Legionella non-pneumophila DNA. Of the exacerbation
sputa, all samples were negative for M. pneumoniae and C. pneumoniae
DNA, whereas one sample was positive for Legionella non-pneumophila
DNA. In both Legionella-positive samples S. pneumoniae was cultured
a level of growth of >105 cfu/mL.
Conclusion: We investigated the possible relationship between presence
of atypical pathogens in patients with stable COPD and in those with
AECOPD using real-time PCR and found no indication for an important
role of Legionella spp., C. pneumoniae orM. pneumoniae in COPD. This
study stresses the biases that nonstandardised serology may introduce
in the context of the possible link between atypical pathogens and
AECOPD.
O411 Community-acquired pneumonia caused by Pseudomonas
aeruginosa: incidence, risk factors, and outcome
C. Garcia-Vidal, L. Mun˜oz, A. Mykietiuk, R. Verdaguer, J. Carratala`,
F. Gudiol (Barcelona, ES)
Objectives: We sought to determine the incidence, risk factors
and outcome of community-acquired pneumonia (CAP) caused by
Pseudomonas aeruginosa.
Methods: Prospective observational study of non-severely immunocom-
promised adults hospitalised with CAP from 1995 through 2005. Patients
with HIV infection, transplantation, and neutropenia were not included.
A comparison between cases of CAP caused by P. aeruginosa and the
remaining cases was performed.
Results: We documented a total of 2,455 consecutive cases of CAP,
21 (0.9%) of which were caused by P. aeruginosa. Four cases were
polymicrobial (Haemophilus inﬂuenzae 2, Streptococcus pneumoniae 1,
and Legionella pneumophila 1). Microbiologic diagnosis was established
by one or more of the following methods: blood cultures 9, Gram
stain and sputum culture 19, and necropsy 1. Compared with the
remaining cases, patients with CAP due to P. aeruginosa had more
frequently chronic obstructive pulmonary disease (COPD) (70% vs.
28.5%; p< 0.001) and were more commonly classiﬁed into Pneumonia
Severity Index high-risk class (group V) (48% vs. 16%; p = 0.001). They
also had received more frequently prior corticosteroid (30% vs. 6%;
p = 0.001) and antibiotic (44% vs. 17%; p = 0.011) therapy. Multivariate
analysis identiﬁed COPD (OR= 6.83) and prior corticosteroid therapy
(OR= 4.22) as independent risk factors. Patients with CAP due to
P. aeruginosa presented more frequently with septic shock at entry
(25% vs. 3.8%; p = 0.001) and multilobar pneumonia (50% vs. 25.4%;
p = 0.019) than the remaining patients. They were also given more
frequently an inappropriate initial empirical antibiotic therapy (68% vs.
9%; p< 0.001). Early (29% vs. 2%; p< 0.001) and overall (55% vs.
8.5%; p< 0.001) case-fatality rates were higher among patients with
CAP due to P. aeruginosa.
Conclusions: CAP caused by P. aeruginosa is uncommon and occurs
mainly in patients with COPD treated with corticosteroids. It frequently
presents with shock and causes high case-fatality rates. The risk factors
delineated in this study should be considered when selecting initial
empirical antibiotic therapy for patients with CAP.
O412 Predictors of positive microbiology in community-acquired
pneumonia subjects: results of a multivariate analysis
J. Garau for the MOTIV Study Group
Objective: In prospective aetiological studies, a microbial cause is
not found in 30−65% of subjects with community-acquired pneumonia
(CAP). The objective of this analysis was to identify predictors of
microbiological documentation in a large CAP trial.
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Methods: In a multinational, phase III study conducted in hospitalised
subjects with CAP, causative organisms were identiﬁed at baseline
by culture, urine antigen testing and/or blood serology. 318 of 733
subjects in the ITT population had microbiologically documented CAP.
A retrospective logistic regression analysis was performed to determine
signiﬁcant predictors for microbiological documentation.
Results: Baseline explanatory variables tested were: age (<65 vs 65
years), gender, history of cardiac disease, history of respiratory disease,
concomitant cardiovascular treatment, concomitant respiratory treatment,
PSI risk class (II and III vs IV and V), SAPS score (12 vs >12), severe
CAP (as per modiﬁed ATS criteria), CURB65 score (0−3 vs 4−5), smok-
ing history, alcohol consumption (abstinent–light vs moderate–heavy),
shock, assisted ventilation, ICU admission, temperature (<39 vs >39ºC),
C reactive protein (CRP; <20 vs >20mg/dL), white cell count
(12 vs >12G/L), previous systemic antimicrobial therapy, failure on
previous systemic antimicrobials, multi-lobar or bilateral involvement,
duration of infection (4 vs >4 days). The following variables
were signiﬁcant predictors in the univariate analysis: PSI risk class
(p = 0.0043), severe CAP (p = 0.0031), SAPS (p = 0.0360), alcohol use
(p = 0.0543), concomitant cardiovascular treatment (p = 0.0294) and CRP
(p 0.0001).
After adjusting for potentially confounding variables, PSI risk classes
IV−V (OR 1.4; 95%CI: 1.02−1.98), severe CAP (OR 1.4; 95%CI:
1.01−1.94), moderate–heavy alcohol consumption (OR 1.9; 95%CI:
1.10−3.24) and CRP 20mg/dL (OR 2.27; 95%CI: 1.66−3.2) were
signiﬁcant predictors of microbiologically documented pneumonia in the
logistic regression model.
Conclusion: This study found that PSI, severe CAP (by modiﬁed ATS
criteria), moderate-heavy alcohol consumption and baseline CRP value
were associated with a higher microbiology recovery rate.
O413 Clinical implications of chest radiographic resolution in hos-
pitalised adults with severe community-acquired pneumonia
A. Bruns, J. Oosterheert, M. Prokop, J. Lammers, E. Hak,
A. Hoepelman (Utrecht, NL)
Objective: In follow-up of treatment of community-acquired pneumonia
(CAP), chest radiographs (CXR) are regularly obtained. However, little
is known about time to resolution of CXR abnormalities and correlation
with clinical ﬁndings. We studied the rate of CXR resolution, evaluated
factors associated with delayed resolution and determined the inﬂuence
of CXR deterioration on prognosis in patients (pts) with severe CAP.
Methods: Of 288 pts enrolled in a multicentre study with severe CAP,
clinical and laboratory data were prospectively obtained and CXR were
taken on admission, at day 7 and at day 28. Pts were followed for
28 days. At days 7 and 28, CXR resolution, deﬁned as absence of CXR
abnormalities related to infection (pulmonary inﬁltrates, pleural ﬂuid
or atelectasis), and CXR deterioration, deﬁned as new or progressive
CXR abnormalities, was determined. Clinical improvement deﬁned
as a respiratory rate <25/min, saturation >90%, PaO2 > 55mmHg,
haemodynamic stability and normal mental state was evaluated at day 7
and clinical cure, deﬁned as discharged in good health at day 28.
Results: All pts [mean age 69.7 years (±13.9); 248 (86%) PSI> 90]
had pulmonary inﬁltrates on admission. Follow-up CXR was available
for 227 pts (79%) at day 7 and for 195 (68%) at day 28. At
day 7, 57 patients (25%) had complete CXR resolution whereas
127 (56%) had clinical improvement (mean difference 31; 95%CI:
25−37). At day 28, 103 patients (53%) had complete CXR resolution
and 152 (78%) had clinical cure (mean difference 25; 95%CI: 19−31).
In multivariate logistic regression analysis, delayed CXR resolution
was independently associated with Streptococcus pneumoniae infection
(Odds Ratio [OR] 1.9; 95%CI: 1.2−3.1), multilobar disease (OR 2.9;
95%CI: 1.3−6.4), dullness to percussion (OR 6.9; 95%CI: 1.5−32.7),
high C-reactive protein (>200mg/l) (OR 4.2; 95%CI: 1.8−9.8) and high
respiratory rate (>25/min) on admission (OR 2.4; 95%CI: 1.1−5.5).
CXR deterioration during follow-up was not correlated with delayed
clinical cure or mortality (P> 0.6).
Conclusion: Complete CXR resolution of severe CAP occurred in
approximately a quarter of pts at day 7 and in about half at day 28.
Persistence or deterioration of CXR abnormalities were not correlated
with a poor prognosis. Therefore, routine follow-up CXR seems not to
be appropriate for patients that respond to therapy and CXR follow-up to
exclude a non-infectious cause should not be performed within 4 weeks
after initial diagnosis.
O414 Is empiric broad-spectrum therapy always necessary in
severe community-acquired pneumonia?
G. Barlow, D. Nathwani, P. Davey (Hull, Dundee, UK)
Objectives: UK guidelines recommend co-amoxiclav/macrolide or a sec-
ond/third-generation cephalosporin/macrolide for severe (CURB65 3)
community-acquired pneumonia (CAP). Observational studies suggest
that adherence to guidelines and atypical pathogen cover results in better
outcomes. There is concern about the ecological impact, however, of
broad-spectrum agents. This study compared mortality in hospitalised
patients who had received amoxicillin/macrolide (narrow spectrum, NS)
with those who had received either co-amoxiclav/macrolide or a second/
third-generation cephalosporin/macrolide (broad spectrum, BS).
Methods: A retrospective cohort study was performed using data
prospectively collected for a quality improvement (QI) study (Barlow
et al. Thorax 2006). Patients were included if they had CAP and been
treated with one of the regimens deﬁned above. Patients were excluded if
their diagnosis had changed before discharge. Descriptive statistics were
stratiﬁed by type of therapy. Comparisons of 30-day mortality were also
stratiﬁed by CURB65 criteria. Univariate and multivariate logistic regres-
sion were used to identify independent risk factors for 30-day mortality.
Results: Of 503 patients included in the QI study, 14 were excluded
because of a change in diagnosis. Of the remainder, 378 (77%)
had received one of the three regimens (NS= 148; BS = 230 of
which 165 co-amoxiclav/macrolide and 65 cephalosporin/macrolide).
As expected, there were signiﬁcant differences (p 0.05) between
the NS and BS cohorts (exposure to the QI intervention, oral
route availability, penicillin allergy, ID/respiratory ward, ID/respiratory
consultant, CURB65 criteria, oxygenation, CRP, temperature, and ITU
admission). When the cohorts were stratiﬁed for severity, 30-day
mortality in the CURB65 3 cohort was higher in the BS group
(43% versus 22%; see table). Age, oral route availability, respiratory rate,
serum urea, and bilateral/multi-lobar changes on CXR were found to be
independent risk factors for death using multivariate logistic regression
(NS versus BS, p = 0.14 with the trend favouring NS).










0 or 1 2/69 (3%) 0/41 (0%) 1/14 (7%) 2.4 0.3
2 7/47 (15%) 5/45 (11%) 4/17 (23.5%) 1.5 0.5
3 6/27 (22%) 28/75 (37%) 18/33 (54.5%) 6.6 0.036
Conclusions: Although confounding could explain our ﬁndings, the
results do not support the paradigm that all patients with severe CAP
require BS therapy. Better methods of identifying patients with severe
CAP who would genuinely beneﬁt from BS therapy and/or a randomised
controlled trial are required.
O415 Magnitude of bacteraemia predicts one-year mortality
K. Gradel, H. Schønheyder, M. Søgaard, C. Dethlefsen, H. Nielsen
(Aalborg, DK)
Objectives: All hospitals in our region use the BacT/Alert® blood culture
(BC) system with a 3-bottle BC set for adults. We hypothesised that the
magnitude of bacteraemia (i.e., number of positive bottles in the initial
BC set) predicts one-year mortality.
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Methods: In a population-based study we analysed all patients with
monomicrobial bacteraemia in North Jutland County, Denmark, 1996–
2004. Data from the County Bacteraemia Registry were linked to
the Hospital Discharge Registry (comorbidity) and the Danish Civil
Registration System (vital status, including date of emigration or death).
Patients with a BC index of 1 (i.e., one positive bottle) were chosen as
the reference group. We computed Kaplan–Meier curves and performed
Cox regression analyses to estimate mortality rate ratios (MRRs) with
95% conﬁdence intervals [CIs] 30 and 365 days after the initial BC
sampling date, ﬁrst in crude analyses, second in analyses adjusted for
age, comorbidity, acquisition of infection (community, nosocomial, or
healthcare-related), and incident or recurrent episode. In addition we
stratiﬁed the analyses on acquisition of infection and pathogen group.
Results: A total of 6,955 patients had 8,152 episodes of monomicrobial
bacteraemia, among which one-year follow-up was possible for 8,108
(99.5%). Of these, 2,539, 1,511 and 4,058 episodes had a BC index
of 1, 2 and 3, respectively. In crude analyses, 30-day MRRs were 0.98
[0.85−1.14] and 1.20 [1.07−1.34] for BC indices 2 and 3, respectively,
and similar MRRs were found after 1 year (0.99 [0.89−1.09] and 1.12
[1.04−1.21]). All estimates remained unchanged in the adjusted analyses.
Results for community-acquired and healthcare-related bacteraemia
episodes were consistent with the non-stratiﬁed results, whereas all
MRRs for nosocomial infections were close to 1. A BC index of 3 had
the strongest long-term prognostic impact in pneumococcal bacteraemia
(n = 855) (adjusted MRR 1.60 [1.09−2.34]).
Conclusions: In patients with community-acquired or healthcare-related
bacteraemia, high magnitude of bacteraemia (i.e., a BC index of 3)
predicted increased 30-day as well as 365-day mortality.
O416 CURB65 may predict 30-day mortality in patients with
bacteraemia
G. Barlow, P. Lillie, M. Parsonage, K. Adams, H. Thaker, P. Moss,
J. Meigh, R. Meigh, S. Mawer, J. Wilson, W. Dibb, J. Baruah (Hull, UK)
Objective: Bacteraemia is an important cause of mortality in hospitalised
patients. CURB65 has been validated as a predictor of mortality in
community-acquired pneumonia (CAP) (Lim et al. Thorax 2003), but
not in other causes of sepsis. The aim of this study was to assess the
performance of CURB65 in patients with bacteraemia.
Methods: A retrospective cohort study was performed using data
routinely collected in the delivery of the Hull Bacteraemia Service.
As part of this service, patients with conﬁrmed bacteraemia are seen
at the bedside by an infectious diseases physician. A typed report,
which includes physiological data, is then sent to the patient’s physician.
Patients were included if they had all CURB65 criteria recorded at
the point of bacteraemia. 30-day mortality was established by hospital
database and stratiﬁed by CURB65 score. A receiver operating curve
(ROC) was produced and area under the curve and 95% conﬁdence
intervals (CI) calculated.
Results: Of 151 patient reports, 61 patients (62% male) had a
full set of CURB65 criteria. 49% of patients were over 65 years
old and 34% were being managed on a renal ward. The most
common bacteria were: MSSA (41% of patients), MRSA (23%);
various Gram-negatives (16%); thought to be signiﬁcant coagulase-
negative staphylococci (15%); Group A−G streptococci (10%); and
enterococci (8%). The most common sources of bacteraemia were:
central venous line (31% of patients); intravenous drug use (15%);
urinary tract (13%); contamination (10%); and skin/soft tissue (8%).
9% of patients were receiving discordant therapy prior to review. Overall,
30-day mortality was 25%. Recrudescence within 90 days occurred in
5.5% of patients. The table shows 30-day mortality stratiﬁed by CURB65
score. The area under the ROC was 0.73 (95%CI: 0.6−0.86).
Conclusions: This is the ﬁrst study to assess the performance of
CURB65 in a non-respiratory infection. Although preliminary, CURB65
appeared to stratify 30-day mortality in patients with bacteraemia. The
cut-off for severe illness may need to be lower, however, than in CAP.
There is the potential, therefore, to identify a low-risk cohort of patients
(i.e. CURB65 = 0) who may be appropriate for an early switch to oral
therapy and discharge from hospital. Likewise, patients at high risk (i.e.
CURB65 2) are more likely to need aggressive therapy according to
the principals of the surviving sepsis campaign. A large prospective study
is warranted.
30-day mortality stratiﬁed by CURB65 score in patients with bacteraemia








O417 Risk factors and outcomes for persistent bacteraemia caused
by Staphylococcus aureus
H. Shaked, R. Hazzan, M. Wattad, H. Konigsberger, B. Rubinovitch,
L. Leibovici, J. Bishara, M. Paul (Petah Tikva, IL)
Objectives: to assess risk factors and outcomes for persistent
bacteraemia caused by Staphylococcus aureus (SA).
Methods: Clinically signiﬁcant episodes of SA bacteraemia were
registered prospectively. Medical records were reviewed; pertinent
demographic, bacteriologic and clinical data were collected and the
presumptive focus of infection was determined. Persistent bacteraemia
was deﬁned as positive blood cultures 48 hrs. Variables evaluated
included: age, gender, functional capacity, healthcare-associated acqui-
sition, co-morbid conditions, McCabe and Charlson scores, presence
of prosthetic devices, intravascular and urinary catheters, mechanical
ventilation, recent surgery or invasive procedures, steroid or cytotoxic
therapy, neutropenia, source of infection, susceptibility to methicillin
and the clinical status and laboratory ﬁndings at the time of the ﬁrst
positive blood culture.
Variable No persistence Persistent
bacteraemia
P-value
Number of episodes 243 91
Recurrent episode of
SA bacteraemia
15 (6.2%) 14 (15.4%) 0.008
Pacemaker 3 (1.2%) 8 (8.8%) 0.01
Prosthetic joint 1 (0.7%) 4 (7.3%) 0.01
Source of infection
Primary 85 (35.4%) 32 (36.0%)
Catheter-related 14 (5.8%) 3 (3.4%)
Skin, soft-tissues 50 (20.8%) 15 (16.9%)
Joint, bone 8 (3.3%) 12 (13.5%)
Pneumonia 22 (9.2%) 2 (2.2%)
UTI 5 (2.1%) 0
Endovascular 25 (10.4%) 14 (15.7%)
Surgical site 20 (8.3%) 5 (5.6%)
Other 11 (4.6%) 6 (6.7%)
Results: We included 334 patients with SA bacteraemia. Statistically
signiﬁcant risk factors for persistent bacteraemia included a recurrent
episode of SA bacteraemia, the presence of a pacemaker or a
prosthetic joint, and endovascular, joint or bone infections as sources of
infection (table). The difference for prosthetic valves was not signiﬁcant
(12.1% with vs. 9.9% without persistent bacteraemia, p = 0.56) and no
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IVDUs were included in our cohort. Persistent bacteraemia was present
among 48/197 (24.4%), 30/73 (41.1%) and 7/10 (70%) of patients who
received appropriate antibiotic treatment, when appropriate treatment
was started on days 0, 3 and 7, respectively. Echocardiography was
performed for 70 (28.8%) patients without vs. 54 (59.3%) patients with
persistent bacteraemia. Invasive procedures or interventions were
performed more frequently with persistent bacteraemia (43/243, 17.7%,
vs. 28/91, 30.8%, p = 0.009). No signiﬁcant differences were noted with
regard to complications at follow-up, including septic shock, mechanical
ventilation, renal failure and days in ICU. Fever duration was longer with
persistent bacteraemia (5.5 vs. 3.1 days, p< 0.001). All-cause 30-day
mortality among patients alive at 48 h was 82/215 (38.1%) vs. 27/87
(31%), p = 0.24.
Conclusions: Identiﬁcation of risk factors for persistent bacteraemia
can support the performance of repeat blood cultures and direction of
appropriate antibiotic treatment. With adequate management of foreign
bodies, persistent bacteraemia may not portend a poorer prognosis.
O418 Clinical and microbiological features of 55 cases of
staphylococcal toxic shock syndrome in France
T. Perpoint, E. Descloux, T. Ferry, G. Lina, M. Bes, F. Vandenesch,
J. Etienne (Lyon, FR)
Objectives: To describe and compare the clinical presentation, the
management, the outcome and microbiological features of menstrual and
non-menstrual staphylococcal toxic shock syndrome (STSS).
Methods: We have prospectively collected cases of suspected STSS in
France from December 2003 to June 2006. STSS was deﬁned by the
CDC diagnostic criteria and cases were divided in conﬁrmed or probable
TSS. The superantigenic toxin gene content were determinated by PCR
for the corresponding isolates.
Results: Among 100 patients suspected to have staphylococcal STSS
in the study period, 55 fulﬁlled the case deﬁnition of conﬁrmed
(20 cases) or probable STSS (35 cases), and 21 women (38%)
presented with menstrual STSS versus 34 patients with non-menstrual
STSS (62%). Non-menstrual STSS occurred in post-operative period
in 7/34 cases (21%). Blood cultures were positive with S. aureus
in 17 cases of non-menstrual STSS (50%) and never in those of
MTSS (p< 0.001). The tst gene encoding TSST-1 was detected in
all but one menstrual STSS cases (20/21, 95%). At least one gene
encoding a superantigenic toxin was positive for all isolates responsible
for non-menstrual STSS. Most of patients with non-menstrual STSS
have primary focal infections, mainly localised on skin or mucous
membranes (22/34 cases, 65%). Mortality occurred rapidly after the
onset of symptoms (median 3 days; range 1−17 days) in seven patients
with non-menstrual STSS (7/32, 22%). Deceased patients were more
aggressively treated in comparison to survivors but they never received
clindamycin, linezolid or intravenous immunoglobulins (IVIg).
Conclusion: We observed that non-menstrual STSS was a more severe
disease as expected. Comparing with menstrual STSS, non-menstrual
STSS patients have a high positive blood culture and mortality rate
(50% and 22%, respectively). This could reﬂect an evolution of the
S. aureus isolates towards a higher virulence and expression of various
superantigenic toxins. Bacteraemia could partially explain the severity
of non-menstrual cases and may be a composite form of shock, frontier
between septic shock and STSS, potentially more severe than STSS itself.
Speciﬁc therapeutic intervention has to be implemented for patients
with non-menstrual STSS and we proposed the following strategy: rapid
wound debridement whatever the importance of local inﬂammation; rapid
addition of anti-toxinic antibiotic such as clindamycin or linezolid; and
prescription of IVIg.
O419 Management of community-acquired bacterial meningitis
R. Koster-Rasmussen, A. Koshin, C. Meyer (Copenhagen, Roskilde, DK)
Objectives: The purpose of the study was to evaluate the quality
of the initial diagnostics and to identify clinical factors correlating
to an unfavourable outcome. Hypothetically, sequelae and mortality
could correlate to age, presence of risk factors, bacterial aetiology,
and the time from the arrival to the hospital to the administration of
relevant antibiotics (time-arrival–ab). The time-arrival–ab was thought
to correlate with the quality of the initial diagnostics.
Methods: All culture positive CSF in Denmark from 2002 and 2003
were identiﬁed by the regional departments of clinical microbiology.
Clinical data was collected retrospectively from medical charts from all
bacterial meningitis (BM) patients in East Denmark.
Unfavourable outcome was identiﬁed as death or invalidating sequelae
(e.g. total deafness). Positive outcome was identiﬁed as none, reversible
or milder lasting means (e.g. deafness on one ear).
Results: 187 patients were included. 20% of patients admitted with
the tentative diagnosis BM and 27% of patients with a typical clinical
presentation got antibiotics later than 2 hours.
The mortality was 12% for patients receiving relevant antibiotics within
2 hours compared to 40% when antibiotics were administered later than
2 hours (P = 0.00001). The general mortality was 23%.
Age >50, presence of 1 or more risk factors, and non-meningococcal
disease were also correlated with a unfavourable outcome (p< 0.001).
58% had a time-arrival–ab <2 hours. 73% of patients with a classical
clinical presentation were treated within 2 hours compared to 29% with
less typical presentation (P< 0.001).
Age was not correlated to classical clinical presentation.
By multivariate analysis age >50, late administration of antibiotics, non-
meningococcal disease, and presence of risk factors were independently
correlated with unfavourable outcome: Age >50 (OR 3.9, P = 0.003),
non-meningococcal disease (OR 3.9, P = 0.046), presence of 1 or more
risk factors (OR 2.4, P = 0.018), time-arrival–ab >2 hours (OR 1.6,
P = 0.007).
Conclusion: A general correlation between time-arrival–ab and the
severity of outcome was found. Age, non-meningococcal disease,
presence of risk factors and time-arrival–ab >2 hours were independently
correlated with unfavourable outcome in the multivariate analysis. The
results may indicate that the outcome could improve further by optimal
initial management of the BM patient.
Applied pharmacokinetics improve
antimicrobial usage
O420 Penetration of telavancin into pulmonary epithelial lining
ﬂuid and alveolar macrophages
S. Wong, J. Shaw, M. Gotfried, S. Barriere, M. Kitt, M. Goldberg
(South San Francisco, Phoenix, US)
Objectives: Telavancin (TLV), a novel, rapidly bactericidal lipoglycopep-
tide with a multifunctional mechanism of action against methicillin-
resistant Staphylococcus aureus and other Gram-positive pathogens, is
undergoing Phase 3 trials for hospital-acquired pneumonia. This study
evaluated the level of TLV in plasma, and its penetration into pulmonary
epithelial lining ﬂuid (ELF) and alveolar macrophages (AM) after IV
administration to healthy subjects.
Methods: Three daily doses were administered as 60-min TLV
10mg/kg IV infusions to healthy subjects (n = 20; mean±SD age, 30±6
years). TLV was assayed (using liquid chromatography–tandem mass
spectrometry) in blood taken preinfusion on Days 1 and 3, and at 0,
1, 3, 5, 7, 11 and 23 h after the Day 3 infusion, and in bronchoscopy
samples obtained on Day 3 at 4, 8, 12 or 24 h after infusion initiation.
Predictive modelling software simulated the pharmacokinetic disposition
of TLV in different compartments.
Results: The pharmacokinetic model included plasma and peripheral
compartments. Pulmonary ELF and AM appeared to be deeper exten-
sions of the peripheral compartment. A chain of catenary compartments
was incorporated to account for the delay in peak AM concentration.
Mean (coefﬁcient of variation [CV]) TLV intercompartmental clearances
were 0.805 (9.2%), 0.000309 (49.1%), 0.00431 (38.4%), 0.334 (46.6%)
and 0.247 (32.6%) mL/h/kg for CL21, CL23, CL24, CL32 and CL42,
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respectively. Mean (CV) rate constants, k0 and k12, were 0.213 (5.6%)
and 0.839 (17.4%) per h, respectively, and the mean (CV) volume of
the central compartment was 62.2 (5.7%) mL/kg. The model predicted
rapid equilibrium with plasma, slow transfer (CL23) to ELF and even
slower transfer (delay + CL24) to AM. The maximum TLV concentration
(Cmax) in ELF was ~3.7mg/mL, which occurred 8 h post dose (Tmax)
due to a very low clearance-in from the peripheral compartment. The
TLV concentration proﬁle of ELF was relatively ﬂat, mainly because
of the high clearance-out to the peripheral compartment. Cmax in
AM (~50mg/mL) occurred approximately 16 h after dosing. These
simulations showed that TLV in ELF and AM have very different
time–concentration proﬁles from those observed in plasma, where Tmax
occurred 1 h after dosing and Cmax was 116 mg/mL.
Conclusion: Compartmental modelling results support the hypothesis
that AM containing TLV originate in the circulation and that TLV
penetrates deeply into non-infected pulmonary tissue.
O421 Pharmacodynamic evaluation of 7 antimicrobials
recommended for secondary peritonitis, including the novel
agent tigecycline, using global resistance data
K.J. Eagye, J.L. Kuti, M. Dowzicky, D.P. Nicolau (Hartford,
Collegeville, US)
Objectives: Inappropriate empiric antibiotic therapy for secondary
peritonitis (SP) promotes poor patient outcomes. The emergence of
resistance in target organisms contributes to this issue. Tigecycline (TG)
is a novel compound with activity against vancomycin-resistant
Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus
(MRSA); it is newly indicated for intra-abdominal infections, and
was equivalent to imipenem (IMP) in clinical trials. We predicted
microbiological success against aerobic species causing SP by evaluating
TG and 6 antimicrobials from classes recommended for SP by the
Infectious Disease Society of America.
Methods: Cumulative fraction of response (CFR) via a 5000-
subject Monte Carlo simulation was predicted for cefepime (FEP),
ceftazidime (CAZ), ceftriaxone (CRO), IMP, levoﬂoxacin (LVX),
piperacillin-tazobactam (TZP) and TG using a pharmacodynamic
analysis incorporating pharmacokinetic variability in patients and global
minimum inhibitory concentration data. Excluding anaerobic bacteria,
isolates collected in the 2004–2005 SENTRY and TEST Programmes
were analysed by individual species then weighted by prevalence in
SP, both with and without Enterococcus. A predicted CFR of 90% was
considered desirable.
Results: Agents with predicted CFRs 90% when modeled against
all species excluding Enterococcus were (dose, %CFR): FEP
(1 g&2 g q12h, 92&95); CAZ (2 g q8h, 94); IMP (500mg q6h, 97);
and TZP (3.375 g q6h, 91). TG displayed %CFR of 85 at the indicated
dose of 50mg q12h. CRO at 1 g and 2 g q24h had %CFRs of 76 and 78;
LVX 750mg q24h showed %CFR of 76. When Enterococcus was
included in the analysis, IMP, TZP and TG showed %CFRs of 93, 88
and 87, respectively. Against individual species, TG had the highest
%CFR vs. Enterococcus, at 100. Against Escherichia coli, the most
prevalent aerobic species causing SP, all agents had 90%CFR except
LVX (%CFR of 75).
Conclusions: Decisions regarding empiric therapy for SP should
consider local epidemiology, as success is strongly inﬂuenced by
species prevalence and susceptibility. Based on this analysis, resistance
contributed to poor attainment of target exposures for CRO and LVX.
When Enterococcus is not included, FEP 1 g or 2 g q12h or CAZ 2 g
q8h given as combination therapy with an agent to cover anaerobes
would be viable choices, as would monotherapy with IMP 500mg q6h
or TZP 3.375 g q6h. When Enterococcus is included in the epidemiologic
mix, IMP, TZP and TG all appear to be viable monotherapeutic choices.
O422 Concentration-dependent selection of resistant mutants of
Enterococcus faecium exposed to linezolid in an in vitro
dynamic model
D. Gilbert, I. Lubenko, A. Firsov, S. Zinner (Providence, US; Moscow,
RU; Cambridge, US)
Objective: Enterococcal resistance to linezolid (LZD) has been reported
from a few clinical studies. Without pharmacokinetic data, these
observations cannot be related to LZD concentrations with respect
to placement in or out of the mutant selection window (MSW),
i.e., the concentration range from the MIC to the mutant prevention
concentration (MPC). To test the MSW hypothesis, E. faecium was
exposed to LZD at concentrations that fell into the MSW for varying
portions of the dosing interval (TMSWs).
Methods: A clinical isolate of E. faecium 392 (MIC 1.8mg/L,
MPC 7mg/L) at a starting inoculum of 8 logCFU/mL was exposed to
b.i.d. LZD for three consecutive days in a hollow-ﬁber two-compartment
model. The simulated ratios of 24-hour area under the curve (AUC) to
MIC were designed to provide TMSWs from 0 to 100 per cent of the
dosing interval. Peripheral compartments of the dynamic model were
sampled during and after treatment to determine bacterial counts and
LZD concentrations (bioassay). Changes in E. faecium susceptibility and
bacterial growth on agar plates containing 2×, 4×, 8× and 16×MIC of
LZD were examined daily.
Results: The AUC/MICs were estimated at 33, 53 and 114 h, the
respective steady-state peak concentration-to-MIC ratios were 4.7, 7.5
and 15.8 and TMSWs were 88%, 55% and 0%. At the two lower
AUC/MIC ratios, E. faecium resistant to 2−16×MIC and 2−8×MIC
of LZD, respectively, were selectively enriched with a concomitant
slight loss in susceptibility. Neither growth on LZD-containing media
nor changes in susceptibility occurred at the high AUC/MIC ratio
that is comparable to the clinically attainable AUC/MIC for this strain
(186/1.8 = 100 h).
Conclusions: This study suggests that (1) selection of mutants
of E. faecium resistant to LZD depends on drug concentration;
(2) both bacterial growth on LZD-containing plates and loss in
susceptibility of E. faecium occur at AUC/MICs similar to those reported
in earlier in vitro studies with ﬂuoroquinolone-exposed staphylococci
and pneumococci; (3) the MSW concept may be used to predict the
anti-mutant concentrations of LZD.
O423 Pharmacodynamics of gentamicin against Pseudomonas
aeruginosa: modelling bacterial response to
drug-selective pressures
V.H. Tam, G. Vo, S. Kabbara, M. Nikolaou (Houston, US)
Objective: We have previously developed a mathematical model
predicting the response of P. aeruginosa (PA) to various ﬂuctuating
pharmacokinetic proﬁles of meropenem (Tam, ICAAC 05). However,
the applicability of the model to other drug-pathogen combinations is
unknown. We extended our model to predict PA response to ﬂuctuating
gentamicin exposures.
Methods: Time-kill studies with 107 cfu/mL of PA ATCC 27853 at
baseline were performed. Gentamicin at 0, 0.5, 1, 2, 4, 8, 16×MIC
was used for 24 h (MIC= 2 ug/mL). The experimental data were used
to derive the best-ﬁt estimates of the model parameters, and PA
response to various gentamicin exposures over 72 h was predicted via
computer simulation. Three parallel differential equations were used,
each characterising the rate of change of drug concentration, overall
susceptibility and microbial burden of the surviving bacterial population
over time, respectively. Various gentamicin proﬁles (t1/2 = 3 h) were
investigated, corresponding to Cmax/MIC (dosing frequency) of 4 (q8),
12 (q24), 36 (q24) and 30 (q12). The computer simulations were
subsequently validated using an in-vitro hollow ﬁber infection model
(HFIM) with similar gentamicin exposures. Samples were obtained at
baseline, 4, 8, 24, 48 and 72 hours to determine the bacterial burden.
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Results: Time-kill studies data were satisfactorily captured by the
model (r2 = 0.96). A signiﬁcant initial reduction in bacterial burden was
predicted for all gentamicin exposures examined. However, regrowth
over time due to resistance emergence was predicted for regimens
with Cmax/MIC (dosing frequency) of 4 (q8), 12 (q24), and 36 (q24).
Sustained suppression of bacterial population over 72 h was predicted
with Cmax/MIC of 30 (q12). These predictions correlated well with our
experimental data in HFIM.
Conclusions: The model was reasonable in predicting extended
PA response to various ﬂuctuating gentamicin exposures qualitatively,
based on limited input data from time-kill studies. In view of its
robustness and efﬁciency, our mathematical modeling and simulation
approach holds great promise as a high-throughput screening tool for
dosing regimen selection in antimicrobial (pre)-clinical development.
O424 PK/PD modelling of linezolid against MRSA
S. Schmidt (Gainesville, US)
Objective: In vitro PK/PD models, based on time-kill curve data, have
become a powerful tool to predict the in vivo situation. To date, several
physiology-based or semi-mechanistic modeling approaches have been
undertaken to develop suitable PK/PD models that ﬁt in vitro data
sufﬁciently well. Widely used simple sigmoid Emax-models meet these
criteria only partly. A further approach was undertaken to address the
weak points of currently used models and applied to model the effects of
linezolid against methicillin-resistant Staphylococcus aureus (MRSA).
Methods: Constant concentration time-kill curves were performed in
triplicates in Mueller-Hinton broth (MHB, DIFCO) using linezolid
concentrations, ranging from 0.25MIC to 16MIC. The change in number
of viable bacteria (CFU/mL) versus time was linked to the antimicrobial
effect of linezolid. MRSA OC 2878 was employed as the test organism.
Samples were taken at 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and
12 hours. A modiﬁed sigmoid Emax-model was ﬁtted simultaneously to
the data using the software Scientist® 3.0 for WindowsTM. To determine
the best model, Model Selection Criterion (MSC) and coefﬁcient of
determination (R2) were taken into account as well as a visual inspection
for goodness of ﬁt.
Results: Two susceptibility stages were deﬁned for MRSA –
stage 1: self-replicating and susceptible to linezolid, and stage 2: un-
susceptible and metabolic inactive. In the log-growth phase, susceptible
bacteria grow with a growth rate constant ks that is greater than their
natural death rate constant kd in a certain ratio. Converging to the
stationary phase this ratio changes in a non-linear manner, described by
an additional Nmax term. In the presence of linezolid a concentration C
dependent kill has to be taken into account. From certain drug speciﬁc
concentrations on, a maximum effect is reached, described by the
maximum kill rate constant kmax. However, both the onset of growth
and kill can be delayed and modeled by exponential terms, characterised
by time t and dg or dk , respectively. The ﬁnal shape of the curve is
smoothed out by a Hill factor/shape factor h. The modiﬁed sigmoid
Emax-model shown below described the data best, resulting in MSC
































)⎤⎦·(1 − e−dkt )
−kd ·
⎛










Conclusion: The proposed model incorporating ﬁve additional terms
could account much better for the in vitro situation than a simple
Emax-model. A simultaneous ﬁt describes the actual time-kill curve data
sufﬁciently well.
O425 Comparative pharmacodynamics of telavancin and
vancomycin with Staphylococcus aureus: multiple-dose
simulations using an in vitro dynamic model
A. Firsov, I. Lubenko, M. Smirnova, E. Strukova, S. Vostrov, S. Zinner
(Moscow, RU; Cambridge, US)
Objective: The anti-staphylococcal pharmacodynamics and killing
kinetics of telavancin (TLV) and vancomycin (VAN) against methicillin-
resistant S. aureus ATCC 43300 were studied in ﬁve-day treatment
courses over a wide range of ratios of the 24-h area under the curve
(AUC) to MIC.
Methods: MICs of TLV and VAN for S. aureus ATCC 43300 were
0.25 and 0.8mg/L, respectively. The respective mutant prevention
concentrations (MPCs) were 5 and 18mg/L. An 18-hour culture of
S. aureus ATCC 43300 at a starting inoculum of 8 logCFU/mL was
exposed to mono-exponential concentration decays of TLV (once-daily
dosing, half-life of 8 h) and VAN (twice-daily dosing, half-life of 6 h).
With each antibiotic, peak concentrations were designed to be equal to
the MIC, above the MIC but below the MPC, i.e., within the mutant
selection window (MSW), and above the MPC. The respective steady-
state AUC/MICs of TLV varied from 50 to 1200 h and those of VAN
varied from 30 to 1200 h. To determine the antimicrobial effect, the area
between the level corresponding to the starting inoculum and the time-
kill curve (ABBC) was calculated from time zero to 144 h. To detect
possible changes in susceptibility to TLV or VAN, bacterial growth on
agar plates containing 2×MIC and 4×MIC of antibiotic was recorded
and the MICs were tested every 24 h.
Results: With both TLV and VAN, anti-staphylococcal effects depended
on the AUC/MIC ratio: the higher the AUC/MIC, the greater the
killing and delay of bacterial regrowth. Linear relationships of ABBC
to log AUC/MIC were established with each antibiotic. Based on these
relationships, the anti-staphylococcal effect of the proposed therapeutic
dose of TLV (10mg/kg; AUC/MIC 3400 h) is 25% greater than that
of two 1-g doses of VAN given at a 12-h interval (AUC/MIC 500 h).
Regardless of whether TLV and VAN concentrations were in or out of
the MSW, no bacterial growth occurred on antibiotic-containing plates
and no change in susceptibility was observed.
Conclusion: These ﬁndings suggest greater anti-staphylococcal efﬁcacy
of TLV relative to VAN at their clinically achievable AUC/MICs.
O426 In vivo pharmacokinetics and intracellular accumulation of
ﬁve antistaphylococcal agents in a murine model of peritonitis
J.H.R. Hessler, A. Sandberg, N. Frimodt-Moller (Copenhagen, DK)
We have recently evaluated a number of antistaphylococcal drugs in vivo
in a murine model of peritonitis, with respect to their intracellular
antistaphylococcal activity.
Objectives: (1) A PK description of azithromycin (AZM), ce-
furoxime (CXM), dicloxacillin (DCX), gentamicin (GEN) and ri-
fampicin (RIF) in plasma and peritoneal exudate following SC injection.
(2) A description of the intracellular accumulation of antibiotics in
peritoneal exudate.
Methods: Female NMRI mice were inoculated IP with Staphylococcus
aureus E19977 in 5% mucin. Two hours later, mice were treated SC
with one of the ﬁve antibiotics. For each individual mouse an aliquot
of peritoneal exudate was saved for differential somatic cell count and
measurement of antibiotic concentration. Pelleted cells (300 g, 10min)
from the rest of the peritoneal exudate were lysed in a small volume of
dH2O. Antibiotic concentrations were measured by bioassay. Intracellular
accumulation was calculated by dividing the intracellular with the
extracellular concentration.
Results: Cmax (total drug) in plasma and peritoneal exudate, respec-
tively, was 4.4 and 0.6mg/L (AZM), 370 and 172mg/L (CXM), 375 and
175mg/L (DCX), 19 and 12mg/L (GEN) and 13 and 5.3mg/L (RIF).
T>MIC (total drug) in plasma and peritoneal exudate, respectively,
was 42 and 12min (AZM), 123 and 209min (CXM), 273 and 273min
(DCX), 132 and 216min (GEN) and 267 and 267min (RIF). Intracellular
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accumulation (range) of antibiotics (total drug) found was 26–106
(AZM), 4−19 (CXM), 2−13 (DCX), 21−36 (GEN), 2−25 (RIF).
Conclusion: The concentrations found for CXM and DCX were
higher than the concentrations found for AZM, GEN and RIF. This
corresponds well with the higher dose injected and the relatively high
antistaphylococcal activity observed in PD studies. The intracellular
accumulation of AZM and RIF found here corresponds well with what
has previously been reported. The intracellular accumulation for CXM,
DCX and GEN found here, are surprisingly high, since b-lactams are
notoriously considered not to accumulate intracellularly, and the 2−4 fold
intracellular accumulation of aminoglycosides take several days, but the
inﬂux correlates well with the good effect seen in the in vivo model.
O427 Proinﬂammatory effects of erythromycin, clarithromycin
and azithromycin on human endothelial cells in vitro
M. Millrose, I. Baumann-Wilschke, J. Webb, R. Stahlmann (Berlin, DE)
An inﬂammatory reaction of the venous vessel is a common clinical
problem that is observed after intravenous application of antibiotics and
other drugs. The local irritation of the endothelium at the site of infusion
leads to an inﬂammatory response with an increased expression of vari-
ous cell surface antigens. Among these are CD 34, E-Selectin (CD 62E),
ICAM-1 (CD 54) and VCAM-1 (CD 106). We studied the effects of
three closely related antibiotics on human endothelial cells in vitro.
We used the endothelial cell line EA.hy 926 and analysed the reaction
by means of ﬂow cytometry (FACScan, Becton Dickinson). Cells were
incubated with clarithromycin or azithromycin at concentrations ranging
from 100mg/l to 800mg/l and at concentrations ranging from 200mg/l to
1400mg/l for erythromycin. Such concentrations occur under therapeutic
conditions at the site of infusion. Subsequently, they were stained with
ﬂuoresceinisothiocyanate- or phycoerythrin-conjugated monoclonal IgG
mouse-antibodies for the four antigens mentioned above. Cells were
incubated with the drugs for 2 h and analysis was carried out after an
additional time period of 22 h. In control cells, we found positively
stained cells at the following levels: CD 34 (2%), E-Selectin (4%),
ICAM-1 (14%) and VCAM-1 (2%). The most pronounced changes
were observed at 800mg/l (erythromycin), 600mg/l (azithroymcin), and
400mg/l (clarithromycin). Erythromycin (800mg/l) caused signiﬁcantly
increased expressions of all epitopes [CD 34 (+6%), E-Selectin (+5%),
ICAM-1 (+15%) and VCAM-1 (+5%)]. At 600mg/l the azalide
azithromycin provokes a stronger upregulation of the proinﬂammatory
antigens: CD 34 (+17%), E-Selectin (+16%), ICAM-1 (+27%) and
VCAM-1 (+17%). Clarithromycin at a concentration of 400mg/l causes a
similar effect as erythromycin at twice this concentration [CD 34 (+6%),
E-Selectin (+7%), ICAM-1 (+23%) and VCAM-1 (+4%)]. Analysis of
the cell surface markers involved in cell-cell-interactions proved to be a
useful approach to further study the mechanism of infusion phlebitis and
to compare the proinﬂammatory effects of related compounds in vitro.
O428 Aminoglycoside-induced apoptosis in cultured renal
(LLC-PK1) and non-renal (J774 macrophages) cells:
comparison between gentamicin and amikacin
S. Denamur, F. Van Bambeke, M.-P. Mingeot-Leclercq, P. Tulkens
(Brussels, BE)
Objectives: Apoptosis is now recognized as an early, and probably
critical determinant in gentamicin (GEN)-induced nephrotoxicity in
animals (Antimicrob Agents Chemother. 2000; 44: 665−75) as well as
in renal cultured cells (Toxicol Sci. 2000; 56: 229−39). Models using
electroporated cells also show that direct delivery of GEN in the cytosol
of cultured renal cells enhances at least 30-fold its capacity to induce
apoptosis (Antimicrob Agents Chemother. 2006; 50: 1213−21). Our aims
were (i) to examine whether the capacity of GEN to induce apoptosis
is restricted to renal cells; (ii) to compare amikacin (AMK) to GEN in
this context, since AMK is generally considered to be less nephrotoxic
than GEN (Antimicrob Agents Chemother. 1999; 43: 1003−12).
Methods: We used non-conﬂuent murine J774 macrophages and porcine
LLC-PK1 renal cells grown to 80% of conﬂuency. Electroporation
was performed on trypsinised LLC-PK1 cells (8 square wave pulses;
800 v/cm; 1ms) as previously described (Antimicrob Agents Chemother.
2006;50:1213−21). Cell viability was checked by measurement of LDH
release (only cultures with <10% release were used for evaluation).
Apoptotic cells were enumerated after DAPI staining by observers
unaware of the experimental conditions, and expressed as percentage
of all visible cells.
Results: The Table shows the extent of apoptosis observed in controls
(no aminoglycoside), in cells exposed to GEN concentrations known
from previous studies to induce marked apoptosis or to AMK equimolar
concentrations. For GEN, apoptosis developed on a concentration-
dependent manner from an extracellular concentration of 1mM for
incubated cells and from 32mM for electroporated cells. For AMK, no
signiﬁcant increase of apoptosis was seen at concentrations tested.
% apoptotic cells
J774 macrophages renal LLC-PK1 cells
incubateda incubatedb electroporatedc
none 3mM none 3mM none 128mM
Gentamicin 0.1 14.9 1.5 12.7 1.8 18.4
Amikacin 0.0 1.2 1.5 0.0 0.8 0.9
a24 h incubation; b48 h incubation; c24 h incubation in drug-free medium
after electroporation in the presence of the drug.
Conclusions: Apoptosis develops in both renal and non-renal cells upon
incubation with GEN. The lack of apoptosis observed with AMK with
both incubated (renal and non-renal) and electroporated (renal) cells
support the concept that this aminoglycoside is intrinsically less toxic
than GEN.
O429 Inhibitors and activator of the P-glycoprotein (P gp) efﬂux
pump modulate the accumulation of daptomycin (DAP) in
THP-1 macrophages and its intracellular activity towards
Staphylococcus aureus
S. Lemaire, F. Van Bambeke, P. Tulkens (Brussels, BE)
Objectives: The concentration of antibiotics in eukaryotic cells can be
reduced by efﬂux pumps such as P-gp, which may impair their activity
against intracellular bacteria (JAC 2003; 51: 1167–1173). DAP is a
lipopeptide antibiotic with an amphiphilic character (calculated logD at
pH 7 and 25ºC: 9.56). Since amphiphilicity is an important determinant
for recognition and transport by P-gp, we have examined whether the
activity of this transporter in macrophages could affect the handling and
intracellular activity of DAP.
Methods: Uninfected THP-1 macrophages were exposed to DAP (24 h)
or to the ﬂuorochrome dimethyloxadicarbocyanine iodide (DIOC2;
a speciﬁc P-gp subtrate; 5 h) and their cell contents measured by
ﬂuorimetry (see JID 2005; 191: 2149–2152 for assay method of
daptomycin). Intracellular activity of DAP was measured against
phagocytised S. aureus (ATCC 25923; MIC in Ca2+ supplemented
MH broth: 0.125mg/L) after a 24 h exposure to an extracellular
concentration of DAP yielding an apparent static effect for intracellular
bacteria (1mg/L; see AAC 2006; 50: 841–851 for description and
validation of the model with other antibiotics). The activity of P-gp
was inhibited by incubation with verapamil (100mM) and GF120918
(0.25mg/L), or stimulated with ouabain (1mM). Gemﬁbrozil (an
inhibitor of the MRP transporters) was used as control.
Results: The data presented in the Table show that P-gp modulators
affect the cell handling and the intracellular activity of DAP in the same
directions (verapamil and GF120918 increase DAP accumulation and
activity, while oubain decrease them both), whereas a MRP inhibitor is
without effect.
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Condition Cellular accumulationa DAP intracell. activity
DIOC2 DAP D log cfub
Controls 547±39 0.29±0.1 0.0±0.1
+ verapamil 726±25* 0.68±0.1* −1.4±0.1*
+ GFl 20918 Not possiblec −1.3±0. 1*
+ ouabain 106±29* 0.10±0.0* + 0.4±0.1*
+ gemﬁbrozil 485±36ns 0. 25±0.1ns +0.1±0.1ns
aApparent cellular to extracellular concentration ratio.
bChange in cfu at 24 h compared to post-phagocytosis inoculum
(~106 cfu/mg cell protein).
cNo assay possible because of interference with GFl 20918 intrinsic
ﬂuorescence.
*Signiﬁcantly different from control (p< 0.05).
nsNot signiﬁcantly different from control.
Conclusions: DAP is a substrate of the P-gp efﬂux transporter in human




O430 Detection of CTX-M-14 b-lactamase in Escherichia coli from
a long-term care and rehabilitation facility in northern Italy
R. Migliavacca, M. Balzaretti, E. Nucleo, M.M. D’Andrea, C. Mugnaioli,
M. Spalla, T. Giani, G.M. Rossolini, L. Pagani (Pavia, Milan, Siena, IT)
Objectives: The presence of ESBL producers (particularly among
uropathogens) in geriatric long-term care and rehabilitation facilities
(LTCRFs) has not been investigated in Italy, until now. The objective
of this study was to evaluate the diffusion of CTX-M type b-lactamases
among Escherichia coli clinical isolates from LTCRFs.
Methods: During the period April 2003–May 2004, a total of 529 E. coli
consecutive non-replicated isolates were collected from inpatients at the
LTCRF-RSA ASP “Golgi-Redaelli” of Milan. All isolates were identiﬁed
and screened for ESBL production using the GNS-530 card of the
VITEK1 system, the double-disk synergy test and/or the conﬁrmatory
CLSI method. IEF coupled with a bioassay, PCR ampliﬁcation and
sequencing were carried out to identify the nature of the blaCTX-M-
type determinants. Conjugation experiments, plasmidic DNA extraction
followed by restriction analisys were also performed. The clonal
relationships between the isolates were evaluated by PFGE of genomic
DNA digested with NotI.
Results: All the E. coli clinical isolates resulted susceptible to
piperacillin-tazobactam; 69/529 (13%) were ESBL producers. Such
strains were obtained mainly from urinary samples (92.8%), in most
cases from catheterised patients (90.6%). The CTX-M-type enzymes
detected in 52/69 (75.4%) E. coli isolates showed a pI 8.2 or 8.4 active
on cefotaxime, cefepime, and aztreonam. 40/52 (76.9%) CTX-M positive
isolates were found to produce also a TEM-1 enzyme. The CTX-M
determinants were transferable in 20/52 (38.4%) cases.
Sequencing results showed that 4/52 (7.7%) strains were CTX-M-14
producers while the remaining were CTX-M-1 producers. There was
a common plasmid in 2/4 of the CTX-M-14 producers, both strains
have been isolated from the Golgi institute. After plasmids restriction
analysis, the CTX-M-1 coding plasmids exhibited different restriction
proﬁles, while 2/4 CTX-M-14 producers resulted clonally related. PFGE
proﬁles demonstrated the presence of at least 9 different clones.
Conclusions: Finding the different CTX-M-1-encoding plasmids in
clonally related and unrelated strains of E. coli from the RSA ASP
“Golgi-Redaelli” indicates a notable spreading potential for these
plasmids and suggests that horizontal transfer could be the principal, but
not the only mechanism of CTX-M enzymes spreading in the hospital
environment. This is the ﬁrst report of a CTX-M-14 gene in E. coli in
Italy.
O431 Epidemiology and genetic features of CTX-M-15-producing
Klebsiella pneumoniae epidemic clones in Hungary in 2005
I. Damjanova, A´. To´th, G. Hajbel-Ve´kony, J. Pa´szti, J. Berta, M. Fu¨zi
(Budapest, HU)
Objectives: To investigate the dissemination and molecular epidemiol-
ogy of CTX-M-15-producing K. pneumoniae epidemic clones (KP-EC)
identiﬁed earlier in Hungary by pulsed-ﬁeld gel electrophoresis (PFGE)
and multilocus sequence typing (MLST).
Methods: 396 ESBL-producing KP clinical isolates were submitted to
the National ESBL Reference Laboratory for conﬁrmation in 2005. On
the basis of phage types 190 isolates from 38 healthcare facilities were
selected for testing by PFGE and representative isolates were further
characterised by MLST.
Antimicrobial susceptibility testing was performed by disk diffusion
according to the CLSI. The carriage of blaCTX-M and ISEcp1
were investigated by PCR and CTX-M amplicons sequenced. The
transferability of ESBL genes in representative isolates was tested and
the plasmid proﬁles analysed.
Results: Three CTX-M-15-producing KP-ECs were identiﬁed all
showing high level resistance to ciproﬂoxacin. The previously described
K. pneumoniae Hungarian epidemic clone (HEC) spread to 31 healthcare
facilities, affecting 124 patients, and causing 3 nosocomial outbreaks.
This clone proved identical to sequence type (ST) 15, carried two gyrA
mutations, a single parC mutation and blaSHV-28. The second epidemic
clone spread to 4 healthcare facilities, affecting 45 patients and causing
2 nosocomial outbreaks. This clone represents a novel sequence type
(data submitted to MLST centre), carrying a single gyrA and a single
parC mutation. The third epidemic clone spread to 3 healthcare facilities,
affecting 21 patients and causing one nosocomial outbreak. This clone
corresponds to ST 11, carrying two gyrA and a single parC mutations.
ISEcp1 was detected exclusively in strains belonging to the ST 11 clone.
Conclusion: In 2005 the number of infections caused by CTX-M-
producing KP rose sharply in Hungary. In addition, a shift was
demonstrated in the occurrence of CTX-M-producing KP clones. Three
multidrug resistant KP-ECs were detected in 38 healthcare facilities
causing large outbreaks and individual nosocomial infections.
O432 Polyclonal distribution of extended-spectrum b-lactamase-
producing Escherichia coli and Klebsiella pneumoniae in
Stockholm
E. Titelman, A. Iversen, A˚. Lagergren, I. Ku¨hn, G. Kahlmeter, C. Giske
(Stockholm, Va¨xjo¨, SE)
Objectives: Previously published Swedish reports on the epidemiology
of extended-spectrum b-lactamase (ESBL)-producing Enterobactericaeae
have identiﬁed CTX-M as the most prevalent ESBL-group in Sweden.
However, no previous reports on the baseline epidemiological situation
in the absence of outbreaks have been published from Sweden. This
study aimed at genotypic characterisation of all ESBLs at the Karolinska
University Hospital in Stockholm during the entire 2005.
Methods: The prevalence of ESBL-production among E. coli and
K. pneumoniae at the Karolinska University Hospital was 0.7% in 2005.
ESBL-positive clinical isolates (n = 160) of E. coli and K. pneumoniae
collected at the Northern (n = 63) and Southern (n = 97) campus of
the hospital during 2005 were investigated. Most isolates (59%) were
derived from out-patient sources, and the majority were from the urinary
tract (81%). Among the remaining 41% of the isolates, 15% were
derived from nursing homes and the rest from hospital in-patients.
PCR was performed with primers covering all known CTX-M variants,
and speciﬁc primers for the CTX-M-1 and -9 groups. CTX-M-negative
isolates were analysed with primers targeting TEM. Subsequently DNA
sequencing was performed. Epidemiological typing was performed with
the PhenePlate (PhP) system. MICs for ceftazidime, cefotaxime and
cefpodoxime were determined with Etest, and susceptibility testing for
other antibiotics was performed with disk-diffusion.
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Results: Among isolates from Northern Stockholm, 59/63 isolates were
positive for CTX-M. CTX-M-15 was the most prevalent subtype (39/59).
CTX-M-14 was found in 17/59 isolates, while 7 isolates produced
CTX-M-2-like or TEM-derived ESBLs. From Southern Stockholm 92/97
isolates were found to be CTX-M positive, out of which 72 were CTX-
M-15 and 17 were CTX-M-14. Two isolates produced CTX-M-22, and
the rest produced either CTX-M-2-like or TEM-derived ESBLs. The
PhP-typing revealed the presence of one Northern clone (n = 16) and one
Southern clone (n = 13). All isolates were resistant to cefpodoxime, and
70% were resistant to ciproﬂoxacin. In vitro susceptibility to ceftazidime
(according to EUCAST) was observed in some CTX-M-14 isolates, and
some TEM-producers were cefotaxime susceptible.
Conclusions: This study identiﬁed CTX-M-15 as the dominating ESBL
genotype in Stockholm. Although two clones of respectively 14 and 16
isolates could be identiﬁed, the majority of the strains were clonally
unrelated.
O433 Faecal carriage of extended-spectrum b-lactamase-producing
Escherichia coli: prevalence and risk factors in different
populations
J. Rodrı´guez-Ban˜o, M.D. Navarro, L. Lo´pez-Cerero, C. Morillo,
M.A. Muniain, A. Pascual (Seville, ES)
Objectives: Extended-spectrum b-lactamase-producing Escherichia coli
(ESBLEC) is an emerging cause of community acquired infections. We
investigated the prevalence of faecal carriage of ESBLEC in different
groups of patients and the variables associated with carriage.
Methods: Faecal carriage of ESBLEC was investigated from June 2005
to September 2006 in 4 groups of persons: outpatients from whom
ESBLEC had been isolated from a clinical sample (group A); living-
together relatives (group B1); non-living-together relatives (group B2);
and patients randomly chosen among those being attended at the
emergency department (group C). Rectal swabs were obtained from all of
them and inoculated in MacConkey-cefotaxime (2mg) and MacConkey-
ceftazidime (2mg). ESBL production was studied following CLSI
recommendations. The following data were collected: demographics, pre-
vious healthcare relation, co-morbidities, previous use of antimicrobials
and proton-pump inhibitors, invasive procedures, feeding habits, and
pets. Multivariate analysis of the association of the different variables
with faecal carriage were performed using logistic regression.
Results: We included 54, 74, 32, and 54 patients in groups A, B1,
B2 and C, respectively. Rectal colonisation by ESBLEC was detected
in 36 (68%), 22 (30%), 5 (16%) and 4 (7%) persons from groups
A, B1, B2 and C, respectively. The prevalence rates were signiﬁcantly
different between group A and all others (p< 0.001), and between
groups B1 and C (p = 0.02). Among people in groups B1, B2 and C,
multivariate analysis showed higher risk of colonisation in relatives of
group A patients, either living with them (OR= 16.1; 95%CI: 4.1−63.6;
p< 0.001) or not (OR= 6.2; 95%CI: 1.2−29.8; p = 0.02), and in those
with co-morbidities (OR= 3.8; 95%CI: 1.4−10.2; p = 0.008), and lower
risk in those eating out more frequently (OR= 0.3; 95%CI: 0.1−0.9;
p = 0.02) and eating pork more frequently (OR= 0.6; 95%CI: 0.3−1.0;
p = 0.06). Previous antimicrobial use was not associated with increased
risk.
Conclusions: Faecal carriage of ESBLEC is more frequent in relatives of
patients from which ESBLEC is isolated from a clinical sample than in
non relatives, suggesting either person to person transmission of isolates/
genetic elements, or acquisition from a common source. Some feeding
habits were associated with carriage, but previous antimicrobial use was
not. Molecular studies are progress to further elucidate the epidemiology
of faecal carriage of ESBLEC.
O434 Occurrence of ESBL-producing Escherichia coli in outﬂow
from a wastewater treatment plant
S. Galvin, D. Morris, P. Hickey, M. Cormican (Galway, IE)
Objectives: This study describes the isolation of extended spectrum
b-lactamase (ESBL) producing E. coli strains in outﬂow from a munici-
pal secondary wastewater treatment plant. The role the environment plays
in the dissemination, maintenance and ampliﬁcation of antimicrobial
resistance is an area of increased scrutiny. Few studies have examined
surface waters and efﬂuent for the presence of antimicrobial resistant
organisms.
Methods: Six samples (1 per week) were collected from the outﬂow of
a municipal secondary wastewater treatment plant between August and
September 2006. These were screened for the presence of E. coli resistant
to ampicillin, cefoxitin, cefotaxime, and ciproﬂoxacin. Resistant isolates
were tested for susceptibility to sixteen antimicrobial agents by Clinical
Laboratory Standards Institute (CLSI) disk diffusion methods, including
the following b-lactams: ampicillin, cefpodoxime, cefotaxime and
ceftazidime. ESBL production was conﬁrmed by the CLSI combination
disk method for ESBL production using cefpodoxime. Conﬁrmed
ESBL producers were screened for blaTEM, blaSHV and blaCTX-M
by PCR using speciﬁc primers. Relatedness of ESBL producers was
determined by pulsed ﬁeld gel electrophoresis (PFGE) using XbaI.
Results: Thirty-four isolates of E. coli resistant to one or more
antimicrobial agents tested were identiﬁed. Seven (21%) were conﬁrmed
as ESBL producers. All 7 conﬁrmed ESBL producers were resistant
to 3 or more antimicrobial agents tested. PCR revealed a blaTEM
gene in all 7, and a blaCTX-M group 1 gene in 3 isolates. PFGE
analysis identiﬁed 5 pulsed ﬁeld proﬁles (PFPs). These were isolated
from samples taken on 3 separate dates. Isolates with indistinguishable
PFPs were isolated from samples taken on different dates. Isolates with
distinguishable PFPs were isolated on the same date.
Conclusion: This is the ﬁrst report of the occurrence of ESBL-producing
E. coli in the outﬂow from a secondary wastewater treatment plant and
reﬂects the extent to which this resistance phenomenon is now very
widely disseminated.
O435 Prevalence of ESBL in the Netherlands: the ONE study
J. Mouton, A. Voss, J. Arends, S. Bernards on behalf of the ONE
Study group
Background: The prevalence of extended spectrum b-lactamase (ESBL)
producers is increasing worldwide. Data on prevalence in The
Netherlands are sparse. Therapeutic options for ESBL producers are gen-
erally limited to ﬂuoroquinolones, aminoglycosides and carbapenems.
Ertapenem is a new broad spectrum carbapenem that may be suited
to use against ESBL-producing enterobacteriaceae. Aim of the ONE
study was to determine the prevalence of ESBL in the Dutch population
and the susceptibility of ESBL producers against Ertapenem and other
antibiotics.
Methods: 22 laboratories equally distributed in the Netherlands partici-
pated in the study. Each lab was asked to collect up to 100 consecutive
enterobacteriacea isolates from clinical samples during a 4 month period.
Isolates from rectal and nose swabs were excluded, as were isolates
from surveillance cultures. A maximum of one isolate per species per
patient was allowed. Isolates were identiﬁed by participating laboratories
using their own standard identiﬁcation technique. MICs were determined
using Etest on site for ertapenem, amoxicillin, amoxicillin/clavulanic
acid, meropenem, piperacillin/tazobactam, ceftazidime, ceftriaxone,
tobramycin, cotrimoxazole and ciproﬂoxacin. Control ATCC strains were
included. Afterwards, strains were collected by the central lab for further
analysis. For ESBL screening, primary isolates of Escherichia coli and
Klebsiella pneumoniae were subcultured on a ESBL screening plate with
ceftazidime and cefotaxim. Colonies growing on the screening plate
were tested for ESBL using the Etest TZ/TZL and CT/CTL strip and if
necessary the PM/PML strip. K. oxytoca was evaluated based on Etest
results of ceftazidime and ceftriaxon. All other enterobacteriacae were
tested with the Etest PM/PML strip to differentiate the ESBL from the
AmpC producers.
Results: The overall prevalence of conﬁrmed ESBL producers was
close to 6%. 43% of all isolates were identiﬁed as E. coli and 12%
as K. pneumoniae, with ESBL prevalences of up to 6% and 8%,
respectively. The MIC90’s (mg/L) were 0.38 for ciproﬂoxacin, 0.125 for
S92 17th ECCMID / 25th ICC, Oral presentations
ertapenem, 0.094 for meropenem, 32 for cotrimoxazole and 2 for
tobramycin.
Conclusion: This was the ﬁrst large scale survey to determine the
prevalence of ESBL-producing enterobacteriaceae in the Netherlands.
The overall prevalence of close to 6% is signiﬁcant and indicates that
there is reason to start monitoring ESBL prevalence on a regular basis
in order to better guide control measures.
O436 Genetic characterisation of highly prevalent MBLs and
OXA carbapenemases in multidrug-resistant Acinetobacter
baumannii strains in a Romanian hospital
R. Cernat, C. Balotescu, V. Lazar, O. Banu, D. Ivanescu, M. Bucur
(Bucharest, RO)
Objective: This study was designed to demonstrate (1) the clonal rela-
tionship, (2) the prevalence and type of acquired metallo-b-lactamases
(MBLs) and oxacillinases with carbapenem-hydrolyzing activity and
(3) the potential risk of integron dissemination among multidrug-resistant
Acinetobacter baumannii strains isolated from cardiovascular devices
associated infections.
Material and Methods: Multiresistant A. baumannii isolates collected
between 2003 and 2006 at the Institute for Cardiovascular Diseases
C.C. Iliescu were tested by VITEK2 automatic system, IPM disc Hodge
test, IPM-EDTA+SMA double disk synergy tests, double disk test in
MH agar plus cloxacillin (250mg/l), microdilution tests of b-lactams
and colistin, IEF, PCR for blaIPM-1, blaVIM-1, blaVIM-2, blaOXA-23,
blaOXA-24, blaOXA-51 and blaOXA-58, class 1- and class-2 integrons
and sequencing for MBL-, OXA-types carbapenemase-encoding genes
and integrons. The clonal relationship between the isolates was evaluated
by PFGE.
Results: 120 IPM-resistant (MIC 8−64mg/l) A. baumannii isolates
were MBL- and multiple OXA-types producers carrying blaIPM-1 and
blaVIM-2 alleles, blaOXA-23 and blaOXA-58-plasmid mediated genes,
respectively. PFGE showed six different clonal lineages. The blaVIM2
gene was carried on a gene cassette inserted into class-1 integrons,
identical to those from P. aeruginosa in Europe and which included
5 different known additional cassettes (arr-3, catB3, aadA1, aacC1 and
aacA4).
Conclusions: This study is the ﬁrst report of the integron-associated
IMP resistance, high prevalence and co-existence of blaIPM-1, blaVIM-2
and blaOXA-23-type among multiple clones of blaOXA-8-type-bearing
multiresistant clinical isolates of A. baumannii in Romania. Taking into
account the very narrow antibiotherapy choices in these infections, the
horizontal transfer of these genes and also the increasing resistance
to colistin, the possibility of a further spreading of carbapenem-
hydrolyzing oxacillinases is of a considerable concern for antimicrobial
chemotherapy.
O437 Diverse metallo-b-lactamases and integron gene cassette
arrays in Pseudomonas spp. and Enterobacter cloacae
isolates from Warsaw, Poland
M.A. Toleman, A. Rokosz, J.A. Patzer, A. Sawicka-Grzelak,
D. Dzierzanowska, T.R. Walsh (Cardiff, UK; Warsaw, PL)
Objectives: To determine the mechanism of resistance and genetic
structures containing resistance genes of 40 multiresistant clinical
isolates collected in Warsaw, Poland from 2002–2005.
Methods: 31 Pseudomonas aeruginosa (PSA), 7 P. putida (PPU),
1 P. stutzeri (PST) and 1 Enterobacter cloacae (EC) isolates, positive by
Etest MBL strips (ABbiodisc) were collected in the years 2001 (1),
2002 (3), 2003 (10), 2004 (11), and 2005 (15). The strains were
investigated for the presence of metallo-b-lactamase genes by class-1
integron PCR followed by digestion with restriction enzymes, Southern
hybridisation and probing with blaVIM probes. Positive isolates were
further investigated by PCR and sequencing with primers designed
against class-1 integron, blaVIM genes and Tn5090 transposase genes.
Results: All isolates were positive by hybridisation with blaVIM-1
and blaVIM-2 radio-labelled probes. Digestion of the class-1 integron
PCR products with HincII produced ten different integron RFLP types
(Types A−J). Type A was found in six PSA, 3 PPU and one PST
strains and consisted of a class-1 integron harbouring aacA4 and
blaVIM-4 gene cassettes. Type B was found in 10 PSA strains and the
individual EC strain, harbouring an integron with aacC4, blaVIM-4 gene
cassettes and the insertion sequence ISPpu17. Eight strains harboured
the blaVIM-2 gene cassette in several different gene arrays and only
one strain of PSA harboured the blaVIM-1 gene cassette. All class-1
integrons were of the more common form including the 3′Conserved
sequence. No class-1 integrons were found that did not have the 3′CS
as has been found in several recent blaVIM-2 isolates from diverse
geographic regions.
Conclusion: Metallo-b-lactamases appear to be increasingly detected in
clinical bacterial isolates from the Warsaw area of Poland, from the initial
isolate in 2001 to ﬁfteen isolates in 2005. The most commonly isolated
MBL genes in this region are the blaVIM-4 fused gene cassette and
the blaVIM-2 gene cassette. Other gene cassettes commonly found are
aacC4, aadB and aadA10, conferring resistance to aminoglycosides. The
ﬁnding of the same integron RFLP types in different species of bacteria
indicates increasing horizontal dissemination of these broad-spectrum
resistance determinants.
O438 Activity of human b-defensin 3 against metallo-b-lactamase-
producing Pseudomonas aeruginosa strains
E. Kazakos, A. Bisiklis, S. Alexiou-Daniel, M. Bajaj-Elliott
(Thessaloniki, GR; London, UK)
Objectives: We sought to evaluate the bactericidal effect of human
b-defensin 3 against metallo-b-lactamase (MBL)-producing P. aerugi-
nosa clinical isolates.
Materials and Methods: A total of 15 unique multidrug-resistant
P. aeruginosa strains were tested that originated from relevant specimens
of patients hospitalised at our hospital. Bacterial identiﬁcation and
antimicrobial susceptibility testing was performed with the VITEK2
automated system. According to their drug susceptibilities all clinical
isolates were categorised into 3 distinct resistance phenotypes. Metallo-
b-lactamase (MBL) production was detected with the use of Etest MBL
strips, according to the manufacturers’ instructions. To determine the
MBL types all isolates were subjected to PCR analysis to conﬁrm
the presence of blaVIM and blaIMP genes. The bactericidal activity
of recombinant hbD-3 was assessed by the liquid microdilution assay
in the presence of 10mM sodium phosphate buffer, as previously
described. Brieﬂy, exponentially growing bacteria (inoculum density
of 1×104 cfu/mL) were exposed to different concentrations of hbD3
(0.5 ug/mL and 0.25 ug/mL). Following incubation for 20min at 37ºC,
0.1ml of each sample was plated onto McConkey agar plates.
Bactericidal effect was expressed as percentage of reduction in numbers
of viable bacteria after 18 to 24 hr incubation at 37ºC in ambient air.
Results: At a concentration of 0.25 ug/mL, the peptide produced a
reduction rate ranging from 55% to 95.4% whereas the use of 0.5 ug/mL
of hbD-3 resulted in 68% to 100% killing. The signiﬁcant variability
in the bactericidal effect observed, appears to be independent of the
isolates’ resistance phenotypes.
Conclusion: Despite the relatively low concentrations used, hbD-3
exhibited bactericidal activity against MBL-producing Pseudomonas
aeruginosa nosocomial strains and therefore it would be an attractive
alternative to current theurapeutic agents.
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O439 In vitro activity of temocillin and other antimicrobial
agents against extended-spectrum-b-lactamase-producing
Enterobacteriaceae isolated from patients hospitalised in
Belgian intensive care units
Y. Glupczynski, D. Huang, C. Berhin, G. Claeys, M. Delme´e, M. Ieven,
D. Pierard, H. Rodriguez-Villalobos, M. Struelens, J. Vaneldere,
J. Verhaegen (Yvoir, Ghent, Brussels, Antwerp, Leuven, BE)
Objectives: Temocillin is a 6-a-methoxy-derivative of ticarcillin with
increased stability to most b-lactamases including AmpC and extended-
spectrum types (ESBL). Data concerning its activity against Enterobac-
teriaceae clinical isolates are however scarce. The aim of this study was
to evaluate the in vitro activity of temocillin against 652 clinical isolates
of Enterobactericaeae collected from patients hospitalised in ICUs at
seven Belgian university hospitals in 2005.
Materials and Methods: Each centre collected prospectively
up to 100 unduplicated Enterobacteriaceae isolates from patients
hospitalised in ICUs for >3 days in order to focus the collection on
nosocomial pathogens. E-test MICs were determined for temocillin
and ﬁve comparators (ceftazidime, piperacillin-tazobactam, meropenem,
ciproﬂoxacin, and amikacin). The presence of ESBL was assessed by
double combination disks (cefotaxime and ceftazidime) and by ESBL
E-tests. ESBLs were characterised by IEF and PCR for bla genes of
SHV, TEM, and CTX-M families and by DNA sequencing.
Results: The prevalence of ESBL-producing Enterobacteriaceae (ES-
BLE) averaged 12% but ranged between 3% and 29% in the different
hospitals. A large diversity of ESBL types was observed within
different species with the predominance of TEM-24 among Enterobacter
aerogenes, CTX-M-1 group in Escherichia coli, and CTX-M-9 group
in Enterobacter cloacae and Klebsiella oxytoca. SHV-derived ESBLs
(SHV-5 and SHV-12) occurred less commonly and mainly in E. cloacae
and Klebsiella spp.
Temocillin was active against >90% of the isolates, with MIC50 and
MIC90 of 4mg/mL and 16mg/mL, respectively. Meropenem exhibited
the best activity overall (susceptibility 99%; MIC50 and MIC90
of 0.064mg/mL and 0.19mg/mL) whereas ceftazidime (21% non-
susceptibility) and ciproﬂoxacin (20% non-susceptibility) scored the
worst. A high frequency of resistance to ceftazidime (89%) and to
ciproﬂoxacin (72%) was observed especially among E. aerogenes. On
the other hand, temocillin retained good activity against ESBL-producing
E. coli (92%) but was found less active against some ESBLE and AmpC-
derepressed producers (E. aerogenes, Serratia marcescens).
Conclusions: These in vitro data illustrate the wide variation in
prevalence of ESBLE isolates in Belgian ICUs and support the usefulness
of temocillin as therapeutic option for infections caused by ESBLE and
other cephalosporin-resistant strains which are causing an increasing
number of infections in critically-ill patients.
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K443 Systems biology in clinical microbiology and infectious
diseases
J. Haas (Munich, DE)
Systems biology is a fast developing research area in life sciences
which combines both experimental and theoretical disciplines and which
investigates all components of complex biological systems (for example
all proteins of a cell). It collects large biological datasets by novel,
high-throughput-based technologies and develops computational tools
for its bioinformatic analysis. It thus allows a holistic view on complex
biological systems and to set up improved biological models, particularly
if several different experimental parameters are integrated (for example
protein interaction and expression proﬁling data). Although Systems
biology is usually based on screening assays and thus starts without bias,
in contrast to hypothesis-driven research, in most cases it eventually leads
to a multitude of novel working hypotheses. Particularly interesting are
hypotheses derived from bioinformatic concepts like network emergence,
robustness and modularity, since it is currently completely unclear if and
how they translate into biology.
Systems biology-based approaches in infectious diseases are even more
complex, as they investigate the interactions between the components
of two distinct biological systems, pathogen and host. On the host side,
cellular components which directly deal with the control of the infection,
i.e. the innate and adaptive immune system, are of particular interest. For
the understanding of the pathogenesis, pathogen products counteracting
these cellular components are similarly important. By integrating all
components of the immune system, Systems biology-based approaches
might be able to generate better disease models than previous reductionist
approaches focusing on only one or few pathogenic aspects. For example,
in herpesviruses, which cause persistent latent infections, both the innate
as well as the adaptive immune system and their components play a role
at different time points after infection and thus have to be considered to
fully understand their pathogenesis.
Recently developed technologies in molecular biology allowing genome-
wide analyses are one of the prerequisites for Systems biology-based
approaches. For example, novel sequencing technologies which are
powerful enough to evaluate whole genomes within short time are able
to detect inter-individual polymorphisms. There is growing evidence
that genetic variations on both the host and the pathogen side are
often crucial for the outcome of infectious diseases. A variety of other
experimental systems have been developed during the last decade and are
meanwhile sufﬁciently potent to allow genome-wide analyses, including
microarrays for transcriptional or protein expression proﬁling, genetic
screening systems like the yeast-two-hybrid system used to identify
pairwise protein interactions and novel mass spectrometry approaches
used for proteomics and metabolomics.
In medicine, Systems biology is currently still largely considered as
a basic research area with little practical relevance. However, it will
lead to substantial changes in medicine within only a few years, not
just because Systems biology-based disease models will considerabley
improve our understanding of the pathogenesis and will accelerate and
rationalise drug discovery, but also since the ability to determinate
individual genetic traits and availability of multi-parameter diagnostics
will eventually lead to a much more personalised medicine, in which
therapeutical interventions are tailored to single individuals.
K444 Clinical implications of viral evolution and variability
C.F. Perno (Rome, IT)
Human immunodeﬁciency virus represents the best model of evolution
on earth. Due to the high rate of replicative cycles, and the error-
prone polymerase (able to make about 1 error out of 10,000–30,000
nucleotides), the entire genome of HIV can be changed every day. Based
on these factors, it has been calculated that HIV genome varies in one
day more than the variability of inﬂuenza virus (another highly variable
virus) in 10 years, and more than the variability of the human genome
during the whole history of mankind.
Despite this immense potentiality, only few mutations that are randomly
produced during the daily replicative cycles are ﬁxed within the viral
genome. This is because of a bottleneck phenomenon related to the
constraint of target cells (unable to support the replication of all
vira strains daily generated) and because the large majority of the
mutations generate variants whose replicative capacity is very low/
absent, or in any case lower than the one that characterised the wild
type strain. For this reason, the number of quasispecies is limited if the
environment (that is immune and pharmacological pressure) does not
change.
Of course the situation changes unpo environment change. In case of
therapeutic pressure, the ability of the virus to rapidly deselect the
wild-type strain in favour of a resistant mutant is a function of the
strength of drug regimen. In case of fully suppressive therapy, the virus
is unable to generate and/or select new variants, the wild-type strain
remains prevalent and the therapy is highly successful. By contrast, if
therapeutic pressure is inconsistent, erratic, or not sufﬁciently potent,
the virus continues its replicative cycles under drug presence, and this
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represents the best environment to select mutant-resistant strains. The
rapidity with which this selection occurs is a function of the genetic
barrier of each drug, that in turn is related to the number of mutations
occurring to generate a new variant fully resistant to each drug. A low
genetic barrier means few (1 or 2) mutations are required to generate
resistant variants, that will occur rapidly. A high genetic barrier (5−6
or more mutations occurring in sequence) makes more difﬁcult and
slower the process of selection of a resistant strain.
These data have a strong clinical implication, in view of the impossibility
(at least today) to eradicate virus infection from the body. Thus, anti-
HIV therapy has to be started before the damage of the immune system
is too advanced, and must be strong and consistent. For this reason, until
today, at least three drugs rationally combined are needed to achieve this
result. A great effort has to be dedicated by physicians and nurses to
the achievement of a very high level of adherence, that represents a key
factor to maintain a long-lasting protection of HIV-disease progression
and a good quality of life.
Atypical mycobacterial infections
O448 Non-tuberculous mycobacteria in a Spanish teaching
hospital during a ﬁve-year period
D. Domingo, R. Carracedo, R. Fillol, T. Alarcon, M. Moreno, S. Agudo,
M. Lopez-Brea (Madrid, ES)
Objective: to know the prevalence of nontuberculous mycobacteria
(NTM) isolated in a teaching hospital during a ﬁve-year period.
Methods: a total of 21,186 specimens obtained from patients attended
at Area 2 of Madrid were studied. Samples were processed by
standard methodology and were inoculated onto solid (Lowenstein and
Coletsos) and liquid media using a semiautomatic equipment (MGIT®).
Mycobacterium tuberculosis complex, M. avium complex, M. gordonae
and M. kansasii strains were identiﬁed by DNA probes (Accuprobe®)
and the rest were studied by biochemical tests, PCR-RFLP or sent to a
Reference Laboratory.
Results: a total of 645 mycobacteria were isolated from 324 patients.
M. tuberculosis complex was the mycobacteria most frequently isolated:
431/645 (66.8%). NTM isolates (336 strains from 111 patients) are
summarised in the table.
Non-tuberculous mycobacteria isolated
Mycobacteria Isolates Patients
M. avium complex 122 5
M. fortuitum 16 14
M. gordonae 15 11
M. kansasii 14 5
M. abscessus 14 3
M. simiae 16 14
M. chelonae 7 6
Others* 13 12
Others: M. lentiﬂavum (3), M. mucogenicum (2), M. septicum (1),
M. thermoresistibile (3), M. xenopi (3) and M. porcinum (1). A small
percentage of NTM (3.1%) was isolated from non-respiratory samples.
In 35 patients (31.5%), NTM were isolated in at least two specimens.
Conclusions:
1. NTM involve an important burden in the clinical mycrobiology
laboratory.
2. Mycobacterium avium complex is the NTM most frequent in our
study.
3. Although the isolation of NTM from repeated specimens of the same
patient is not rare (31.5%), the clinical relevance of these data remains
controversial.
O449 Incidence of disseminated Mycobacterium avium complex
infection in the USA compared to three European regions
B. Salzberger, B. Heindel, P. Hartmann, B. Ehrenstein, G. Fatkenheuer
(Regensburg, Cologne, DE)
Objective: The incidence of invasive Mycobacterium avium complex
(MAC) infections in HIV-infected patients differs widely in studies
from different geographical regions. Comparative studies have not been
done yet. We analysed the incidence of atypical mycobacteriosis in
different geographical regions using a large dataset of HIV-infected
patients enrolled in a randomised trial of MAC prevention. Monthly
blood cultures were taken in this trial, giving the opportunity to estimate
incidence rates.
Methods: Data from a multinational, multicentre trial of prevention of
MAC infection with clarithromycin in HIV-infected patients with less
than 100 CD4 cells were analysed (Pierce, NEJM 1996). We estimated
the incidence of disseminated MAC infection (deﬁned by the ﬁrst
positive blood culture with MAC) in 4 different geographical regions
(USA, UK, France and Germany) in a Cox-proportional hazard model,
stratifying by use of prophylaxis on an intention-to-treat analysis.
Results: 682 patients (pts) were included in the study (USA 333, UK 36,
F 175, G 136). Patient characteristics (age, gender, body mass index,
CD4 cells/mcl) between these regions were well comparable. Overall
19% of pts from the USA, 25% from the UK, 10% from France and
8% from Germany developed invasive MAC-infection. In a multivariate
Cox proportional hazard analysis corrected for CD4 cell counts at
baseline the risk ratio (RR) of disseminated MAC for patients from
France was 0.24 (p< 0.01) and for pts from Germany 0.25 (0.01)
compared to the USA. The incidence in the UK was not different from
that in the USA.
Conclusions: The incidence of MAC infections in HIV-infected patients
differs widely between the USA and different European regions. This
may have important consequences for preventive strategies.
O450 Infections due to non-pigmented rapidly growing
mycobacteria in Madrid, 2005
J. Esteban, N. Zamora, L. Ferna´ndez, I. Gadea, J. Cacho,
R. Cias, R. Daza, D. Domingo, J. Garcı´a, D. Garcı´a de Viedma,
E. Go´mez-Mampaso, E. Palenque, M.J. Ruiz-Serrano (Madrid, ES)
Objectives: To determine the incidence, clinical signiﬁcance, and
epidemiology of the isolates of non-pigmented rapidly growing
mycobacteria (NPRGM) in Madrid, Spain, during 2005.
Methods: Patients with isolates of NPRGM were selected prospectively
during the year 2005. All the isolates were identiﬁed according
recommended biochemical tests and PCR-RFLP Analysis of the hps65
gene. Clinical charts were reviewed according to a predeﬁned protocol,
and clinical signiﬁcance was evaluated according to accepted criteria.
Molecular epidemiology was analysed using RAPD technique with
3 primers (OPA-2, IS 976FP and INS 2). Identity between strains was
considered when they shared identical pattern between them with all the
primer sets.
Results: NPRGM were identiﬁed in 70 patients (incidence:
1.51 cases/100,000 inhabitants). 74 strains were available for evaluation.
The identiﬁed species were Mycobacterium abscessus (5 cases),
M. chelonae (9 cases),M. fortuitum (40 cases),M. peregrinum (10 cases),
M. mageritense (5 cases), and M. mucogenicum (1 case). The isolates
were considered clinically signiﬁcant in 18 cases (25.7%, incidence:
0.39 cases/100,000 inhabitants): 4 M. abscessus, 5 M. chelonae, and
9 M. fortuitum. 6 cases were respiratory infections (4 in patients
with cystic ﬁbrosis), 7 were nosocomial infections (3 catheter-
related bacteraemia), 2 were soft-tissue abscesses, 1 canaliculitis, and
1 bacteraemia in an HIV patient. No cases were detected due to
M. peregrinum, M. mucogenicum, or M. mageritense. The strains were
isolated mainly from respiratory samples (56 cases), being signiﬁcant
only in 6 of these cases (10.7%), whereas clinical signiﬁcance was
considered in 12 cases out of 16 patients with nonrespiratory isolates
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(75%) (p< 0.001). RAPD analysis showed no relationship from different
cases.
Conclusions: NPRGM could be responsible of clinical syndromes in
1/4 of the cases, and this association was different for the species
studied. Non-respiratory isolates were signiﬁcant in 3/4 of the cases. The
predominant species in our environment isM. fortuitum (57.1% of cases),
although the most signiﬁcant one was M. abscessus. No relationships
among isolates from independent cases were detected, suggesting
transmission routes other than interhuman.
Acknowledgments: This study was supported by a grant from the Fondo
de Investigaciones Sanitarias (FIS PI030146). N. Zamora was funded by
a grant from the Fundacio´n Conchita Ra´bago de Jime´nez Dı´az (Madrid,
Spain).
O451 Mycobacterium szulgai causes tuberculosis-like disease in
Zambia
P.C.A.M. Buijtels, W. Tietge, R. Niebuur, B. Berntsen, D. van Soolingen,
P.L.C. Petit (Rotterdam, NL; Sesheke, ZM; Bilthoven, NL)
Introduction: In Africa, the diagnosis of tuberculosis is almost
invariably based on the microscopic examination of Ziehl–Neelsen
stained clinical material. However, not only Mycobacterium tuberculosis,
but also non-tuberculous mycobacteria (NTM) yield a positive result
in microscopic examination for acid-fast bacilli (AFB). Furthermore, a
signiﬁcant part of the patients, especially HIV-positives, may represent
AFB-negative, but culture-positive mycobacteriosis.
Objective: To investigate the clinical relevance of isolation of NTM in
Africa, in the light of the increasing prevalence of HIV.
Methods: In Sesheke, Zambia, 64 (HIV positive and negative) patients,
who were chronically ill for more than two weeks, were included in
the study. Sputum was collected and cultured for mycobacteria using
Mycobacteria Growth Indicator tubes. The isolated Mycobacterium
cultures were identiﬁed by 16S rRNA gene sequencing.
Results: Thirty out of 64 (47%) patients yielded positive Mycobacterium
cultures that were identiﬁed as M. tuberculosis (8 times), M. szulgai
(7), M. avium-intracellulare (3), M. simiae (1) and M. terrae (1). Ten
isolates were not suitable for identiﬁcation due to contamination, re-
culture problems, etc. Thirteen of the 30 culture-positive patients (43%)
were also positive in microscopic examination, including four patients
with NTM infections. Especially the patients infected by M. szulgai
manifested symptoms highly similar to regular tuberculosis caused by
M. tuberculosis. DNA ﬁngerprinting analysis revealed four different
patterns among the seven M. szulgai isolates, excluding the possibility
of a laboratory cross-contamination or a common source of infection.
Only two out of seven patients with a M. szulgai infection responded
well to treatment by tuberculostatics.
Conclusion: The contribution of NTM, and especially of M. szulgai, to
tuberculosis-like diseases in both HIV positive and negative patients in
Africa may be underestimated.
O452 Administration of TNF-a did not inhibit
Mycobacterium avium infection in the mouse lung
M. Fujita, S. Ikegame, E. Harada, H. Ouchi, I. Inoshima, Y. Nakanishi
(Fukuoka, JP)
Objective: Mycobacterium avium causes chronic and progressive
respiratory infection. TNF-a plays a central role in innate immunity
against mycobacteriosis. Although administration of TNF-antibody has
been reported to cause mycobacteriosis including non-tuberculous
mycobacteriosis, study concerning administration of TNF-a in non-
tuberculous mycobacteriosis remains insufﬁcient. In this study, we
investigated the effect of TNF-a administration in M. avium infection in
mice.
Methods: Clinically isolated strains ofM. avium were used. Proliferation
of M. avium within peritoneal macrophages in the existence of
recombinant human TNF-a were examined. Wild type of C57Bl/6 mice,
perforin-deﬁcient mice or TNF-a overexpression mice were administered
M. avium (1×107 cfu/body) intratracheally. Recombinant human TNF-a
(10 ug/body) was injected into wild mice or perforin-deﬁcient mice on
day 0 and day 7 after M. avium administration. Mice were sacriﬁced on
day 21, 60 after M. avium administration. The lung homogenates were
inoculated on Middlebrook 7H10 agar plates for counting the number of
colonies. Tissue sections of the lungs were stained by hematoxylin and
eosin or Ziehl–Neelsen methods.
Results: In vitro study: administration of recombinant human TNF-a
inhibited proliferation until day 3, but not day 7. In vivo study:
administration of recombinant human TNF-a did not inhibit M. avium
infection based on the lung histology and bacterial number in the lungs
of perforin-deﬁcient mice. In TNF-a transgenic mice, M. avium induced
several lymphoid tissues proliferation. Bacterial proliferation in the lung
was not inhibited compared to wild type mice.
Conclusion: Both exogenous and endogenous TNF-a administration did
not attenuate M. avium infection in vivo. The present data indicate
that the role of TNF-a against M. avium is different from that of
M. tuberculosis.
New antimicrobial compounds overcoming
common resistance mechanisms
O453 Mercapto-phosphonate compounds as broad-spectrum
inhibitors of the metallo-b-lactamases
P. Lassaux, M. Hamel, M. Gulea, P. Mercuri, L. Horsfall, C. Bebrone,
A-C. Gaumont, J. Fre`re, M. Galleni (Lie`ge, BE; Caen, FR)
Objectives: One of the emergent factors for the b-lactam antibiotic
resistance of pathogenic bacteria is the production of metallo-
b-lactamases (MBLs), which are able to hydrolyse the b-lactam ring
in a broad spectrum of substrates, particularly the carbapenems. MBLs
have been divided into three different sub-classes B1, B2 and B3 based
on sequence similarities [1]. In this report, we investigated the inhibitory
effect of mercapto-phosphonate derivatives against MBLs.
Methods: The laboratory of P Metzner (University of Caen, France)
synthesized 12 different mercapto-phosphonate compounds with the
ability to inhibit the subclass B1 VIM-4, the subclass B2 CphA and
the subclass B3 L1 MBLs respectively. Consequently, we determined
the competitive inhibition constant (Ki) as described by DeMester
et al. [2]. We also measured the minimal inhibition concentration (MIC)
for Escherichia coli recombinant strains producing VIM-4, CphA or L1,
for ampicillin or imipenem in the presence or absence of mercapto-
phosphonate compounds.
Results: In the present study, we show that all the mercapto-
phosphonates, with the exception of compound 1a, behaved as
good competitive inhibitors (Ki< 15mM) for CphA. Their activities
against the sub-classes B1 and B3 enzymes were more contrasted.
In addition, the presence of free Zn++ abolished the inhibitory
activity of compound 2b. The compound behaving as zinc chelator
could explain this phenomenon. Nevertheless, the (2-sulfanylphenyl)
phosphonic acid, the (4-bromophenyl)(sulfanyl)methyl phosphonic acid
and the [(2,4-dichlorophenyl)(sulfanyl)methyl] phosphonic acid were
good inhibitors (Ki< 15mM) against the different studied enzymes and
can be used as leads to the synthesis of new MBL inhibitors. Our tests
indicated that the presence of compounds 2b, 4a and mgfg decreased
the MIC value for imipenem.
Conclusion: In this study, we show that members of the phosphonates
group are able to enhance the inhibition of Zn b-lactamases. This is
the ﬁrst report of new inhibitors possessing a strong activity against the
different sub-classes of MBLs.
Reference(s)
[1] Galleni M, Lamotte-Brasseur J, Rossolini GM, Spencer J, Dideberg
O, Frere JM. Antimicrob Agents Chemother 2001; 45(3): 660−3.
[2] De Meester F, Joris B, Reckinger G, Bellefroid-Bourguignon C, Frere
JM, Waley SG. Biochem Pharmacol 1987 Jul 15; 36(14): 2393–403.
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O454 The activity of NXL101 against community-associated
methicillin-resistant Staphylococcus aureus
I. Morrissey, J. Lowther, R. Adkin, D. Cooper, J. Northwood, R. Janes
(London, UK; Romainville, FR)
Objectives: To evaluate the novel topoisomerase inhibitor NXL101
against community-associated (CA) methicillin-resistant S. aureus
(MRSA).
Methods: A total of 54 CA-MRSA were investigated: 48 being
recent clinical isolates from community sources within Europe and
further deﬁned as CA-MRSA by cefoxitin 30 mg disc zone of
inhibition 19mm, possessing staphylococcal cassette chromosome mec
type IV or IVa and having full susceptibility to gentamicin (GEN).
The remaining 6 were CA-MRSA reference isolates from the Network
on Antimicrobial Resistance in Staphylococcus aureus (NARSA)
collection. MIC was determined for NXL101, GEN, azithromycin (AZI),
clindamycin (CLI), dalfopristin–quinupristin (D−Q), daptomycin (DAP),
levoﬂoxacin (LFX), linezolid (LZD) and vancomycin (VAN) by CLSI
broth microdilution.
Results: Summary MIC data are shown in the table. NXL101 was the
most active agent against CA-MRSA. A high percentage of resistance
was observed to LEV and AZI, but full susceptibility was shown to most






Resistant MIN 50% 90% MAX
NXL101 – – – 0.015 0.06 0.12 0.5
AZI 44.4 0 55.6 0.25 >64 >64 >64
CLI 75.9 0 24.1 0.06 0.12 >8 >8
D−Q 100 0 0 0.25 0.25 1 2
DAP 100 – – 0.12 0.5 1 1
GEN 100 0 0 0.12 0.25 0.5 0.5
LEV 22.2 0 77.8 0.12 8 16 >32
LM 100 – – 0.5 2 2 4
VAN 100 0 0 0.5 1 1 1
Conclusion: NXL101 showed excellent activity against CA-MRSA, and
may offer a viable alternative for the treatment of CA-MRSA and other
S. aureus infections in the future.
O455 Comparative dose studies of API-1252 and linezolid against
hospital-acquired and community-acquired methicillin-
resistant Staphylococcus aureus in a murine thigh model
M. Banevicius, N. Kaplan, D. Vaughan, D. Nicolau (Hartford, US;
Toronto, CA)
Objectives: API-1252 is a novel antimicrobial, with a mechanism of
action targeting fatty acid biosynthesis, currently in development as a
new class of oral and intravenous anti-staphylococcal agents. In this
study, comparative single-dose response experiments were performed
with API-1252 and linezolid to assess their quantitative oral efﬁcacy
against hospital-acquired (HA)-MRSA and community-acquired (CA)-
MRSA.
Methods: MICs were determined by CLSI guidelines. Single dose PK
studies were conducted. The thighs of neutropaenic mice were inoculated
(~106) with a single isolate of HA-MRSA or CA-MRSA. API-1252
and linezolid were administered orally in single doses ranging from
1 to 300mg/kg. CFU were determined in infected thighs 24 hours post-
dose. Efﬁcacy was determined as the change in CFU/thigh at 24 hours
versus the 0 hour controls.
Results: MICs of API-1252 and linezolid against both isolates were
0.004 and 2mg/L, respectively. For the HA-MRSA, CFU reduction was
seen with API-1252 doses of 10mg/kg. While the 10mg/kg dose
displayed a variable effect for the CA-MRSA, doses of 40mg/kg of
API-1252 resulted in sustained antibacterial activity. Linezolid doses of
100mg/kg were required to maintain sustained antibacterial activity
over the 24 hour exposure period for both isolates. With both MRSA
isolates, the 80% maximally effective dose (ED80, mg/kg), ED50, and
ED5 were 4−20× lower for API-1252 when compared to linezolid.
Pharmacodynamic index correlations showed that the fAUC/MIC of API-
1252 was the best predictor of efﬁcacy. For both MRSA strains the API-
1252 fAUC/MIC ranges resulting in the ED80, ED50, and ED5 were
32−69, 29−32, and 6−25, respectively. These ED values were similar to
that observed with MSSA for API-1252 (ICAAC 2006, Abstract F1-759).
Conclusion: These data demonstrate the superior dose-response of API-
1252 as compared to linezolid against HA-MRSA and CA-MRSA in
the mouse thigh model. fAUC/MIC appears to best characterise the PD
proﬁle of this novel agent. The low efﬁcacious fAUC/MIC values support
the further development of API-1252 as a novel oral and intravenous
agent for challenging staphylococcal infections.
O456 Deletion analysis of LysK, a bacteriophage-derived protein
with anti-MRSA activity
M. Horgan, G. O’Flynn, G.F. Fitzgerald, A. Coffey, O. McAuliffe,
R.P. Ross (Fermoy, Cork, IE)
The emergence of multi-drug-resistant pathogens, including methicillin-
resistant Staphylococcus aureus (MRSA), combined with the absence of
new antibiotics from the pharmaceutical sector demands that alternative
anti-MRSA agents are scientiﬁcally evaluated and developed as a matter
of urgency. Recent studies have shown the enormous potential of the use
of phage endolysins as potential therapeutics.
Objectives: To characterise the staphylococcal phage K-derived protein,
LysK, a bifunctional endolysin with antimicrobial activity against
MRSA, with a view to identifying the domain or domains responsible
for lytic activity.
Methods: The lysK gene was PCR-ampliﬁed from phage K cDNA and
cloned into the pTOPO (Invitrogen) vector. The domain architecture of
LysK was studied by performing deletion analysis on the intact LysK
protein using PCR and/or slicing by overlap extension (SOEing) PCR on
this pTOPO clone. To assess the activity of LysK deletion derivatives,
constructs were recreated in the pQE60 (Qiagen) expression system.
SDS-PAGE and zymogram assays were used to visualise the activity
of LysK and its deletion derivatives in pQE60 and to assess which
domain(s) the lytic activity of LysK could be ascribed to.
Results: Bioinformatic analysis of LysK (495 amino acids) suggests
that it has a modular structure, containing two peptidoglycan hydrolase
domains, CHAP (endopeptidase activity) and Amidase_2 (N-acetyl-
muramoyl-L-alanine amidase activity), at the N-terminus and a cell-
wall binding domain at the C-terminus (SH3b). Analysis of deletion
derivatives of LysK conﬁrmed that while Amidase_2 and SH3b domains
had no signiﬁcant activity alone, the CHAP domain was as active as
the intact LysK, displaying an identical lytic spectra when examined by
zymographic assays. While attempting to deﬁne the smallest possible
functional CHAP domain with antimicrobial activity, we found that the
endopeptidase activity associated with the CHAP domain is contained
within the ﬁrst 161 amino acids of LysK. Further deletions resulted in
a complete loss of antimicrobial activity. The 161 amino acid truncated
CHAP has been found to be active against the main MRSA strains
emerging in hospitals in the local area.
Conclusion: The CHAP domain of LysK has catalytic properties similar
to that of LysK itself, highlighting the possibility of creating chimeric
proteins with different substrate speciﬁcities, thus expanding their lytic
capabilities.
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O457 The activity of NXL101 against ﬂuoroquinolone-resistant
clinical isolates of Staphylococcus aureus
I. Morrissey, J. Lowther, M. Soltani, J. Northwood (London, UK;
Romainville, FR)
Objectives: To evaluate the novel topoisomerase inhibitor NXL101
against ﬂuoroquinolone-resistant (FQR) S. aureus (SA).
Methods: MIC against 39 FQR SA and the control strain ATCC29213
(Cont) was determined for NXL101, levoﬂoxacin (LFX), ciproﬂoxacin
(CFX), moxiﬂoxacin (MFX) and gemiﬂoxacin (GFX) by CLSI broth
microdilution. Topoisomerase gene (grlA, grlB, gyrA & gyrB) quinolone
resistance determining regions (QRDRs) were ampliﬁed and sequenced
and the effect of reserpine (RES, 20mg/L) on MIC (i.e. the role of
FQ efﬂux) was evaluated to determine mechanism(s) of resistance.
Results: MIC, QRDR and efﬂux data are shown in the table. Most FQR
SA possessed combined GrlA (S80F)–GyrA (S84L) changes. Others had
additional changes in GrlA, GyrA or GrlB, but none were found in
GyrB. The effect of RES on CFX MIC was variable, but this did not
affect FQ MIC as much as QRDR changes. Other FQ were less affected
by RES than CFX. NXL101 MIC ranged from 0.03 to 1mg/L (mode
0.06/0.12mg/L) and was not affected by any QRDR changes. Some
RES effect was observed with NXL101, but most FQR SA had similar
NXL101 MIC to the Cont strain (for which NXL101 MIC was not
affected by RES).
No. of AA Change Efﬂux MIC range (mg/L)
Isolates Grl A GrIB GyrA NXL MFX GFX LFX CFX
10 S80F – S84L ++ 0.06−0.25 2 2−8 8−16 32–512
5 S80F S84L +++ 0.06−1 2 2−8 8−16 256
5 S80F S84L N 0.12−0.25 2−4 2−8 8−16 16–256
3 S80F S84L + 0.06−0.5 2−4 2−8 8−16 32–256
2 S80F D432V S84L ++ 0.25 8 16−32 32 256
1 S80F, P144S E422D S84L ++ 0.12 4 8 8 256
1 S80F, P144S E422D S84L + 0.12 4 8 16 256
1 S80F, P144S – S84L N 0.06 2 4 16 16
1 S80F, E84K – S84L +++ 0.06 8 8 16 256
1 S80F, E84K – S84L ++ 0.12 8 8 32 256
1 S80F, E84K – S84L + 0.06 4 8 16 128
1 S80F, E84K – S84L N 0.06 8 16 32 256
1 S80F, E84K – S84V N 0.06 8 4 16 256
1 S80F, E84G – S84L ++ 0.06 8 32 32 128
1 S80F D132N S84V ++ 0.03 4 2 16 128
1 S80F – S84L,
G106D
+ 0.5 2 2 8 16
1 S80Y D432H S84L +++ 0.06 4 2 16 256
1 S80Y D432N S84L ++ 0.12 4 8 32 256
1 S80Y – S84L ++ 0.25 2 2 8 16
Cont – – – N 0.06 0.06 0.015 0.25 0.25
aEfﬂux: effect of RES on CFX MIC: +++ (4−6 dilutions decreased), ++ (2−3 dilutions decreased), + (1 dilution
decreased), N (no effect).
Conclusion: NXL101 retained activity against highly FQR SA
exhibiting a range of QRDR mutations and CFX efﬂux. NXL101 must
target topoisomerases in a manner distinct to that of FQs.
Harnessing the host response for anti-
infective therapy
S459 Controlling pathogenic bacteria with phage lytic enzymes
V.A. Fischetti (New York, US)
Bacteriophage lytic enzymes are highly evolved molecules used by the
phage to quickly destroy the bacterial cell wall to release phage progeny.
We have exploited the rapid and lethal action of these enzymes to destroy
pathogenic and biological warfare bacteria on mucous membranes
and in blood. These enzymes in general are speciﬁc for the species
or strain from which they were produced, thus avoiding destruction
of the surrounding normal commensal organisms found on mucosal
surfaces. We now have enzymes that are speciﬁc for Streptococcus
pyogenes, S. pneumoniae, Bacillus anthracis, Staphylococcus aureus,
Enterobacter faecalis/E. faecium and group B streptococci. Our results
show that in vitro 107 bacteria can be reduced to sterility seconds
after enzyme contact. In animal model experiments, we were able to
colonise mice with either streptococcal or pneumococcal species (orally
or nasally) and remove these completely with phage enzymes delivered
to these sites using a single enzyme dose. In a septicaemia model
with S. pneumoniae, bacteria are reduced by >2-logs from the blood
of infected animals with a single intravenous dose of enzyme. A lytic
enzyme called PlyG from the gamma-phage of B. anthracis was speciﬁc
for all worldwide isolates of B. anthracis. The enzyme speciﬁcally
killed B. anthracis with no effect on other bacilli or other organisms.
When >1 LD100 of B. anthracis bacilli were delivered i.v. to mice
we observed a progression of symptoms, leading to survival of only
10% of animals followed for 12 days. When PlyG was injected i.v.
15min after infection, a signiﬁcant therapeutic effect was observed in
which 90% of the mice recovered fully. Resistance to the enzymes has
not been found nor do antibodies neutralise their activity. Furthermore,
a combination of antibiotic and enzyme has been shown to work
synergistically resulting in efﬁcient lethal activity in cases of antibiotic
resistant bacteria. Thus, phage lytic enzymes are a new reagent that may
be used in hospitals, nursing homes and the general population to control
antibiotic resistant pathogenic bacteria in blood and on mucosal surfaces,
offering a capability previously unavailable.
S461 Two-component signal transduction systems of pathogenic
bacteria as targets for anti-infective therapy
K. Stephenson (Leeds, UK)
Two-component signal transduction systems are ubiquitous in bacteria
and are woven within the fabric of the regulatory processes that are used
to sense environmental change and respond accordingly. These systems
allow the bacterial cell to continually re-programme patterns of gene
expression rapidly and in deﬁned ways to bring about cellular adaptation
as a direct consequence of speciﬁc environmental signals. To achieve
this function two-component systems are composed of a signal ligand-
responsive sensor histidine kinase that is usually an integral membrane
protein, and a response regulator that is often a transcriptional regulator.
Signal ligands are sensed by the sensor histidine kinase resulting in
ATP-dependent autophosphorylation and the subsequent transfer of the
phosphoryl moiety to the cognate response regulator inﬂuences its DNA
binding and transcriptional activity, and therefore gene expression.
For bacterial pathogens these signal transduction pathways are frequently
key elements in the regulation of a myriad of virulence responses
that facilitate colonisation, survival and persistence within the host
environment and at speciﬁc host sites. Examples of the types of
virulence attributes modulated by two-component systems include
bioﬁlm formation, quorum sensing, resistance to host defence peptides,
and secreted toxin production. In addition, two-component systems that
are essential for bacterial viability are known to exist. For these and
other reasons two-component signalling systems and their variants have
been recognized as targets for the development of anti-infective drugs.
In this presentation the features of two-component systems that make
them potentially attractive targets for the development of novel anti-
infectives will be discussed. The mechanisms of action and limitations of
some classes of previously developed two-component system inhibitors
will also be discussed, as will the current and future perspectives for the
development of selective inhibitors of these bacterial signalling systems.
Endemic MRSA – is control possible?
S464 If the question concerns MRSA, the solution contains
detergent
S. Dancer (Glasgow, UK)
The global increase of methicillin-resistant Staphylococcus aureus
(MRSA) has generated much attention over the last decade. The public
have linked the so-called ‘superbug’ with their experience of dirty
hospitals, but the precise role of cleaning in the control of this organism
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is unknown [1]. There is some support for a link between poor hygiene
in hospitals and MRSA, since its epidemiological characteristics permit
survival in the clinical environment as well as make it potentially
vulnerable to the cleaning process [2]. Unfortunately, we cannot assess
the risk of acquiring MRSA from the clinical environment because there
is no way of measuring the effect of cleaning. Perhaps it is time to
introduce microbiological standards for surface levels in hospitals [3].
This would not only allay concerns over the grading of hygiene by visual
assessment, but would provide a means whereby the removal of dirt
becomes an evidence-based science [3,4]. Without such evidence, the
importance of a clean hospital will continue to remain speculative.
Even if the beneﬁts of cleaning are well established, bufﬁng the ﬂoors
to a shine will not reduce the number of patients acquiring MRSA.
Floors may form a repository for a variety of organisms but they do
not play a major role in HAI [5] Pathogens are delivered to patients
on hands, and it is more likely that contaminated hand-touch sites are a
greater risk for MRSA acquisition [3,6]. Such areas should be prioritised
when managing cleaning schedules, since a targeted approach to hospital
cleaning might be a useful control factor for MRSA [7].
We will never be able to guarantee consistent hand hygiene nor a
sustained reduction in antibiotic consumption. Improvements in cleaning,
however, are not insurmountable [1]. More research on the association
between MRSA and environmental hygiene is urgently required. Basic
cleaning could deliver signiﬁcant cost beneﬁts in MRSA control and
could ultimately be our only defence against this organism.
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S465 Decolonisation strategies
J. Kluytmans (Breda, NL)
Carriage of MRSA is most often transient but can be persistent. In
patients carriage is associated with an increased risk for the development
of infection. Healthcare workers who carry MRSA may transmit the
micro-organism to patients. To control transmission and prevent the
development of infection, eradication of carriage may be indicated.
The decision to start decolonisation therapy should be carefully balanced
with the risk for the development of resistance. Factors that are associated
with increased failure rates are: the presence of wounds or other skin
lesions, the presence of indwelling devices, multisite carriage and the
presence of reservoirs at home. In individuals without these risk factors
treatment with mupirocin nasal ointment is succesfull in the majority
of subjects. It is often combined with the application of antiseptic
showering. In individuals who fail on this topical treatment or with the
presence of risk factors for failure, systemic antimicrobial treatment is
indicated. Well-designed trials are not available so at present an evidence-
based recommendation can not be made. The existing data indicate
that a combination of two agents including rifampicin is preferred. The
choice of the agents should be based on the susceptibility testing results.
Treatment failure may be based on recolonisation from a persisting
reservoir at home. Therefore, in patients who (repeatedly) fail on
decolonisation therapy these sources should be sought for.
Foodborne infections: from starter to ﬁnish
S466 Food safety and monitoring of foodborne infections
F. Boelaert, S. Bronzwaer, S. Potier Rodeia, P. Makela (Parma, IT)
The European Food Safety Authority (EFSA) was set up in 2002
following a decade of food scares and a loss of conﬁdence by the
European public which led to a complete overhaul of the European
Union food safety system and policies. EFSA’s mission is to provide
Risk Assessment on matters related to Food and Feed Safety and to
communicate on these risks.
In 2005, twenty-four Member States, Iceland, Norway, and Switzerland
submitted information on the occurrence of zoonoses, zoonotic agents,
antimicrobial resistance and foodborne outbreaks to the European
Commission and EFSA.
Campylobacteriosis was found to be the most frequently reported
zoonotic disease in humans within EU. Reported Campylobacter cases
increased by 7.8% compared to the previous year rising to an incidence
rate of 51.6 cases per 100,000 people and to a total of 197,363 recorded
cases. Salmonellosis remained the second most frequent zoonosis with
171,775 reported human cases, despite the fall by 9.5% to an incidence
rate of 38.2 compared to 2004.
Salmonella was most often reported from fresh poultry and pig meat
where proportions of positive samples up to 18% were detected. In table
eggs, ﬁndings of positive samples ranged from 0% to 6%, but over the
past 5 years, an overall decreasing trend in occurrence of Salmonella
in the eggs was observed. In animal populations, Salmonella was most
frequently detected from poultry ﬂocks.
Salmonella, Campylobacter and viruses were the most important causes
of reported foodborne outbreaks in 2005. Egg and bakery products
were the most common reported sources of Salmonella outbreaks,
whereas broiler meat was an important source for both Salmonella and
Campylobacter outbreaks. Foodborne virus outbreaks were most often
caused by drinking water, fruits and vegetables.
Relatively high proportions of Campylobacter and Salmonella isolates
from animals and food were resistant to antimicrobials commonly used
in treatment of human diseases. This is especially the case for resistance
to ﬂuoroquinolones in Campylobacter isolates from poultry. Foodborne
infections caused by these resistant bacteria pose a particular risk to
humans due to possible treatment failure.
When the results of the routine monitoring of laying-hen ﬂocks are
compared to the results from an EU-wide, fully harmonised Salmonella
baseline study in laying-hen holdings, the prevalences in the baseline
study are remarkably higher than those in routine monitoring. This
reﬂects the different sensitivities of sampling scheme and sample types
used and demonstrates that a harmonised protocol should be used when
comparing the situation in one Member State with another.
S467 Food-borne Yersinia infections – from molecular pathogenesis
to laboratory diagnosis
J. Heesemann (Munich, DE)
Yersinia enterocolitica and Y. pseudotuberculosis infections (yersin-
iosis) occur predominantly in the northern hemisphere. The clinical
manifestations range from acute gastroenteritis to divers postinfectious
sequelae, most notably reactive arthritis. The pathogenicity of these
Gram-negative bacteria has been studied intensively during the last
decades, resulting in identiﬁcation and molecular characterisation of a
set of chromosomally and extrachromosomally (plasmid pYV) encoded
pathogenicity factors (PF). Here, the function of the PFs in the context
of cell culture and animal infection models will be discussed.
The most intriguing PFs are the yersinia outer proteins (Yops) which
are “microinjected” into host cells via a type 3 secretion system
(T3SS) and function as “tranquilliser” towards the innate host defence.
Several PFs of yersiniae have become prototypic members of growing
families of PFs: such as the invasin, the trimeric autotransporter
(TATA) Yersinia adhesin (YadA) and the siderophore yersiniabactin
encoded by high pathogenicity island (HPI). The Yersinia invasin (Inv)
is closely related to the intimins (EaeA) of enteropathogenic (EPEC)
and enterohaemorrhagic Escherichia coli (EHEC). The Yersinia adhesin
(YadA) is a trimeric autotransporter and member of the oligomer coiled-
coil adhesin (Oca) family which comprises adhesins of Haemophilus
inﬂuenzae (Hia), Moraxella catarrhalis (UspA) and other species. The
yersiniabactin biosynthetic gene cluster of the HPI is widely spread
among members of the family of Enterobacteriaceae and has become
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a marker for extraintestinal pathogenicity, in particular in E. coli.
The molecular analysis of the pathogenicity of Yersinia has not only
improved our understanding of bacterial mechanism of invasion and
persistence but has also provided us with new tools for laboratory
diagnosis and prevention. Several PFs turned out to be useful antigens
for (i) differentiation between virulent and avirulent Y. enterocolitica,
(ii) detection of a class-speciﬁc serum antibody response (serological
diagnosis) and (iii) vaccination. Moreover, the T3SS of yersiniae is
suitable for delivery of antigens to antigen presenting cells and, thus,
opens a new strategy for the design of oral live vaccine carrier strains.
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S468 Diarrhoea-causing Escherichia coli pathotypes – which genes
to target for identiﬁcation?
T. Pa´l, A´. Sonnvend (Pe´cs, HU)
In the past decades various groups of Escherichia coli associated
with diarrhoeal diseases in man have been recognized. Currently, the
most frequently identiﬁed pathotypes are the enteropathogenic (EPEC),
enterotoxigenic (ETEC), enteroinvasive (EIEC), enterohaemorrhagic
(EHEC), enteroaggregative (EAEC) and diffusely adherent (DAEC)
E. coli strains. Individual classes are deﬁned on the basis of more
or less characterised interactions between the bacterial cell and the
host when inducing diarrhoea. There are several problems associated
with the recognition of these strains in the laboratory. Easily detectable
phenotypic markers sufﬁciently speciﬁc and sensitive to distinguish these
strains from their non-pathogenic counterparts are not known. Although
certain virulence factors (toxins, adhesins, invasins) are always, or often
present in particular groups, the detection of their expression frequently
goes beyond the capabilities of diagnostic laboratories. The use of
molecular methods speciﬁc to genes of these factors, often in multiplexed
PCR systems, is currently the most straightforward diagnostic approach.
The detection of some of these genes (e.g. Shiga toxin, stx, or intimin,
eae) can serve screening purposes but their identiﬁcation may not prove
the actual virulence of the isolate. Virulence factors can be shared by
members of different pathotypes, and can be present in isolates recovered
from healthy individuals or in non-pathogenic strains. For some classes
it is still not clear which particular combination(s) of these genes are
necessary to cause disease (e.g. EAEC), while in others the existence
of subgroups with various pathogenic potential are already known to
exist (e.g. EPEC, or Shiga toxin producing strains). Currently, the lack
of straightforward diagnostic algorithms limits our knowledge on the
epidemiology of diarrhoea-causing E. coli. Furthermore, more data on
the incidence of these pathotypes should help to understand the role of
the individual host’s susceptibility in the outcome when encountering
these strains.
S469 Quinolone resistance in the food chain
J. Vila (Barcelona, ES)
Since their discovery antimicrobials have been extensively used in
livestock and poultry, with signiﬁcant beneﬁcial effects on food animal
health and production efﬁciency. Most classes of antimicrobials
used in animals, including ﬂuoroquinolones, have human analogues.
Fluoroquinolones (FQ) are used in animal production primarily for:
(1) therapy; (2) prophylaxis; (3) infection control (metaphylaxis); and
(4) growth promotion in healthy animals. In contrast to human medicine
in which treatment is customarily directed at the patient, entire groups
of animals may be treated with the use of medicated feed and/or water.
Moreover, growth-promoting dosages are usually at low concentrations
for extended time periods, therefore both practices are a potentially
signiﬁcant driving force in accelerating the emergence of resistant
bacteria in these animals that can be transferred through contact or
food to infect humans. The acquisition of quinolone resistance in Gram-
negative bacteria is mainly due to chromosomal mutations either in
topoisomerase genes (mainly gyrA and parC) or in genes associated with
a decreased uptake or by increased efﬂux of quinolones. In addition,
a plasmid conferring low levels of quinolone resistance linked to the
presence of the qnr gene, which encodes a protein protecting DNA gyrase
and topoisomerase IV from quinolones, has been reported. The above
mentioned mechanisms have been described in both Escherichia coli and
Salmonella spp. and generate an increased level of FQ resistance in a
step-wise model, with the ﬁrst mutation found either in the gyrA gene
or in genes involved in efﬂux pump(s), such these producing an over-
expression of acrAB. However, Campylobacter spp. easily acquire high
levels of FQ resistance associated with a mutation in the gyrA gene,
likely because this microorganism does not have topoisomerase IV.
Several studies have demonstrated an association between FQ use in
animals and the subsequent isolation of FQ-resistant bacteria from
the same animal. Antimicrobial-resistant enteric pathogens can reach
humans through direct animal contact, or more commonly, through
ingestion of contaminated water or foods.
Three scenarios may be proposed by which the use of FQ in food
animals could affect the treatment of diseases in humans: (1) FQ-resistant
bacterial pathogens are selected, and food is contaminated during
slaughter and/or preparation. After consumption of the food, these
pathogens cause an infection that requires antibiotic treatment and
therapy is compromised; (2) FQ-resistant bacteria non-pathogenic to
humans are selected in the animal. When the contaminated food
is ingested, the bacteria transfer FQ-resistance determinants, such as
plasmid carrying the qnr gene, to other bacteria in the human gut,
commensal and potential pathogens; and (3) FQs remain as residue in
food products, which allow the selection of antibiotic-resistant bacteria
after the food is consumed.
In conclusion, ongoing surveillance of the antimicrobial susceptibility
proﬁles of foodborne pathogens is needed to identify emerging
antimicrobial-resistant phenotypes within the food production contin-
uum. Moreover, barriers to stop the dissemination of FQ or other
antimicrobial-resistant bacteria from animals to humans should be
improved.
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O470 Tuberculosis in the very old: a ten-year experience
M. Salvado´, C. Garcia-Vidal, J. Martinez-Lacasa, M. Rodriguez-
Carballeira, N. Freixas, M. Riera, C. Nicola´s, J. Garau (Terrassa, ES)
Objectives: It has been suggested that tuberculosis (TB) in the elderly
is often atypical and difﬁcult to diagnose. There is a lack of information
about TB in people over 80 years of age. The aim of this study was to
examine current clinical manifestations, time to diagnosis and outcomes
in old (65 years) and in very old (80 years) patients with TB.
Methods: An observational study of prospectively collected data
of consecutive patients with tuberculosis from January 1995 to
December 2004 in a single institution. Patients under the age of 18
with immunodeﬁciency (HIV, transplant, inﬂiximab use) or suspected
imported disease (less than ﬁve years of residence in Spain) were
excluded.
Results: Out of a total of 449 patients with documented TB, 319 adult
patients were included; of these, 210 (65.8%) were under the age of 65
and 109 (34.2%) were 65 [27 (8.4%) were 80 years]. The mean age
of the younger group was 37.1 (range 18−64), and that of the older
group was 75.5 (range 65−98). Comorbidities (measured by Charlson
index) were signiﬁcantly associated with older age (1.43 vs. 0.43;
p< 0.001). Pulmonary tuberculosis was more frequent in the younger
group (73.8% vs. 49.5%; p< 0.001) and had a higher rate of cavitation
in the chest X-ray (27.6% vs. 2.75%; p< 0.001). Extra-pulmonary and
disseminated tuberculosis were more common in the elderly (50.4% vs.
26.1%; p< 0.001). No signiﬁcant differences were observed between
groups in time to diagnosis (65.34 vs. 59.44 days; p = 0.66). Drug toxicity
was signiﬁcantly higher in the elderly (22% vs. 9.8%; p = 0.006), mainly
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due to hepatic toxicity. Tuberculosis-related mortality (30-day mortality)
was higher in the elderly (18.3% vs. 1.6%; p< 0.001), mainly due to
acute respiratory failure (30%). The subset of patients older than 80
years had a signiﬁcant higher TB-related mortality (44.4% vs. 9.8%;
p = 0.01) compared with those between 65 and 79 years. No signiﬁcant
differences in co morbidities or in clinical manifestations were observed.
Conclusion: Tuberculosis in the elderly and in the very old had a higher
frequency of atypical features and disseminated TB, more adverse drug
reactions and increased TB-related mortality. Data suggest that TB in
the ninth decade has a mortality rate 2-fold higher than in the age group
of 65 to 79 years.
O471 A risk of tuberculosis persists in patients treated with
anti TNF-a antagonist therapy despite prophylactic
guidelines: identiﬁcation of main risk factors
D. Salmon, F. Tubach, P. Ravaud, R. Chiche Manian, C. Michelet,
P. Dellamonica, N. Benammar, X. Mariette, O. Lortholary on behalf
of RATIO
Introduction: Ofﬁcial guidelines for TB screening and chemoprophy-
laxis have been elicited in France (2002 modiﬁed in 2005) as in other
countries for patients who begin TNF-a antagonist therapy. Our objective
was to assess the impact of these guidelines on TB incidence in such
patients.
Methods: A prospective cohort study involving 486 clinical departments
in mainland France was designed by a multidisciplinary group (RATIO)
to describe opportunistic infections, severe bacterial infections or
lymphomas occurring in patients treated with anti TNF. In accordance
with national health authorities, all cases are notiﬁed to RATIO.
All TB cases were validated by an experts committee. A case–control
study (25 ﬁrst TB cases matched with respect to gender and subjacent
illness with 2 control patients for each case) was performed.
Results: We report 37 cases of tuberculosis that occurred within 2.5
years in patients treated with TNF antagonists in France (inﬂiximab
18 cases, adalimumab 17 cases and etanercept 2 cases). Median age
was 61 years (range 20−83). Median anti TNF treatment duration at
onset was 33 weeks (2−231). Indication was rheumatoid arthritis in
25 cases, ankylosing spondylitis in 10 cases, Takayashu disease in
1 case. All patients were taking concomitant immunosuppressive agents:
prednisone (15), methotrexate (13), salazopyrine (5) or azathioprine (4).
No one had received antituberculous chemoprophylaxis before starting
anti TNF therapy. Before anti TNF therapy, results of the intradermal
tuberculin test (Mantoux test) was <5mm in 18 patients, between 5 and
10mm in 7 patients, >10 mm in 1 patient and not done in 3 patients.
In the multivariate analysis, the case–control study identiﬁed the
following risk factors of TB: age (OR= 1.05 [1.03; 1.07], p = 0.02), last
anti TNF received (reference etanercept OR= 1; adalimumab OR= 14.6
[1.65; 129.0], p = 0.01; inﬂiximab OR= 5.9 [0.74; 47], p = 0.09) and
methotrexate treatment (OR= 0.28 [0.01; 1.08], p = 0.01).
Conclusion: Although national guidelines for TB prophylaxis have been
elicited, TB remains a risk associated with anti TNF-a therapy. The risk
of TB is higher for older patients and for those treated with adalimumab
and inﬂiximab than with etanercept.
O472 Assessment and management of tuberculosis infection in
patients due to start anti-TNF-a treatment
S. Casas, O. Gasch, J. Lora-Tamayo, D. Reina, X. Joanola,
L. Gonzalez, M. Guerra, M. Santin (Barcelona, ES)
Objectives: To evaluate a protocol for assessment of tuberculosis (TB)
infection in patients due to start treatment with anti-TNF agents and to
evaluate the efﬁcacy and safety of chemoprophylaxis in anti-TNF treated
patients.
Methods: Prospective evaluation of all patients referred to the
Tuberculosis Unit of a third-level teaching hospital (Jan 2003–Oct 2006),
for assessment of TB infection prior to initiation of anti-TNF treatment.
Diagnosis of TB infection was based on anamnesis for TB risk, two step
tuberculin skin testing (TST) and chest X-ray. Patients were followed
up throughout the period of chemoprophylaxis and adherence was
monitored by determining isoniazid metabolites in urine (or urine colour
when appropriate). A positive TST was deﬁned as an induration 5mm.
Results: 210 patients, 64% women, mean age 52 years, were evaluated.
Baseline illness: 60.5% rheumatoid arthritis, 13.8% cutaneous psoriasis,
13.3% psoriatic arthritis, 11% ankylosing spondylitis, and 1.4% Crohn’s
disease. Thirty-eight (80.2%) patients were on immunosuppressive
treatment. Thirty-one (14.9%) patients had BCG-vaccination, 6 had been
treated for TB, and 2 had prior positive TST. Of 201 patients who
underwent TST, 84 (41.8%) resulted positive (59 and 25 in the ﬁrst
and second test respectively), and 117 (58.2%) resulted negative.
Chemoprophylaxis was given to 79 (39.3%) patients: 78, isoniazid for
9 months and 1 rifampin for 4 months. Three patients (3.8%) experienced
a 5-fold increase of transaminase level above the ULN. After a 237
patient–years follow up, one of the 130 patients who ﬁnally received
anti-TNF treatment developed TB (0.42%; 95%CI: 0.01−1.71). His two-
step TST resulted negative and he began on adalimumab. Five months
later, TB developed.
Conclusion: Systematic and protocolised assessment for TB infection
and its treatment when indicated is a reliable and useful method to
prevent anti-TNF-associated TB. Our data show that two-step TST is
helpful to detect TB infection in a signiﬁcant number of patients.
Prolonged treatment with isoniazid seems to be safe in anti-TNF treated
patients.
O473 QuantiFERON-TB Gold In-Tube is more reliable in
smear-negative tuberculosis
M. Reichmuth, K. Mu¨hlemann, T. Bodmer (Berne, CH)
Objectives: Interferon-gamma release assays (IGRA), such as the
QuantiFERON®-TB Gold In-Tube (QFT-GIT; Cellestis Ltd., Carnegie,
Australia), are increasingly used for the diagnosis of tuberculosis (TB).
These tests exploit immunological mechanisms that normally contain
Mycobacterium tuberculosis (Mtb) infecting the human host. Failed con-
tainment results in clinical TB and is associated with proliferating Mtb.
We thus wondered if in this situation indeterminate or negative QFT-
GIT results were associated with positive microscopy, thus serving as a
surrogate for the bacterial burden.
Methods: Between November 2004 and October 2006, 67 consecutive
patients with culture-conﬁrmed TB were prospectively enrolled. Patients
had received no or less than 14 days of antituberculous therapy
(n = 58) or were recruited within two months since begining treatment
(n = 9). Severe immunosuppressive conditions were present in 14 (21%).
QFT-GIT was performed according to the manufacturers’ instructions.
Laboratory investigations included ﬂuorescence microscopy for acid-
fast bacilli, and culture on both liquid and solid media. Univariate and
multivariate analysis were done in StatView® version 5.0 (SAS Institute
Inc., Cary, NC).
Results: Overall, 52%, 36%, and 12% of the patients had pulmonary,
extrapulmonary, or combined pulmonary and extrapulmonary TB,
respectively. In one patient, no microscopy result was available as
Mtb was only detected in blood culture. Microscopy was positive in
40/66 patients (61%; 95%CI: 49−72%); respiratory and extrapulmonary
specimens were smear-positive in 30/39 (77%) and 10/27 (35%) of
TB patients, respectively. Overall, QFT-GIT was positive in 51 (76%;
95%CI: 65−85%) TB patients; indeterminate or negative QFT-GIT
results occurred in 6 (9%) and 10 (15%) TB patients, respectively.
Age and gender did not inﬂuence the QFT-GIT test result. However, the
likelihood of having a negative or indeterminate QFT-GIT test result was
signiﬁcantly and independently associated with a positive microscopy
(odds ratio [OR] 5.8, 95%CI: 1.2−28.2%; p = 0.03) and with immune-
suppression (OR 3.2, 95%CI: 0.91−11.4, p = 0.08).
Conclusions: To our knowledge this is the ﬁrst study that demonstrates
a signiﬁcant association of smear-positive TB and negative or
indeterminate QFT-GIT results. This association was independent of,
and stronger than, the effect of concomitant immune-suppression. The
ﬁnding has implications for the use of QFT-GIT in clinical practice.
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O474 Utility of the IFN-g assays using Mycobacterium
tuberculosis-speciﬁc antigens for the diagnosis of latent
infection in contacts of people with sputum smear-positive
pulmonary tuberculosis
M. De Souza Galvao, I. Latorre, C. Mila, M. Jimenez, C. Prat,
N. Altet, L. Haba, M. Perez, J. Ruiz-Manzano, V. Ausina, J. Dominguez
(Barcelona, ES)
Objective: To determinate IFN-g response by speciﬁc T cells with
QuantiFERON-TB GOLD (QFN-TB GOLD) (Cellestis, Australia) and
T-SPOT.TB (Oxford Immunotec, United Kingdom) in contacts of people
with sputum smear-positive pulmonary tuberculosis.
Materials and Methods: We included 91 individuals enrolled in contact
tracing studies after exposure to a sputum smear-positive pulmonary
tuberculosis case. Blood samples and isolated peripheral blood isolated
mononuclear cells were stimulated withM. tuberculosis-speciﬁc antigens
ESAT-6 and CFP-10. We determined the IFN-g production in whole-
blood supernatants samples by EIA with the QFN-TB GOLD assay and
in mononuclear cells by ELISPOT with the T-SPOT.TB assay. Both
IFN-g tests were performed according to the manufacturer’s instructions.
Tuberculin skin test (TST) was administered by the Mantoux method
using two tuberculin units of PPD RT23 (Statens Serum Institut,
Denmark). Induration was measured after 48−72 h. Indurations higher
than 5mm were considered positive.
Results: We included 91 individuals with a exposure higher to 6 h/day,
62 of them with BCG vaccination scar. The percentage of positive
results for TST, T-SPOT.TB and QFN-TB GOLD, in non-vaccinated
and vaccinated individuals were the following: 71.4% and 94.9%;
70.4% and 47.3%; and 57.7% and 40.3%, respectively. The overall
concordance between T-SPOT.TB and QFN-TB GOLD was higher
(k = 0.632). Between vaccinated individuals that initiate a prophylaxis
treatment, T-SPOT.TB was negative in 45.7% of cases, and QFN-TB
GOLD in 59.2%.
Conclusions: (1) Both in vitro assays seem to have lower interference
results with the BCG vaccination than TST, which suggest a higher
speciﬁcity for QFN-TB GOLD and T-SPOT.TB assays. (2) Utilisation
of these tests can help to reduce the number of unnecessary prophylaxes.
O475 Duration of exposure to a case of smear positive tuberculosis
and rates of positive whole-blood interferon gamma test and
tuberculin skin testing
P. Lillie, H. Thaker, G. Anderson, K. Cartlich, M. Goodrick, R. Meigh,
G. Barlow, A. Newton, P. Moss (Hull, UK)
Objective: Duration of exposure to tuberculosis (TB) is a major risk
factor for transmission of the disease. Current WHO guidelines, based
on transmission of TB on aeroplane ﬂights, recommend an 8 hour period
as a cut off for screening. However this was before the routine use of
IFN-g assays. We compared Mantoux skin testing with QUANTIFERON-
TB GOLD (QFN) in a hospital associated outbreak, stratifying patients
by duration of contact.
Methods: Hospital contacts of the index case were screened in a
sequential manner (close contacts sharing the same room for 8 hours,
contacts on the same ward for 8 hours and contacts on ward <8 hours).
Contacts were screened by TB specialist nurses with both Mantoux skin
testing and QFN. A 15mm cut off for reading Mantoux tests was used.
Data on symptoms, duration of exposure and prior BCG vaccination
were recorded.
Results: 36 contacts were referred for screening, of whom 29 were
screened, 28 with both QFN and Mantoux. 20 patients had 8 hours
exposure, with 8 (40%) having a positive QFN test compared with
3 (15%) a positive Mantoux test. Of the 9 patients with <8 hours
exposure 1 (11.1%) had a positive QFN test, 2 (22.2%) having positive
Mantoux tests. 60% of positive Mantoux tests were known to have had
BCG vaccination, with 22.2% of QFN positive patients having had BCG.
QFN and TST results stratiﬁed by 8 hour exposure
Duration of exposure
<8 hours >8 hours
QFN +ve 1 8
QFN −ve 8 12
TST +ve 2 3
TST −ve 7 17
Conclusion: QUANTIFERON-TB GOLD testing in a hospital associated
outbreak of TB correlates well with 8 hour duration of exposure, in
agreement with WHO guidelines. Bigger prospective studies, comparing
IFN-g assays with Tuberculin skin testing, are needed to conﬁrm this
ﬁnding.
O476 Larger scale transmission of and isoniazid-
resistant/rifampicin intermediate-resistant Mycobacterium
tuberculosis strain
J. van Ingen, P.E.W. de Haas, G. de Vries, M.J. Boeree,
D. van Soolingen (Bilthoven, Rotterdam, Nijmegen, NL)
Objectives: Nation-wide surveillance on transmission and resistance of
Mycobacterium tuberculosis in the Netherlands has functioned since
1993. Presumably due to a lower transmissibility and a well-organised
tuberculosis control, transmission of multi-drug resistant tuberculosis
(MDR-TB) was so far limited to single secondary cases. However, a
MDR strain with an unusually low level of rifampicin resistance (MIC
1−2mg/l) was transmitted from a single source to nine persons, of whom
three developed active disease so far.
In the current study we assessed the molecular basis of the INH and
rifampicin resistance of the outbreak strain and its implications for
transmissibility and therapy.
Methods: The katG and rpoB gene of the MDR strain were sequenced
and the minimum inhibition concentration (MIC) to INH and rifampicin
was determined. DNA ﬁngerprinting of M. tuberculosis isolates and
conventional contact tracing was performed to investigate the spread
of the MDR strain.
Results: The respective outbreak strain had a Ser315Thr mutation in
the katG gene (k315). INH resistant strains with k315 mutation were
previously found to maintain a higher transmissibility than other INH
resistant strains. An Asp516Tyr mutation was found in the rpoB gene
(r516). Phenotypically, most of the outbreak isolates were interpreted
resistant, but a part of the isolates were read as susceptible, which
confused the therapy guidance and the surveillance of MDR-TB.
Conclusion: The relatively high rate of transmission of this k315/r516
variant may be related to evolutionary development of M. tuberculosis
to maintain its transmissibility despite the adaptation to withstand the
therapy by our most important anti-mycobacterial drugs; INH and
rifampicin. More studies are needed to investigate the contribution of
k315/r516 MDR strains to transmission of MDR-TB.
The consequences of the unusual low level of rifampicin resistance for
therapy guidance and surveillance will be determined. It is considered
to introduce the term “intermediate susceptibility” to indicate this level
of rifampicin resistance.
O477 Evaluation of a new version of the “RT-TB” triplex real-time
PCR assay for the rapid diagnosis of Mycobacterium
tuberculosis in clinical samples
W. Sougakoff, G. Millot, C. Truffot-Pernot, N. Veziris, F. Brossier,
V. Jarlier (Paris, FR)
Objectives: The “Real Time TB” assay (RT-TB) is a new multiplex
real time PCR assay that allows the rapid detection and differentiation
of the M. tuberculosis complex from other mycobacteria. The
assay targets the IS6110 element and the RD9 speciﬁc region that
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differentiate M. tuberculosis (IS6110 positive – RD9 positive) from the
other mycobacterial species included in the M. tuberculosis complex
(IS6110 positive – RD9 negative). We recently evaluated the ﬁrst version
of the RT-TB kit, demonstrating that the assay is sensitive, particularly in
smear negative–culture positive clinical samples. Here, we report on the
evaluation of a new version of the RT-TB assay in which the labelling
of the IS6110 probe has been modiﬁed in order to improve its stability
and detection level.
Methods: The new RT-TB BioRad kit includes an IS6110-BRD04 probe
(instead of IS6110-Tamra in the previous version) that increases by
10-fold the sensitivity of detection of the IS6110 amplicons. Fifty-two
clinical samples collected in routine (sputa, bronchoalveolar and gastric
lavages) were included. DNA preparations and RT PCR reactions were
carried out according to the manufacturer’s instructions. A new speciﬁc
software developed by the manufacturer was used for the automated
analysis of the RT-TB ampliﬁcation results.
Results: In the present study, 2 samples were found to contain inhibitors
(as indicated by the negative ampliﬁcation signals of the corresponding
internal controls). The 8 smear positive samples included in the study
were all found to be IS6110-POS and RD9-POS. Interestingly, 4 of them
showed <1 acid fast bacilli per ﬁeld on microscopic examination.
The good sensitivity of the test was conﬁrmed by 2 smear negative
samples which were both found to be IS6110-POS and RD9-POS by
the RT-TB assay. These two samples were conﬁrmed to be positive for
M. tuberculosis by the Roche Amplicor assay. Finally, the 40 remaining
smear-negative samples were all found to be negative for IS6110 and
RD9, suggesting that the increased sensitivity of the new IS6110-BRD04
probe does not impair the speciﬁcity of the test.
Conclusion: The results obtained for the ﬁrst evaluation of the new
version of the RT-TB kit suggest that the assay is sensitive and speciﬁc
and may be very promising for the detection ofM. tuberculosis in clinical
samples containing few bacilli. Further experiments are in progress to
conﬁrm these preliminary data.
O478 Rapid detection of rifampin resistance mutations in
clinical isolates of Mycobacterium tuberculosis by Dot-Blot
hybridisation assay
M. Varma-Basil, R. Pathak, S. Ahmed, A. Bhatnagar, M. Bose (Delhi, IN)
Objectives: A Dot-Blot hybridisation assay that detects all mutations
occurring in theM. tuberculosis rpoB hot-spot region is being developed.
The assay uses ﬁve probes, capable of binding to a different target
segment within the rpoB hot-spot region of the wild-typeM. tuberculosis
genome. The present study is a preliminary investigation to assess the
suitability of the assay for detection of resistance mutations in rpoB in
clinical isolates of M. tuberculosis from Delhi, India.
Methods: Susceptibility testing of 142 isolates of M. tuberculosis was
carried out by proportion method and conﬁrmed by BACTEC 460TB
system. Dot-Blot assay was performed on 106 isolates with two of the
probes hybridising to the wild-type sequence of M. tuberculosis, from
codons 522 to 527 (Probe D) and 528 to 533 (Probe E). Absence of
hybridisation with any of the probes in the assay when a mutation
was present indicated Rifampicin resistance, a surrogate marker for
Multidrug-resistant M. tuberculosis.
Results: Susceptibility testing of 142 isolates revealed isoniazid
resistance in 53.5%, rifampicin resistance in 41%, streptomycin
resistance in 53% and ethambutol resistance in 37% of strains. Forty-
ﬁve strains (32%) were multidrug resistant. Further analysis of the
data showed that 96.4% of rifampicin-resistant strains and 100% of
ethambutol-resistant strains had co resistance to one or the other
antituberculous drug. It was also interesting to note that 77% of
the rifampicin-resistant strains were multidrug resistant, while the
corresponding ﬁgure for ethambutol-resistant strains was 87%.
Dot-Blot hybridisation assay with probes D and E was carried out on 106
isolates of M. tuberculosis, of which 43 were resistant to rifampicin. Of
the rifampicin-resistant isolates tested, 15 did not hybridise with probe E,
indicating a mutation at this site. The results of 10 strains were conﬁrmed
by sequencing when a mutation was detected in 9 strains at codon 531
and in one of them at codon 533. The remaining 28 rifampicin-resistant
strains, which hybridised with probe E, may have a mutation at a site
other than that complimentary to probe E. Of these, 10 hybridised with
probe D, indicating a mutation at the site complimentary to probe D
(codons 522 to 527). Of the 63 rifampicin-susceptible isolates, 62 (98%)
hybridised with probes D and E, indicating a wild-type sequence.
Conclusions: The Dot-Blot assay was found to be a sensitive and speciﬁc
assay.
O479 Rapid detection of multidrug-resistant and heteroresistant
tuberculosis in one day using the new molecular-biological
test Genotype MTBDRTM
H. Hoffmann, G. Murmusaeva, G. Uzakova, B. Shrestha, I. Bozo,
S. Yann, K. Feldmann (Gauting, DE; Tashkent, UZ; Kathmandu, NP;
Santa Cruz, BO; Donetzk, UA)
MDR-TB is deﬁned by resistance of the respective pathogen (Mycobac-
terium tuberculosis complex, MBTC) against INH and rifampin RMP.
Mortality of MDR-TB is double compared to sensitive TB. Phenotypic
drug-susceptibility-testing (DST) lasts up to 8 weeks. Following the
DOTS and waiting for DST results, MDR-TB patients are miss-treated
with INH and RMP. A new resistance test, Genotype MTBDRTM
(G-MDR), has been released, detecting MDR-TB. The test is based on
PCR and hybridisation.
For its validation, 64 strains have been characterised by threefold DST
on solid and liquid media. 100% of RMP resistances (n = 31) and 90% of
INH resistances (n = 49) were detected by G-MDR. Speciﬁty was 100%.
112 TB isolates from highly endemic countries were analysed: 31 from
Bolivia, 58 from Nepal and 23 from Ukraine. 93% of RMP-resistances
were detected with G-MDR. The sensitivity for detection of INH
resistance increased with the prevalence of MDR-TB in the respective
countries from 64% in Nepal, 74% in Bolivia, 83% in Usbekistan,
to 86% in the Ukraine. All G-MDR assays for Nepalese strains were
performed in the National Reference TB-Laboratory in Katmandu,
demonstrating that the test is robust enough to be applied in developing
countries. Finally, the test was applied to 35 sputum specimen from
Usbekistan, which were all positive in microscopy. All MDR cases have
been detected. Additionally, heteroresistance to INH and RMP could be
visualised in nine cases.
Genotype MTBDRTM is a fast, easy to perform and robust test,
applicable in highly endemic countries. Its sensitivity for the detection
of RMP resistance is 100%, for INH up to 90% depending on the MDR
prevalence. It is an excellent tool for the detection of heteroresistance.
The test can be performed from microscopically positive sputum,
reducing the DST time to zero days.
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O480 Characterisation of Neisseria meningitidis B causing invasive
disease in the Czech Republic
P. Kriz, J. Kalmusova, M. Musilek, J. Felsberg, R. Haugvicova,
D. Caugant, K. Jolley, M. Maiden (Prague, CZ; Oslo, NO; Oxford, UK)
Objectives: Invasive meningococcal disease (IMD) caused by Neisseria
meningitidis B is endemic in the Czech Republic and its long-term
incidence is stable (0.5/100,000 population), reaching peaks in the
youngest age groups (up to 22.6/100,000 for 0−11 months olds and
2.7/100,000 for 1−4 years olds). The aim of this study was to characterise
N. meningitidis B isolates from IMD and to assess the coverage of
vaccines against N. meningitidis B.
Methods: The total number of N. meningitidis B isolated from IMD in
the Czech Republic in the period 1993–2006 (Nov. 8) was 474. In all
isolates serogrouping and sero/subtyping was performed. Subtyping by
Whole Cell ELISA (WCE) was replaced by PorA sequencing recently
(http://neisseria.org/nm/typing/). Sequence types (STs) were identiﬁed
by multilocus sequence typing (MLST) in accordance with the MLST
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website (http://pubmlst.org/neisseria/). The number of N. meningitidis B
IMD isolates investigated by MLST was 366.
Results: Sero/subtyping showed high heterogeneity: among 474
isolates, 88 phenotypes were found. The most frequent pheno-
type was B:4:P1.15 (15.4%), followed by B:15:P1.7,16 (8.2%) and
B:15:P1.5 (5.7%). 15.4% of isolates were not typeable/subtypeable
by WCE. PorA sequencing of these isolates further identiﬁed their
heterogeneity. MLST conﬁrmed this high heterogeneity: 142 STs,
belonging to 16 clonal complexes, which represent 79.2% of isolates.
There were three prevailing complexes: ST-18 complex (19.1%),
ST-32 complex (18.8%) and ST-41/44 complex (16.9%). The Czech
N. meningitidis B population is different compared to western Europe:
109 of the STs (76.8% of STs) and one clonal complex (ST-292 complex)
were described for the ﬁrst time in the Czech N. meningitidis B isolates.
Coverage of sero/subtypes by currently being developped vaccines
against N. meningitidis B is low (maximum 44.5% for nine-valent
meningococcal B PorA vaccine).
Conclusion: Detailed characterisation of N. meningitidis B isolates from
IMD in the Czech Republic in the period 1993–2006 showed their high
heterogeneity and low coverage by currently available vaccines against
N. meningitidis B.
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Ministry of Health of the Czech Republic and made use of the Multi
Locus Sequence Typing website (http://pubmlst.org/neisseria/) sited at
the University of Oxford and funded by the Wellcome Trust and
European Union.
O481 Detection by DHPLC of 23S rDNA mutations responsible
for clarithromycin resistance in Helicobacter pylori
C. Coulon, C. Lascols, S. Pissard, L. Deforges, J.C. Delchier,
C.J. Soussy, E. Cambau (Cre´teil, FR)
Objectives: Resistance to clarithromycin is the leading cause of decrease
in H. pylori eradication. Since 23S rRNA mutations correlated with
in vitro and in vivo clarithromycin resistance, routine detection of these
mutations will be helpful to adapt the antibiotic treatment.
Methods: A total of 123 clinical strains of H. pylori consecutively
isolated between 2004 and 2005 in our hospital have been studied.
Clarithromycin MICs were determined by both the agar dilution and
E-test method. A 147-bp fragment, encompassing the nucleotides
involved in clarithromycin resistance at positions 2146 and 2147 in
23S rDNA, were ampliﬁed and analysed by denaturing high pressure
liquid chromatography (WAVE® systems, Transgenomic). The DHPLC
analysis was done on PCR products after mixing PCR product from
the tested strain with that from a wild-type susceptible reference strain
in order to create heteroduplexes. The 23S rDNA was also studied by
direct sequencing for all clarithromycin-resistant strains and a large part
of susceptible strains.
Results: DHPLC proﬁles were identical to that of the wild-type strain for
85/123 (69%) strains, which were all susceptible to clarithromycin (MICs
from 0.06 to 0.5mg/l) except two strains for which a mix of susceptible
and resistant (MIC of 8 and 256mg/l) strains was observed. DHPLC
proﬁles were different from that of the wild-type strain for 35 strains
(28.5%) which were all resistant to clarithromycin (MICs from 6 to
>256mg/l) except one strain for which again a mix of susceptible (MIC
of 0.05mg/l) and resistant strains was observed. For 3 (2.5%) strains, we
obtained undetermined DHPLC proﬁles, i. e. neither a proﬁle identical
to a wild-type strain or a mutated strain. Different DHPLC retention
proﬁles were observed for the two main mutations, A2146G (n = 3) and
A2147G (n = 32). No strain harbouring the A2146C was observed. We
also evaluated the minimal proportion of resistant strains with a mutated
allele that can be detected. This was about 25% with DHPLC as with
sequencing methods.
Conclusion: DHPLC method is a reliable method to detect 23S rDNA
mutations predictive of clarithromycin resistance.
O482 Comparison of a molecular screening method with
traditional culture for the detection of Salmonella spp. and
Campylobacter jejuni in faeces
R. de Boer, T. Schuurman, E. van Zanten, K. van Slochteren, H. Scheper,
B. Dijk-Alberts, L. Mo¨ller, M. Kooistra-Smid (Groningen, NL)
Objective: Salmonella spp. and Campylobacter jejuni are the major
causes of bacterial gastro-enteritis in the Netherlands. Conventional
diagnosis is based on detection of both species in faeces by traditional
culturing which usually takes several days. We developed a sensitive
molecular screening method (MSM) for the detection of both species
which decreases the turn-around time signiﬁcantly. This study describes
the comparison of this real-time PCR based screening method with
routine culture for the detection of Salmonella spp. and C. jejuni in
faeces.
Methods: A total number of 2,067 stool samples were analysed at
our laboratory. Routine culture was performed on faecal samples and
consisted of enrichment, selective culture and phenotypic identiﬁcation.
The molecular method consisted of a semi-automatic DNA extraction
in combination with real-time PCR assays for Salmonella spp. and
C. jejuni. PCR positive samples as well as samples which demonstrated
PCR inhibition were cultured afterwards, consisting of the identical
procedure as described for routine culture. Also, data regarding time
to generate ﬁnal results were collected for the MSM.
Results: A total number of 2,055 samples were included for validation
of Salmonella spp. The detection of Salmonella spp. improved by 15%
with molecular screening; sensitivity was 100% and speciﬁcity 99%. For
C. jejuni 2,009 samples were included and detection improved by 25%;
sensitivity was 97% and speciﬁcity 75%. PCR inhibition was observed
in less than 1.9% of all samples. The time to generate ﬁnal results was
less than 24 hours for all PCR negative samples (with exception of the
inhibited samples), and in comparison to traditional culture there was no
delay observed in generating results of culture conﬁrmed PCR positive
samples.
Conclusions:
1. The MSM has a great potential for rapid detection of Salmonella spp.
and C. jejuni in faeces.
2. Time to generate ﬁnal results for negative samples was reduced
dramatically to less than 24 hours.
3. The detection of Salmonella spp. and C. jejuni will improve
considerably with molecular screening.
4. Automation of the extraction and detection procedures will further
speed up the process and improve standardisation of the molecular
screening procedure.
O483 Staphylococci speciation and Panton-Valentine leukocidin
detection by matrix-assisted laser desorption ionisation
time-of-ﬂight mass spectrometry
D. Dare, H. Li, H. Sutton, C. Stratton, Y. Tang (Manchester, UK;
Nashville, US)
Objectives: A rapid proteome analysis has proven useful for microbial
identiﬁcation. We assessed a matrix-assisted laser desorption ionisation
time-of-ﬂight (MALDI-TOF) mass spectrometry for the rapid identiﬁca-
tion and differentiation of staphylococcal species as well as the detection
of Panton-Valentine Leukocidin (PVL) toxin from clinical staphylococcal
isolates.
Methods: Staphylococcal clinical isolates recovered from blood culture
were included in the study. Phenotypic identiﬁcation and differentiation
between Staphylococcus aureus and coagulase-negative staphylococci
(CoNS) were determined by colony morphology, catalase, and a
Staphaurex latex agglutination. CoNS speciation was performed by using
a bioMe´rieux/VITEK API STAPH system. Methicillin resistance in
S. aureus strains was conﬁrmed by disk diffusion. The PVL gene was
detected by a real-time TaqMan PCR assay.
Results: Among a total of 115 staphylococcal isolates, 41 (35.7%),
44 (38.3%), and 30 (26.1%) were identiﬁed as CoNS, methicillin-
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resistant Staphylococcus aureus (MRSA), and methicillin-susceptible
S. aureus (MSSA), respectively, by the MALDI-TOF with correct
identiﬁcation rates of 100%, 97.7% and 93.3%, in comparison with those
identiﬁed by phenotypic methods. The agreement rate was 75.6% with
those determined by the API STAPH when these CoNS isolates were
identiﬁed into species level by the MALDI-TOF. Seven PVL-positive
MRSA isolates were correctly recognized by the MALDI-TOF with
100% accordance with the results determined by real-time PCR. The
whole process, from the sample preparation to result analysis, can be
completed between 1.5 and 2.5 hours, which greatly shortens the time
usually needed for current phenotypic identiﬁcation.
Conclusion: MALDI-TOF mass spectrometry provides a rapid and
relevant system for clinical identiﬁcation of staphylococci. Detecting
PVL protein directly from clinical isolates provides a bacterial
identiﬁcation system that is desirable in clinical diagnostic services.
O484 Development of a multiplex PCR assay for enterotoxigenic
Bacteroides fragilis and detection of this emerging pathogen
in cases of community-acquired diarrhoea in the UK
L.R. Macfarlane-Smith, K.G. Kerr, A.M. Snelling (Bradford, Harrogate,
UK)
Objectives: Bacteroides fragilis is the Gram-negative anaerobe isolated
most often from human infections. Some B. fragilis strains produce a
20 kDa enterotoxin (BFT). Enterotoxigenic B. fragilis (ETBF) have been
isolated from various diarrhoeic animal species and epidemiological
studies worldwide note a signiﬁcant correlation between ETBF and
human diarrhoeal disease, especially in children. The prevalence of
ETBF in gastrointestinal diseases in the UK, however, has not been
investigated, partly due to the lack of a simple identiﬁcation test that
can be used in diagnostic laboratories. The aim of this study was to
develop a sensitive and speciﬁc multiplex PCR assay for the detection
of ETBF directly from faeces, and to investigate if ETBF are associated
with cases of community-acquired diarrhoea in the UK.
Methods: Primers were designed from published enterotoxin sequences
to amplify 416 bp of bft, and multiplexed with primers amplifying 293 bp
of nanH (+ve control for presence of B. fragilis). The assay was validated
against 136 strains from 52 species. DNA was extracted from stools
using the QIAamp DNA stool mini kit (Qiagen). Spiking experiments
were used to determine sensitivity of the assay. Stool was obtained from
193 cases of community-acquired diarrhoea, selected on the basis that
no other bacterial pathogen had been identiﬁed. Where bft was detected
in DNA extracts, a second novel multiplex PCR assay was used to
determine which of the 3 bft isoforms was present.
Results: The PCR assay for ETBF was found to be 100% speciﬁc and
had a detection limit of 104 cfu/g stool. 13% (25/193) of the diarrhoea
samples gave a positive result for bft and nanH. The predominant isoform
in the ETBF +ve samples was bft-1 (n = 20, 80%). Three samples had
bft-2 and 1 had bft-3. A diarrhoeal sample from a 1-yr old male yielded
PCR amplimers for both bft-1 and bft-2 suggesting carriage of at least
2 different ETBF strains.
Conclusion: The multiplex PCR assay was highly speciﬁc for ETBF and
allowed detection without the need for culture. This is the ﬁrst report
of ETBF in community-acquired diarrhoea in the UK. The distribution
of isoforms in the clinical samples was similar to earlier reports from
Europe, but the occurrence of 2 different bft isoforms in a faecal sample
has not been described before. The ﬁnding of ETBF in a high proportion
(13%) of samples for which there was no other bacterial explanation for
the diarrhoea merits further investigation of this pathogen.
O485 Recently identiﬁed viruses contribute signiﬁcantly to acute
respiratory infections in children
A. Pierangeli, C. Scagnolari, S. Trombetti, P. Di Marco, F. Midulla,
C. Moretti, G. Antonelli (Rome, IT)
Objectives: More than half of all episodes of acute respiratory
infection (ARI) have none of the pathogen identiﬁed in paediatric as well
as adult populations. It is likely that the prevalence of viral infection
is underestimated because of the large number of respiratory viruses
involved in respiratory tract infection. A number of novel respiratory
pathogens had been identiﬁed since 2001, i.e. human metapneumovirus
(hMPV), coronaviruses NL63 and HKU1, human bocavirus (hBoV);
they are not currently diagnosed but could contribute signiﬁcantly to
the burden of ARI. A molecular approach was undertaken to detect
nearly all respiratory viruses, including hMPV, NL63, HKU1 and hBoV
in hospitalised children suffering from acute respiratory tract infection.
Methods: Most respiratory viruses were detected prospectively in
nasal washes from children hospitalised for ARI in a paediatric
department at the University “La Sapienza” hospital of Rome. HKU1
and bocavirus were searched for retrospectively, on frozen aliquots of
samples. Reverse transcription-PCR assays followed by sequencing of
the ampliﬁed fragments were undertaken to detect fourteen respiratory
viruses: inﬂuenza A and B, RSV, hCoV OC43 and 229E, adenovirus,
rhinovirus, parainﬂuenza viruses 1−3, hMPV, NL63, HKU1 and hBoV.
Results: In 103/227 children (45.4%), at least one viral pathogen was
identiﬁed; 86/227 (37.9%) had an infection with one of the virus
investigated; 17/227 (7.5%) had a dual infection, with a total of
120 viruses identiﬁed. The most common agent was RSV, followed
by rhinovirus and parainﬂuenza virus 3. Overall, hMPV infections
represented about 8% of all viral illness. One NL63 case was detected;
no positive to HKU1 was found. Bocaviruses were detected in 12 cases
(11% of all virus positive cases), half of which in co-infections. Almost
all patients who had hBoV as the sole pathogen had pneumonia; in
addition, it was detected in one children hospitalised for bronchiolitis.
Conclusions: Detection of the recently characterised metapneumovirus,
coronaviruses NL63 and HKU1, and bocavirus contributed a signiﬁcant
proportion (17.5%) of all positive samples.
This study is a conﬁrming report of NL63 and hBoV circulation in Italy,
reported in late 2006. Interestingly, bocavirus was a frequently detected
respiratory agent and was associated with clinically important illnesses.
O486 Implementation of a real-time RT-PCR assay to improve
diagnostics of dengue virus infections
A. Dumoulin, H.P. Marti, M. Panning, H.H. Hirsch (Basle, CH;
Hamburg, DE)
Objectives: Dengue viruses (DENV) are the most common insect-borne
viral pathogens diagnosed in travellers returning from tropical zones. The
symptoms caused by DENV range from self-limited, ﬂu-like illness,
to life-threatening haemorrhagic fever. DENV are immunologically
grouped in four serotypes and secondary infection by a different serotype
is presumably one of the factors favouring the haemorrhagic presentation.
Routine diagnostics rely on the detection of DENV-speciﬁc IgM and
IgG. However, because of the low antibody titres in the early phase
of disease, serology is prone to false negative results. By allowing
detection of the virus in this early phase, RT-PCR can close the diagnostic
gap. The objective of this study was to improve the quality of DENV
diagnostics at the Zentrum fu¨r Infektionsdiagnostik (ZID, Basel) by real-
time quantitative RT-PCR, for early detection and molecular typing.
Methods: Serological testing of patient samples was performed by
using a rapid commercial assay detecting DENV speciﬁc IgM and
IgG. A quantitative pan-dengue real-time RT-PCR (PAND PCR)
protocol was used to detect DENV independently of the subtype.
Classiﬁcation into the four DENV subtypes was achieved using a
serotype speciﬁc multiplex real-time RT-PCR protocol. Commercial kits
for RNA extraction (QIAamp®, Qiagen) and one-step RT-PCR (iScript®,
Biorad) were used. Overall, 98 serum samples were analysed with both
methods: subset A was a retrospective panel of 25 IgM positive serum
samples; subset B consisted of 73 serum samples (22 IgM positive,
51 IgM negative) collected prospectively at the ZID between April and
November 2006.
Results: Of 47 IgM positive samples, 17 (36%) were positive by PAND
PCR (subset A: 4 from 25, 28%; subset B: 13 from 22, 59%). Of
51 IgM negative samples (all subset B), 6 were positive by PAND
PCR (12%). The detected viral load ranged from 255 copies/mL to
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7.137 copies/mL (median 1.335 copies/mL). Two PAND PCR positive
and 4 negative samples were sent to a reference laboratory for
conﬁrmation. In one case, the result was discordant. Of 16 samples
tested with the serotype speciﬁc RT-PCR, 13 (81%) could be attributed
to a subtype: 7 to subtype I, 2 to subtype II, 2 to subtype III and 2 to
subtype IV.
Conclusion: Our results show that a combination of serological and RT-
PCR are required for rapid and reliable dengue virus diagnostics at all
stages of infection.
O487 RespiFinder-kit: simultaneous detection of 15 atypical
viruses commonly involved in respiratory tract infections
M. Reijans, G. Dingemans, G. Simons (Maastricht, NL)
Objective: Acute respiratory tract infection is the most widespread
type of acute infection in adults and children. The number of
pathogens involved is numerous. The objective is the development of
a multiparameter assay which enables the detection of all pathogens
commonly involved in respiratory tract infections. The RespiFinder test
currently involves inﬂuenza A, B and H5N1 virus, respiratory syncytial
virus A and B, parainﬂuenza virus type 1, 2, 3 and 4, coronavirus 229E,
OC43 and NL63, rhinovirus, human metapneumovirus and adenovirus
(subgenera A, B, C, D, E and F). The aim was to obtain the same
speciﬁcity and sensitivity as singleplex QPCR and to complete detection
and differentiation within 6 hours.
Method: The RespiFinder-kit is based on a new multiplex PCR
technology which enables simultaneous ampliﬁcation of up to 40
fragments. Detection of a virus is dependant on two speciﬁc probes.
These two probes hybridise adjacently to each other. After ligation of
the speciﬁc probes, all targets are ampliﬁed with one universal primerset.
The ampliﬁed fragments can be discriminated by size fractionation.
A competitive internal RNA control is added to each sample allowing
discrimination between a true negative sample and a negative sample
due to a PCR failure. Prior to the multiplex ampliﬁcation, viral RNA is
converted into cDNA using an one step RT-PCR followed by a limited
number of PCR cycles.
Results: The RespiFinder-kit was compared with singleplex QPCR
assays as well as conventional culturing procedures. Sensitivity of the
assay was compared with QPCR using serial dilutions of virus cultures.
The same sensitivity was obtained with the RespiFinder-kit as with
QPCR. Clinical samples were tested with all three approaches. This
showed increased sensitivity of the two nucleic acid based tests over the
conventional diagnostic procedures. The results with the RespiFinder-kit
and the QPCR assay showed a high degree of correlation.
Conclusions: We showed that the RespiFinder-kit enables simultaneous
detection of 15 viruses commonly involved in respiratory tract infections
within 6 hours and with the same sensitivity and speciﬁcity as singleplex
QPCR reactions.
O488 High prevalence of Legionella pneumophila in severe
community-acquired pneumonia, as determined by a
commercially available PCR assay
N. Poblet-Mas, M. De la torre, J.M. Sirvent, L.J. Garcia-Gil (Girona, ES)
Objectives: Legionella pneumophila is one of the main causative agents
of severe community acquired pneumonia (CAP). When legionellosis
occurs, it can be fatal if diagnosis and treatment are not promptly
established, particularly in elderly and immunocompromised patients.
Therefore, rapid detection and diagnostic methods are needed to improve
the outcome of infected patients and to reduce unnecessary antibiotic
therapy. The main goals of this work were:
– To assess the use of a new PCR-based method to support
L. pneumophila diagnosis in patients with severe CAP, as compared
to current laboratory methods.
– To determine the prevalence of L. pneumophila in severe CAP,
requiring admission in intensive care unit (ICU).
Methods: A total of 95 clinical specimens (BAL, blood and urine) from
39 patients admitted in the intensive care unit (ICU) with severe CAP,
were collected from December 2004 to October 2006. The presence of
Legionella pneumophila was assayed simultaneously by the antigen urine
test (Binax®), by microbiological culture in selective charcoal medium
and by conventional PCR using a commercially available kit (Legiofast,
Microbial SL).
Results: PCR analysis of Legionella pneumophila was positive in
21 patients (56.4%) whereas only 9 (23.1%) resulted positive when
the enzyme immunoassay technique was used. No positive results were
obtained by plate culture. No false negatives were obtained with the
PCR kit. Moreover, all positives with Legiofast were in accordance with
clinical parameters of Legionella infection.
Conclusions: The PCR assay used in this work enables a rapid and
sensitive diagnosis using as low as 200 ml of urine. Prevalence of
L. pneumophila is signiﬁcantly higher when analysed by PCR as
compared to the urine antigen test (P = 0.01), suggesting that the
prevalence of this pathogen in severe CAP is higher than suspected so far.
Since urine antigen test is restricted to serogroup 1 of L. pneumophila,
the fact that the PCR kit detects serogroups 1 to 15 may help to explain
this difference. The use of this PCR as a complement of conventional
techniques is recommended to improve the detection of L. pneumophila
in clinical laboratories.
O489 Cost-effective method for differentiation between
Salmonella species and other members of the
Enterobacteriacae referred to the national Salmonella
reference laboratory in England and Wales
T. Peters, C. Maguire (London, UK)
Objectives: Traditional methods for isolation and identiﬁcation of
Salmonella species require a series of biochemical and serological tests.
Our purpose was to determine the cost effectiveness of incorporating
molecular testing for differentiation between S. enterica, S. bongori
and other members of the Enterobacteriacae. The latter are commonly
referred to our laboratory for conﬁrmation as “probable salmonellas” or
Salmonella cultures are received contaminated with other organisms.
These require selective isolation prior to identiﬁcation. This in turn
requires time and expense, including special media, additional exposure
to microbes and more technologist time to perform subcultures. As many
laboratories face budgetary constraints including loss of personnel, we
propose a simple, cost-effective method of conﬁrming Salmonella sp.
prior to typing.
Method: We tested over 350 known Enterobacteriacae with a simple
PCR assay. On the basis of their initial biochemistry, e.g. atypical results,
we also tested 250 “probable salmonella” isolates referred to us for
typing. Oligonucleotide primers were prepared according to the sequence
of the chromosomal invA gene and the PCR assay was performed from
a boiled cell template. An internal ampliﬁcation control (IAC) was
included to indicate possible PCR inhibitors. The trial now aims to
evaluate 6-month resource use and costs of both PCR and traditional
methods.
Results: The primers were speciﬁc as no ampliﬁcation products were
obtained for over 150 isolates of non-Salmonella Enterobacteriacae
covering 20 species. In contrast, we were able to detect the target
amplicon from a wide range of Salmonella strains and sub-groups.
All 96 serovars (211 isolates) tested were shown to carry the invA gene.
Most of the “probable Salmonella spp.” did not produce a PCR product.
Further work conﬁrmed them as non-salmonellas. For the isolates that
did demonstrate the presence of the invA gene, further testing found
that these were salmonella cultures contaminated with other organisms.
Current cost savings already demonstrated by using the PCR assay were
largely attributable to the time taken by the technologist to perform all
the traditional tests before producing a ﬁnal customer report.
Conclusion: This assay provides a cost-effective rapid means of
distinguishing between routine specimens that have been misidentiﬁed
as Salmonella strains and those that do actually require further selection
and typing.
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O490 blaOXA-58 gene is overexpressed and contributes to the
carbapenem heteroresistance in Acinetobacter baumannii
A. Ikonomidis, A. Tsakris, A. Vasdeki, A. Maniatis, S. Pournaras
(Larissa, Athens, GR)
Objectives: To characterise the carbapenem heteroresistant phenotype in
Acinetobacter baumannii strains and elucidate the underlying molecular
mechanism.
Methods: The study included ﬁve A. baumannii strains with subcolonies
grown within the carbanepem inhibition halo in disc diffusion assay.
Susceptibility status was tested by the disc diffusion assay and
carbapenem MICs were determined by Etest and Etest MBL. Genotyping
was performed by ERIC-PCR. Heteroresistant subpopulations were
recovered by population analysis and subsequently tested by Etest and
disc diffusion. Expression of genes blaOXA-51, blaOXA-58 and ampC
was quantiﬁed by Real-Time PCR. Outer membrane proteins were
analysed by SDS-PAGE. The presence of ISAba1 and ISAba3 relatively
to blaOXA-51 and blaOXA-58 was tested by PCR mapping. OXA-58
inhibition experiments with 200mM NaCl were performed to check the
contribution of blaOXA-58 to the carbapenem heteroresistance.
Results: All strains were resistant to all tested antimicrobials except
carbapenems and colistin and negative for metallo-b-lactamase. ERIC-
PCR showed four genotypic proﬁles. Etest MICs for carbapenems ranged
from 0.38 to 32mg/L for imipenem and 0.38 to 6mg/L for meropenem.
Population analysis showed imipenemMIC of heteroresistant populations
from 4 to 128mg/L while meropenem MIC from 0.50 to 16mg/L
with respective frequencies ranging from 4×10−6 to 9×10−5 and from
2×10−−6 to 2×10−4. All strains showed heteroresistant subpopulations
with lower carbapenem susceptibility. Four of them were unstable
after subcultures in drug-free medium, while one produced stable
carbapenem heteroresistant subpopulations. Real-Time PCR showed
increased expression of blaOXA-58 in both imipenem and meropenem
heteroresistant populations, whereas genes blaOXA-51 and ampC were
unchanged. OMP analysis showed no particular differences. One isolate
was positive for ISAba1 which was unrelated to blaOXA-51 and two
isolates were positive for ISAba3, adjacent to blaOXA-58 allele. OXA-58
inhibition experiments using 200mM NaCl showed approximately 4-fold
reduction of carbapenem MIC in the heteroresistant subpopulations.
Conclusions: Gene blaOXA-58 appears to elevate carbapenem MICs
in carbepenem heteroresistant A. baumannii strains. Thus, laboratory
susceptibility assays may need to be adjusted in order to detect the
heteroresistant subpopulations.
O491 Pseudomonas aeruginosa with a novel blaVIM-4/blaP1b and
a second class-1 integron, efﬂux pumps overexpression and
repressed porin OprD
M. Maniati, A. Ikonomidis, P. Mantzana, A. Maniatis, S. Pournaras
(Larissa, GR)
Objectives: To investigate the resistance mechanisms in a multi-
drug resistant Pseudomonas aeruginosa isolate which was positive for
metallo-b-lactamase (MBL).
Methods: Strain P. aeruginosa 140 was studied. Identiﬁcation and
susceptibility testing to antipseudomonal antimicrobials was performed
by the VITEK2 automated system. MICs of imipenem, meropenem,
ceftazidime, aztreonam, gentamicin and piperacillin/tazobactam were
determined by agar dilution. Etest MBL and the imipenem–EDTA double
disc synergy test (DDST) were done to detect MBL production. PCR
for gene blaVIM and conserved segments of class-1 integrons was
performed. Mating experiments were performed by mixed broth mating
using P. aeruginosa PU21 (rif r) as recipient and plasmid isolation with
alkaline lysis. Quantitative real-time reverse transcription-PCR (QRT-
PCR) was performed in order to detect transcripts of genes mexB,
mexY and ampC. Relative expression levels in strain 140 were compared
against those in a susceptible isolate. Outer membrane proteins (OMPs)
were analysed by SDS-PAGE.
Results: Isolate PA140 was resistant to all tested antimicrobials except
aztreonam. Agar dilution MIC of imipenem was 512 and that of
meropenem 128mg/L, while MICs of both gentamicin and piperacillin/
tazobactam were >512mg/L. MICs of ceftazidime and aztreonam were
32 and 8mg/L, respectively. Etest MBL exhibited marked decrease in
MICs of imipenem compared to imipenem-EDTA (256 and 1.5mg/L
respectively) and DDST was positive. PCR revealed two class-1
integrons. The MBL-associated integron was sequentially consisted of
genes blaVIM-4 and blaP1b coding for b-lactamases VIM-4 and PSE-1/
CARB-2 respectively. The second integron comprised sequentially of
genes aac(6′)-Ib and blaOXA-35. Plasmid extraction did not reveal
any visible plasmids and no transcojugants were produced by mating
experiments. QRT-PCR revealed overexpression of genes mexB and
mexY as well as a fairly detectable expression of gene ampC in strain
PA140 relatively to the susceptible strain. Also, OMP analysis revealed a
lower intensity of a protein band of MW≈ 46 kD in strain 140, consistent
with OprD.
Conclusions: A P. aeruginosa clinical isolate harboured a novel class-1
integron with two (blaVIM-4 and blaP1b) b-lactamase gene cassettes and
a second integron. The isolate was highly carbapenem- and multidrug-
resistant, had reduced production of porin oprD and overexpressed efﬂux
pumps MexAB-OprM and MexXY-OprM.
O492 VIM-2 metallo-b-lactamases genes found in Pseudomonas
aeruginosa and Acinetobacter spp. from Russia and
associated with unusual integrons
M.A. Toleman, I. Collin, S. Sidorenko, E. Cherkashyn, D. Ivanov,
V. Tishkov, T.R. Walsh (Cardiff, UK; Moscow, RU)
Objectives: To determine the mechanism of resistance of eight multi-
resistant clinical isolates collected by the National Research Centre of
Antibiotics, Moscow, Russia in 2005.
Methods: Strains were identiﬁed using an API 20 NE kit. The MICs
were determined using Etest ESBL or MBL strips (AB biodisk, Solna,
Sweden) and a wide range of antimicrobial test discs. Isolates positive by
Etest MBL strips were further investigated for resistance determinants by
PCR using blaVIM, blaIMP, blaSPM-1, blaGIM, blaSIM-1 and class-1
integron speciﬁc primers, as well as primers designed to the transposition
genes of Tn5090. Amplicons were sequenced by using custom designed
primers using standard methods.
Results: Six strains were identiﬁed as P. aeruginosa and one as
Acinetobacter spp. All strains were resistant to imipenem >256mg/L
which reduced in the presence of EDTA from 1 to 8mg/L (MBL
Etest strip). All isolates were multi-resistant and only sensitive to
colistin. Five P. aeruginosa isolates harboured the blaVIM-2 gene
cassette in a class-1 integron containing the gene cassette array:
aacA7, blaVIM-2, dhfrB5 and aacA5. The structure was very unusual
as it did not contain a 3′ conserved sequence (3′CS). However, it
did contain Tn5090 transposition genes, absent from most commonly
found integron structures. The integron array was identical to those
found in P. aeruginosa strains harbouring the blaVIM-2 gene recently
characterised from the USA and Norway, and very similar to one recently
characterised from India. One strain of P. aeruginosa and an isolate of
Acinetobacter spp. also contained the blaVIM-2 gene in a normal class-1
integrons as gene cassettes in the ﬁrst position that also contained an
OXA-2 gene cassette.
Conclusion: The absence of a 3′CS and the presence of the tniC
transposition gene suggests that the integron containing the VIM-2 allele
in most of the P. aeruginosa isolates predates the formation of both
the 3′CS and a deletion event that immobilised the Tn5090 transposon
that carries the class-1 integron. The geographic widespread location of
this particular integron structure – including blaVIM-2, suggests recent
worldwide dissemination.
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O493 VIM-2 metallo-b-lactamase emerges in Pseudomonas
aeruginosa isolated from India
M.A. Toleman, H. Vinodh, U. Sekar, K. Vijaylakshmi, T.R. Walsh
(Cardiff, UK; Chennai, IN)
Objectives: To determine the mechanism of high-level carbapenem
resistance in P. aeruginosa, isolated from a bronchoalveolar lavage of
a 60 year old male suffering from ventilator-associated pneumonia in
2003, from Chennai, India.
Methods: The MICs to various antimicrobials were assessed by Etest.
The presence of a carbapenemase was determined by hydrolysis of
imipenem with and without EDTA (25mM). A MBL-like phenotype
was conﬁrmed by the MBL Etest strip (AB biodisk, Solna). PCR was
performed using blaVIM, blaIMP, blaSPM-1 blaGIM blaSIM and class-1
integron speciﬁc primers, as well as primers designed to the transposition
genes of Tn5090. Amplicons were sequenced by using custom designed
primers followed by sequencing using standard methods. The genetic
location of the blaMBL resistance gene was investigated by conjugation
experiments with P. aeruginosa PA01, Southern hybridisation and
plasmid isolation.
Results: The P. aeruginosa isolate harboured a class-1 integron contain-
ing an array of aacA7, blaVIM-2, dhfrB5 and aacC6-II gene cassettes.
The 59 base element of the aacC6-II gene cassette was truncated by the
insertion of ISPa21. The class-1 integron structure was very unusual as it
did not contain a 3′ Conserved Sequence (3′CS) consisting of fused qac
and sul1 genes. However, it did contain Tn5090 transposition genes,
absent from most commonly found class-1 integron structures. The
integron array was very similar to a structure found in a P. aeruginosa
strain harbouring the blaVIM-2 gene recently characterised from the
USA. Conjugation and plasmid isolation experiments failed to transfer
resistance to PA01; however, Southern hybridisation demonstrated that
blaVIM-2 is carried on a plasmid. The concomitant loss of resistance to
ceftazidime and the blaVIM-2 gene was observed after overnight growth
at 37ºC conﬁrming the hybridisation data.
Conclusion: This is the ﬁrst description of P. aeruginosa strains
harbouring blaVIM-2 from India. This further extends the geographic
distribution of this multi-resistance conferring allele. The absence of a
3′CS and the presence of the tniC transposition gene suggests that this
integron predates the formation of both the 3′CS and a deletion event
that immobilised the Tn5090 transposon that carries the class-1 integron.
O494 Plasmid analysis and location of the OXA-40 carbapenemase
gene in multidrug-resistant endemic clones of Acinetobacter
baumannii
E. Sevillano, C. Valderrey, I. Rosales, E. Fernandez, F. Calvo,
L. Gallego (Bilbao, ES)
Objective: To analyse the presence of plasmids and to demonstrate the
relation of these structures with the bla OXA-40 carbapenemase.
Methods: Isolates belonging to endemic clones I and II were selected
from the collection of isolates of A. baumannii obtained from a
hospital in Northern Spain during the years 1999, 2002 and 2005. The
representatives were three per year and clone including OXA-40 positive
and negative isolates. Clonal relatedness was conﬁrmed by ampliﬁcation
experiments with M13 and AP3 primers and PFGE with Apa I enzyme.
Alkaline lysis method and commercial kits were used to detect the
plasmid content. To locate bla OXA-40 Southern transfer hybridisation
experiments were carried out using a speciﬁc DNA probe labelled with
digoxigenin. Preliminary mapping of plasmid DNA was achieved with
EcoRI, PstI and Hind III restriction enzymes.
Results: Plasmids of similar sizes were observed in all isolates belonging
to both clones, frequently combined in groups of several structures. The
size of the plasmids were 125, 112, 84, 32, 8, 4, 3.4 and 2.5 kb. Our
results showed that the same plasmids were in both clones and that there
were some structures which were always presented in groups. Concerning
the blaOXA-40 location we could see different signals on different
bands. Although some isolates showed a chromosomal positive signal,
the majority of them also showed it on different plasmids. Although high
diversity was found, it was the plasmid of 32 kb the main structure where
the positive hybridisation signal was seen. Mapping of a representative
isolate containing that plasmid showed different fragments were the
blaOXA-40 gene could be located.
Conclusion: Although the predominant clones producing the OXA-40
carbapenemase in our environment are genetically unrelated they bore
plasmids of the same size. Isolates from both clones bore plasmids from
2.5 to 125 kb frequently associated in groups. We could see the same
plasmids in isolates obtained along the period of study which means that
they are stable among the population. The predominant location of the
blaOXA-40 gene was on plasmids.
O495 New VIM-2-like metallo-b-lactamases in Pseudomonas
aeruginosa from Germany and Bulgaria
I. Schneider, E. Keuleyan, R. Rasshofer, A. Bauernfeind (Munich,
DE; Soﬁa, BG)
Objectives: The incidence of Pseudomonas aeruginosa strains resistant
to carbapenems due to the production of class-B metallo-b-lactamases
(MBLs) is increasing world-wide. We analysed the b-lactamases of
carbapenem-resistant P. aeruginosa strains from Germany and Bulgaria.
Methods: MICs were determined by the microdilution technique
according to CLSI-guidelines. Double disc synergy test with EDTA and
the Hodge-test were carried out. Oligonucleotides speciﬁc for various
groups of MBLs were used to identify the bla gene. Assuming the
bla genes to be part of an integron, primers binding to intI1 and
qacEdelta1 were used for PCR and sequencing.
Results: P. aeruginosa 166301 from Munich had an MIC of 64mg/L for
meropenem and of 8mg/L for imipenem. P. aeruginosa 9553 from Soﬁa
had an MIC of 64mg/mL for both drugs. Hydrolysis of carbapenems
in the Hodge-test and an inhibitory effect of EDTA suggested the
presence of MBLs. Sequencing revealed VIM-2-like b-lactamases in
both strains. In comparison to VIM-2 the b-lactamase of P. aeruginosa
166301 showed one nucleotide exchange (C164T) causing an amino acid
substitution from serine to leucine at position 54 while the enzyme
of P. aeruginosa 9553 had another nucleotide exchange (A584T)
resulting in an amino acid substitution from tyrosine to phenylalanine at
position 218. Both VIM-genes were located on class-1 integrons. While
blaVIM-2-like of P. aeruginosa 166301 was bracketed by two copies
of the aminoglycoside acetyltransferase gene aac(6′)-Ib′, the integron of
P. aeruginosa 9553 contained no further gene cassettes.
Conclusion: The detection of two novel VIM-2 variants with different
amino acid substitutions and genetic environment in Germany and
Bulgaria underlines ongoing multifocal evolution of the VIM-2 gene.
O496 Multiresistant Klebsiella pneumoniae from NYC hospitals
contain b-lactamase KPC-2 or KPC-3 and porin changes
T. Gootz, F. Dib-Hajj, M. Lescoe, R. Huard, P. Della Latta (Groton,
New York, US)
Objectives: Multiply antibiotic resistant K. pneumoniae with high MICs
to carbapenems have been endemic in several NYC hospitals since
1997. Recent evidence suggests that such strains have acquired genes
encoding KPC carbapenemases and are spreading to other regions of
the Eastern USA. Fourteen carbapenem-resistant strains isolated from the
NY-Presbyterian Hospital in 2005 were examined for their susceptibility
to antimicrobials, b-lactamase content and presence of mutations in ompk
porin genes that would confer carbapenem resistance.
Methods: MICs were determined in cation adjusted Mueller–Hinton
medium using a microtiter plate method with a ﬁnal test volume of
200mL. Bla and ompk genes were ampliﬁed by PCR using primers and
control strains previously characterised. Pulsed ﬁeld gel electrophoresis
(PFGE) was performed on all isolates in order to compare their identity.
Results: Fourteen non-clonal strains were cultured from clinical samples
including sputum (1), tracheal aspirate (2), wound (2), urine (5) and
blood (4). All were non-susceptible to meropenem and imipenem, ce-
fepime, cefotaxime, ceftazidime, and pip-tazo by the microtiter method.
Seven, six and twelve were non-susceptible to amikacin, gentamicin and
tobramycin, respectively. Only four were susceptible to ciproﬂoxacin.
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Thirteen strains were susceptible to tigecycline (MIC 2mg/mL). Strains
were examined for the presence of carbapenemases using primers for
blaKPC and blaOXA 23, 24, 25, 26, 27, 33, 40, 48, 49, 51 and 58, as well
as metallo-b-lactamases. Amplicons were obtained with all strains with
primers for blaKPC; sequencing revealed that 13 contained blaKPC-2
and one contained blaKPC-3. We also examined the ompk35, 36 and 37
porin genes in these strains. Sequencing data indicated that 9/14 strains
contained a 1 bp insertion at NT245 in ompk35 resulting in a stop codon.
The ompk35 sequence was absent in one strain. Most of the strains had
from 3 to 10 aa long inserts into OmpK36 and 37 but these did not cor-
relate with obvious functional disruption in the sequence of these porins.
Conclusion: Endemic outbreaks of multi-drug-resistant K. pneumoniae
in NYC hospitals are becoming a concern and such resistant strains
have spread to other areas of the Eastern USA. Presence of KPC-
class carbapenemases in many of these strains account for high-level
resistance to carbapenems and loss of functional outer membrane porins
may contribute to resistance to these and other antimicrobials.
O497 Outbreak of carbapenem-resistant Acinetobacter baumannii
isolates producing the carbapenem-hydrolysing oxacillinase
OXA-97 (OXA-58-like) in a university hospital in Tunisia
L. Poirel, W. Mansour, O. Bouallegue, N. Boujaafar, P. Nordmann
(Le Kremlin Bicetre, FR; Sousse, TN)
Objective: To characterise the clonal relationship and the b-lactamase
content of carbapenem-resistant Acinetobacter baumannii isolates
recovered in a University Hospital in Tunisia (Sousse) during a four-
year period.
Methods: Forty-six non-repetitive carbapenem-resistant Acinetobacter
baumannii isolates were recovered during the October 2001–October
2005 period from urine, pus, broncheal and blood samples. The presence
of oxacillinase or metallo-b-lactamase genes was performed by PCR,
cloning and sequencing. In particular, genes coding for the carbapenem-
hydrolyzing oxacillinases (CHDL) OXA-23, OXA-40 and OXA-58
subgroups were searched. Genotyping was done by pulsed ﬁeld gel
electrophoresis (PFGE) after ApaI restriction.
Results: The A. baumannii isolates were mostly from patients
hospitalised in intensive care units. MICs determination allowed to divide
these isolates into two main phenotypical groups, both being resistant
to most b-lactams including carbapenems. Twenty-two A. baumannii
isolates possessed the blaOXA-97 gene encoding the novel carbapenem-
hydrolysing oxacillinase OXA-97 differing from OXA-58 by a single
amino acid substitution (Gly to Ala at position DBL35). OXA-97
exhibits the same hydrolysis proﬁle as OXA-58, hydrolysing penicillins
and carbapenems but sparing expanded-spectrum b-lactams. Genotyping
revealed that the OXA-97-positive A. baumannii isolates belonged to a
single clone, although six distinct genotypes were identiﬁed thus deﬁning
subclones. The blaOXA-97 gene was located on plasmids varying in
size and they were all transferred to an A. baumannii reference strain by
electroporation, whereas mating-out assays were unsuccessful. Only one
isolate harboured the blaOXA-97 gene on its chromosome.
The other twenty-four carbapenem-resistant A. baumannii isolates did
not produce any carbapenemase and they did not possess any CHDL
gene. They were clonally related according to PFGE analysis.
Conclusion: This study constitutes the ﬁrst description of dissemination
of a CHDL enzyme in Africa and reports on the identiﬁcation of
the novel OXA-97 being closely related to OXA-58. As observed for
OXA-58 in other countries, the gene coding for OXA-97 was mostly
located on plasmids and identiﬁed in A. baumannii isolates being the
source of an outbreak. Interestingly, this epidemiological survey showed
that outbreaks of two different carbapenem-resistant A. baumannii strains
had occurred in that hospital during the same period of time.
O498 Prevalence of AmpC among cephalosporin-resistant
Escherichia coli and Klebsiella spp.
K. Schønning, A. Friis-Møller, H. Fjeldsøe-Nielsen (Hvidovre, DK)
Objective: To identify AmpC producing strains among E. coli and
Klebsiella resistant to cephalosporins.
Methods: 152 E. coli and Klebsiella isolates identiﬁed as resistant
to cephalosporins during routine examination for extended spectrum
b-lactamase (ESBL) production were tested by combination disk method
for inhibition by clavulanic acid to identify ESBL-producing strains.
Further testing for susceptibility to cefoxitin and cefepime was done to
identify putative AmpC producing strains. Strains resistant to cefoxitin
were tested by the AmpC-disk test. This test discriminates between
cefoxitin-resistance caused by cephamycinase activity in test-positive
strains and other causes (e.g. loss of permeability or altered drug target)
in test-negative strains.
Results: 68 of the 152 cephalosporin-resistant isolates exhibited
resistance to cefoxitin and were classiﬁed as putative AmpC-producers.
When further tested with the AmpC-disk test, 47/68 strains tested
positive and were classiﬁed as AmpC producing; resistance to cefoxitin
of the remaining 21 strains was not accountable for by b-lactamase
production. 20/47 AmpC-disk test positive strains were inhibited by
clavulanic acid and were classiﬁed as both AmpC and ESBL producing.
These strains were signiﬁcantly less sensitive to cefepime than the
26 strains not inhibited by clavulanic; the latter strains were classiﬁed
as exclusively AmpC producing.
Conclusion: AmpC is prevalent in cephalosporin resistant E. coli and
Klebsiella spp. In the present study 19% of the strains were classiﬁed as
AmpC producing and of these strains 43% were also ESBL producers.
Whether the latter group is truly AmpC producing or the positive AmpC
disk test is the result of cephamycinase activity of the ESBL present
is presently unknown. Molecular characterisation of the b-lactamases
produced by the strains is in progress and may help resolve this question.
O499 Identiﬁcation of CTX-M-15 extended-spectrum b-lactamase
in a clinical isolate of Shigella sonnei in Ireland
D. Morris, N. DeLappe, G. Doran, J. O’Connor, G. Corbett-Feeney,
M. Cormican (Galway, IE)
Objectives: To evaluate isolates of Shigella species from Ireland for
Extended Spectrum b-lactamase (ESBL) production and associated
antimicrobial resistance. ESBLs confer resistance to the oxyimino
cephalosporins. In recent years the CTX-M b-lactamases, which
preferentially hydrolyse cefotaxime, have been reported with increasing
frequency worldwide. ESBL production in Shigella has previously
been reported infrequently. Previous reports of ESBL production in
Shigella spp. include a CTX-M-3 in Shigella sonnei in Turkey, CTX-
M-2 in Shigella ﬂexneri in Argentina, and CTX-M-14 in Shigella sonnei
in Korea. This is the ﬁrst report of CTX-M-15 in Shigella spp.
Methods: Shigella species received between January 2003 and October
2006 were tested for susceptibility to a panel of 14 antimicrobial
agents including the following b-lactam agents: ampicillin, ceftazidime,
cefotaxime, and cefpodoxime, in accordance with CLSI disk diffusion
methods. ESBL production was conﬁrmed by the CLSI combination
disk method for ESBL production using cefpodoxime. Conﬁrmed ESBL
producers were screened for blaCTX-M by PCR using speciﬁc primers.
Strains encoding blaCTX-M-9, M-15, M-25, M-2 were used as positive
controls. Amplicons were sequenced using primers homologous to those
used for PCR.
Results: Forty-six isolates of Shigella spp. (25 S. ﬂexneri, 18 S. sonnei,
2 S. dysenteriae, 1 S. boydii) were received between January 2003 and
October 2006. A single Shigella sonnei isolated from stool of an 8 yr old
child was resistant to cefotaxime and cefpodoxime, and was conﬁrmed
as an ESBL producer in accordance with CLSI criteria. Co-resistance to
ampicillin, streptomycin, sulphonamides, tetracycline, trimethoprim, and
gentamicin was observed. No association with foreign travel was noted.
PCR and sequencing revealed this isolate harboured a blaCTX-M-15.
Conclusion: This is the ﬁrst report of CTX-M-15 in Shigella spp. CTX-
M-15 has been reported extensively in clinical isolates of Escherichia
coli. Its identiﬁcation in Shigella sonnei, the leading cause of shigellosis
in industrialised countries, is signiﬁcant.
